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Abstract 
The homomeric α7 nAChR is a ligand gated ion channel found throughout the CNS 
and PNS and is one of the most commonly expressed nicotinic receptors in the 
human brain. The α7 nAChR is expressed in particularly high levels in brain regions 
associated with learning and memory, such as the cerebral cortex and the 
hippocampus. Experimental evidence supports the involvement of this receptor in 
schizophrenia and Alzheimer’s disease (AD), modulators of the α7 nAChR have been 
extensively reviewed for the treatment of the cognitive deficits associated with these 
pathologies. Multiple α7 nAChR agonists have successfully entered clinical trials. 
Unfortunately, due to unfavourable side effects and pharmacokinetic issues the 
majority of these studies have been discontinued.  
SEN12333 (45) represents a promising, novel chemotype of α7 nAChR agonist. The 
current work explores systematic modification to structural features of SEN12333 
(45) and the effect upon binding affinity, selectivity and functional activity. 
Investigations were conducted into modification of the alkyl chain linker, amide 
bond, heterocyclic ring and biaryl ring system of SEN12333 (45). These studies have 
revealed the four carbon chair linker and trans amide bond conformation of 
SEN12333 (45) to be optimal for binding affinity and functional activity at the α7 
nAChR. The nature of the heterocyclic ring was found to be essential for binding 
affinity where the use of branched or bicyclic amines resulted in a complete loss of 
affinity at α7 nAChRs. Studies of the nature of the biaryl ring system of SEN12333 
(45) have revealed various modifications are tolerated. Compound 208 represents the 
most potent congener of SEN12333 (45), displaying an 8-fold improvement in 
binding affinity. Structural motifs from known α7 nAChR agonist 139 have also been 
incorporated in the hope of improving binding affinity and drug like properties whilst 
maintaining high selectivity for the α7 subtype.  
The use of mono-substituted cubylamines as blood-brain barrier (BBB) permeability 
agents was investigated in the hope that these could be utilised to enhance the brain 
concentrations of an α7 nAChR agonist. The preliminary results are promising and 
reveal cubylamines 302–304 to display a similar trend to the corresponding 
established adamtane amines and warrants further evaluation. 
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Chapter 1 - Introduction 
 Mental Health and its effect on society 1.1
Mental health is an essential component of general health. The World Health 
Organisation (WHO) constitution states “Health is a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity” and 
consequently defines mental health as more than merely the absence of mental 
disorders or disabilities.
1
 It is a state of well-being in which an individual 
comprehends his or her own abilities and has the ability to cope with the regular 
stresses of life, work productively and contribute to his or her community. In this 
sense, mental health is the foundation for individual well-being and the effective 
functioning of a community.  
In the majority of countries, particularly 3
rd
 world and developing countries, mental 
health services are severely short of both human and financial resources. With more 
than 450 million people estimated to suffer from mental disorders and many more 
predicted to have mental problems, this presents a serious problem for society.
2
 The 
financial burden of mental illness is felt not only by the individual but also by their 
family, friends and the wider community and can constitute factors such as cost of 
medical treatment, loss of income and the cost of social security and continual care 
and support.  
Schizophrenia and Alzheimer’s disease (AD) are some of the highest costing 
neuropsychiatric disorders, even in comparison to other illnesses such as stroke and 
cardiac disease.
3
 AD is the most common form of dementia, with an estimated 5.2 
million Americans of all ages suffering from the disease in 2013.
4
 This estimate 
includes 5 million people under the age of 65 and approximately 200,000 of those 
suffer from early onset AD. Eighty percent of care provided in the community is 
provided by unpaid caregivers (most often family members), with fewer than 10 
percent of older adults receiving care from paid caregivers. Unpaid caregivers are 
primarily immediate family members, but may include relatives and friends. In 2012, 
these people provided an estimated 17.5 billion hours of unpaid care, a contribution 
to the nation valued at over $216 billion.
4
 It is projected that the United States will 
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need an additional 3.5 million health care professionals by the year 2030 to maintain 
the current ratio of health care professionals to the elderly population.
4
 As the 
number of people with Alzheimer’s disease and other dementias is predicted to grow 
from 5.2 million to 13.1 million over the next 40 years, spending for their care will 
increase dramatically.
5
 Their health care, long term care and hospital aggregate 
payments are projected to increase from $203 billion in 2013 to an estimated $1.2 
trillion in 2050.
4,5
 The current treatment regimens often have severe side effects and 
do not address the issue of disease progress or patient health. 
Schizophrenia is a devastating disorder for most people who are affected, and 
extremely costly for families and society. Schizophrenia is a disease that typically 
begins in early adulthood; between the ages of 15 and 25, with the average age of 
onset being 18 in men and 25 in women.
6
 The direct and indirect costs of 
schizophrenia and associated suicides are vast, financial costs of illness totalled 
$1.85 billion in 2001, which equates to $50,000 per year on average for each of more 
than 37,000 Australians suffering from the illness.
7
 The cost of schizophrenia in the 
United States in 2002 was estimated to be $62.7 billion.
8
 Moreover, the burden of 
disease – the pain, suffering, disability and death – was greater for schizophrenia 
than for ovarian cancer, rheumatoid arthritis or HIV/AIDS, and of similar magnitude 
to leukaemia and melanoma.
7
 Antipsychotics are the current main line of treatment 
for patients suffering schizophrenia; however, these do not alleviate the debilitating 
cognitive dysfunction or negative symptoms associated with the disease.  
There is a strong demand for treatments which alleviate all aspects of these 
debilitating diseases, not only for the well-being of patients and caregivers but also 
due to the ever increasing demand these diseases place on society. An ideal treatment 
would target the underlying problems of these diseases (rather than the symptoms) to 
stop the progress of (or even reverse) the devastating symptoms of these diseases. 
The fundamental cause for both these diseases is understood to occur in the 
cholinergic system. 
 Cholinergic Transmission  1.2
One of the most abundant neurotransmitters in the central nervous system (CNS) and 
peripheral nervous system (PNS) is acetylcholine (ACh – 1, Figure 1). It is 
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synthesised by the enzyme acetyltransferase and is regulated by two distinct types of 
ACh receptors; the metabotropic muscarinic receptors (mAChRs), and the ionotropic 
nicotinic receptors (nAChRs). Both types of receptors are expressed in neuronal and 
non-neuronal cells and are activated by the endogenous agonist ACh (1).
9,10
 The 
mAChRs are heptahelical G-protein coupled receptors (GPCRs), defined by their 
activation from the toxin muscarine (2, Figure 1) (from the mushroom Amanita 
muscaria) and their inhibition by atropine (3, Figure 1), (a toxin from Atropa 
belladonna).
11
 There exist five subtypes of mAChRs, denoted as muscarinic M1–M5 
receptors, each possessing a unique distribution within the CNS and PNS.
11
 
Activation of these receptors is comparatively slow and occurs on the millisecond to 
second timescale. In the PNS, the main effect of this activation is decreased heart 
rate, stimulation of glandular secretion and also smooth muscle contraction.
11
 In the 
CNS, mAChRs are known to be implicated in various sensory, vegetative, cognitive 
and motor functions.
9,10
 
The second type of AChR is the fast ionotropic nAChR which belongs to the 
superfamily of ligand gated ion channels, also encompassing γ-aminobutyric acid 
(GABA), glycine, glutamate, and serotonin (5-HT3) receptors.
12
 In contrast to 
mAChRs, nAChRs are known for their activation by the exogenous agonist (-)-
nicotine (4, Figure 1). These nAChRs can be divided into two distinct groups; 
muscle or neuronal receptors which are characterised by their major sites of 
expression. Muscle nAChRs are found at the skeletal neuromuscular junction where 
they mediate neuromuscular transition. Neuronal nAChRs are found throughout the 
PNS and CNS.
13
 Within the CNS, they mediate numerous processes such as 
neurotransmitter release, cell excitability and neuronal integration, all of which are 
essential for the physiological functions of sleep, arousal, fatigue, anxiety and 
various other cognitive functions.
14,15
 Neuronal nAChRs are also known to 
participate in key areas of synaptic plasticity and are implicated in areas of attention, 
learning, memory and development. It is becoming increasingly evident that 
perturbation of this transmission can lead to a range of dysfunctions during 
development, adulthood and aging and the identification of these receptors as a 
therapeutic target has generated extensive interest in the scientific community.
12,15
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Figure 1 . Common agonists and antagonists of the cholinergic syst em. 
 Nicotinic Acetylcholine Receptor Structures  1.3
The nAChRs consist of a cationic channel assembled from five transmembrane 
subunits arranged around a central, water-filled pore.
16
 Structural information about 
nAChRs has originated from the isolation and purification of muscle nAChRs from 
the electric organ of the electric ray Torpedo marmorata, which expresses the 
nAChR at densities approaching a crystalline array.
17
 This afforded a source of 
starting material for receptor purification as protein from this organ is comprised of 
40% nAChRs. It was further discovered that muscle type nAChRs bind with almost 
covalent affinity to the toxin α-bungarotoxin (α-BTX), inhibiting their function and 
resulting in debilitating paralysis at the neuromuscular junction..
18,19
 These findings 
lead to the utilisation of α-BTX affinity columns to separate nAChRs from other 
proteins in detergent solubilised electric organs.
20
  
The NH2 terminal protein sequence was obtained from the purified protein and by 
employing newly emerging techniques in reverse genetics, the identification, cloning 
and sequencing of the genes encoding for these receptors was completed. It is 
assumed these genes have progressively diverged from a common ancestor through 
gene duplications and mutations resulting in the current structure observed in 
humans. Closely related nAChRs have been conserved throughout evolution in very 
simple forms of life, such as in molluscs and worms where there is greater than 80% 
amino acid homology within the same subunit.
17,21
  
To date, there have been 12 genes cloned which code for the nAChR subunits. These 
genes encode structurally homologous proteins which contain a relatively 
hydrophilic extracellular amine domain (approximately 200 amino acids), followed 
by three hydrophobic transmembrane domains (TM1–TM3), a large cytoplasmic 
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loop of variable size and amino acid sequence and also a fourth hydrophobic 
transmembrane domain with a variable extracellular COOH- terminal sequence.
13,22
 
The structure of the nAChR is depicted in Figure 2. 
 
Figure 2 . Basic structure of nAChRs.
2 3
 Amino acids conserved in most nAChRs are identified 
using the Torpedo subunit numbering system. Residues in green are important to the subunit 
contributing to the agonist-binding pocket and orange residues are important to the β or negative face 
of the agonist-binding site. Orange residues with black dots are required for gating the channel. 
Amino acids in TM2 are important for establishing the channel gate in grey, and those important to 
relieving the gate are in blue. Residues lining the pore (green) are important to determine ion 
selectivity and conductance such as Glu241 that, in part, determines the permeability to Ca
2+
.
 
The lone 
Cys418 in TM4 contributes to measuring the response of nAChRs dependent on the lipid 
environment. The blue “Y” are N-linked glycosylation sites whose relative locations (except near the 
Cys-loop) vary among subunits. 
Subunits are initially classified as α or non-α; an α subunit is defined by the presence 
of a Cys-Cys pair of amino acids in the vicinity of the entrance to TM1 (residues 
191–192 in the Torpedo marmorata α1 subunit). The pentameric channel in muscle 
nAChRs is comprised of five distinct subunits; α1 and four non-α subunits – β1, δ, γ 
and ε with two distinct receptors constructed from a combination of these subunits.23 
The embryonic muscle nAChR contains the α1, β1, δ and γ combination in a 2:1:1:1 
stoichiometry. In adults, the γ subunit is replaced by the ε subunit and this defines the 
second type of muscle nAChR (Figure 3). This switch in gene expression is a 
defining step for muscle development and generation throughout life.
17
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Figure 3 .  The structure of muscle nAChRs.
23
  
In the case of neuronal nAChRs, there have been 8 α-subunit genes cloned, termed 
α2–α7, α9 and α10 and 3 non-α-like subunits, termed β2, β3 and β4 cloned to date. A 
greater diversity is seen in these receptors than the muscle nAChRs as a result of the 
increased number of subunits available to form the pentameric receptor channel.
23
 
Genes encoding for the α-subunits are termed CHRNA(1-10) and genes encoding for 
the β subnits are defined as CHRNB(1-4). The additional δ, ϒ and ε subunits are 
respectively encoded by the genes CHRND, CHRNG and CHRNE.
17
 The 
chromosomal location and genetic features which characterise the human nAChR 
subunits are summarised in Table 1.
23
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Table 1.  Chromosomal location and genetic features of human nAChR subunits .  
Receptor 
NCBI
a
 
Name/Subunit 
Chromosome 
Number/Band 
Gene, kb 
Exons 
(Coding) 
mRNA 
(Coding 
bp) 
Protein 
(amino 
acid) 
CHRNA1 2q31.1 16.64 9 1816 482 
CHRNA2 8p21.2 18.51 0 2684 529 
CHRNA3 15q25.1 28.24 6 2321 622 
CHRNA4 20q13.33 14.75 6 2206 627 
CHRNA5 15q25.1 29.71 6 3578 515 
CHRNA6 8p11.21 15.93 6 2164 494 
CHRNA7 15q13.2 142.25 10 6162 534 
CHRNA9 4p14 19.63 5 2015 479 
CHRNA10 11p15.4 5.8 5 1945 450 
CHRNB1 17p13.1 12.65 11 2557 501 
CHRNB2 1q21.3 12.25 6 5866 502 
CHRNB3 8p11.21 39.99 6 2293 458 
CHRNB4 15q25.1 17.48 6 2972 498 
CHRND 2q37.1 10.48 12 2941 517 
CHRNG 2q37.1 6.6 12 2187 517 
CHRNE 17p13.2 5.3 12 3030 496 
a
 National Centre for Biotechnology Information (NCBI) 
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 Neuronal nAChRs 1.4
Heterologous expression systems have previously been used to determine possible 
subunit combinations of the pentameric core of neuronal nAChRs.
24,25
 To date, two 
main subfamilies of neuronal nAChRs have been identified; α-BTX sensitive 
receptors and α-BTX insensitive receptors. The α-BTX sensitive receptors are 
homopentameric and comprised of a single subunit α7, α8 or α9, where the α7 
containing receptor is the only one widely distributed in the mammalian CNS. The 
specificity of these receptors for α-BTX has enabled determination of their precise 
cellular and subcellular localisation through binding studies. High levels of 
expression are seen in the cortex, hippocampus and sub-cortical limbic regions; low 
levels of expression are evident in the thalamic regions and basal ganglia.
26,27
 
Receptors insensitive to α-BTX, in contrast, are heteropentameric and are comprised 
of an α (α2–α6) subunit and a β (β2–β4) subunit, for example, the α4β2 receptor. There 
also exist more complex heteropentameric receptors made from a combination of 
more than one type of α and β subunits for example α4β2β4. This more complex 
group of receptors includes neuronal nAChRs which contain subunits α5 and β3 
which do not form channels when expressed alone or in combination with any other 
single α or β subunit.28-30 The α4β2 subtype was the first to be characterized both 
pharmacologically and biochemically in the rat brain and is known to be the main 
neuronal nAChR subtype in subregions such as the cortex, striatum, superior 
celliculus, lateral geniculate nucleus and cerebellum.
31,32
 Since it is the most 
abundant high affinity nicotine-binding nAChR in the brain; mice containing a β2 or 
α4 subunit knockout show a major loss of high affinity receptors for nicotinic 
agonists in the CNS.
33
  
Distribution studies of receptor subtype mRNA have shown that the α3, α6, β3 and β4 
subunits have a somewhat restricted distribution in the brain. However, in the 
neuronal populations where they are expressed (eg α6β3 in midbrain dopamine 
neurons or α3β4 in medial habenula neurons) they can comprise the majority of 
subpopulations of nAChRs with a significant function.
26
 Heteropentameric neuronal 
nAChRs containing the α2β2, α2β4, α3β2, α6β2 and α6β4 subunit combinations can exist 
either as the described heteropentamers or combine to form more complex subtypes. 
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For example α4α6β2 is expressed in the striatum and visual pathways, α2α4β2 is 
present in the retina, and the α3α4β2 subtype is expressed in the cerebellum.
34,31
 Co-
expression of multiple α or β subunits typically results in only a specific combination 
of subunits forming a heteropentameric receptor; exemplified by the fact that rat 
midbrain dopaminergic neurons express the α4, α5, α6, β2 and β3 subunits but the 
receptors preferentially formed are solely α6β3 and α4β2.
35,36
  
Factors affecting subunit assembly are not well understood and can be affected by 
chaperone molecules, relative subunit concentrations and the intrinsic affinities 
between subunit pairs. Additionally, although one subtype of neuronal nAChRs can 
predominate within a specific brain region, this is often combined with the presence 
of more than one of the other subclasses.
37
 Individual neurons have also been shown 
to express multiple classes on nAChRs with neighbouring neurons showing 
significantly different nicotinic responses, a fact that must be considered when 
targeting these receptors therapeutically.
38
 The regional distribution and subunit 
organisation of the main nAChR subtypes in rodent CNS is summarised in Figure 4. 
The human α7 nAChR is known to share 93% sequence identity with its rat 
homologue.
39,40
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Figure 4.  Regional distribution and subunit organisation of neuronal nAChRs in the 
rodent CNS.
26
 The subtypes present in the cortex, cerebellum, hippocampus, interpenduncular 
nuclear, medial habenula and pineal gland have been identified through binding immunoprecipitation 
and/or immunopurification assays in tissue from rat and/or wild-type and/or knockout mice. 
 The α7 nAChR 1.5
The α7 nAChR

 subtype displays a restricted distribution within the brain (Figure 
4); its expression is particularly evident in regions associated with cognitive function 
such as the hippocampus, cortex and several subcortical limbic regions.
41,26
 Within 
the hippocampus, α7 receptors are known to presynaptically facilitate the release of 
transmitters such as glutamate or GABA
42
 or exert a direct postsynaptic action 
through mediation of fast synaptic transmission.
16,43
 Low expression levels of α7 
receptors are seen in thalamic regions and basal ganglia.
44-46
 α7 receptors are also 
found in perisynaptic locations, where they modulate other inputs to neurons and 
serve to activate a variety of downstream signalling pathways.
47,48
 The α7 receptors 
located on autonomic ganglia are involved in fast synaptic transmission despite their 
perisynaptic location.
 43,49
  
Investigations of native α7 receptors confirm that they are highly permeable to 
calcium, similar to N-methyl-D-aspartate (NMDA) receptors, however, unlike the 
                                                 

 From this point onwards the α7 nAChR will be referred to as α7 or the α7 receptor 
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latter they do not require depolarisation of the plasma membrane in order to promote 
the influx of calcium.
13
 It is thought that the high degree of Ca
2+
 permeability causes 
the majority of their functions: Ca
2+
 influx potentially facilitates transmitter release 
when presynaptic α7 receptors are activated, depolarising post-synaptic cells and 
serving as a secondary messenger to initiate various cell processes such as promoting 
neuronal survival.
50
 However, the effects of Ca
2+
 entering through α7 receptors are 
limited by a rapid receptor desensitisation (further discussed in section 5.2), therefore 
preventing excitotoxicity as a result of excessive influx.
13
 The α7 receptor functions 
are also modulated by other divalent cations including Zn
2+
, Mg
2+
, Pb
2+
 and Cd
2+
, 
which all potentiate the ACh-induced response.
24,51
 Extracellular Ca
2+
 also modulates 
both the activation and deactivation of α7 receptors in cultured hippocampal 
neurons.
52
  
1.5.1 Binding site  
The ACh (1) binding site in the homopentameric α7 receptor, (which also binds the 
high affinity exogenous agonist nicotine (4), is present at the interface formed by the 
opposing sides of the same α7 subunit.
53
 The α7 receptor therefore contains five 
potential binding sites per receptor complex. In contrast, heteropentameric receptors, 
have two binding sites per receptor complex, present at the interface between the α 
and β subunits, where the α subunit is defined as the principal component and the 
non-α subunit comprises the complementary component.54,55 Generally, the 
stoichiometry of heteropentameric receptors contains two α subunits containing the 
principal component of the ACh binding site (α2, α3, α4 or α6) and two non-α subunits 
containing the complementary portion of the binding site (β2 or β4). The fifth subunit, 
equivalent to β1 in muscle type nAChRs does not participate in ACh binding and can 
be comprised of the α5, β3, β2 or β4 subunits. Possible locations of agonist binding for 
the varying receptor subtypes are illustrated in Figure 5.
26
 Different binding sites 
formed by differing subunits results in varying affinities for agonists and antagonists 
co-existing within a given oligomer and creates a challenge for targeted drug 
design.
56
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Figure 5.  Organisation and structure of heteropentameric and homopentameric 
subtypes.
26
 The pentameric arrangement of nicotinic acetylcholine receptor subunits in the 
heteropentameric α4b2, α4α6β2β3, α6β2β3 and homopentameric α7 subtypes and localization of the 
subunit interfaces of the ACh-binding site are shown.  
In terms of the α7 receptor, recent crystallisation and structural determination of 
ACh-binding proteins (AChBP) from the snails Lymnaea stagnalis and Bulinus 
trancatus and the saltwater mollusc Aplysia California, have assisted in defining the 
molecular details of the ligand binding sites.
57-59
 These homopentameric soluble 
proteins are known to have an affinity spectrum similar to that of α7 receptors and 
there are several amino acids known to contribute to the ACh-binding site (Figure 
6).
60
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Figure 6. Schematic representation and structure of the ACh-binding site on the α7 receptor. Model of 
the α7 receptor obtained from comparative modelling, using the X-ray crystallography structure of 
ACh-binding protein in the presence of nicotine. Residues identified by biochemical labelling are 
shown. For clarity, only two monomers are represented. Amino-acid residues of the principal side of 
the binding site are shown in green, and complementary side are shown in beige. Nicotine is shown in 
red. 
Residues conserved from Torpedo marmorata at the α7 binding site include aromatic 
amino acids Tyr94, Trp152 and Tyr154, Tyr191 and Tyr199 and Trp56 and Gln58. 
As previously mentioned in section 3, bridged cysteine residues Cys193 and Cys194 
are only present within α subunits and interact with nicotinic ligands in the co-crystal 
of AChBP.
55,61
 These disulphide bridges construct and direct specific aromatic 
residues within the binding site to provide it with an overall negatively charged 
character; it is assumed that the positive charge commonly carried by nicotinic 
ligands is neutralised by these residues.
62,63
 The cationic ammonium centre evident in 
almost all nAChR agonists forms a cation-π interaction with the conserved 
tryptophan residue (Tyr191). Studies of co-crystals of the AChBP with bound 
agonists reveal that this tertiary or quaternary pharmacophore binds in the middle of 
the ‘aromatic box’ comprised of tyrosine and tryptophan residues within the binding 
site.
23
 NMR Studies, utilising ACh (1) as a bound agonist, have further revealed the 
distance of this ammonium group from the tryptophan residue to be consistent with a 
cation-π interaction.64 The cation-π interaction is increasingly recognised as an 
important noncovalent binding interaction relevant to structural biology.
65
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Theoretical and experimental studies have revealed the cation-π interaction to be 
quite strong and have further established its role in biological recognition.
65,66
 
1.5.2 Functional states of α7 receptors 
Emerging models have suggested that upon ACh (1) or nicotine (4) binding to the α7 
receptor, substantial rearrangement occurs amongst the invariant amino acids in the 
vicinity of the binding pocket. In particular, there is a convergence of the aromatic 
residues towards the ligand from both the α subunit and non-α subunit faces, which, 
subsequently interact through hydrophobic Van Der Waals interactions.
23
 The β-
strands move a considerable distance towards the receptor core allowing the key 
Cys-Cys bridged pair to interact with the ligand, which, combined with the 
interaction of the key aromatic residues, effectively trap the ligand in the binding site 
(Figure 7). As a result of this, significant torque is formed in the receptor through 
alterations in the relative positioning of the β-barrel like loops, rotating the 
extracellular surface of the pentamer and influencing the position of residues vicinal 
to the extracellular segment of TM2, ultimately relocating residues critical to channel 
gating. The resulting ion pore generated by TM2 is crucial to the establishment of the 
ion gate, selectivity and channel conductance.
23
 As TM2 lines the channel pore, it 
also contains the amino acids contributing to the channel gate where, in the absence 
of a bound ligand, the TM2 helices from the 5 subunits form a barrier of hydrophobic 
residues pointing towards the cytoplasmic side of the cell and preventing ion flow. 
The importance of these residues is demonstrated in mutagenic studies. Upon 
substitution for more hydrophilic residues, only partial gating relief is evident and 
there is an increase in nonspecific channel permeability. Instructively, mutation of 
these residues has also been linked to the prevalence of epilepsy.
67
 To successfully 
allow ion flow into the channel, ligand binding stimulates rotation of the extracellular 
domain which is translated into TM2 helical rotation, resulting in transient removal 
of the hydrophobic barrier residues from the channel pore, increasing its diameters 
and facilitating the influx of ions. (Figure 7). 
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Figure 7 . Ligand binding and proposed mechanism for pore opening .
23,68
 Taken from 
electron microscopy studies of channel gating from the Torpedo nAChR (Protein Data Bank code 
2BG9) and from high-resolution studies of the AChBPs. 
Whilst open, neuronal nAChRs conduct cations, resulting in a local depolarisation of 
the membrane and producing an intracellular signal.
69-71
 From the agonist-bound 
open state, α7 nAChR channels alternate to a non-conducting state, either through 
ligand dissociation (known as deactivation), or through an agonist-bound 
conformational change resulting in the high-affinity, non-conducting desensitised 
state (Figure 8).
17
 In the absence of a ligand, the equilibrium between the different 
receptor conformations is determined by the intrinsic isomerisation coefficients and 
agonist binding stabilises both the open and the desensitised states. There exist two 
types of desensitised ‘closed’ states namely intermediate (I) or high (D) which are 
refractory to activation on a timescale of milliseconds (I) or minutes (D). The 
desensitised states maintain a high affinity for agonists with high micromolar and 
very high nanomolar dissociation constants for the I and D states respectively.
55
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Figure 8.  Functional states of neuronal nAChRs . 
Desensitisation of the α7 receptor is a complex process, the mechanism and rate of 
which can be influenced by factors such as subunit composition and kinase and 
phosphatase activity.
72
 Desensitisation of α7 receptors is known to desensitise 
rapidly; in cultured hippocampal neurons desensitisation occurs within 1 second.
38
 
The functional knockout of the receptor by desensitisation is reversible; a 15–30 
second time interval seems sufficient for complete recovery from desensitisation 
within the hippocampus.
73
 Desensitisation recovery rates are dependent on time and 
the amount of agonist exposure; it is widely accepted that desensitisation as basal 
conditions does not prevent nicotinic transmission, which only occurs at high activity 
states.
39
 The main reason postulated for the existence of desensitisation is the 
removal of potentially harmful overstimulation of the cell.
39
 The densensitisation of 
α7 nAChRs may also be a key mechanism for cognitive properties as it may expand 
the variability of α7 receptor mediated functions to provide extra computational 
power to the neuron. The differential desensitisation of GABAergic and 
glutamatergic elements in the ventral tegmental area results in sustained long term 
potentiation, especially for the glutametergic component, which provides long-term 
stimulation of local dopaminergic neurons.
72
 Ventral tegmental area dopaminergic 
neurons provide limbic input to the nucleus accumbens and express both the α7 and 
non α7 receptor.
37
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The desensitization of α7 receptors is known to be dependent on the agonist 
concentration.
74
 A comprehensive description of receptor desensitisation by Katz and 
Thesleff
75
 is depicted in Figure 9. Application of a medium to high concentration 
(µM to mM) of an agonist resulted in activation of nAChRs and desensitisation 
followed by recovery upon agonist removal, a process defined as ‘classical 
desensitisation’ which develops in the range of tens of milliseconds depending on 
nAChR subtype composition.
76
 Low agonist concentrations were shown to induce 
receptor desensitisation even without apparent activation, a process known as ‘high 
affinity desensitisation’. This is a much slower process occurring in the seconds to 
minute time frame and typifying chronic agonist exposure. Extensive agonist 
exposure (for example, nicotine) can result in high affinity receptor desensitisation 
and substantial alterations to receptor sensitivity resulting from upregulation of α7 
receptors.
77
  
 
Figure 9.  Various mechanisms of agonist -induced modulation of receptor 
responsiveness.  
The receptor model proposed by Katz and Thesleff is further updated and described 
in Figure 10a.
76
 The model depicts typical allosteric protein behavior, where in the 
absence of a ligand, the α7 receptor is distributed between several discrete 
conformations. The agonist simply increases the probability of transitions between 
the states.
55
 In this model, the agonist is defined as A and the receptor as R, while R* 
and D respectively represent the resting, open and desensitised states. According to 
Katz and Thesless
75
 desensitisation onset is agonist-dependent and recovery was 
found to be agonist independent.  
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Figure 10 a . Cyclic,  kinetic model of desensitisation. b. Complete cyclical model of 
receptor desensitisation.  
At low agonist concentrations, the ligand stabilises the AD desensitised complex 
through binding to the pre-existing desensitised (D) receptors. This results in a 
disruption of equilibrium between R and D receptors, which is restored by the 
movement of receptors from R to D. Functional desensitisation is observed as a 
relative loss of receptors that can be activated.
78
 This model was updated in 1982
79
 to 
incorporate the finding that responses to low doses of agonists was non-linear and 
indicative of multistep binding (Figure 10b).
78
  
The addition of the intermediate desensitised state (I) reflects the bio exponential 
time course of desensitisation and onset. The authors reported that the two distinct 
components of desensitisation did not behave independently. Recovery was faster 
following brief exposure rather than extended exposure to agonists and this reflects 
the relative accumulation of receptors in the intermediate I state. Deep transition (R 
to I) can be relatively more sensitive than shallow transitions (I to D) and the four 
possible states can also incorporate binding of multiple agonist molecules, adding to 
the complexity of this process.
80
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1.5.3 Changes to α7 nAChRs during development and aging  
Expression patterns of α7 receptors undergoes considerable change during 
development and aging in all animal species.
14
 Binding studies utilising 
3
H-Nicotine 
(4) and 
125
I-α-BTX during development have revealed that various subtypes possess 
differing temporal and spatial behaviours.
14
 Binding sites of 
125
I-α-BTX (α7 nAChRs) 
in the human foetal brain remain constant between 10 and 24 weeks. After birth and 
throughout life their concentration slowly decreases in the hippocampal CA1 region, 
entorhinal cortex, thalamus and in the striatum.
81
 Concentrations remain constant in 
the frontal cortex and cerebellum.
82
  
Expression patterns of α7 receptors highlight their role throughout brain development 
as their concentration is elevated during periods of synapse formation. In vitro 
experiments have suggested that the α7 receptor may also control the development of 
neuronal architecture, stabilise synapse formation and orient and control neurite 
outgrowth.
83,84,50
 These data highlight the importance of α7 receptors during two 
critical periods of brain life; early pre- and perinatal circuit formation and cell 
degeneration throughout aging. The use of nicotinic drugs throughout these time 
periods is of considerable importance and therefore represents α7 receptor a valid 
therapeutic target. Nicotinic exposure to the foetal brain, as a result of maternal 
passive smoking or via breast milk, can significantly alter brain circuitry and 
administration of nicotinic drugs in this time period can increase the levels of 
nAChRs in a subtype selective manner.
85
  
The strong implication of α7 receptors in cognitive function and their mechanistic 
malfunction or loss of receptors, has linked them to pathologies like Alzheimer’s 
Disease (AD), dementia with lewy bodies, Down’s Syndrome, autism and 
Parkinson’s Disease (PD).86 Genetic studies have further linked α7 receptors to 
schizophrenia and epilepsy and mutagenic mice studies have highlighted their 
involvement in pain mechanisms, anxiety and depression.
13,12
 The involvement of α7 
receptors in a wide range of neuronal dysfunctions and age-related mental illnesses is 
therefore evident and the use of nicotinic drugs to halt or inhibit brain degeneration 
and improve age-related intellect decline is a current therapeutic area of 
interest.
13,87,88
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 The α7 receptor in neurological disease 1.6
1.6.1 The α7 receptor in schizophrenia  
Schizophrenia is a complex disorder with dysfunction evident through positive 
symptoms (hallucinations, delusions and thought disorder), negative symptoms 
(social withdrawal, anhedonia, apathy) and cognitive deficiencies (attention, 
memory, executive function).
89
 Several of the positive (psychotic) symptoms have 
been treated with the discovery of ‘typical’ antipsychotic drugs in the 1950’s. 
However, these result in undesirable, extrapyramidal side effects such as blunting, 
social withdrawal and anhedonia, limiting their use as therapeutic agents.
90
 Some of 
these side effects have been addressed through the development of newer ‘atypical’ 
antipsychotics. However, these are largely inefficient at treating the negative and 
cognitive symptoms of schizophrenia sparking the search for alternative treatment 
strategies.
90
  
Data from epidemiological studies have revealed a large portion of schizophrenic 
patients to be chronic smokers in comparison to the general population. The smoking 
rate in schizophrenic patients ranges from 70–90% and is much higher than 25% of 
the general population.
91
 Furthermore, schizophrenic patients are said to have 
elevated daily cigarette consumptions, extract more nicotine per cigarette and favour 
stronger cigarettes prompting the suggestion that smoking is a form of self-
medication to alleviate the symptoms of the disease.
92
 This view is further enforced 
by the fact that nicotine is known to normalise several deficits in sensory processes 
associated with schizophrenia particularly the auditory P50 suppression deficiency.
93
  
The P50 auditory evoked potential is a positive electro encephalography waveform 
occurring 50 msec following exposure of an auditory stimulus. In healthy subjects, 
presentation of a pair of auditory stimuli with a 500 msec inter-stimulus interval 
results in a significant reduction in response to the second stimulus.
93
 In the case of 
schizophrenic patients, there is a failure to adequately inhibit the P50 response to the 
second stimulus, which is interpreted as a result of cognitive impairment seen in 
schizophrenics and reflects attention deficits and a lack of attention sustainment. The 
inability to inhibit the second stimulus P50 response is thought to result from an 
inability to filter trivial information leading to an overload of sensory data, which in 
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turn results in an altered comprehension of the surrounding environment and a failure 
to think coherently.
93
 Sensory gating deficits in patients suffering schizophrenia have 
been linked to chromosome 15q14 which is proximal to the α7 locus.
94,95
 A decreased 
density in α7 receptors has also been seen in patients with schizophrenia
96
 and 
expression of a novel variant of α7 receptor CHRNA7-2 has been found to be 
reduced below control levels in the prefrontal cortex of patients with schizophrenia.
97
 
Schizophrenic patients are also known to demonstrate greater deficits on the 
neuropsychological battery and the Repeatable Battery for the Assessment of 
Neuropsychological Status (Repeatable battery) than healthy subjects and also as 
compared to subjects suffering from bipolar disorder.
98,99
 
Clozapine is a superior, atypical antipsychotic used for the treatment of 
schizophrenia and is known to block the 5-HT3 receptor resulting in release of ACh 
(1).
6,100,101
 Relative to other antipsychotics, clozapine treatment is known to 
normalise P50 suppression in schizophrenic patients leading to improved clinical 
symptoms.
102-104
 Clozapine treatment is known to reduce the incident of smoking in 
schizophrenia sufferers and animal model studies in DBA/2 mice have shown the 
auditory sensory gating deficit to be enhanced by clozapine, where upon treatment 
with α7 antagonist α-BXT, this effect is blocked.
105
 Unfortunately, clozapine 
treatment results in a range of unwanted side effects, the most serious of which 
includes agranulocytosis, i.e. granulate count less than 500/mm
3
.
106
 Less serious and 
more common side effects include sedation, hypersalivation, tachycardia, 
hypotension, hypertension, weight gain, constipation, urinary incontinence and 
fever.
106
 Whilst the majority of these can be managed medically the vast list of side 
effects and risk of agranulocytosis renders clozapine unacceptable as the main line of 
treatment for schizophrenia. It is therefore only utilised as a last resort and highlights 
the need for novel therapeutics. In combination these findings highlight the role of 
the α7 receptor in the mechanism of auditory sensory gating deficits and emphasise 
its potential for therapeutic intervention.   
Extensive effort has been put into the development of α7 agonists for the treatment of 
schizophrenia and many compounds have successfully entered clinical trials and are 
summarised in Table 2. Unfortunately, none of these compounds have successfully 
reached the market. 
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Table 2.  Clinical progression of α7 agonists for the treatment of schizophrenia .  
Compound Structure 
Development 
Status 
Company 
GTS-21 (5) 
 
Phase II Comentis 
EVP-6124 (6) 
 
Phase II 
EnVivo 
Pharmaceuticals 
RG3487/MEM3454 
(7) 
 
Phase II 
(discontinued) 
Roche/Memory 
Pharmaceuticals 
PHA-543613 (8) 
 
Phase I 
(discontinued) 
Pfizer 
PHA-568487 (9) 
 
Phase I 
(discontinued) 
Pfizer 
CP-810123 (10) 
 
Phase I 
(discontinued) 
Pfizer 
TC-5619 (11) 
 
Phase II Targacept 
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SSR180711 (12) 
 
Phase II 
(discontinued) 
Sanofi-Aventis 
 
Partial α7 agonist GTS-21 (5) enhanced cognitive performance in the Repeatable 
battery for the Assessment of Neuropsychological Status in a cohort of non-smoking 
schizophrenic patients and confirmed the proof of concept relating to the role of 
nAChRs in schizophrenia.
107,108
 The P50 auditory gating deficit was also normalised 
in this study. EnVivo pharmaceuticals have reported an improvement in cognitive 
deficits upon treatment with EVP-6124 (6), an α7 agonist and 5-HT3 antagonist as 
measured by the Cogstate battery tests. Improvement trends were seen on the 
Raven’s Progressive Matrices Test in a Phase II, double-blinded, placebo-controlled 
clinical trial in both smoking and non-smoking schizophrenic patients.
109
 These 
results were in agreement with previous data on the effects of GTS-21 (5) which 
demonstrated improvement of cognitive impairment in monkeys.
110
 Treatment with 
GTS-21 (5) in schizophrenic patients on antipsychotic drugs showed an improvement 
in gating deficits and attention.
107,108
 More recently, functional magnetic resonance 
imaging (fMRI) and pharmacogenetic analyses have also revealed GTS-21 5 to 
reduce posterior default network activity via α7 receptors in schizophrenic patients.
111
  
Roche and Memory have previously conducted studies on schizophrenic patients 
assessing the effect of MEM3454 (7) on the electrophysiological biomarkers P50 
sensory gating, mismatch negativity and P300. While positive results were observed 
and an improvement detected in the cognition of schizophrenics, MEM3454 (7) is no 
longer listed in the Roche pipeline for treatment of schizophrenia.
112
 The 
advancements of α7 agonists PHA-543613 (8), PHA-568487 (9) and CP-810123 (10) 
by Pfizer into Phase I clinical studies were recently reported. All compounds were 
potent agonists of α7 nAChRs with rapid brain penetration, high oral biolavailability 
in rats and favourable human ether-a-go-go (hERG) profiles.
113,114
 Further, 
development of these compounds was discontinued as a result of the prevalence of 
adverse cardiovascular events in humans.
113-115
 Furthermore, while CP-810123 (10) 
displayed favourable preclinical findings in various animal cognition models, it did 
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not display any improvement of cognition at any dose tested in human trials and 
studies were discontinued due to lack of efficacy.
116
 It is assumed that these adverse 
cardiovascular events are not related to activation of α7 receptors as research into 
compounds including EVP-6124 (6) suggests these receptors can be safely targeted 
in the clinic.  
A full agonist of α7 receptors, TC-5619 (11), has demonstrated efficacy in animal 
models of positive and negative symptoms of schizophrenia.
117
 It displayed long-
lasting memory enhancement in object recognition paradigms over a wide dose 
range. Phase I studies of TC-5619 (11) in healthy male volunteers have revealed 
single and multiple doses to be well tolerated. The Cognitive Drug Research 
cognitive test battery also revealed a statistically significant improvement in attention 
power in subjects taking TC-5619 (11).
118
 Recently, a randomised exploratory Phase 
II trial of TC-5619 (11) was conducted for the treatment of the cognitive dysfunction 
and negative symptoms in a range of schizophrenic males. Patients were treated with 
quetiapine or risperidone monotherapy (atypical antipsychotics) and were 
randomised to 12 weeks of placebo or TC-5619 (11) treatment. Primary efficacy 
outcome was measure using the Groton Maze Learning task (GMLT) of the Cog 
state Schizophrenia Battery (CSB) and secondary outcome measurements included 
CSB composite score, scale for assessment of negative symptoms (SANS), clinical 
global impression – global improvement (CGI-I), CGI-severity and subject global 
impression cognition. GMLT statistically favoured TC-5619 (11) treatment as did the 
SANS measurements. A statistically significant drug effect upon working memory 
was also evident in tobacco users. Treatment with TC-5619 (11) was generally well 
tolerated with no clinical safety problems reported. These findings further support 
the potential development of TC-5619 (11) and α7 receptor agonists for treating the 
cognitive dysfunction and negative symptoms of schizophrenia.
118
  
Sanofi-Aventis has reported 4-bromophenyl 1,4-diazabicyclo[3.2.2]nona-4-
carboxylate hydrochloride (SSR180711, 12, Table 2) to be a partial agonist with 
selective affinity for the human and rat α7 receptor (Ki = 14 and 22 nM 
respectively).
119
 Studies of SSR180711 (12) have demonstrated improvement of 
cognitive deficits in multiple rat models of schizophrenia.
119
 In particular, 
SSR180711 (12) potentiated latent inhibition (LI) in normal rats and reversed 
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amphetamine induced LI disruption, two predictive models of activity against the 
positive symptoms of schizophrenia.
120,121
 An increase of α7 receptor binding sites in 
the rat brain was observed following treatment with SSR180711 (12) and 
subsequently it successfully entered Phase II clinical trials.
122
 Studies were 
discontinued due to cataract development in subjects and a narrow therapeutic index.  
1.6.2 The α7 receptor in Alzheimer’s disease 
AD is one of the most prevalent sources of dementia and mental deterioration in 
elderly people. AD is a progressive, neurodegenerative disorder with an average 
duration of 8.5 years from onset of clinical symptoms until death.
123
 The 
characteristic pathological markers of AD include a loss of neurons and synapses 
within the entorhinal area, hippocampus, basal forebrain, ventral striatum and 
eventually cerebral isocortex.
124,125
 Initially, the typical symptoms of AD include 
short-term memory impairment and later stages are defined by a general decline in 
cognition, deterioration of language, spatial and motor abilities and also behavioural 
and psychological symptoms such as hallucinations. Neuropathologically, AD is 
defined by the presence of extracellular neuritic plaques comprised of the amyloid-β 
(Aβ) peptide and neurofibrillary tangles (NFT) originating from 
hyperphosphorylation of tau protein and a resulting loss of neurons.
125  
Aβ peptides are formed from the Aβ precursor protein (APP) through enzymatic 
cleavage from two amyloidogenic proteases, β- and γ- secretases.126 Cleavage of 
APP by α-secretase, in contrast, generates a soluble form of APP (sAPP) and inhibits 
the formation of Aβ peptides. Though Aβ peptides are considered neurotoxic, sAPP 
is known to bear a neuroprotective effect via modulation of neuronal excitability, 
synaptic plasticity, neurite outgrowth, synaptogenesis and cell survival.
127,128
 
Secretase cleavage of APP by enzymes other than α-secretase give rise to Aβ 
peptides with variations in length where the 37-, 40- and 42-residue forms are the 
most prominent
127
 and the increased ratio 1-42 peptide (Aβ42) is associated with the 
disease.
129
 Aβ peptides are natively unfolded proteins and can therefore adopt 
various tertiary and quaternary structures in vivo and in vitro such as monomers, 
oligomers and fibrils.
130
  
Neuronal cell death in AD preferentially occurs in the basal forebrain, which is the 
primary source of cholinergic innervation in the brain, and results in a marked 
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reduction of cholinergic markers in the cortex.
131
 A selective reduction of receptors is 
evident in the AD brain, particularly in regions harbouring plaques and NFT 
suggesting a link between the neuropathology of AD and receptors.
132,133
 There is a 
significant loss of receptors in various neocortical areas and also the hippocampus 
where a 30–50% reduction of α7 receptors is highlighted by reduced α-BXT 
binding.
134,135
  
The cholinergic system is known to be implicated in learning and memory 
performance and α7 receptors are highly expressed in the hippocampal formation – a 
brain region essential for cognitive functions and with a key role in mediation of the 
actions of ACh (1) and nicotine (4). Presynaptic α7 receptors in the hippocampus are 
also known to induce and mediate glutamate and/or GABA release in this brain 
region.
136-138
 Rapidly desensitizing, ACh-induced inward currents within 
hippocampal CA1 interneurons are mediated by α7 receptors.
73
 Collectively these 
findings suggest that α7 receptors are critical for various types of cholinergic synaptic 
transmission within the hippocampus.
73
  
Symptoms of AD are affected by genetic variations in α7 receptors. A significant loss 
in ACh binding sites and impaired nAChR synthesis is observed in autopsies of 
numerous neocortical areas, the hippocampus, the thalamic reticular nucleus and in 
basal forebrain neurons of AD patients.
139,136,140
 The protein levels of α7 receptors is 
reduced by 36% in the hippocampus of post-mortem AD patient brains, however, no 
change is detected in the temporal cortex, suggesting that α7 protein level changes in 
AD brains are region specific.
133
 The most vulnerable neurons in AD appear to be 
those expressing α7 receptors and these findings highlight the involvement of this 
receptor subunit in the pathogenesis of AD, suggesting that its downregulation may 
play a key role in disease progression.  
The Aβ peptide has been shown to bind with high affinity to neuronal α7 receptors 
and this interaction results in intraneuronal accumulation of Aβ1-42 (Aβ42)–α7 receptor 
complexes
141,142, rapid tau phosphorylation, severe impairment of α7 receptor 
channels, deficits in cholinergic neurotransmission and neuronal cell death.
143,144
 
This indicates chronic perturbation of α7 receptors by Aβ42 in AD brains can result in 
neuronal dysfunction and neurodegeneration leading to accumulation of Aβ-rich 
amyloid plaques and phosphorylated-tau NFTs. It has since been shown that despite 
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elevated levels of APP and amyloid deposits, deletion of the α7 receptor subunit in 
mouse models of AD results in protection from dysfunction in synaptic integrity, 
learning, memory and behaviour.
145
 Disruption of the Aβ42–α7 receptor interaction 
represents a novel therapeutic approach in the reduction of Aβ42 mediated functional 
deficits, neurodegeneration and the clinical, pathological features of AD. In 
combination, the changes in α7 receptor expression and the interaction of this 
receptor subunit with Aβ plaques indicate the α7 receptors play a key role in the 
progression of this disease and that α7 receptor agonists are a valid therapeutic target 
for the treatment of AD.
146
  
Researchers at AstraZeneca have identified (2′R-spiro-[1-azabicyclo[2.2.2]octane]-
3,2’(3’H)-furo[2,3-b]pyridine (AZD0328, 13, Figure 11) as a selective, partial 
agonist of α7 receptors with high affinity for native rat and recombinant human α7 
receptors (4.7 nM and 3.0 nM respectively) and low affinity for the other nAChR 
subtypes.
147
 In vivo low dose administration (0.00138 mg/kg) of AZD0328 (13) 
results in a significant increase in cortical dopamine release and improvement in both 
conditioned response learning and memory retention in an object recognition task.
148
 
An improvement in cognitive performance was evident with AZD0328 (13) 
treatment, with doses titrated down to 0.0016 and 0.00048 mg/kg from a cognitively 
impairing dose of 0.48mg/kg and provided a sustained enhancement of working 
memory for one month or more following acute treatment.
112
 A Phase I, randomised, 
double-blind, placebo controlled clinical study was recently commenced to assess the 
safety, tolerability, pharmacokinetics and pharmacodynamics of AZD0328 (13). 
Whilst AZD0328 (13) displayed favourable pharmacokinetics and the only 
unfavourable side effect was gastrointestinal effects in half of patients receiving 
treatment, it failed to show any clinically relevant treatment related changes, effect 
on cognition or trends in vital signs, laboratory, ECG variables or Spielberger strate-
trait anxiety inventory values. Therefore AZD0328 (13) was withdrawn from the 
clinic. 
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Figure 11.  α7 receptor agonists for AD. 
Researchers at Bayer have identified N-[3R-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-
(methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF, 14, Figure 11) as a 
selective agonist for the α7 receptor (Ki = 62 nM) that did not show agonist activity at 
the other nAChR subtypes. ABBF (14) acted as an antagonist of the 5-HT3 receptor 
(Ki = 60 nM) and at higher concentrations at the α3β4, α4β2 and muscle type 
nAChRs.
149
 ABBF (14) demonstrated enhanced social recognition memory in rats 
(0.3–1 mg/kg, p.o) and this effect was blocked by α7 antagonist methyllycaconitine 
administration at 10 µg indicating mediation via α7 agonism.
149
 ABBF (14) also 
improved working memory of aged rats in a water maze repeated acquisition 
paradigm (1 mg/kg, p.o) and object recognition in mice (0.3–1 mg/kg, p.o). 
Additionally, rats trained to distinguish nicotine (4) (0.4 mg/kg s.c) from a vehicle, 
did not generalise to ABBF (14) (0.3–30 mg/kg, p.o) which suggests the nicotine 
indication is not mediated by α7 receptors and that selective α7 agonists do not 
possess the abusive liability of nicotine (4).
149
 The results of the ABBF (14) studies 
further support the use of α7 agonists as therapeutic agents for the cognitive deficits 
seen in AD.  
Researchers at Abbott laboratories have reported a novel biaryl diamine, 2-methyl-5-
(6-phenylpyridazin-3-yl)octahydropyrrolo[3,4-c]pyrrole (A-582941, 15, Figure 11), 
that exhibits a binding affinity for rat and human α7 receptors with a Ki of 10.8 nM 
and 16.7 nM respectively.
150,151
 15 was a selective, partial agonist of α7 receptors 
(EC50 = 4.76 µM, activity = 52%) and displayed acceptable pharmacokinetic 
properties with excellent distribution to the CNS in rodents.
151
 A-582941 (15) 
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improved cognitive performance in behavioural assays such as the monkey delayed 
matching-to-sample, rat social recognition and mouse inhibitory avoidance models, 
which respectively capture the domains of working memory, short term recognition 
memory and long term memory. In vitro and in vivo studies indicated that AB-
582941 (15) activates signalling pathways ERK1/2 and cAMP response element 
binding protein (CREB) phosphorylation, which are known to be implicated in 
cognitive functions.
151
 A-582941 (15) displayed acceptable secondary 
pharmacodynamic and tolerability profiles as assessed in various assays of 
cardiovascular, gastrointestinal and CNS functions. The pre-clinical data of 15 was 
recently reported and investigation into any potential carcinogenic effects produced 
no significant findings.
152
 Biter and co-workers recently reported that A-582941 (15) 
increased phosphorylation of the inhibitory regulating amino acid residue Ser-9 on 
glycogen synthase kinase 3β (GSK3β): a prominent kinase responsible for tau 
hyperphosphorylation in the neuropathology of taupathies such as front temporal 
dementia and AD.
153
 Increased phosphorylation of Ser-9 of GSK3β was seen in 
mouse cingulate cortex and hippocampus. This increase was not evident in α7 
receptor knockout mice. Continuous infusion of A-582941 (15) resulted in decreased 
phosphorylation of tau in hippocampal CA3 mossy fibres and spinal motoneurons 
within hypothermia-induced tau hyperphosphorylation mouse and AD transgenic 
APP/tau mouse models respectively.
153
  
Researchers at Memory Pharmaceuticals have reported N-[(3S)-1-
azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide (MEM3454, 7, Figure 11) as 
an orally active α7 agonist with high affinity at rat α7 receptors (Ki = 6 nM) and 
human recombinant 5-HT3 receptors (Ki = 2 nM). MEM3454 (7) is a partial agonist 
of α7 receptors (EC50 = 0.4 nM) and an antagonist of native guinea pig 5-HT3 
receptors. MEM3454 (7) was selective for α7 receptors over the other nicotinic 
receptor subtypes and also other CNS receptor subtypes.
154
 In various behavioural 
paradigms representative of multiple cognitive domains such as episodic, spatial, 
working, attention and executive memory function, MEM3454 (7) has demonstrated 
efficiency in young and aged rodents as well as non-human primates.
155
 Currently 
MEM3454 (7) is under development for the treatment of AD cognitive impairment; a 
Phase IIa trial has evaluated varying doses of MEM3454 (7) in 80 patients with mild 
to moderate AD.
156
 Significant improvements were seen in the two lower doses (5 
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and 15 mg/daily) with the only adverse effect being constipation. A second Phase II 
trial was initiated in April 2009 to examine the safety and efficacy of 4 varying doses 
of MEM3454 (7) as an adjunct therapy to donepezil (5 or 15 mg/daily) in patients 
suffering mild to moderate AD. Unfortunately the study was discontinued with no 
reason given in the report.  
Agonists of α7 have been identified as promising therapeutics for the treatment of 
schizophrenia and AD, and many ligands have successfully entered clinical trials. 
Unfortunately, due to unfavourable side effects and pharmacokinetic issues, the 
majority of these studies have been discontinued. The known α7 ligands currently 
and previously in clinical trials display relatively little structural diversity, having 
been developed through lead optimization of few, common chemotypes. 
Consequently, most of them possess the same cross-reactivity profiles with other 
sites and similar unwanted side effects. Whilst these leads have provided valuable 
SAR data and have assisted in redefining the α7 pharmacophore models, there is a 
strong demand for structurally diverse α7 receptor agonists with more desirable drug-
like properties and improved cross-reactivity profiles for research in this field to 
continue successfully. 
 The α7 receptor pharmacophore 1.7
Pharmacophoric models of α7 receptors began with the initial description by Beers 
and Reich
157
 that specifies that the binding of nicotinic agents to the receptor is 
mediated by two key pharmacophoric elements: a coulombic interaction involving 
the alkylammonium moiety; and a hydrogen bond with an acceptor group 
approximately 5.9 Å from the centre of the positive charge (Figure 12).  
 
Figure 12 . Classic ammonium cationic recognition motif for α7 receptors.  
This model reflects the endogenous agonist ACh (1) where the desirable distance is 
reached if the carbonyl oxygen serves as the H-bond acceptor. This structural pattern 
is also evident in a range of molecules with varying rigidities that are active as either 
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agonists or antagonists. The alkaloid cystisine (16) is a rigid molecule of equipotency 
to nicotine (4) and contains a fused ring system which reduces conformational 
flexibility (Figure 13). In the chair conformation, the positive charge formed by 
amine protonation is located approximately 5.9 Å from the proposed H-bond 
acceptor site on the amide oxygen (Figure 13).
157
 The prototypical agonist nicotine 
(4) has more conformational flexibility than cystisine (16), however, possible 
conformations are restricted by steric interactions between hydrogens on the 
pyrrolidine and pyridine rings. Based upon X-Ray crystal structure, NMR and dipole 
moment data
158
; the most likely conformation positions the positive charge 5.9 Å 
from the centre of the van der Waals surface of the pyridine nitrogen.
157
 The capacity 
of structurally distinct agonists nicotine (4), ACh (4) and cystisine (16) to all possess 
the desired spatial requirements to successfully activate the α7 receptor highlight the 
structural diversity possible for ligands at the α7 receptor. The vast range of ligands 
having the ability to activate this receptor has resulted in several expansions of the 
initial pharmacophoric model. 
 
Figure 13. Agonists at α7  receptors.  
Quinuclidine (QN, 17, Figure 14) is a full agonist of α7 receptors and a partial 
agonist of α3β4 receptors with an efficacy of 46% that of ACh (1) at α7 receptors and 
is a key motif seen in numerous selective agonists.
159
 QN (17) is of similar size to 
selective α7 agonists tropane (18) and DMP (19) (Figure 14) and their overlay shows 
a close alignment of the nitrogen (protonated at physiological pH) and hydrophobic 
elements.  
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Figure 14. Agonists at α7  receptors and structural overlays. 
The overlay of tropane (18) and QN (17) highlight the absence of a single methyl 
group and sparked further structural exploration of the non-selective agonist QN (17) 
(Figure 14). 
 Three unique but simple modifications of QN (17), as summarised in Figure 15, 
resulted in increased selectivity for α7 receptors and were consequently used in 
further defining pharmacophoric models.
160
 Methylation of the quinuclidine nitrogen 
to give methylquinuclidine (MQN, 20) resulted in a selective α7 receptor agonist of 
lower potency. However, all activity at α3β4 receptors was lost. Addition of an extra 
oxygen to give quinuclidinone (QN-O, 21) or quinuclidinol (QN-OH, 22) also 
resulted in a loss of activity at α3β4 receptors and reduced efficacy at α7 receptors as 
compared to QN (17). The orientation of these polar groups from the amine 
correlates with the distance between the charged nitrogen and hydroxyl group in 
choline.
160
 Whilst addition of a single methylene unit was sufficient to enhance α7 
selectivity for QN (17), larger hydrophobic groups are also tolerated in α7 agonists 
and result in enhanced potency and efficacy.
161
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Figure 15. Modifications of QN (17).  
The incorporation of benzylidene groups into nonselective agonist anabaseine gives 
the α7 selectivity of GTS-21 (5) (Figure 16) and other related compounds.
161
 A series 
of benzylidene quinuclidines containing either an unsubstituted benzene group or 
with a para-methoxy substituted benzene group were made with both the (E) and (Z) 
configurations (Figure 16).  
 
Figure 16. Conjugation of quinuclidine. 
Benzylidene quinuclidines with the (E) configuration (23 and 24), although less 
efficacious than QN (17) and MQN (20) were relatively potent and selective agonists 
of α7 receptors. Efficacy was reduced for compounds containing the (Z) configuration 
(25 and 26) and these compoundsalso activated α3β4 receptors.
160
 These findings 
resulted in the development of three different structural models for selective α7 
activation, generated by overlaying α7 agonist series and detecting the shared 
disposition of like atom types. Derived from prototypical drugs sharing these motifs 
they are named as the choline motif, the tropane motif and the benzylidene motif and 
are summarised in Figure 17 where the original two point motif of Beers and 
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Reich
157
 is also shown for emphasis of the geometrical context of the various models 
(Figure 17). 
 
Figure 17 . Pharmacophore models of α7 receptors leading to selectivity. Three key 
recognition motifs are superimposed on an arbitrary Cartesian frame of reference illustrating spatial 
relationships between the motifs. Red signifies the universal ammonium (cationic) recognition motif 
for α7 receptors. Blue defines the tropane motif which recognises small aliphatic groups. Green 
represents the choline motif, a putative hydrogen bond acceptor. Orange represents the benzylidene 
motif, an extended region accommodating planar aromatic moieties.  
The choline motif is defined by incorporation of an oxygen-containing polar group 
such as hydroxyl or carbonyl moieties, separated from the charged nitrogen by a 
distance of approximately 3.4 Å (or two carbon atoms). The tropane motif involves 
recognition of hydrophobic groups in a specific geometric orientation around the 
classic ammonium pharmacophore. The improved α7 selectivity previously seen upon 
addition of a methyl group supports the tropane motif and suggests other small 
selective agonists such as DMP (19) use this motif. This view is further confirmed by 
molecular overlays of QN (17) and tropane (18). The benzylidene motif is similarly 
defined by recognition of a hydrophobic group in a spatially different orientation to 
the tropane site. The recognition site for this motif ranges from 7 to 10 Å from the 
charged nitrogen for all agonists. This distance is based upon the distance from the 
charged nitrogen to the end of the aromatic ring for agonists anabaseine, and BQNE 
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(23). As substituents on the aromatic ring can modulate agonist activity, the receptor 
pocket which recognises the benzylidene motif is thought to include residues which 
provide recognition as well and discrimination of aromatic ring systems.  
1.7.1 Pharmacophoric elements of selective α7 agonists.  
Though certain features are defined to be common to all α7 agonists, the diversity and 
range of ligands for this receptor is vast. Generally, drugs in current development 
contain a cationic centre, a hydrogen bond acceptor and one or more hydrophobic 
elements. In terms of the cationic centre, the quinuclidine scaffold is by far the most 
common. The basic nitrogen occupies a bridgehead position within the azabicyclic 
system and provides optimal electrostatic interaction with negligible steric demand. 
The strong basicity of quinuclidine derivatives (pKa ~ 10-11) results in α7 ligands 
residing in the cationic form under physiological conditions. Numerous azabicyclic 
moieties have been described in the patent literature
162-166
 and are summarised in 
Table 3; some of these require multi-step syntheses and incorporate stereogenic 
centres. The azabicyclic system not only affords the cationic centre but also forms a 
spacer, comprising two or three carbon atoms between the protonated nitrogen and 
the hydrogen bond acceptor or hydrophobic fragment.
167
 Ligands of α7 containing an 
azacyclic cationic centre such as pyrrolidine display much lower affinities.
168
  
Table 3.  Cationic centre moieties commonly seen in α 7 agonists (nitrogens protonated 
at physiological pH).  
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The hydrogen bond acceptor moieties commonly present in α7 ligands are 
summarised in Table 4 and are usually oxygen-containing. Comparative binding 
studies of a series of ligands containing either a carbamate, urea, amide or 
sulphonamide hydrogen bond accepting group reveal minimal differences between 
the carbamate, urea and amide containing ligands and suggest a putative interaction 
between the carbonyl moiety and the receptor. The bulky sulphonamide group 
impedes approach to the binding site and thus diminishes activity.
169
 Transformation 
studies of the carbamate group of AR-R17779 (27, Figure 18) to the corresponding 
carbonate, reversed carbamate, lactone, lactam or urea, gave compounds which 
ranged from having moderate affinity (560 µM) to being completely inactive. 
Methylation of the carbamate contained within AR-R17779 (27) decreases binding at 
α7 and results in a non-selective ligand of equal affinity towards both α7 and α4β2 
receptors.
170
 Linear oxygen linkers are more amenable to adjustment and give rise to 
a diverse range of α7 ligands in which the distance between the quinuclidine and 
hydrophobic part of the ligand is optimal with a two atom spacer.
171
  
Table 4.  Hydrogen bond acceptor moieties commonly seen in α 7 agonists.  
   
   
  
 
  
 
 
The incorporation of a hydrophobic unit attached either directly to the cationic 
nitrogen or via a hydrogen bond acceptor, is known to enhance the binding of α7 
ligands. Although N-methylation of carbamate AR-R17779 (27) resulted in loss of 
Chapter 1 Introduction 
 
37 
 
affinity and selectivity, substitution with a 5-bromothiophene ring produced a 
compound with enhanced affinity (Ki = 4 nM).
172
 There was a distinct preference for 
the (R) configured spirocentre.
172
 Extension of the hydrophobic portion of AR-
R17779 (27) to give more lipophilic analogues maintains selectivity at α7 and shows 
a substantial improvement in affinity.
170
 Distribution of electron density in the 
hydrophobic part of α7 ligands is necessary for π-interactions in the binding site. 
Optimisation is achieved via two methods: variation of aromatic ring substituents; or 
positional alteration of the heteroatoms within the aromatic ring systems.
167
 This is 
highlighted in Table 5 which describes the common hydrophobic motifs seen in α7 
ligands.  
Table 5 . Common hydrophobic elements seen in α 7  agonists.  
    
 
 
 
 
   
 
  
  
 
Generally, the aromatic or heteroaromatic ring is conjugated with the hydrogen bond 
acceptor, however, some examples exist in which the pharmacophoric elements are 
bridged via one or more sp
3
 hybridised carbon atoms.
171
 Few ligands exist where the 
cationic fragment is attached directly to a heteroaromatic hydrophobic system. The 
nitrogen or oxygen heteroatom is thought to interact with the receptor as a hydrogen 
bond acceptor. Incorporation of a terminal hydrogen bond donor group such as 
hydroxyl, amino, carboxyl or urea at the appropriate position on the hydrophobic 
portion of the ligand can result in enhanced affinity.
167
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1.7.2 Ligands at α7 receptors 
As there is not one single defined pharmacophore for the α7 receptor, multiple 
structural classes of agonists have been reported. Structural families commonly 
characterised in the literature are shown in Figure 18. and represent the elaboration 
of the most basic cationic centre, tetramethylammonium (TMA 28).
160
 
 
Figure 18. Ligands at the α7 receptor  
Of the quinuclidine-like compounds, ABBF (14) is a putative, full agonist of human 
α7 receptors (EC50 = 3 µM) and an antagonist for other nAChRs (IC50 values of 1–8 
µM).
149
 AR-R17779 (27) is a full agonist of α7 receptors with negligible agonist or 
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antagonist activity for other receptors tested.
173
 Compounds (29), (30) and (31) were 
all reported as high affinity agonists of α7 receptors, where binding data supports 
their selectivity.
172,174,171
 JN-403 (32) was reported to be a potent, partial agonist of 
α7 in Xenopus laevis oocytes with an efficacy of 50% that of ACh (1) and is an 
antagonist of 5-HT3 and other nAChRs evaluated.
175
 PHA-543613 (8) and PNU-
709829 (33) were both reported as selective agonist of α7 receptors with minimal 
activity at α3β4 and muscle type nAChRs.
176
 SSR-180711 (12) and TC-1698 (34) 
were reported to be potent partial and full agonists respectively.
119,177
 Tilorone (35), 
the only linear amine of the series is a partial agonist of α7 receptors with minimal 
activation of other nAChRS. Antagonist activity was detected at α4β2 and more 
potently at α3β4 nAChRs.
178
  
The dimethyl piperidinium salt (19) and the pyrrolidine derived A-844606 (36) are 
both partial but selective agonists of α7 with antagonist activity at α3β4 and 5-HT3 
receptors.
178,179
 In common with the other benzylidene anabaseines, benzylidene 
anabaseine based 37 and cinnamylidene anabaseine (38) are both α7 selective partial 
agonists and are effective antagonists at other nAChR subtypes.
180-184
 Nicotine 
derived ACME (39) and S24795 (40) were both reported as partial agonists of α7 
receptors, their selectivity must be confirmed.
185,186
 Tropane derived compounds 
include cocaine methiodide (41), tropinone (42) and tropisetron (43). Cocaine 
methiodide (41), unlike cocaine itself, is a selective activator of rat, human and chick 
α7 receptors expressed in oocytes and a weak antagonist at other nAChR subtypes 
studies.
187
 Like tropane (18), tropinone (42) and tropisetron (43) are both partial 
agonists of α7 with 64% and 30% efficacy respectively compared to ACh (1) 
(Tropane 18 itself has an efficacy of 25%). Both compounds show antagonist activity 
of 5-HT3 and α3β4 receptors.
179,188
  
 The Discovery of SEN12333  1.8
Through the course of high throughput screening as part of a multi-disciplinary 
treatment approach to schizophrenia and AD, researchers at Siena Biotech have 
identified N-4-[4-(2,4-dimethoxyphenyl-piperazin-1-yl]butyl-4-pyridin-2-
ylbenzamide (44, Figure 19) as a weak, partial agonist of the α7 receptor (EC50 = 2.8 
µM).
189
 From this initial hit, research was focused on the development of a new 
series, of molecules with enhanced potency and more favourable drug-like 
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properties. Efforts were made to reduce the number of rotatable bonds, molecular 
weight and the relatively high number of hydrogen bond acceptors which could 
influence the polar surface area of the molecular and hamper its ability to permeate 
the brain. Brief SAR, exploration including removal of the arylpiperazine moiety and 
reversal of the amide bond, resulted in the development of SEN12333 (45, Figure 
19) which was identified as a full agonist of the α7 receptor (EC50 = 1.6 µM). Further 
in vitro characterisation revealed its selectivity for the α7 receptor over a panel of 
other nicotinic (α3β4, α4β2 and α1) and highly homogenous receptors (5-HT3).
189
 This 
was further confirmed in a panel of over 70 binding sites, which encompassed the 
major classes of neurotransmitters, growth factor and peptide receptors; no 
significant activity was detected at compound concentrations of 10 µM. SEN12333 
(45) exhibited minimal hERG inhibition and also possessed favourable drug-like 
properties including desirable molecular weight, log P, polar surface area and a 
favourable number of rotatable bonds. In vivo SEN12333 (45) treatment (3 mg/kg 
i.p) led to an improvement in episodic memory in novel object recognition tasks in 
rats subjected to conditions of spontaneous forgetting and cognitive disruptions. 
SEN12333 (45) displayed the ability to attenuate these pharmacologically induced 
deficits via either the glutamatergic or cholinergic system, reversing deficits induced 
by either MK-801 or scopolamine respectively.
190
 These improvements were blocked 
by the α7 receptor antagonist MLA. SEN1233 (45) also prevented a scopolamine-
induced deficit in a passive avoidance task and was shown to normalise the 
apomorphine-induced deficit of prepulse inhibition (PPI), highlighting its 
effectiveness for the treatment of the cognitive domains attention and perceptual 
processing. Neuroprotection of SEN12333 (45) was demonstrated in quisqualate-
lesioned animals where upon treatment (3mg/kg/day i.p) with SEN12333 (45) which 
led to a significant protection of choline acetyltransferase-positive neurons in the 
lesioned hemisphere.  
In combination, these findings highlight pro-cognitive effects of SEN12333 (45) and 
support its potential use in the treatment of the neurodegenerative and psychiatric 
disorders schizophrenia and AD. These results are enhanced further by its excellent 
brain penetrability and favourable pharmacokinetic profile. Of particular interest was 
the observation that SEN12333 (45) did not correspond to any of the previously 
described pharmacophores of α7 receptors and represented a novel agonist structural 
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class. This is of particular importance as it can potentially avoid off-target binding 
and exhibit a reduction in side effects which are common to other, known classes. 
 
Figure 19.  Structure of 44  and SEN12333 (45).  
 Aims of the present project  1.9
As previously discussed in Section 8, SEN12333 (45) represents a novel scaffold 
with affinity at α7 receptors and negligible off-target CNS affinity. Following 
subjection to various functional and behavioural paradigms, SEN12333 (45) presents 
promising results as an AD and schizophrenia therapeutic with potential for 
optimisation and clinical development.  
From the structure of SEN12333 (45), a generalized scaffold can be deduced (Figure 
20) and features a basic centre, carbon chain linker, amide bond and biaryl ring 
system.  
 The first aim of this project was to systematically modify each portion of 
SEN12333 (45) with the intent of improving affinity at α7 receptors, whilst 
maintaining selectivity for this receptor.  
 The second aim of the project was to analyse all newly synthesised 
SEN12333 (45) analogues for affinity at the α7 receptor and selectivity over 
other nicotinic substypes α4β2 and α3β4. These modifications were to be 
achieved in a manner that would maintain (or improve) the desirable drug-
like properties of SEN12333 (45).  
 Accordingly, the third aim of this project was to investigate the 
physicochemical properties of all newly synthesised analogues, specifically: 
calculated 1-octanol–water partition coefficient (cLogP), polar surface area 
(PSA) and ligand lipophilicity efficiency (LLE). It was envisioned that these 
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properties would provide an indication of the efficacy of newly synthesised 
analogues in vivo.  
 The final aim of the project was to investigate the blood brain barrier (BBB) 
permeability of selected polycycles with the hope of incorporating these into 
a newly synthesised α7 ligand to enhance its concentration levels in the brain. 
The pharamacological background of the BBB and selected permeability 
agents will be discussed in Chapter 8.  
 
Figure 20 . Generalised scaffold of SEN12333 (45) . 
 
 
Chapter 2 Linker length exploration 
 
43 
 
Chapter 2 - Linker length exploration 
2.1 Introductory remarks  
High oral bioavailability is often a key concept in the development of bioactive 
molecules as therapeutic agents. The majority of drugs marketed worldwide are 
administered orally and their efficacy is therefore dependent upon oral bioavailability 
(%F). %F is defined as the amount of drug that reaches systemic circulation after 
absorption and first pass clearance, and often informs the dose of drug administered 
for therapeutic effect.
191
 Whilst our structural modifications to SEN12333 (45) were 
aimed at identification and improvement of the molecular features required for 
binding affinity and activity, we also wanted to maintain its favourable drug-like 
properties, particularly, its high oral bioavailability. Poor oral bioavailability can 
result in varied exposure to the active drug and is often the reason for drug 
candidates failing to progress from clinical trials to the market. The focus of this 
chapter was to examine the effect of structural modifications to the alkyl chain 
contained within SEN12333 (45, Figure 21); the alkyl tether imparts a large degree 
of freedom within the molecule and as will be discussed below, the number of 
rotatable bonds has significant impact upon the oral biolavailability of a molecule. 
 
Figure 21.  Carbon chain linker of SEN12333 (45).  
Structural analysis of orally administered drugs and drug candidates was pioneered 
by Lipinski and his observations are currently the main guide for correlating physical 
properties and successful drug development.
192,193
 This analysis has culminated in a 
set of guidelines which focuses on the importance of lipophilicity (octanol-water 
partition), molecular weight (MW), and the number of hydrogen bond donors and 
acceptors.
194
 In addition to the properties defined by Lipinski, other factors have 
been observed to affect oral bioavailability. Reduced molecular flexibility – as 
measured by the number of rotatable bonds and polar surface area of total hydrogen 
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bond count has been found to be an important predictor of oral bioavailability, 
independent of MW.
195
 As the number of rotatable bonds and polar surface area 
generally increase with MW, this may in part explain the importance of the 
molecular weight parameter as a predictor of oral bioavailability.
195
 Furthermore, the 
number of rotatable bonds in a molecule is directly correlated with the degree of 
conformational freedom within the molecule. The observed drug binding to a 
receptor provides a measure of the total interactions between the two entities, 
however, it provides minimal information of the three dimensional nature of their 
interactions. In conformationally flexible molecules it is known that the lowest 
energy conformation is not necessarily the biologically active form; components of 
the drug-receptor binding can be used to perturb the drug conformation.
196
 Consistent 
with this, the free energy of drug-receptor binding is defined as  
∆G = T∆Srt + nDOFEDOF + ∑nxEx 
where T∆Srt is defined as the loss of overall rotational and translational energy of the 
bound drug molecule; nDOF is the number of internal degrees of conformational 
freedom in the drug molecule; EDOF is the corresponding energy associated with the 
change in entropy resulting from the loss of each such degree of conformational 
freedom, and EX is the intrinsic binding energy associated with functional group X of 
which there are nx present in the drug.
196
 This equation was applied to over 200 
molecules to give their change in free energies of binding. The analysis of this study 
relating binding annd conformational freedom has revealed a negative correlation for 
the term relating to the number of degrees of internal rotational freedom. 
Additionally, the group of molecules that were deemed a poor fit to their binding site 
generally included larger molecules with several degrees of conformational freedom 
and numerous polar groups. In accordance with this, the potent dihydrofolate 
reductase (DHFR) inhibitor methotrexate (46, Figure 22) was calculated to have an 
extremely weak receptor match and a calculated binding energy which did not 
correlate with its dissociation constant, implying that not all of the functional groups 
in methotrexate are contributing to binding.
196
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Figure 22.  Structure of methotrexate (46).  
Based on potential energy calculations, X-ray structures and synthetic studies, the 
bound form of methotrexate (46) is thought to be a high energy conformation where 
a portion of the binding energy is sacrificed to achieve the appropriate 
conformation.
197,198
 In combination, these findings indicate that excessive 
conformational freedom within a molecule and a high number of rotatable bonds can 
not only result in decreased oral bioavailability, but it can also lead to an undesirable 
drug-receptor match, with the active form of a drug potentially being in a high 
energy conformation.  
Previous work by Zanaletti and co-workers on the α7 selective agonist (47, Figure 
23) (which bears structural similarities to SEN12333 (45)), has focused upon 
exploration of the carbon chain linker to determine the most favourable distance 
between the two key pharmacophoric elements: the basic centre, and the amide 
group.
199
 Results from their studies have revealed that the basic N-homopiperazine 
centre of 47 participates in the known interaction with the backbone carbonyl of 
residue Trp143, and the amide-pyrazole motif participates in key interactions with 
residue Tyr185. The carbon chain linker acts as a spacer to tether these two groups 
and is expected to play a key role in biological activity.  
 
Figure 23 . Structure of agonist 47 .  
Previous work describes the synthesis of analogues of 47 with varying alkyl chain 
lengths ranging from n = 1 to n = 4 (48–50, as shown in Table 6). A reduction in two 
methylene units as in derivative 48 results in reduced activity. The required distance 
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between the basic nitrogen and amide-pyrazole system is not achieved, therefore the 
key interactions with the receptor are not formed. Reduction and elongation of the 
linker by a single methylene unit resulted in compounds 49 and 50 respectively, both 
of which displayed comparable activity to 47. Compound 49 was selected as the lead 
for further structure-activity investigations based on the fact that a high molecular 
weight and high number of rotatable bonds can unfavorably affect brain penetration 
and oral bioavailability.
199,200
  
Table 6.  Effect of alkyl chain modification of 47  on α7 activity.  
 
compound n ClogP MW 
Rotatable 
bonds 
α7 pEC50 ± 
SEM (n)
a
 
47 3 1.9 413.5 8 
6.90 ± 0.02 
(28) 
48 1 1.7 385.5 6 
5.07 ± 0.11 
(2) 
49 2 1.4 399.5 7 
6.04 ± 0.04 
(2) 
50 4 2.4 427.5 9 
5.92 ± 0.11 
(2) 
a
 All functional activities measured in a calcium flux assay and data reported is averaged from 
multiple experiments (n).  
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2.2 Alkyl chain analogues of SEN12333 (45) 
Similar to compound 47, the butyl chain of SEN12333 (45) tethers the morpholine 
and pyridylanilide groups and little is known about the desired spatial orientation of 
the two pharmacophoric units. The butyl chain also increases the number of rotatable 
bonds within the molecule and allows for a large degree of conformational freedom. 
To determine the most favourable distance between the morpholine and 
pyridylanilide groups of 45, the synthesis of analogues containing either contracted 
(51–53) or elongated (54) alkyl chain linkers were proposed. We also sought to 
potentially reduce the number of rotatable bonds and degree of conformational 
freedom within 45, and in turn, gain greater insight into the mode of binding at α7 
receptors. In accordance with this, a hexyl chain analogue (n = 6) was not 
investigated as it would introduce additional rotatable bonds and degrees of 
conformational freedom. 
 
Figure 24.  Proposed alkyl chain analogues.  
2.2.1 Molecular Modelling  
Molecular modelling was first undertaken to predict the possible variations in the 
binding modes of ligands 51–54 and 45. A homology model of the α7 receptor was 
generated by using the ‘Prime’ suite in Maestro.201 As described in Section 5 the 
AChBP is a soluble protein found in the snail Lymanaea stagnalis
202
, produced and 
stored in glial cells and released in an ACh-dependent manner into the synaptic cleft, 
where it modulates synaptic transmission.
61
 The mature AChBP is 210 residues long 
and forms a stable homopentamer, aligning with the N-terminal domains of 
penetameric ligand gated ion channels and lacking the transmembrane and 
intracellular domains present in the superfamily.
202
 The AChBP is known to be 
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related to the α-subunit of nAChRs with the majority of residues conserved within 
the nAChR family being present within the AChBP, including those important for 
ligand binding.
61
 The L. stagnalis AChBP also has pharmacological properties 
similar to that of α7 receptors with relatively weak affinity for ACh (1) with an 
approximately ten fold higher affinity for nicotine (4)
203
 and an affinity for the 
competitive antagonists d-tubocurarine and α-BXT.202 The crystal structure of the 
AChBP from L. stagnalis (PDB Code: IUW6) was therefore selected for use in 
generating a template for the model.
61,57
  
The sequence of the α7 receptor (accession code: AAA83567) as obtained from the 
national centre for biotechnology information (NCBI) was aligned on the template. 
The five subunits of the α7 receptor were individually generated and merged to form 
an α7 receptor pentameric model. The OPLS_2005 all-atom force field was used for 
energy scoring of the protein and surface generalised born (SGB) continuum 
solvation model for treating solvation energies and effects.
204
 Preparation of the 
predicted model for docking was then completed with the protein preparation wizard 
and included the addition of hydrogens, assignment of bond orders and creation of 
disulphide bonds. The corrected structure was then optimised through restrained 
minimisation using ‘impref minimisation’ by selecting hydrogens only so that heavy 
atoms remained untouched. The docking studies were then completed using the 
‘Glide’ software as provided in Maestro.205 A docking model was generated by 
formation of a receptor grid around nicotine (4) (which was also the ligand from the 
template provided in the model) as a reference for the active site between two 
adjacent α7 monomers. Minimisation of the ligands under study was completed using 
OPLS_2005 forcefield using water as the solvent and ‘constant dielectric’ as 
electrostatic treatment, in the Maco-model module of Maestro. The ligands were then 
protonated at pH 7.4 and were ready to be docked flexibly into the active site using 
extra-precision (XP) mode.
206
  
Three known ligands with agonist activity at α7 receptors: AR-R17779 (27), ACh (1) 
and nicotine (4) were first docked into the model in order to understand the ligand-
receptor interactions. All three ligands interacted comparably with the receptor as 
shown in Figure 25. The protonated nitrogen of these ligands was found to form 
cation-π interactions with one of the five aromatic amino acids which comprise the 
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wall of the hydrophobic pocket (Chain A: Trp77 and Chain B: Tyr115, Trp171, 
Tyr210 and Tyr217). The other important common interaction was that all 
compounds form a hydrogen bond with the hydroxyl group of Ser172 (Chain B). 
Agonist activity appears to be contingent upon these two interactions.  
 
Figure 25.  AR-R17779 (27), acetylcholine (1), and nicotine (4) docked into the active 
site of the α7 receptor model. Hydrogen bonding with Ser172 is also shown. Image drawn using 
ICM browser. 
Compounds 45 and 51–54 were then docked into the α7 receptor active site to predict 
the effect of chain length variation of α7 receptor activity. The five ligands were 
shown to dock in a similar fashion, with the exception of 54 (n = 5) which docked in 
an alternative orientation in order to accommodate the elongated chain. The results 
are shown in Figure 26.  
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Figure 26.  Compounds 45  and 51–54  docked into the active site of the α 7  receptor 
model. Hydrogen bonding with  Gln139 is also shown. Image drawn using ICM 
browser.  
The docking poses and the XP docking summary
206
 is summarised in Table 7 and 
shows all ligands except 51 (n = 1) to form cation-π interactions with the receptor. 
All ligands except 54 (n = 5) form a hydrogen bond with Gln139, and none interact 
with Ser172.  
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Table 7.  Summary of XP
206
 docking results for ligands 45  and 51–54 .  
XP Term 
a
 
Compound 
51 52 53 45 54 
GScore -0.67 -6.35 -8.98 -10.59 -11.13 
Lipophilic 
EvdW 
-2.65 -3.56 -3.16 -3.88 -4.93 
PhobEn 0 0 -1.93 -2.15 -1.72 
HBond -1.12 -0.99 -1.1 -0.80 0 
Electro -0.57 -0.75 -0.69 -0.65 -0.51 
Sitemap -0.14 -0.05 -0.16 -0.01 -0.18 
PiCat 0 -2.26 -1.52 -2.36 -1.99 
LowMW -0.50 -0.41 -0.46 -0.37 -0.32 
Penalties 5.96 3.21 1.62 1.14 0 
RotPenal 0.35 0.45 0.41 0.49 0.52 
a
Description of XP terms. GScore: total Glide score; LipophilicEvdW: ChemScore lipophilic pair 
term and fraction of the total protein-ligand vdW energy; PhobEn: Hydrophobic enclosure reward; 
HBond: ChemScore H-bond pair term; Electro: Electrostatic rewards; Sitemap: Sitemap 
ligand/receptor non-H-bonding polar/hydrophobic and hydrophobic/hydrophilic complementarity 
terms; PiCat: Reward for cat-π interactions; LowMW: Reward for ligands with low molecular 
weight; Penalties: Polar atom burial and desolvation penalties, and penalty for intra-ligand contacts; 
RotPenal: Rotatable bond penalty. 
 
The docking results predict an increase in activity within this series when chain 
length is increased from n = 4 (45, SEN12333) to 5 (54) methylene units, as 
indicated by the increase in G-score from -10.59 to -11.13. Compound 51 (n = 1) 
showed a relatively large, negatively contributing ‘penalty’ for polar atom burial, 
desolvation, and intra ligand contacts and returned a G-score of only -0.67 and was 
therefore predicted to be the least active. 
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2.3 Synthesis of alkyl chain analogues of SEN12333 
(45) 
To confirm the validity of the molecular modelling studies, the synthesis of 
contracted and elongated alkyl analogues (51–54) was undertaken. SEN12333 (45) 
was also synthesised for comparative purposes. The synthesis began with 
commercially available ω-bromoalkanoic acids (55–59) which range from n = 1 to n 
= 5. The acids were converted into their corresponding acid chlorides via treatment 
with oxalyl chloride. Subsequent nucleophilic acyl substitution with 4-bromoaniline 
in the presence of triethylamine furnished anilides 60–64 in excellent yields (Scheme 
1). Alkylation of morpholine by bromoalkanes 60–64 was then achieved under 
Finkelstein conditions with triethylamine as a base to give compounds 65–69 in good 
yields.  
 
Scheme 1. Synthesis of compounds 45 and 51–54.  Reagents and conditions: (a) (COCl)2, rt, 45 min; 
(b) 4-Bromoaniline, NEt3, CH2Cl2, –78 °C to rt, 4 h, yield over 2 steps; (c) Morpholine, NaI, NEt3, 
DMF, reflux, 16 h, 64-85%; (d) Pd[(PPh3)4], pyridine-3-boronic acid, MeCN-sat. aq. Na2CO3 (1:1), 
reflux, 18 h, 67–83%. 
The final step in the synthesis involved the palladium-catalysed Suzuki coupling of 
bromoarenes (65–69) with 3-pyridylboronic acid. The Suzuki reaction is the most 
commonly used palladium catalysed cross coupling in the pharmaceutical industry 
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and constitutes 22% of all C-C bond constructions.
207
 The first observed Suzuki 
coupling to prepare biaryls is shown in Scheme 2.
208
 
 
Scheme 2.  The first reported biaryl Suzuki coupling.  
Since then, various modifications have been realised for the reaction conditions, 
however, a combination of Pd[(PPh3)4] or Pd[Cl2(PPh3)2] and aqueous sodium 
carbonate in 1,2-dimethoxyethane is reported to be satisfactory for most reactions.
209
 
The use of other bases such as triethylamine, sodium hydrogen carbonate, caesium 
carbonate, thallium(I) carbonate and potassium phosphate are tolerated and the 
reaction is reported to be most successful for aryltriflates and iodo- and bromo- 
arenes.
210-212
 Phosphine based palladium catalysts are generally used due to their 
increased stability upon prolonged heating and the reaction is reported to be 
unaffected by the presence of water, tolerate a broad range of functionalities 
including alkyls, alkenyls and alkynyls and yield non-toxic by products.
213,214
  
The reaction mechanism of the Suzuki coupling is depicted in Figure 27 and follows 
the general catalytic cycle for the cross-coupling reaction of organometallics. The 
first step of the palladium cycle involves the oxidative addition of the active 
palladium species Pd(0), to the aryl halide (Ar-X). This Pd(0) species is produced via 
in situ reduction in the case of Pd[Cl2(PPh3)2], Reaction with base gives the Ar-
Pd(II)-OH species which then undergoes transmetallation with the boronate 
intermediate, the more active form of the coupling partners. The excess base is 
exchanged with the Ar′ substituent on the organo boron species to give the palladium 
complex Ar′-Pd(II)-Ar. The final step involves reductive elimination of the coupled 
biaryl product Ar′-Ar and regeneration of the active Pd(0) catalyst completing the 
catalytic cycle.  
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Figure 27.  Catalytic cycle of the Suzuki reaction.  
For the Suzuki coupling of bromoarenes 65–69, Pd[(PPh3)4] was synthesised from 
Pd(II)Cl2 according to the conditions described by Coulsen and co-workers 
(Scheme 3).
215
 
 
Scheme 3.  Synthesis of Pd[(PPh3)4]. Reagents and conditions: (a) (i) DMSO, reflux 4 h (ii) 
NH2NH2•H2O 98%. 
Bromoarenes 65–69 were then subjected to the Suzuki coupling conditions 
previously shown in Scheme 1 and gave the coupled ligands 51–54 and 45 in varied 
but generally good yields.  
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2.4 Binding affinities of ligands 45 and 51–54.  
To further confirm the validity of the modelling, 45 and 51–54 were subjected to 
competition binding assays against racemic [
3
H]±epibatidine (EB) according to the 
conditions described in Section 11.9.1. To confirm selectivity for the α7 subtype 
binding assays were performed not only on cells expressing the α7 receptor subtype 
but also those expressing the α4β2 and α3β4 nAChR subtypes. All in vitro studies were 
conducted by collaborators at the Department of Pharmacology and Physiology, 
Georgetown University School of Medicine, Washington DC.  
The binding affinities of these analogues are shown in Table 8. Compounds 45, 51–
54 displayed Ki values ranging from 0.50 µM to greater than 10 µM. The difference 
of more than two orders of magnitude was in contradiction to the prediction of the 
docking studies. The highest binding affinity was exhibited by SEN12333 (45) (Ki = 
0.50 µM). Elongation of the alkyl tether of 45 by a single methylene unit (54) 
resulted in more than an order of magnitude reduction in α7 binding (Ki > 10 µM) and 
contradicts the improved affinity predicted by the docking studies. Relative to 
SEN12333 (45) the corresponding ethylene- and propylene- congeners (52 and 53 
respectively) exhibited similarly diminished α7 binding (Ki > 10 µM in both cases). 
The ligand with the shortest alkyl linker (n = 1) of the series, 51, exhibited α7 affinity 
less than eight times that of 45 itself and also contradicts the results of the docking 
studies where it was predicted to have the lowest affinity of the series.
204
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Table 8 . Binding affinities and selectivies of 45  and 51–54 .  
Compound n 
Ki
a
 (µM) Physicochemical properties 
α7 α4β2 α3β4 cLogP
b 
PSA
b 
LLE
c 
51 1 
3.9 ± 
1.5 
>10 >10 1.85 53.93 3.52 
52 2 >10 >10 >10 2.04 53.93 ND
d 
53 3 >10 >10 >10 2.28 53.93 ND
d 
45 4 
0.5 ± 
0.03 
>10 >10 2.25 53.93 4.05 
54 5 >10 >10 >10 2.78 53.93 ND
d 
a
Ki values represent the mean ± SEM of three independent experiments. 
b
 Calculated using 
ChemDraw12.0 
c
 calculated according to equation LLE = pIC50 (or pKi) – cLogP. 
Table 8 also describes the physicochemical properties of compounds 51–54 and 45, 
namely, the cLogP, PSA and LLE. Drug lipophilicity is reportedly changing less 
over time in comparison to other physical properties, which suggests it is a key 
drug-like property.
216,217
 The success of a lead compound in drug development is 
therefore strongly influenced by its lipophilicity and in accordance with this, the role 
of LogP in influencing drug potency, pharmacokinetics and toxicity has been 
recognised for numerous years.
217
 This property largely reflects molecular 
desolvation in transfer from aqueous phases to cell membranes and to protein 
binding sites, predominantly hydrophobic in nature. Compounds with elevated 
lipophilicity run the risk of an increased likelihood of binding to multiple targets and 
subsequent pharmacologically based toxicology, as well as poor solubility and 
metabolic clearance.
217
 Lipophilic bases can potentially trigger cardiovascular 
toxicological effects through interaction with hERG channels and tissue toxicity 
through promotion of cellular phospholipidosis.
218
 cLogP Is a composite property 
dependent upon molecular size, polarity and hydrogen bonding, with larger values 
indicating high lipophilicity.
219
 Its conceptual straightforwardness and ease of 
calculation has resulted in it being the most widely used predictor of lipophilicity and 
drug-likeness.
220
 In terms of absorption and permeability, the ‘rule of five’ guidelines 
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define the optimum for cLogP to be less than 5, further to this, a cLogP value in the 
range 0–3 is considered optimal for blood brain barrier (BBB) penetration.192,194,221 
The average clogP value of marketed CNS drugs is 3.43.
222
 The PSA of a molecule 
describes the surface area belonging to polar atoms and most commonly correlating 
with nitrogen and oxygen, and including their attached hydrogens.
195
 It is a 
descriptor that has been shown to correlate with passive molecular transport through 
membranes and therefore, allows for prediction of transport properties of drugs.
195
 
Overall oral bioavailability does not depend solely on absorption but also upon 
dissolution, gut transit time and first-pass metabolism. PSA is commonly utilised in 
drug design in the optimisation of a drug’s capability to permeate cell membranes 
such as the BBB.
223
 PSA of approximately 120 Å
2
 is deemed necessary to permeate 
cell membranes and 60–70 Å2 is required to cross the BBB.224 As previously 
mentioned, the most common way to measure drug-likeness of a compound is by its 
lipophilicity. Previous analyses of the effects of lipophilicities on drug failures have 
concluded that highly lipophilic compounds convey significant risks in terms of 
development, particularly in relation to increased chances of nonspecific toxicity.
216
 
Upon examining the patent literature, it has since been noted that pharmaceutical 
companies are producing molecules with somewhat elevated cLogP values.
225
 As a 
result, the development of a novel index known as ligand lipophilicity efficiency 
(LLE) has served as an important guide in the process of lead optimisation, and also 
as a tool for the selection of preclinical candidates.
226
 LLE is defined as: 
LLE = pIC50 (or pKi) – cLogP 
A typical oral drug with cLogP of 2.5 and potency within the range of 1–10 nM 
suggests a target LLE of 5 to 7 or greater, a value >5 is considered highly optimised 
for drug discovery. The advantages of high in vivo potency are low total doses in 
humans and decreased disadventitious compound related toxicity.
216
 In essence, the 
target objective for molecular optimisation is to enhance potency without elevating 
lipophilicity.  
Whilst the newly synthesised compounds 51–54 (Table 8) all display acceptable 
cLogP and PSA values, the lack of binding affinity (pKi) for compounds 52–54 
render their LLE value inadequate. Compound 51 (n = 1) displays an optimal cLogP 
value of 1.85, however, it’s diminished binding affinity results in a LLE value of 
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only 3.52. SEN12333 (45) similarly has an optimal cLogP value (2.25) and exhibits a 
promising LLE value of 4.05, highlighting the potential for further optimisation of 
this structure and improvement of its LLE value.  
2.5 Functional activity of ligands 45 and 51–54. 
Compounds 51–54 and SEN12333 (45) were also evaluated on rat recombinant α7 
receptors expressed in Xenopus oocytes according to the conditions described in 
Section 11.9.2.  
Only SEN12333 (45) exhibited partial agonist activity, activating the receptor by 
approximately 11% compared to the maximal ACh response, with an EC50 of 9.5 µM 
(95% confidence interval 3.4-26) (Figure 28). The remaining analogues (51–61) did 
not exhibit any agonist or antagonist activity when tested at 100 µM.  
 
Figure 28.  Effect of SEN12333 (45) on rat recombinant α7 receptors expressed in 
Xenopus oocytes.  SEN12333 (45) exhibited partial agonist activity, activating the receptor by 
approximately 11% compared to the maximal ACh response. The EC50 value was 9.5 µM (95% CI 
3.4-26). Data are mean ± SEM from 4 oocytes. 
2.6 Concluding remarks  
In conclusion, four new analogues of SEN12333 (45) have been synthesised to 
explore the effects of variation of the alkyl chain. Docking studies were successfully 
carried out for all new compounds and SEN12333 (45) itself. Contraction and 
elongation of the alkyl chain in SEN12333 (45) resulted in distinct changes in α7 
affinity, and optimal binding is conferred by a 4 methylene unit linker (as found in 
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SEN12333 (45)). However, the variation of binding affinity is not predicted by 
molecular docking to a α7 receptor homology model and demonstrates the limited 
predictive utility of this model for the rational design of α7 receptor agonists. 
SEN12333 (45) is calculated as having ideal physicochemical parameters for oral 
absorption and more importantly BBB penetration. Although a 4-carbon chain 
appears to offer ideal inter-functional group distances for interaction with α7 
receptors, its binding affinity still warrants improvement. Future work will focus on 
the exploration of modification of other functional groups present within SEN12333 
(45) to address this issue. 
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Chapter 3 - Variation of the amide bond 
3.1 Introductory remarks  
The work discussed in the previous chapter focused predominantly on how variation 
in linker length of α7 agonist SEN12333 (45) influenced binding affinity and 
functional activity. The focus of this chapter is to examine the order- and isostere 
replacement of the amide functional group and to also briefly examine what effect 
the presence of the pyridine nitrogen within the biaryl system has. The 
physicochemical properties of all analogues will continue to be examined to ensure 
the favourable drug-like properties of SEN12333 (45) are maintained. The lead 
compound 44 resulting in SEN12333 (45) discovery, contains an amide bond with a 
reversed order to that of SEN12333 (45). As there is limited structure activity 
relationship data available for the amide bond of SEN12333 (45), we were interested 
in exploring if reversal of the amide bond direction was a necessity for binding and 
activity at α7 receptors.  
The transposition of amide to reverse-amide is a concept well-known to medicinal 
chemistry.
227-229
 Previous work by Glase and co-workers
230
 into the design of 
dopamine D4 receptor agonists for use in the treatment of schizophrenia and attention 
deficit hyperactivity disorder (ADHD) have identified PD16807 (70, Figure 29) as 
having agonistic activity. However, minimal stability towards acid hydrolysis was 
displayed and it was believed the amide bond linkage was the main cause. Matulenko 
and co-workers
231
 proposed a solution of reversal of the atom arrangement in the 
amide functionality based upon previous work with similar heterocyclic 
bioisosteres.
232
 The resulting anilide compound 71 (Figure 29) displayed improved 
potency at D4 receptors, maintained agonistic activity, and more importantly, 
exhibited increased stability to acid hydrolysis.
231
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Figure 29.  D4  Agonists for the treatment of schizophrenia and ADHD.  
The synthesis of analogues 72 was therefore proposed to examine the effect of amide 
bond reversal in SEN12333 (45). Analogues 73 and 74 (Figure 30) were also 
proposed to examine the presence of the pyridine nitrogen in the terminal aromatic 
ring of both amide derivatives to determine if this was required for binding and 
activity at α7 receptors.  
 
Figure 30.  Proposed analogues examining amide bond reversal and aromatic 
heterocycle presence.  
Aside from investigating the order of atom arrangement in the amide bond, 
investigations were also conducted into replacement of the amide linker with a 
tetrazole group. The selection of a tetrazole linker is based upon the knowledge that 
tetrazoles are cis-amide isosteres
233
 and it was envisioned that this would provide us 
further mechanistic detail into the binding mode of SEN12333 (45) at α7 and 
potentially reduce the number of rotatable bonds within the molecule. There are two 
regioisomeric tetrazoles to be studied (Figure 31) and it was envisioned that one 
series would be accessed from SEN12333 (45) and analogues containing this original 
amide bond connectivity (73) to give 75 and 76 respectively, whereas the other 
tetrazole series could be accessed from the related ‘reverse-amide’ bond analogues 
72 and 74 resulting in 77 and 78 respectively. Prior to the synthesis of these 
tetrazoles it is worthwhile to examine the use of tetrazole-containing molecules in 
medicinal chemistry.  
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Figure 31.  Proposed tetrazole containing analogues.  
3.2 Tetrazoles in medicinal chemistry  
The use of tetrazoles in medicinal chemistry first arose in the form of 5-substituted-
1H-tetrazoles due to them being bioisosteric with carboxylic acids in biologically 
active molecules.
234,235
 5-Substituted-1H-tetrazoles have similar pKa values to 
carboxylic acids (4.5–4.9 vs 4.2–4.4 respectively) and also retain a planar 
structure.
236
 The free N-H bond of tetrazoles renders them acidic molecules with the 
heterocycle possessing the ability to stabilise a negative charge through electron 
delocalisation.
236-238
 In accordance with this, 5-substituted tetrazoles containing a 
free N-H bond are similarly termed tetrazolic acids (Figure 32). Orbital analysis by 
Sadlej-Sosnowska have revealed the 2H tautomer to be of increased stability, 
possessing a larger portion of electron delocalisation than the 1H tautomer.
239
 Similar 
to their carboxylic acid counterparts, tetrazoles are ionised at physiological pH (7.4). 
However, the anionic tetrazole has been shown to be almost ten times more 
lipophilic than the corresponding carboxylate, an important consideration in drug 
design as molecules must be able to traverse cell membranes.
233
 Other well-known 
basic carboxylic acid surrogates include carboxamides, sulfonamides, acyl 
sulfonamides, sulfamides and phosphates, but they each lack some of the desirable 
properties displayed by tetrazoles.  
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Figure 32.  Tetrazolic acids as b ioisosteres of carboxylic acids.  
In terms of their pharmacokinetic profile, tetrazolic acids are generally known to be 
more resistant to metabolic degradation than the corresponding carboxylates. They 
are resistant to the majority of the Phase II bioconjugation pathways, which can often 
result in increased availability of a drug.
233
 However, tetrazoles containing an 
additional basic moiety can also exist as zwitterions leading to poor absorption 
properties for potential drug candidates. Furthermore, the use of tetrazole isosteres 
may have a significant impact upon binding of a molecule to a receptor. This is due 
to the distribution of charge over a greater molecular surface area complicating 
contact with the receptor. Similarly, the larger size of the heterocycle may also 
reduce the binding affinity at the active site either by less favourable orientations of 
functional groups or through steric hindrance. As a result, the use of tetrazoles as 
bioisosteres is not always conclusive or predictable. Selected case studies highlight 
these various effects.
240
  
There is accumulating evidence that 1,5-disubstituted tetrazoles are suitable 
bioisosteres for cis-amide bonds in peptidomimetics (Figure 33).
241
 Marshall and 
Zabrocki have demonstrated that peptides containing a 1,5-disubstituted tetrazole 
unit like 79 may be an effective conformational mimic for the corresponding 
peptides, which prefer to adopt a cis-amide bond conformation or which require pre-
organisation of the amide bond to act as enzyme substrates, as in 80.
242-244
 The 
importance of such a synthetic probe is evident through investigations of the role of 
peptide bond cis-trans isomerism in the geometry of molecular recognition.  
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Figure 33.  1,5-Disubstituted tetrazoles as cis-amide isosteres.  
Various synthetic and conformational studies on analogues of the peptide bradykinin, 
known to dilate blood vessels
245
, have revealed peptides containing a tetrazole in 
place of an amide bond were able to adopt a majority of the conformations available 
to the parent compound.
241-243,246 
 There exist numerous biologically active molecules containing the tetrazole 
heterocycle (Figure 34). Some of the earliest findings involved the tetrazole-derived 
nicotinic acid analogue 81 being excreted essentially unchanged after a 24 h period 
when administered to dogs. Nicotinic acid itself was rapidly metabolised and this 
example highlights the resistance of tetrazolic drug substances to metabolism leading 
to a longer duration of action, (albeit with a loss of potency in this instance).
247,248
 
Cardiazol (82) is a CNS-active analeptic studied by a number of investigators and 
forming the subject of a considerable number of patents for its use in the treatment of 
barbiturate poisoning.
249
 Losartan (83) is an angiotension II antagonist and a best-
selling drug used for the treatment of hypertension.
250,251
 Antagonist 83 represents by 
far the most successful tetrazole containing drug with annual sales in the US 
averaging US$904 million.  
 
Figure 34 . Biologically active tetrazole compounds.  
In terms of synthetic preparation, 5-substituted tetrazoles are formed by the reaction 
of nitriles and azides. The initial literature method reported in 1932 employs the 
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reaction of hydrazoic acid and organic cyanides.
252
 This process is generally thought 
to occur through a concerted 1,3-dipolar cycloaddition mechanism (Scheme 4) where 
the nitrile acts as the dipolarophile toward the azide, (which may or may not be 
hydrogen bonded to the amine source). Cycloaddition through intermediate 84 leads 
to the resonance tetrazolium anions 85 and 86, which upon protonation lead to 
tetrazolic acid 87. The toxicity of hydrazoic acid and its explosive nature are a great 
disadvantage to this procedure. To circumvent the use of hydrazoic acid, 5-
substituted tetrazoles have been synthesised by 1,3-dipolar cycloadditions between 
much less hazardous starting materials, such as nitrile ions and azides ions, namely 
sodium azide.
253
  
 
Scheme 4.  Synthesis of 5-substituted tetrazoles.  
Cycloaddition of alkylazides with nitriles or isonitriles would yield 1,5 and/or 2,5-
disubstituted tetrazoles. 1,5-Disubstituted tetrazoles can alternatively be prepared via 
nucleophilic substitution of imidoyl chlorides by azide ions (Scheme 5).  
 
Scheme 5.  Synthesis of 1,5-disubstituted tetrazoles.  
It was envisioned that tetrazole analogues 75–78 would be synthesised by conversion 
of the appropriate amide into the imidoyl chloride, and subsequent reaction with an 
azide anion. 
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3.3 Synthesis of amide and reverse-amide analogues  
Compound 73 (containing the original amide bond order) was synthesised by 
subjecting previously synthesised amide 68 to the Suzuki coupling reaction 
previously described using phenylboronic acid (Scheme 6).  
 
Scheme 6.  Synthesis of analogue 73 .  
Reagents and conditions. (a) Pd(PPh3)4, phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 
h, 68%. 
An alternative synthesis for compounds 72 and 74 containing the reversed amide 
bond order was proposed and is depicted in Scheme 7. Commercially available N-
(ω-bromobutyl)phthalimide 88 was reacted with morpholine under Finkelstein 
alkylation conditions to give amine 89 in excellent yield.  
 
Scheme 7. Synthesis of 72 and 74. Reagents and conditions: (a) Morpholine, NaI, NEt3, THF, reflux, 
16 h, 66%; (b) NH2NH2•H2O, EtOH, reflux, 1 h; (c) 4-Bromobenzoyl chloride, NEt3, CH2CH2, –78 °C 
to rt, 2 h, 64% over two steps; (d) Pd(PPh3)4, 72 = pyridine-3-boronic acid, 74 = phenylboronic acid, 
MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 72: 70%, 74: 91%. 
Successful cleavage of the phthalimide group by hydrazinolysis was achieved by 
subjecting compound 89 to refluxing ethanol in the presence of hydrazine hydrate. 
Unfortunately, low yields (<40%) of the free amine 90 were obtained after 
purification. Amine 90 was isolated as a colourless oil; and its ever-present pungent 
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odour prompted us to notice its structural similarities to putrescine (92) (Figure 35). 
Putrescine (92) is a malodorous, organic compound related to cadaverine (93). Those 
α,ω-alkyldiamines are produced by the breakdown of amino acids in living and dead 
organisims, and are known to be largely responsible for the odour of putrefying flesh. 
Putrescine (92) is known to melt at 27.5 °C and is extremely volatile.
254
 It is often 
unable to be detected in studies of human remains as a result of its volatility. Based 
on the structural similarities between putrescine (92) and amine 90 we postulated that 
our low yields were a result of its volatile nature. To circumvent this problem we 
immediately treated the crude residue of amine 90 with 4-bromobenzoyl chloride in 
the presence of triethylamine to give our desired amide 91 in a good yield of 64% 
over two steps. A Suzuki cross-coupling reaction of 91 with either pyridine-3-
boronic acid or phenylboronic acid then gave analogues 72 and 74 in good yields.  
 
Figure 35.  Structural similarities of amine  90 , putrescine (92) cadaverine (93). 
With compounds 72–73 in hand and SEN12333 (45) previously synthesised (Section 
2.2) we then focussed our attention on the conversion of these compounds into their 
corresponding tetrazoles.  
3.4 The synthesis of tetrazole analogues  
To begin with, SEN12333 (45) was treated with phosphorus pentachloride in 
dichloromethane at ambient temperature for 2 h to give what was presumed to be the 
corresponding imidoyl chloride (Scheme 8). Without isolation, addition of 
trimethylsilylazide (1.5 equiv) at 0 °C and continued stirring at ambient temperature 
for 16 h, subsequent basic workup furnished the desired tetrazole 75. Following 
chromatographic purification the overall yield was 40%. A mechanism which 
accounts for this transformation is shown in Scheme 9.  
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Scheme 8. Synthesis of 75. Reagents and conditions: (a) (i) PCl5, CH2Cl2, rt, 2 h; (ii) TMSN3, 0 °C, 
16 h, 40%. 
Vilsmeier-type activation of the amide gave the corresponding imidoyl chloride. The 
substituted imidoyl chloride then undergoes facile nucleophilic displacement with the 
azide ion to generate an imidoyl azide intermediate which then subsequently cyclises 
to give the desired 1,5-disubstituted tetrazole (Scheme 9). 
 
Scheme 9.  Mechanism of tetrazole formation.  
The synthetic procedure itself proved exceptionally robust and was adopted for the 
synthesis of the remaining tetrazoles. The protocol was applied to amides 72–73 to 
yield their corresponding tetrazoles as shown in Table 9. The reaction proceeded in 
good yield for all analogues and no differences in yield or reaction purity were seen 
when comparing tetrazole formation from anilides (45 and 73) or benzamides (72 
and 74). 
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Table 9.  Synthesis of tetrazoles 76–78 .  
Starting amide Tetrazole product Yield (%) 
 
 
71 
 
 
78 
 
 
57 
 
Crystals of SEN12333 (45) and tetrazole 75 were grown by slow recrystallization in 
CH2Cl2 and hexane and were subjected to X-Ray analysis to further predict the mode 
of binding of the amide and tetrazole analogues. The Oak Ridge Thermal Ellipsoid 
Plots (ORTEP) of SEN12333 (45) and tetrazole 75 are shown in Figure 36 and 
Figure 37 respectively. SEN12333 (45, Figure 36) has a large degree of 
conformational flexibility and it is immediately apparent that its lowest energy 
configuration state adopts a trans amide conformation to linearise the structure and 
minimise steric interactions. In contrast, the tetrazole ring present within compound 
75 locks the amide bond into a cis conformation (as illustrated in Figure 37). It is 
evident that the compound 75 resides permenantly in a bent form. If the binding 
conformation of SEN12333 (45) is similar to the low energy, trans amide 
conformation depicted in Figure 36, these studies suggest the mode of binding of 
SEN12333 (45) and tetrazole 75 to be vastly different. It was envisioned that this 
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would additionally provide greater insight into the binding mode of SEN12333 (45), 
specifically, if the amide bond was residing in either a cis or trans conformation.  
 
Figure 36.  ORTEP representation of SEN12333 (45). 
 
Figure 37.  ORTREP representation of tetrazole 75 .  
3.5 Binding affinities of amido-varied compounds  
All newly synthesised compounds and SEN12333 (45) as a reference, were then 
evaluated in competitive binding assays to determine their affinity and selectivity for 
the α7 receptor according to the conditions described in Section 11.9.1. The results 
are summarised in Table 10. All compounds were selective for the α7 subtype. 
However, a large range of affinities was evident. Removal of the pyridine nitrogen 
from reference compound 45 to give biphenyl analogue 73 resulted in a decrease in 
potency (670 vs 2300 nM). Reversal of the amide bond order of SEN12333 (45) to 
give 72 lead to a marked decrease in potency (11,000 nM), however, this decrease in 
potency was restored in reverse-amide biphenyl analogue 74 (1800 nM). These 
results suggest the original amide bond order of SEN12333 (45) is optimal and that 
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the pyridine nitrogen is not essential for binding or selectivity at α7 receptors. The 
main feature which appears to be maintaining the binding affinity within these series 
of compounds is the morpholine ring. Conversion of compounds to their 
corresponding tetrazole resulted in a loss of potency at α7 receptors with binding 
requiring concentrations over 150 µM for all tetrazole analogues. Considering the 
high concentrations required for the tetrazole series a definite determination of the 
effect of the pyridine or biphenyl compounds in this series cannot be made. In 
contrast to compounds 45 and 72–73, tetrazoles synthesised from the original amide 
bond order were of decreased potency compared to tetrazoles synthesised from 
analogues containing the reversed amide bond order (75 and 76 approximately 220 
µM vs. 77 and 78 approximately 160 µM). These findings illustrate the tetrazole 
motif is not tolerated as an amide isostere in this series of compounds. This could be 
attributed to one or a combination of the effects including the electronics of the 
tetrazole ring, increased steric bulk, or the cis conformation of the tetrazole isostere 
as illustrated in Figure 37. Additionally, these results suggests that the active binding 
conformation of SEN12333 (45) contains an amide bond in the trans configuration.  
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Table 10.  Binding affinities of newly synthesised compounds.  
Compound 
Ki (nM)* 
Physicochemical 
properties 
α7 α4β2 α3β4 cLogP
b 
PSA
b 
LLE
c 
 
670 ± 
119 
> 
10,000 
> 
10,000 
2.25 53.93 3.92 
 
2,300 ± 
1,000 
> 
10,000 
> 
10,000 
3.58 41.57 2.06 
 
11,000 
±4,000 
> 
10,000 
> 
10,000 
1.93 53.93 3.02 
 
1,800 ± 
200 
> 
10,000 
> 
10,000 
3.28 41.57 2.46 
 
216,000 DNC 
>10,00
0 
2.08 65.15 1.59 
 
236,000 DNC 
>10,00
0 
3.47 52.79 0.16 
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165,000 DNC 
>10,00
0 
2.81 65.15 0.97 
 
156,000 DNC 
>10,00
0 
4.31 52.79 -0.5 
a
 Competition curves were constructed in which 10 concentrations of a sample were included (n = 1), 
DNC = does not converge Ki values are the Mean ± SEM of three to six independent measurements. 
For low binding affinity compounds, estimated Ki value ranges were provided. 
b
 Calculated using 
ChemDraw12.0 
c
 calculated according to equation LLE = pIC50 (or pKi) – cLogP. 
In accordance with the work from Chapter 2, the physicochemical properties cLogP, 
PSA and LLE were similarly described for all newly synthesis compounds (Table 
10). All compounds display acceptable PSA values and cLogP < 5. The LLE value of 
SEN12333 (45) is somewhat diminished as compared to its value from the results in 
Chapter 2 (3.92 vs 4.05); this is a result of the slightly lower binding affinity of 
SEN12333 (45) seen in the present assay. Whilst biphenyl compound 74 displays a 
similar binding affinity to that of SEN12333 (45) (670 vs 1800 nM respectively), its 
decreased LLE value of 2.46 suggests that it may not be as successful in vivo. While 
the cLogP and PSA values of 72 and 74 are acceptable, their LLE values (3.02 and 
2.46 respectively) also suggest their limited potential in vivo. Tetrazole containing 
analogues 75–78 all display unacceptable LLE values and confirms their 
inappropriateness for use as amide isosteres for SEN12333 (45) and related 
compounds (72–73). 
3.6 Functional activity of amido-varied compounds 
at α7 receptors 
To determine their agonistic activity at α7 receptors compounds 45 and 72–78 were 
evaluated in a fluorescent calcium assay using a GH4C1 cell line expressing rat α7 
receptors and in line with the conditions described in Section 11.9.3. Unfortunately, 
aside from SEN12333 (45), only compounds 73 and 74 showed agonistic activity at 
α7 receptors (Figure 38 and Figure 39). This was to be expected given the 
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concentration range tested and the Ki values from the binding studies (Table 10). The 
EC50 of SEN12333 (45) was reported to be 0.86 µM. The biphenyl analogue 73, 
retained agonistic activity at α7 receptors with an EC50 of 1.7 µM. Reverse-amide 
biphenyl analogue 74 similarly maintained agonistic activity with an EC50 of 2.0 µM. 
These results highlight that the incorporation of the tetrazole functionality was also 
detrimental to agonistic activity at α7 receptors. 
 
Figure 38 . Dose response curve of SEN12333 (45) on rat α7 GH4C1 cells; EC5 0 = 0.86 
µM. 
.  
 
Figure 39.  Dose response curve of 73  (cb3024) and 74  (cb3070) on rat α7 GH4C1 
cells; 73 : EC50  = 1.7 µM, 74: EC50 = 2 µM. 
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3.7 Concluding remarks 
In summary, seven new analogues of SEN12333 (45) have been synthesised to 
examine the effects of amide bond order, the use of a tetrazole as an amide bond 
isostere, and the importance of the pyridine nitrogen within the biaryl system on 
compound efficacy. The original amide bond order of SEN12333 (45) was found to 
be optimal – reversal of the amide bond resulted in a significant loss of binding and 
agonistic activity at α7 receptors (45 vs 72). Biphenyl analogues of the reverse amide 
series were found to be more potent than their corresponding phenyl-pyridine 
analogues (74 vs 72) and importantly maintained agonistic activity at α7 receptors. 
Furthermore, the biphenyl motif of 74 was found to restore the potency lost in the 
reversed amide pyridine compound 72. The use of a tetrazole functionality as an 
amide bond bioisostere resulted in a dramatic loss of potency and a complete loss of 
agonist activity for all types of analogues. The most potent compound of the series 
was still SEN12333 (45), Ki = 670 nM). This amide bond order appears to be optimal 
for binding and activity at α7 receptors. The results of the present chapter relating to 
amide bond order and the effect of the pyridine nitrogen within the biaryl ring system 
are inconclusive and do not reveal a distinct trend. It appears that the morpholine ring 
is the most important factor within this series of compounds for maintaining affinity 
at α7 receptors. Therefore, future investigations will examine alteration of the 
morpholine ring and also continue to simultaneously explore the effect of amide 
bond order and importance of the pyridine nitrogen.  
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Chapter 4 - The heterocyclic ring 
4.1 Introductory remarks 
The work outlined in the previous chapter focussed on how changes to the amide 
bond and biaryl ring system of lead compound SEN12333 (45) influenced binding 
affinity and functional activity of the compounds. This was achieved by altering the 
order of amide bond connectivity and synthesising the tetrazole derivatives of these 
compounds. The importance of presence of the pyridine was simultaneously 
investigated. The focus of this chapter involves alteration to the aliphatic 
heterocyclic morpholine ring (the basic centre, Figure 40) and the resulting affect on 
binding affinity, selectivity and drug-like properties. In addition to exploring the 
basic centre, we decided to simultaneously continue our explorations from Chapter 3. 
As the results from Chapter 3 were inconclusive and did not reveal a clear trend we 
sought to determine how the new heterocyclic basic centres would be influenced by 
the reverse amide bond order and the pyridine nitrogen (Figure 40).  
 
Figure 40.  Structural modifications of SEN12333 (45). 
Altering the morpholine ring was considered significant due to the importance of 
nitrogen-containing heterocycles to the field of drug discovery. This is highlighted 
by the fact that ‘heterocycle synthesis’ is the second most frequently performed 
reaction in pharmaceutical laboratories, and the synthesis of N-heterocycles accounts 
for more than 89% of those reactions.
255
 In numerous bioactive molecules, rings 
directly participate in interactions with receptors, through either heteroatoms forming 
hydrogen bonds with appropriate protein residues or through hydrophobic 
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interactions, π-π stacking or cation-π interactions.256 Electronic ring properties such 
as their distribution over the ring core, and atomic charges influence the reactivity of 
a molecule, which is related to its metabolic stability and toxicity.
256
 In terms of early 
stage drug discovery, the key factors involved in the choice of heterocycle are to 
maintain or improve the activity of the ligand while improving its absorption, brain 
penetration and/or metabolic stability characteristics.
257
 Alternative core structures 
must be selected with the aim of providing satisfactory absorption, distribution, 
metabolism, excretion and toxicity (ADMET) properties to the final library.  
The initial SAR exploration that led to the incorporation of the morpholine ring into 
SEN12333 (45) was brief and focused predominantly on the incorporation of 
branched acyclic tertiary amines (94), substituted 6-membered rings (95–97) and 
azepane rings (98 and 99) (shown Table 11).
189
 Steric bulk around this portion of the 
molecule was tolerated to a limited degree at α7 receptors and generally resulted in a 
decrease in potency. Additional substitution on the heterocyclic ring (95–97) was 
less desirable and resulted in a dramatic decrease in potency, particularly evident in 
compound 97. The larger azepane ring 98 was well tolerated, however, further 
substitution on this ring, as illustrated by compound 99, resulted in decreased 
potency.  
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Table 11 .  Basic centre heterocyclic ring exploration of SEN12333 ( 45).  
 
Compound basic centre EC50 ± SEM (n) (µM) 
SEN12333 (45)  
 
1.65 ± 0.43 (4) 
94 
 
3.27 (1) 
95 
 
2.47 ±0.77 (3) 
96 
 
2.78 ± 0.58 (3) 
97 
 
>30 (1) 
98 
 
0.54 (1) 
99 
 
2.66 (1) 
 
Due to the limited SAR on the heterocyclic ring of SEN12333 (45) and the majority 
of this work being done on substituted cyclic and branched acyclic amines, our 
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investigations focussed upon replacement of the morpholine ring with cyclic amines 
that more closely represented an isostere of morpholine. The proposed analogues are 
depicted in Table 12. Morpholine was replaced in stepwise progression by the small 
azacycles piperidine, 1-methylpiperazine, (1S,4S)-2,5-diazabicyclo[2.2.1]heptane 
and 2-oxa-6-azaspiro[3.3]heptane. The importance of each of these heterocycles in 
drug design and their chemistry and synthesis (where relevant) will be discussed 
separately. Investigations into amide bond connectivity and the importance of the 
pyridine nitrogen were simultaneously continued (Table 12). The synthesis of these 
new compounds also allows for direct comparison between SEN12333 (45) and 
analogues 73–72, the synthesis and testing of which was described in the previous 
chapter.  
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Table 12.  Proposed analogues to be synthesised.  
  
Compound R X Compound R X 
45 
 
N 72 
 
N 
73 CH 74 CH 
100 
 
N 102 
 
N 
101 CH 103 CH 
104 
 
N 106 
 
N 
105 CH 107 CH 
108 
 
N 110 
 
N 
109 CH 111 CH 
112 
 
N    
113 CH    
4.2 Piperidines 
4.2.1 Piperidines in medicinal chemistry  
Piperidine-containing compounds and their derivatives are fast becoming 
increasingly popular building blocks for medicinal and synthetic organic chemistry. 
The piperidine ring is present in numerous natural or synthetic compounds with 
interesting biological activities. Structural similarities between the piperidine ring, a 
six-membered ring containing one nitrogen atom, and morpholine – where one CH2 
is replaced by an oxygen atom, have previously been described.
258
 The obsence of 
the oxygen atom results in piperidine being slightly more basic than morpholine 
(pKa 11.2 vs 8.36 respectively).
259
 Quantitative analyses of biologically active 
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compounds have revealed secondary and tertiary piperidines to be present in 5.5 and 
10.5% of all compounds analysed.
255
 This compares to 3.4 and 4.2% respectively for 
secondary and tertiary morpholine containing compounds.
255
  
Some examples of marketed drugs containing the piperidine functionality are 
displayed in Figure 41. Paroxetine (114, Paxil™) is a highly potent, selective 
serotonin reuptake inhibitor (SSRI) currently used to treat major depression, 
obsessive compulsive disorder, as well as social and generalised anxiety.
260-262
 
Methylphenidate (115, Ritalin™) is the psychotropic drug most commonly used to 
treat individuals suffering from developmental attention-deficit-hyperactivity 
disorder.
263
 Risperidone (116, Risperdal™) is an atypical antipsychotic drug utilised 
mainly in the treatment of schizophrenia, but also for the mixed and manic states 
associated with bipolar disorder.
264
 
 
Figure 41.  Marketed drugs containing the piperidine motif.  
In terms of α7 selective agonists, Zanaletti and co-workers
199
 have explored the 
requirement of the azepane heterocyclic ring contained within compound 49 by its 
substitution with various functionalities as summarised in Table 13. The authors had 
noted previously that basicity did not have a dramatic effect upon α7 activity, 
provided that pKa was sufficient for protonation of the basic nitrogen at physiological 
pH.
265
 Steric hindrance, as illustrated by the modulation of the ring size, was shown 
to have limited impact on α7 activity with no relevant loss of potency noted between 
analogues 117 and 118 and analogues 119 and 120. Compound 117 containing the 
piperidine functionality was deemed the most promising candidate in terms of α7 
activity and selectivity and was chosen for subsequent SAR investigation. No agonist 
activity was observed for α1, α3 and 5HT3 receptors for any of the further compounds 
evaluated.
199
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Figure 42.  Structure of 49 .  
Table 13.  pKa, activity and selectivity of analogues.  
 
 Selectivity
b
 pIC50 (µM) 
Compound X n pKa
a 
α7 
activity 
pEC50 ± 
SEM (n) 
α1 α3 5HT3 
117 CH2 1 9.4 
6.38 ± 
0.05 (5) 
<4.5 <4.5 <4.5 
118 CH2 2 9.6 
6.04 ± 
0.04 (2) 
<4.5 5.1 <4.5 
119 O 1 7.2 
5.18 ± 
0.11 (2) 
NT NT NT 
120 O 2 8.6 
5.93 ± 
0.02 (2) 
NT NT NT 
a
 pKa was calculated using ACD/pKa DB, release 12.00. 
b
 All functional activites were measured in a 
calcium flux assay. Only compounds with α7 pEC50 higher than 6 were considered suitable for the 
selectivity evaluation. NT indicates not tested.  
Similarly Ghiron and co-workers
266
 reported an increase in potency at α7 receptors 
when substituting a morpholine heterocycle for a piperidine moiety in their SAR 
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investigations of urea-containing analogues of SEN12333 (45), as illustrated in 
Figure 43.  
 
Figure 43.  Urea containing analogues . 
4.3 Synthesis of piperidine containing analogues 
Analogues 100 and 101 were readily made from previously synthesised amide 63, 
(Section 2.3) via amide 121, the synthesis is summarised in Scheme 10.  
 
Scheme 10. Synthesis of analogues 100 and 101. Reagents and conditions: (a) piperidine, NaI, Et3N, 
THF, reflux, 16 h, 82%; (b) Pd[(PPh3)4], 100 = pyridine-3-boronic acid, 101 = phenylboronic acid, 
MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 100: 71%, 101: 52%. 
Reverse amide connectivity compounds 102 and 103 containing the piperidine 
functionality were synthesised analogously to the related morpholine derivatives as 
previously described in Section 2.3. Their synthesis is summarised in Scheme 11 and 
was achieved in good yields.  
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Scheme 11. Synthesis of analogues 102 and 103. Reagents and conditions: (a) piperidine, NaI, NEt3, 
THF, reflux, 16 h, 74%; (b) NH2NH2H2O, EtOH, reflux, 1 h,; (c) 4-bromobenzoyl chloride, NEt3, 
CH2CH2, –78 °C to rt, 2 h, 50% over two steps; (d) Pd(PPh3)4, 102 = pyridine-3-boronic acid, 103 = 
phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 102: 63%, 103: 67%. 
With the synthesis of piperidine containing analogues 100–101 and 102–103 
complete, we turned our attention to the synthesis of analogues containing the 4-
methylpiperazine basic centre. 
4.4 4-Methylpiperazines  
4.4.1 4-Methylpiperazines in medicinal chemistry  
Like the piperidine motif, the piperazine functionality is becoming increasingly 
prevalent in biologically active molecules, with secondary piperazines constituting 
5.2% of all secondary amines and tertiary piperazines accounting for roughly 
11.4%.
255
 As the presence of the additional protonated nitrogen in the piperazine 
motif was deemed to be undesirable for our SAR studies, the 1-methylpiperazine 
motif was instead selected. The 4-methylpiperazine motif is seen in numerous orally 
available, bioactive molecules, however, its most prominent example is Sildenafil 
(125) (Figure 44). Sildenafil (125) is a rapidly absorbed, orally available drug used 
in the treatment of male erectile dysfunction. It is a specific and selective inhibitor of 
phosphodiesterase Type 5 (PDE5), an enzyme which is an important modulator of 
smooth muscle relaxation in the corpus cavernosum and in 2013 averaged sales in 
the United States of America of approximately US$ 1.2 billion.
267
 More recently, 
Lieber and co-workers have introduced the 4-methylpiperazine functionality (derived 
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from 1-methylpiperazine) to infer potency and selectivity in their search for 
peroxisome proliferator-activated receptor selective ligands with inverse agonistic 
properties.
268
 This work culminated in the development of DG172 (126, Figure 44) a 
novel peroxisome proliferator-activated receptor selective ligand which exhibited 
high binding affinity (IC50 = 27 nM) and potent inverse agonistic properties. 
Additionally, 126 was bioavailable after oral application to mice and suggests it to be 
an invaluable tool in elucidating the functions and therapeutic potential of these 
receptors.
268
  
 
Figure 44 . Biologically active molecules containing the 4-methylpiperazine motif.  
4.4.2 Synthesis of 4-methylpiperazine containing compounds  
Compounds 104 and 105 were obtained from the previously synthesised amide 63 
(Section 2.3), via amide 127, as described in Scheme 12.  
 
Scheme 12. Synthesis of 104 and 105. Reagents and conditions: (a) 1-methylpiperazine, NaI, NEt3, 
THF, reflux, 16 h, 51%; (b) Pd(PPh3)4, 104 = pyridine-3-boronic acid, 105 = phenylboronic acid, 
MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 104: 57%, 105: 68%. 
Compounds 106 and 107 containing the reversed amide connectivity and the 4-
methylpiperazine motif were synthesised in parallel to the analogous morpholine 
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compounds as detailed in Section 2.3. Their synthesis is shown in Scheme 13 and 
proceeded with acceptable yields.  
 
Scheme 13. Synthesis of compounds 106 and 107. Reagents and conditions: (a) 1-methylpiperazine, 
NaI, NEt3, THF, reflux, 16 h,91%; (b) NH2NH2•H2O, EtOH, reflux, 1 h; (c) 4-bromobenzoyl chloride, 
NEt3, CH2CH2, –78 °C to rt, 2 h, 35% over two steps; (d) Pd[(PPh3)4], 102 = pyridine-3-boronic acid, 
103 = phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 102: 55%, 103: 71%. 
With the completion of analogues 104–105 and 106–107 containing the 4-
methylpiperazine basic centre, we now focussed our attention on the synthesis of 
compounds containing the (1S,4S)-2,5-Diazabicyclo[2.2.1]heptane basic centre. 
4.5 (1S,4S)-2,5-Diazabicyclo[2.2.1]heptane 
4.5.1 (1S,4S)-2,5-Diazabicyclo[2.2.1]heptanes in medicinal chemistry  
(1S,4S)-2,5-Diazabicyclo[2.2.1]heptane (DBH) (131, Figure 45) is a rigid piperazine 
homologue that has been extensively used in medicinal chemistry, with some 
prominent examples of biologically active molecules containing 131 summarised in 
Figure 45. The most notable example is danofloxacin mesylate (132, Advocin™), a 
fluoroquinoline antibiotic commonly used in the area of veterinary medicine.
269,270
 
Compound 132 is administered intravenously or as an intramuscular injection and is 
particularly effective in cattle and pigs for the treatment of respiratory and enteric 
disease.
271
 Unlike other fluoroquinolones, the activity of danofloxacin (132) results 
from its ability to inhibit microbial DNA gyrase therefore preventing replication and 
transcription of bacterial cells.
272,273
 Chemists at Wyeth have used DBH to confer 
potency and selectivity to a series of pyrazolopyrimidine type I B-Raf kinase 
inhibitors, including 133, which displays effective antiproliferative activity against 
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multiple tumour cell lines.
274
 Researchers at Merck have investigated 6-
aminonicotinamides that incorporate a DBH unit, exemplified by 134, as potent and 
selective histone deacetylase 1 inhibitors (HDAC1) with antitumor activities.
275
  
 
Figure 45.  Bioactive-131-containing molecules.  
Relating to nAChRs, Barlocco and co-workers
276,277
 initially discovered (1S,4S)-2-
(6-chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane (135) to be a potent α4β2 
nAChR ligand (Ki = 6 nM in the [
3
H]cytisine binding assay, Table 14). Barlocco 
subsequently reported that the 5-N-methyl analogue (136) exhibited diminished 
binding affinity (Ki = 139 nM), while a second methylation yielding 5-N,N-
dimethylated quaternary ammonium salt (137) restored α4β2 nAChR binding affinity 
(Ki = 4.3 nM).
179
 Studies by Li and co-workers
278,279
 on substituent control to confer 
nAChR subtype selectivity, revealed that replacement of the chloro substituent in 
135 with a phenyl group as in (1S,4S)-138 resulted in not only a dramatic attenuation 
of α4β2 nAChR binding affinity, but also an enhancement of affinity at the α7 
subtype. Similarly, the 5-N-methyl analogue (1S,4S)-139 displayed weak affinity at 
α4β2 nAChRs but appears to improve the α7 nAChR affinity. Furthermore, the 
quaternary ammonium salt (1S,4S)-140 displayed α7 receptor binding in the 
picomolar range (Table 14).
279
 Whilst the poor CNS access of 140 limits its 
therapeutic potential, its favourable binding properties have resulted in its use as a 
preferred radioligand for in vitro binding studies at α7 receptors.
150
 Of interesting 
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note is the different biological activity and selectivity of the two possible 
enantionmers. Whilst the α4β2 binding was enhanced in the (1R,4R,)-diamine series 
(Table 14), the opposite trend was seen for α7 affinity, where (1S, 4S)-139 and 
(1S,4S)-140 were significantly more potent than their (1R,4R) counterparts (Table 
14).
279,276
 Consistent with its low affinity for the native rat α4β2 receptor, (1S,4S)-139 
did not shown an agonist response at concentrations <100 µM in cells expressing the 
recombinant human α4β2 nAChR or show any activation of other heteromeric nAChR 
subtypes (α3β4 and α4β4) which suggests good selectivity for α7 over other nAChR 
subtypes can be achieved with this scaffold.
279
 These preliminary results reveal aryl 
substitution on the pyridazine ring and 5-N-methylation on 2,5-diazabicyclo[2.2.1] 
increase the affinity at α7 receptors. Comparing enantiomers, (1S, 4S) compounds 
were preferable due to their increased selectivity for α7 over α4β2 subtypes and also 
their 20-30 fold increased potency in the α7 binding assay. Therefore it was the 
(1S,4S) DBH enantionmer that was the subject of further investigation. 
Table 14. DBH containing compounds with nAChR affinity.  
  
Compound R 
Ki (nM) 
Compound R 
Ki (nM) 
α4β2 α7 α4β2 α7 
135 H 6 303 138 H 31200 10.1 
136 Me 139 1480 139 Me 12700 9.3 
137 Me2•I 4.3 21.5 140 Me2•I 700 0.066 
 
These previously reported results prompted us to incorporate the (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane core into the structure of SEN12333 (45). As such, the 
synthesis of analogues 108–111 was proposed (Figure 46). Prior to discussing their 
synthesis it is worthwhile to look at the synthesis of the (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane core itself.  
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Figure 46 .  Proposed analogues to be synthesised.  
4.5.2 Synthesis of the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane core 
The first synthesis of the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane core was pioneered 
by Portoghese and Mikhail in 1966 starting from trans-hydroxy-ι-proline (141) 
(Scheme 14).
280
 Proline 141 was tosylated in aqueous sodium hydroxide to give the 
desired N-tosylated product 142. Subsequent treatment with diazomethane gave the 
methyl ester (143) which was then reduced to N-tosylhydroxy-ι-prolinol (144). 
Tosylation of 144 gave the tritosyl derivative 145. The trans stereochemistry of this 
key intermediate is essential for the following ring closure, as displacement of the 
primary tosyloxyl group by an amine nucleophile results in transient intermediate 
146 which then undergoes internal ring closure by SN2 expulsion of the secondary 
tosyloxy substituent. Refluxing compound 145 in excess benzylamine yielded the 
desired 2,5-diazabicyclo[2.2.1]heptane 147. No compounds corresponding to 
intermediate 146 or displacement of only the secondary tosylate could be detected, 
suggesting that displacement of the primary tosyloxy group proceeds as the rate-
determining step followed by rapid internal cyclisation.  
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Scheme 14 . Original synthesis of 2,5-diazabicyclo[2.2.1]heptane.
2 80
 
Although that key cyclization step was accomplished smoothly, unveiling the free 
amine 131 proved highly problematic. Concomitant removal of the 
toluenesulfonamide and benzyl protecting groups of compound 147 using sodium in 
liquid ammonia only delivered the desired product 131 in low yield (<30%). A 
stepwise deprotection regime was therefore investigated. Subjecting compound 147 
to the action of concentrated hydroiodic acid and red phosphorus under refluxing 
acetic acid, gave the expected benzylated product as its hydroiodide salt (148•2HI) in 
76% yield. However, 148 proved resistant to subsequent hydrogenolysis, 
necessitating conversion into the corresponding dihydrochloride, which underwent 
hydrogenolysis to give 131 as its dihydrochloride salt (131•2HCl). Attempts to 
remove the benzyl protecting group of compound 147 prior to sulfonamide cleavage 
reportedly gave poor yields of the corresponding product. 
Improvements on this procedure by Jordis and co-workers have employed the use of 
an alternative N-Boc protecting group strategy. The N-Boc protected ditosylate 149 
could be prepared in moderate yield over four steps from proline 141, Scheme 15.
281
 
The ease of removal of both protecting groups of compound 147, via hydrogenation 
or acid hydrolysis, prompted us to follow a similar synthetic strategy 
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Scheme 15.  Modified synthesis of 131 .
281 
In our hands, Fischer esterification of proline 141 afforded 150 quantitatively as its 
hydrochloride salt. Protection of the amino group of 150 as its tert-butyl carbamate 
(151) followed by chemoselective reduction of the ester gave diol 152 in excellent 
yield, without the need for purification (Scheme 16). Treatment of diol 152 with an 
excess tosyl chloride and pyridine then yielded a mixture of mono- (153) and di-
tosylated (149) products.
282
 Increased yields of di-tosylated 149 could not be 
obtained upon extended reaction times and elevated temperatures.  
 
Scheme 16. Modified synthesis of 147. Reagents and conditions: (a) SOCl2, MeOH, reflux, 17 h, 
quant; (b) Boc2O, NEt3, CH2Cl2, 0 °C to rt, 17 h, 97%; (c) LiBH4, THF, 0 °C to rt, 24 h, 94%; (d) 
TsCl, pyridine, CH2Cl2, rt, 3 d, 149: R = Ts, 45% 153: R = H, 35%; (e) see conditions Table 15.  
Although the key double displacement cyclisation of ditosylate 149 with 
benzylamine to give compound 147 was reported by Jordis and co-workers
281
 to 
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proceed in 79% yield under both autoclave conditions of high temperature and 
pressure and in refluxing toluene, such a result could never be replicated in our 
laboratory. Previous reports by Yakovlev and co-workers to replicate the double 
displacement cyclisation of ditosylate 149 also resulted in a low yield of compound 
147.
283
 Yakovlev and co-workers
283
 proposed that under the forcing reaction 
conditions, thermolysis of the Boc protecting group resulted in an intermediate that 
underwent dimerisation to 154 (Scheme 17). By lowering the reaction temperature to 
40–45 °C (in benzene), compound 147 was obtained in good yield (78%), albeit after 
45 days. Additionally, the 20 °C difference in melting point range reported for 
compound 147 by the two research groups pointed to a discrepancy in the synthetic 
outcome of the reactions. 
 
Scheme 17.  Formation of by-product 154 .   
Upon subjecting ditosylate 149 to the cyclisation conditions previously described by 
Jordis and co-workers
281,284
 (Table 15, entry 1) no yield of the desired product 147 
could be obtained. Numerous reaction conditions were trialled examining the effect 
of base (Table 15, entry 5), microwave irradiation (Table 15, entries 5 and 9) and 
increased pressure (Table 15, entries 2, 4 and 8). Changing the solvent from toluene 
to the polar, aprotic solvent acetonitrile, (known to favour SN2 substitution), resulted 
in the cyclised product being obtained in a low yield of 29%. The cyclisation to form 
the DBH core was also attempted utilising methylamine as the amine source, 
obliterating the subsequent need for N-Boc deprotection and N-methylation. 
Numerous conditions were trialled and are shown in Table 15 (entries 10–14), 
unfortunately, none of the desired product was ever isolated.  
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Table 15.  Attempted cyclisation of compound 149 .  
Entry Solvent 
BnNH2 
(equiv) 
Temp. (°C) Time (h) Yield
a
 
1 toluene 3 100  14  0
b
  
2 toluene 3 100
c
 16 0
b
 
3 DMF 3 80 16  trace 
4 DMF 3 80
c
 16  trace 
5 DMF 3 100
d
 0.5  
0
b
 
6 MeCN
 
 1.1
 e
 70 17  
0
b
 
7 MeCN 3 70 17  29% 
8 MeCN 3 70
c
 17  
0
b
 
9 MeCN 3 70
d
 17 
0
b
 
10 MeCN 3
f 
60 14 
0
b 
11 MeCN 3
f 
60
c 
9 
0
b 
12 MeCN 1.1
e,f 
60
c 
10 
0
b 
13 MeCN 3
g 
60 15 
0
b 
14 MeCN 3
g 
60
c 
9 
0
b 
a
 Isolated yield after chromatography; 
b
 starting material was consumed; 
c
 reaction performed in a 
sealed tube; 
d
 reaction performed under microwave heating, 150W, 247 PSI; 
e
 triethylamine (2.5 
equiv) was added to the reaction mixture 
f
 MeNH2•HCl was used instead of BnNH2; 
g
 MeNH2 (2.0 M 
in THF) was used instead of BnNH2  
Due to the low yields continually obtained of compound 147 and also the 
problematic formation of ditosylate precursor 149 (where substantial quantities of the 
product from monotosylation of the primary hydroxyl group (153) were always 
obtained), the synthetic pathway described in Scheme 16 was deemed unacceptable. 
Our requirement for substantial quantities of DBH 131 prompted the development of 
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a novel synthetic strategy, again starting with the inexpensive proline derivative 141. 
Our new protocol is depicted in Scheme 18.
285
  
Diol 152 was synthesised according to the conditions previously described in 
Scheme 16 and on a 12 g scale. Mono-tosylation of the primary alcohol of 152 was 
then achieved in good yield by the slow addition of tosyl chloride (1 equivalent, 10 
h) via a syringe pump and mild heating. Azide displacement of the tosylate then gave 
azide 155. Numerous conditions were trialed for this transformation and are 
summarised in Table 16, the use of trimethylsilyl azide and tetra-n-butylammonium 
fluoride in THF (entry 4) proved optimal. Mesylation of the secondary hydroxyl 
group then gave compound 156 in excellent yield. A mesyl group was used instead 
of the usual tosylate to reduce the steric bulk we proposed was hindering the 
cyclisation of 149. Staudinger reduction of azide 156 resulted in spontaneous 
transsannular cyclisation, as the liberated primary amine group displaced the mesyl 
group, furnishing the mono protected (1S,4S)-2,5-diazabicyclo[2.2.1]heptane 
building block 157 in excellent yield. An increased yield of 97% was achieved when 
conducting the cyclisation on a 200 mg scale.
285
 The presence of rotamers of 
compound 157 was first confirmed through temperature controlled NMR 
experiments and further confirmed from NMR saturation exchange experiments (see 
appendix).
286
 Gratifyingly, this synthetic sequence was amenable to multigram 
synthesis as N-Boc-(1S,4S)-DBH (157) is a key starting material for the synthesis of 
the previously proposed analogues (108-111). A mechanism to account for this 
transformation is shown in Scheme 19. Triphenylphosphine reacts with the azide to 
generate a phosphazide (158), where upon loss of N2 forms an iminophosphorane 
(159 and 160). Aqueous work up leads to the amine (161) and the stable phosphine 
oxide (162). 
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Scheme 18. Modified synthesis of 157.
285
 Reagents and conditions: (a) TsCl, Pyridine, CH2Cl2, 40 
°C, 18 h, 69%; (b) TMSN3, TBAF, THF, reflux, 18 h, 79%; (c) MsCl, NEt3, CH2Cl2, 0 °C, 30 min, 
95%; (d) PPh3, H2O, THF, rt, 18 h, 71%. 
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Table 16.  Conditions trialled for formation of azide 155 .  
Entry Reagent Solvent Conditions Yield (%) 
1 NaN3 DMF rt, 17 h 9 
2 NaN3, Bu4N
+
I
−
 THF 
rt, 16 h then 
reflux 6 h 
product 
detected 
3 
TMSN3, 
TBAF 
THF rt, 20 h 
mainly 
unchanged 
starting 
material, some 
product 
detected 
4 
TMSN3, 
TBAF 
THF 60 °C, 18 h 79% 
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Scheme 19.  Staudinger reduct ion and cyclisation of 156 .  
Although this route employs trimethylsilyl azide, it avoids high reaction temperatures 
and pressures, and has the added advantage of shorter reaction times. Trimethylsilyl 
azide is generally considered a safer alternative to sodium azide and has been 
recently used in the one pot multigram synthesis of the antiviral agent (−)-
Oseltamivir (Tamiflu®).
287
 The great advantage of this procedure is that each 
operation can be performed on multigram scale, providing synthetically useful 
quantities of DBH 157 in short amount of time. Unlike previously reported syntheses 
of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane cores, removal of the carbamate protecting 
group proved facile (Scheme 20). Treatment of DBH 157 with hydrochloric acid 
produced the amine 131 as its dihydrochloride salt in quantitative yield. For our 
purpose compound 157 was most useful as it contained a secondary amine in the 
(1S,4S)-2,5-diazabicyclo[2.2.1]heptane core which could be readily alkylated and 
then the carbamate group subsequently cleaved when necessary.  
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Scheme 20. Carbamate deprotection of 157.
285
 Reagents and conditions: (a) MeOH, HCl, 2 h, quant. 
4.5.3 Synthesis of analogues 274, 108–111 
The synthesis of compounds 108 and 109 began with the alkylation of amine 157 
with previously made amide 63, to give compound 163, followed by the appropriate 
Suzuki cross-coupling reaction (Scheme 21). Cleavage of the N-Boc protecting 
group of compounds 164 and 165 followed by nitrogen methylation via reductive 
amination yielded the desired analogues 108 and 109 in good yield.  
Scheme 21. Synthesis of compounds 108 and 109. Reagents and conditions: (a) 157, NaI, NEt3, THF, 
reflux, 17 h, 84%; (b) Pd(PPh3)4, 164 = pyridine-3-boronic acid, 165 = phenylboronic acid, MeCN/sat. 
aq. Na2CO3 (1:1), reflux, 18 h, 164: 93%, 165: 59%; (c) HCl, MeOH, RT, 2 h,; (d) 37% aq. HCOH, 
NaBH(OAc)3, ClCH2CH2Cl, RT, 18 h, 108: 48%, 109: 53% over 2 steps. 
The synthesis of the reverse amide analogues 110 and 111 followed synthetic 
procedures previously described (Scheme 11) and is depicted in Scheme 22.  
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Scheme 22. Synthesis of compounds 110 and 111. Reactions and conditions: (a) 157, NaI, NEt3, 
THF, reflux, 16 h, 76%; (b) NH2NH2H2O, EtOH, reflux, 1 h; (c) 4-Bromobenzoyl chloride, NEt3, 
CH2CH2, –78 °C to rt, 2 h, 66% over two steps; (d) Pd(PPh3)4, 169 = pyridine-3-boronic acid, 170 = 
phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 169: 89%, 170: 80%; (e) HCl, MeOH, 
RT, 2 h; (d) 37% aq. HCOH, NaBH(OAc)3, ClCH2CH2Cl, RT, 18 h, 110: 58%, 111: 62% over 2 
steps. 
In summary, a novel and practical synthetic pathway has been developed for the 
synthesis of the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane core which was amenable to 
multigram synthesis. The (1S,4S)-2,5-diazabicyclo[2.2.1]heptane moiety was then 
successfully incorporated into four newly synthesised ligands 108–111 for biological 
evaluation at α7 receptors. With these ligands in hand, we now focused our attention 
on the synthesis of the remaining 2-oxa-6-azaspiro[3.3]heptane containing 
compounds. 
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4.6 2-Oxa-6-azaspiro[3.3]heptane containing 
compounds  
4.6.1 The physicochemical properties of 2-oxa-6-azaspiro[3.3]heptanes 
The majority of compounds produced in pharmaceutical and chemical research 
contain fused or linked, five- and/or six-membered rings, which may be either 
saturated or unsaturated.
288,289
 In comparison, the incidence of four-membered rings 
is rare. In the area of drug discovery, incorporation of the oxetane functionality has 
been previously described to alter the physicochemical and biochemical properties of 
the parent compound.
290
 Oxetanes are viewed as potentially attractive structural 
motifs for drug discovery due to their high polarity and outstanding ability to 
function as an acceptor of hydrogen bonds.
291
 Additionally, these functionalities 
permit the investigation of novel chemical space within biology and medicine.
292
  
Previous work by Carriera and co-workers have described the oxetane functionality 
as a surrogate of gem-dimethyl groups in drug discovery.
290
 Studies have previously 
suggested that the oxetane moiety retains a high H-bonding avidity, likeable to that 
of aliphatic carbonyls. Subsequent work by Carriera and co-workers focused upon 
establishing a point of reference for the oxetane/C=O analogy through the 
comparative examination of properties of spirooxetane analogues of piperidones 
(174), pyrolidones and azetidinones.
293
 The reported series was of partial interest in 
light of its structural relationship to morpholine (171) and examined a number of 
physiochemical and biochemical properties.
293
 Spirooxetane analogues resembled 
morpholine and their reported properties are summarised in Table 17.  
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 Table 17.  Physicochemical and biochemical properties of spirooxetane analogues 
related to morpholine. 
Compound Structure
a 
Log D
b
 
(log P)
c
 
Sol
d
 
Clint 
(hu/m)
e
 
pKa
f
 
171 
 
1.5 (1.6) 8000 9/8 7.0 
172 
 
0.5 (1.2) 24000 3/7 8.0 
173 
 
0.8 (3.1) 290 0/16 9.6 
174 
 
1.2 (1.6) 4000 120/88 7.5 
175 
 
0.9 (3.1) 450 8/18 9.6 
a
 R = piperonyl, all compounds studies were tagged with a piperonyl residue to facilitate analytical 
measurements. 
b
 Logarithmic n-octanol/water distribution coefficient at pH 7.4. 
c
 Intrinsic lipopilicity 
of the neutral base according to the equation logP = logD + log10 (1 + 10
(pKa-pH)
). 
d
 Intrinsic solubility 
of the neutral base. The values were obtained from the experimental thermodynamic solubility [µg 
mL
-1
] in phosphate buffer (50 mm) at pH 9.9 and 22.5 ± 1 °C, and corrected for the pKa
 
value. 
e
 
Intrinsic clearance rates [min
-1
 mg
-1
 µL] measured in human (hu) and mouse (m) liver microsomes. 
f
 
Amine basicity in H2O measured spectrophotometrically at 24 °C.  
All oxetanes were found to be chemically stable at pH 1–10 (37 °C, 2 hours), 
particularly noteworthy for the highly strained azetidine 172. The introduction of the 
oxetane functionality into cyclic amines notably reduces their basicity, while the 
lipophilicity was reported to increase markedly as the oxetane unit is positioned 
closer to the nitrogen atom.
293
 This trend arises from the reduction in basicity, 
leading to a higher proportion of the neutral species at pH 7.4. However, the intrinsic 
lipophilicities (logP) of the oxetanes are all significantly below those of the 
Chapter 4 The heterocyclic ring 
 
 
102 
 
corresponding gem-dimethyl derivatives (173) and those of the parent amines (175). 
The distinct polarity of the oxetane moiety is a quality reflected in their generally 
higher intrinsic solubility.
293
 Generally, the polarity of an oxetane unit resides 
between that of a gem-dimethyl unit and that of a carbonyl group. Further 
comparisons of oxetane 172 (Figure 47, blue outline), morpholine 171 (drawn in 
green) and piperidone 174 (shown in yellow) reveal spirocycle 172 to be longer than 
morpholine (171), displaying its polar ether approximately 1.3 Å further from the 
corresponding oxygen atom. Whilst the lone pairs of electrons on the oxygen atom in 
oxetane 172 and ketone 174 have the same spatial orientation, in morpholine 171 and 
oxetane 172, they are orthogonal (Figure 47).
293
 A superposition of X-Ray crystal 
structures is depicted in Figure 47. This suggests the possibility of alternative 
hydrogen binding between ligand and receptor through the incorporation of 
spirocycle 172 into the ligand of interest. 
 
Figure 47.  Superposition of X-ray crystal structures.
29 3
 
Whilst morpholine 171 and oxetane 172 exhibit similar basicities, oxetane 172 is 
considerably less lipophilic and more soluble, suggesting that it is particularly 
promising for further applications in molecular design and drug discovery. From this 
study it was concluded that the oxetane unit can be utilised to develop novel isosteres 
of morpholine. Such analogues are promising owing to both their physicochemical 
properties and ease with which the oxetane functionality can be incorporated into 
structures.  
In relation to SEN12333 (45), the syntheses of oxetane-containing derivatives 112 
and 113 was proposed (Figure 48), with the aim of determining whether expanding 
the space around the morpholine ring was tolerated and also creating additional, 
favourable hydrogen bonds between the ligand and receptor. The 2-oxa-6-
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azaspiro[3.3]heptane functionality was selected based upon its structural similarities 
to morpholine and desirable physicochemical properties, such that the favourable 
drug like properties of SEN12333 (45) would be maintained, if not improved. Prior 
to discussing the synthesis of these analogues it is worthwhile to briefly mention the 
prevalence of oxetanes in pharmaceuticals and nature.  
 
Figure 48.  Proposed analogues to be synthesised.  
4.6.2 Oxetanes in biologically active molecules  
Currently, all marketed drugs that contain the oxetane ring are derived from the one 
family of natural products. Commercially developed by Bristol-Myers-Squibb, 
paclitaxel (176, Taxol™) was first isolated from the bark of the western yew tree 
(Taxus brevifolia) and is, together with the structurally related docetaxel (177, 
Taxotere™), currently utilised in cancer chemotherapy (Figure 49).294 The 
mechanism of action of both compounds involves interference with regular 
breakdown of microtubules during cell division.
294
 Computational studies have 
examined the structural consequences of the oxetane in Taxol and concluded that the 
unit results in rigidification of the overall structure.
295
 A key hydrogen bond 
interaction is also formed with a threonine-OH group within the putative binding 
pocket.
296
 Consistent with these findings, replacement of the oxetane functionality 
with azetidine, thietane or selenetane correlated with lower activity.
297,298
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Figure 49.  Structures of 176  and 177 .  
Few other natural products contain oxetanes. However, the majority in which they 
are found are terpenoids. Initially isolated from the soil bacterium Bacillus 
megaterium NK84-0218, oxetanocin A (178, Figure 50) inhibits the reverse 
transcriptase of HIV by mimicking adenosine, a feature which triggers considerable 
interest both synthetically and commercially.
299,300
 Primarily synthesised by platelets, 
thromboxane A2 (179) promotes vasoconstriction, platelet aggregation and 
bronchoconstriction. With a half-life of just 30 seconds in plasma, the oxetane ring 
(embedded in an acetal) is rapidly hydrolysed to give the inactive thromboxane B2 
(180).
291
 Oxetin (181) was first isolated from fermentation broths of Streptomyces sp 
OM-2317 and was discovered to elicit herbicidal as well as antibacterial effects. 
Investigations are continuing as to its full biological activity.
301
 Synthetic small 
molecules incorporating oxetane rings include insecticide EDO (182). Compound 
182 is 25 times more potent than common insecticide 
dichlorodiphenyltrichloroethane (DDT), and it also shows activity against DDT-
resistant strains of Musca domestica. Additionally, in contrast to the notorious 
environmentally persistent DDT, EDO is biodegradable.
302
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Figure 50.  Structures of 178–182 .  
4.6.3 Synthesis of oxetane analogues 112 and 113  
Tribromopentaerythritol (183) provides ready access to 2-oxa-6-
azaspiro[3.3]heptane. Initial cyclisation with tosylamide with concomitant ether 
formation, yielded compound 184 (Scheme 23). Subsequent cleavage of the N-tosyl 
protecting group through sonication in the presence of magnesium gave the desired 
amine 185 which could be stored conveniently as it stable oxalate salt (Scheme 23). 
Alkylation of the oxetane nitrogen 185 with previously synthesised amide 63 gave 
compound 186 which was readily converted into the desired ligands by the 
appropriate Suzuki coupling reactions in good yields.  
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Scheme 23. Synthesis of compounds 112 and 113. Reagents and conditions: (a) TsNH2, KOH, EtOH, 
reflux, 3 d, 60%; (b) Mg, MeOH, sonication, 2 h, 70%; (c) 63, NaI, NEt3, THF, reflux, 16 h, 74%; (d) 
Pd(PPh3)4, 112 = pyridine-3-boronic acid, 113 = phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), 
reflux, 18 h, 112: 70%, 113: 90%. 
With the completion of the synthesis of oxetane-containing analogues 112 and 113, 
we next focused our attention upon investigation of the binding affinities of all newly 
synthesised compounds examining the effect of the basic centre.  
4.7 The binding affinities of all morpholine-varied 
analogues of SEN12333 (45) 
SEN12333 (45) analogues synthesised with a morpholine altered heterocycle, as well 
as SEN12333 (45) as a reference were then evaluated in competitive binding assays 
to determine their affinity and selectivity for the α7 receptor as described in Section 
11.9.1. All compounds were selective for the α7 subtype over the α4β2 and α3β4 
subtypes and a range of affinities were obtained with the results summarised in 
Table 18.  
 Replacement of the morpholine ring of SEN12333 (45) with a piperidine 
functionality as in analogues 100–101 and 102–103 resulted in an increase in 
potency at α7 receptors, evident by the direct comparison of SEN12333 (45) 
and 100 (Ki: 670 nM vs 220 nM). In contradiction with the results from 
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section 3.5, conversion into the biphenyl analogue  101, resulted in an even 
further increase in potency over the phenyl-pyridyl analogue 100 (Table 18, 
entries 3 and 2 respectively). Similar to Section 3.5, reversal of the amide 
bond order (102) resulted in a decrease in potency. This was restored by 
conversion of 102 into its corresponding biphenyl analogue (103).  
 Incorporation of the 4-methylpiperazine functionality as the basic centre 
(104) resulted in a decrease in potency compared to SEN12333 (45). Potency 
was somewhat restored by conversion into the corresponding biphenyl 
analogue (105). The 4-methylpiperazine analogue 106, containing the reverse 
amide bond order, exhibited a complete loss of potency at α7 receptors. 
Interestingly, potency (albeit low) and selectivity were restored in the related 
biphenyl analogue 107. It is postulated that either the increased steric bulk of 
the methyl group may have inhibited the ability of these ligands to interact 
with the active site of the α7 receptor. Furthermore, 1-methylpiperazine offers 
two sites for protonation at physiological pH. Whilst protonation is assumed 
to reside predominantly on the 1-position, this may have significant effects on 
binding at α7 receptors.  
 Unfortunately, inclusion of the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane 
functionality, which commonly sees an increase in potency for α7 agonists, 
resulted in a dramatic loss of potency for this structural class of ligands, 
evident in the direct comparison of SEN12333 (45) and 108. Similar to all 
compounds of this series, biphenyl analogue (109) was of improved potency. 
This effect was also seen in the reverse amide derivatives 110 and 111. As 
with the 1-methylpiperazine containing compounds, this loss of affinity may 
be the result of either the increased steric bulk of the (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane core, altered electronics of this heterocyclic ring 
or the additional site for protonation.  
 Incorporation of the 2-oxa-6-azaspiro[3.3]heptane moiety similarly resulted 
in a loss of affinity at α7 receptors (45 vs 112). This was slightly improved in 
biphenyl analogue 113. Again, this may result from the 2-oxa-6-
azaspiro[3.3]heptane unit being slightly longer than the morpholine 
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functionality or may potentially arise from the altered hydrogen bonding 
capacity of the 2-oxa-6-azaspiro[3.3]heptane moiety. 
Within this series of compounds the results show that binding affinity is not 
solely dependent upon the heterocyclic ring as in Section 3.5. Upon alteration of 
this basic centre, the effect of the amide bond order and pyridine nitrogen 
become more enhanced and reveal discrete structural trends. The original amide 
bond order of SEN12333 (45) appears to be optimal and the pyridine nitrogen 
does not seem to be essential for α7 affinity. Its removal consistently results in an 
improvement for affinity within this series of compounds.  
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Table 18.  Binding affinities of morpholine-varied ligands. 
Structure
 
Binding affinity Ki (nM)
a
 
Physicochemical 
properties 
α7  α4β2  α3β4  
cLog
P 
PSA LLE 
 
670 ± 
119 
>10,000 
>10,00
0 
2.25 
53.9
3 
3.92 
 
220 ± 
30 
>10,000 
>10,00
0 
3.46 44.7 3.20 
 
190 ± 
30 
>10,000 
2600 ± 
200 
4.79 
32.3
4 
1.93 
 
1400 ± 
200 
>10,000 
>50,00
0 
3.15 
44.7
0 
2.70 
 
410 ± 
80 
>10,000 
>10,00
0 
4.49 
32.3
4 
1.90 
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9330 
DNC 
>30,00
0 
1.32 
47.9
4 
3.71 
 
1620 DNC 
>80,00
0 
2.65 
35.5
8 
3.14 
 
>1000 
>10,000 
>10,00
0 
1.00 
47.9
4 
ND 
 
5400 ± 
700 >10,000 
>10,00
0 
2.35 
35.5
8 
2.92 
 
>10000 
>10,000 
>10,00
0 
1.07 
47.9
4 
ND 
 
3200 ± 
100 
>10,000 
>10,00
00 
2.41 
35.5
8 
3.08 
72000 
± 8000 >10,000 
>10,00
0 
0.76 
47.9
4 3.38 
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6100 ± 
500 >10,000 
>10,00
0 
2.11 
35.5
8 
3.10 
 
19000 
± 2000 
>10,000 
>50,00
00 
2.40 
53.9
3 
2.32 
 
17000 
± 3000 
>10,000 
>50,00
0 
3.73 
41.5
7 
1.04 
a
 Competition binding assays were carried out in membrane homogenates of stably transfected cells or 
rat forebrain tissue as described previously. The nAChRs were labeled with [
3
H]-epibatidine. The Kd 
values (nM) for [
3
H]-epibatidine used for calculating Ki values were 0.3 for α3β4, 0.04 for α4β2 and 1.8 
for α7. Ki values are the mean ± SEM of three to six independent measurements. For low binding 
affinity compounds, estimated Ki value ranges were provided; 
b 
DNC = does not converge; 
c
 ND = not 
determined. 
Consistent with the work of Chapters 2 and 3, the physicochemical properties of all 
newly synthesised analogues have been calculated and is summarised in Table 18. 
All compounds display acceptable PSA values. However, whilst all compounds 
exhibit cLogP < 5, the influence of the cLogP value over the LLE measurement is 
unmistakably obvious. Within the present assay, the LLE of SEN12333 (45) is 3.92; 
while compounds 100 and 101 display respectively a 3 and 3.5 fold increase in 
potency relative to SEN12333 (45), however, their LLE values are much lower, 3.2 
and 1.9 respectively. This is a direct result of their increased cLogP values (3.46 and 
4.79 respectively vs 2.25 of 45) and is particularly evident in the more lipophilic 101. 
Interestingly, while compound 104 is a much weaker binder at α7 receptors (Ki = 
9330 nM), its low cLogP value results in an LLE value similar to that of SEN12333 
(45) (3.70 vs 3.92 respectively). Though compound 104 is unsuitable for further 
development due to its low binding affinity, the importance of lipophilicity is 
Chapter 4 The heterocyclic ring 
 
 
112 
 
highlighted. The importance of binding affinity upon LLE values and drug-likeness 
is evident in compounds 109, 108–111 and 112–113. Whilst these compounds 
display acceptable cLogP values, their extremely low binding affinities diminish 
their LLE values and render them unsuitable for further development (despite 110 
exhibiting an LLE value similar to that of 45). In combination, the binding affinities 
and physicochemical properties of the compounds in Table 18 emphasise the 
importance of not only binding affinity, but also physicochemical parameters, 
particularly lipophilicity, for developing a molecule suitable for further development 
and use in vivo.  
4.8 Concluding remarks  
The findings of Chapter 4 have uncovered some unique trends not evident in the 
results seen in Chapter 3. The original amide bond order appears to be optimal for 
potency at α7 receptors and biphenyl derivatives have superior α7 nAChR binding 
over their corresponding phenyl-pyridyl analogues . The potency lost by reversing 
the amide bond can be somewhat restored through the use of the biphenyl motif. In 
terms of the heterocyclic ring: small, unsubstituted 6-membered rings appear to be 
ideal for affinity at α7 receptors. The potency of SEN12333 (45) can be improved 
through the incorporation of the piperidine functionality and has resulted in the most 
potent compounds of the series (100 and 101). Unfortunately the increased 
lipophilicity of these compounds have decreased their LLE values below the LLE of 
SEN12333 (45). The diminished affinity of compounds containing slightly larger or 
bicyclic heterocycles, 1-methylpiperazine, (1S,4S)-2,5-diazabicyclo[2.2.1]heptane or 
2-oxa-6-azaspiro[3.3]heptane, suggests the requirement for minimal steric bulk about 
the heterocyclic ring in the SEN12333 (45) scaffold. This also highlights the need for 
specific electronics around this portion of the molecule and suggests that more basic 
amines are favourable (as seen in piperidine containing compounds).  
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Chapter 5 - The biaryl ring system 
5.1 Introductory remarks 
The work outlined in the previous chapter described how modifications to the basic 
centre of lead compound SEN12333 (45) influenced binding affinity. This was 
achieved through substitution of the aliphatic morpholine motif, in addition to 
synthesising the reverse-amide and biphenyl analogues. The focus of this chapter 
will be the aromatic moiety of the molecule. Specifically, how the use of alternative 
biaryl ring systems affect binding at α7 receptors (Figure 51).  
 
Figure 51.  Structural modifications of SEN12333 (45). 
The importance of biaryl ring systems within medicinal chemistry is highlighted by 
the knowledge that C-C bond forming reactions constitute 11.5% of the most 
frequently performed reactions in pharmaceutical laboratories. Within this subset, the 
Suzuki cross coupling is the most commonly employed and accounts for 40% of all 
C-C bond forming reactions.
255
 Strong attractive interactions between π-systems 
have been known for over half a century; researchers from various chemical sciences 
have used ‘aromatic interactions’ to rationalise their observations.303,304 Such 
interactions are known to control a wide array of phenomena, and aromatic 
interactions have been exploited in template-directed synthesis to topologically 
prepare complex molecules, and to control the enantioselectivity of reactions in 
asymmetric synthesis.
305-308
 The arrangements of molecules in solids, liquid crystals 
and solution are known to be affected by aromatic stacking interactions.
309,310
 In 
terms of biological systems, aromatic stacking interactions have been identified as 
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key components in the vertical base-base interactions that stabilise the double helical 
structure of deoxyribonucleic acid (DNA),
311,312
 the tertiary structure of proteins,
313
 
and porphyrin aggregation.
314,315
 Furthermore, X-ray crystal structures have 
identified stacked aromatic contacts between drug molecules and the aromatic 
residues in the side-chains of proteins.
316-318
 
In terms of SAR exploration of the biaryl moiety of SEN12333 (45), no data is 
available for analogues of SEN12333 (45) itself. Instead, biaryl investigations were 
conducted on the original hit compound 44 and the piperidine analogue of 
SEN12333 - 100 (Table 19). The initial investigation into modifying the aromatic 
moiety of hit compound 44 was brief with studies predominantly examining the 
effect of ortho substitution on the terminal aromatic ring.
189
 The synthesised 
compounds (187–189) retained activity at α7 but did not show an improvement in 
potency over the initial hit (44). The importance of ortho substitution is highlighted 
in the unsubstituted compound 190 where agonist activity at α7 is lost. Activity in 
this series also appears to be dependent on the presence of a biaryl moiety as 
illustrated in the poor activity of compounds 191 and 192. Interestingly, upon 
modification of original hit 44 to SEN12333 (45) the pyridine nitrogen in the 
terminal aromatic ring has moved from the 2- to 3-position without any apparent 
explanation or previous SAR investigations. As such, the 2- and 4-position pyridine 
analogues of SEN12333 (45) have yet to be investigated. In terms of SAR of 
SEN12333 (45), investigations into the aromatic moiety have been conducted on the 
related compound (100). The results reveal a relatively flat SAR with no clear trend 
or explanation as to why the chosen analogues were selected for further 
investigation. Of the analogues studied, compounds with hydrogen bonding potential 
on the pendant aryl ring generally exhibited increased potency (193 and 194). Meta 
substitution on the terminal ring with bromine resulted in a loss of potency (195), 
however, substitution with an isobutyl ether, as in 196, resulted in an improvement in 
potency relative to 100. Consistent with aromatic moiety investigations of hit 
compound 44, biaryl compounds were more potent than mono aryl derivatives (197 
and 198). However, the comparison of 197 and 191 revealed the second series of 
compounds to be intrinsically more potent. Replacement of a biaryl moiety with a 
fused ring similarly resulted in a decrease in activity as evident in compound 199. 
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Table 19.  Aromatic moiety Exploration of 44  and 100 .  
 
 
Compound 
aromatic 
moiety 
EC50 ± 
SEM (n) 
(µM) 
Compound 
aromatic 
moiety 
EC50 ± 
SEM (n) 
(µM) 
44 
 
2.84 ± 
0.23 (32) 
100 
 
0.53 (1) 
187 
 
6.03 ± 
3.75 (3) 
193 
 
0.09 ± 0.01 
(2) 
188 
 
5.77 ± 
2.26 (3) 
194 
 
0.16 ± 0.04 
(2) 
189 
 
2.91 ± 
0.37 (2) 
195 
 
2.07 (1) 
190 
 
>30 (1) 196 
 
0.24 ± 0.06 
(2) 
191 
 
>30 (1) 197 
 
1.35 ± 0.27 
(2) 
192 
 
>30 (1) 198 
 
>30 (1) 
 199 
 
10.93 (1) 
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Further work by Haydar and co-workers examined the effect on the first ring of the 
biaryl system in SEN12333 (45) and detailed the development of a novel series of 
ligands (Series 3, Figure 52), which is developed from two known, previously 
studied series (Series 1 and 2).
265
 Series 1 is representative of SEN12333 (45), whilst 
Series 2 described replacement of the amide group with a urea functionality.
266
 Series 
2 generally exhibited enhanced potency at α7 receptors compared to Series 1; 
however, it also demonstrated low selectivity particularly against the homologous α3 
receptor, unfavourable hERG activity and substantial cytochrome inhibition.
266
 The 
development of series 3 resulted in compounds with a good level of potency, 
improved selectivity, an optimal hERG profile and no cytochrome P450 inhibition.
265
 
Series 3 retained two hydrogen bond donors and therefore encompasses the 
possibility of additional interactions compared to series 1 and 2. 
 
Figure 52.  Series 1, 2 and 3 with pharmacophoric elements: basic centre (blue), 
carbon chain (black), central linker (green) and biaryl system (red).  
Compound 200 served as a starting point for further SAR investigation by Zanaletti 
and co-workers as shown in Table 20. Their α7 activity, selectivity over homologous 
receptor subtypes and initial profiling data is also included. The selection of 
analogues studied in Table 20 explores the effects of ring substitution in terms of 
steric hindrance, torsional angle of the biaryl system and electronic effects on the 
aromatic rings.
265
 The resulting data reveals that modification to the terminal 
aromatic ring has no significant impact on α7 activity. Moderate loss of potency 
relative to the starting molecule (200), was evident in compound 201 bearing the 
most electron poor ring. In contrast, para-methoxy substitution as in 202 resulted in a 
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5-fold increase in potency. The presence of a furan ring (as in compound 205) 
correlates with a loss of potency.  
Table 20.  Evaluation of Series 3 pyrazole derivatives .  
 
Compound R ClogP Activity
a
 at α7 (µM) 
± SEM (n) 
Selectivity
a
 
α1 α3 5HT3 
200 
 
4.6 2.13 ± 0.87 (2) NT NT NT 
201 
 
2.6 6.22 ± 0.37 (2) NT NT NT 
202 
 
3.9 0.43 ± 0.12 (3) >30 3.3 >30 
203 
 
3.9 1.70 ± 0.07 (4) NT NT NT 
204 
 
3.9 1.45 ± 0.96 (2) >30 6.4 >30 
205 
 
3.3 4.18 ± 0.21 (2) NT NT NT 
a 
All functional activities were measured in either calcium influx or membrane potential assays using a 
fluorescence imaging plate reader. Compounds with Emax >70% of nicotine were considered to be full 
agonists. The reported compounds gave values >90%. Only compounds with α7 activity lower than 1.5 
µM were considered suitable for selectivity evaluation. NT indicates not tested.  
5.1.1 Proposed analogues to be synthesised  
Based upon the studies previously described in Section 5.1
189,199,265,266
, to further 
explore the impact of modifications to the aromatic moiety of SEN12333 (45), the 
synthesis of the analogues shown in Table 21 was proposed. Compounds 206 and 
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207 would examine the affect of the position of the pyridine nitrogen in the terminal 
aromatic ring. Following on from the positive results exhibited by compound 194 
(Table 19), the incorporation of a fluorine substituent onto the terminal ring of 45 is 
explored with analogue 208. The synthesis of pyrazole containing compounds 209–
211 was also proposed to examine the effect of substitution of this biaryl motif onto 
SEN12333 (45). Derived from the work by Li and co-workers
279
, (as previously 
described in section 4.4.1), the pyridazinyl-phenyl motif of lead compound 139 was 
transposed onto SEN12333 (45) resulting in the proposed compound 212. The 5-
indolyl motif, also described by Li and co-workers
279
, was incorporated in the 
proposed compound 213.  
Table 21.  Proposed analogues to be synthesised  
Compound Structure Compound Structure 
206 
 
210 
 
207 
 
211 
 
208 
 
212 
 
209 
 
213 
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5.2 The synthesis of pyridinyl regioisomers 206 and 
207  
Compounds 206 and 207 examine the effect of the position of the pyridine nitrogen 
within the terminal aromatic ring of SEN12333 (45). As no clear reason was reported 
as to why the pyridine nitrogen was moved from the 2-position in original hit 44 to 
the 3-position in SEN12333 (45), this was considered extremely important. The 2-
pyridyl and 4-pyridyl boronic acids were not initially on hand for the ultimate Suzuki 
coupling, so it was envisioned that the synthesis of compounds 206 and 207 would 
initially begin with a one-pot C-H arylation procedure developed by Baran and co-
workers.
319
 Prior to discussing the synthesis of 206 and 207 it is worthwhile to 
review the chemistry of C-H arylation.  
5.2.1 C-H arylation of electron-deficient heterocycles with arylboronic 
acids.  
As previously mentioned in Section 2.3, the Suzuki coupling between arylboronic 
acids and aromatic halides is one of the most widely employed in chemical science 
(Figure 53).
207
 A much less studied and underappreciated coupling reaction is the 
Minisci reaction, which involves the silver(I)-catalysed addition of nucleophilic, 
alkyl-centred radicals to electron deficient heterocycles (Figure 53).
320
 The main 
disadvantage to the Minisci reaction is the limited access to nucleophilic radicals, 
particularly of the aryl variety.
321
 The most prevalent procedure to arylate electron-
deficient heterocycles is through the direct addition of an organometallic reagent 
followed by rearomatisation.
322
 This method often results in low to moderate yields, 
is only applicable to electron-deficient heterocycles and has low functional group 
tolerance.
319
 Recent work by Baran and co-workers has detailed the development of a 
silver(I)-catalysed addition of arylboronic acids to a variety of electron-deficient 
heterocycles (Figure 53).
319
 The net C-H arylation was reported to occur at ambient 
temperature, and be amenable to large scale synthesis, with high tolerance to a wide 
variety of functional groups and substrates.
319
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Figure 53 . Overview of Suzuki,  Minisci Reactions, and C -H arylation.  
In theory, a mild C-H arylation of heterocycles which parallels the Minisci reaction 
would involve a facile route to aryl radicals. Mild generation of these reactive 
intermediates would ideally proceed from stable, readily accessible starting materials 
and avoid the need for the harsh, impractical or environmentally hazardous reaction 
conditions commonly utilised in accessing these reactive intermediates.
321,323-325
 
Minisci’s conditions for the oxidative decarboxylation of alkylcarboxylates are 
known to fail on their aryl counterparts (Figure 54). It was postulated by Baran and 
co-workers that homolytic cleavage of the C-B bond in an arylboronic acid could be 
induced in a method comparable to decarboxylation.
319
 By employing conditions 
similar to those employed in the Minisci reaction with alkyl carboxylic acids 
(catalytic silver(I) nitrate in the presence of persulfate), it was discovered that 
arylboronic acids can couple with protonated electron-deficient heterocycles at room 
temperature (Figure 54).
319
 In contrast to previous work involving the coupling of 
aryl radicals and pyridines, the heterocycles can be used as limiting reagents instead 
of being the solvent.
326,327
  
 
Figure 54.  Initial findings by Baran and co -workers.  
Baran’s standard conditions could be applied to a range of heterocycles when using 
p-tolylboronic acid as a standard coupling partner and proved fairly general for 
several classes of electron-deficient heterocycles with yields ranging from 30% to 
>90%.
319
 Regioselectivity on the heterocycle was predominantly favoured for the 2- 
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and 4-positions with bis-addition rarely occurring. The scope of the aryl-boronic acid 
was then explored using 4-(tert-butyl)pyridine (214) as the heterocycle substrate and 
revealed several electron-poor to electron-rich arylboronic acids to be tolerated. The 
electron-rich aryl-boronic acids exhibited shorter reaction times, while many of the 
more electron-poor boronic acids required a second addition of AgNO3/K2S2O8 to 
force the reaction to completion.  
We proposed that the use of pyridine and 4-(nitrophenyl)boronic acid would generate 
the biaryl ring systems contained within compounds 206 and 207 in one pot. The 4- 
position of pyridine is unsubstituted so C-H arylation was predicted to occur at both 
the 2- and 4- positions providing the biaryl ring systems of 206 and 207 respectively.  
As depicted in Scheme 24, pyridine (215) was treated with trifluoroacetic acid and 
reacted with 4-(nitrophenyl)boronic (216) acid in the presence of silver(I) nitrate and 
potassium persulfate (Scheme 24) to yield both 2-(4-nitrophenyl)pyridine (217) and 
4-(4-nitrophenyl)pyridine (218) in moderate and low yields (27% and 11%) 
respectively. These compounds were readily separated by chromatography. 
 
Scheme 24. C-H arylation to give compounds 217 and 218. Reagents and conditions: (a) CF3COOH, 
cat. AgNO3, K2S2O8, CH2Cl2, H2O, rt, 24 h, 217: 27%, 218: 11%. 
Palladium catalysed hydrogenation of 217 then yielded aniline 219, followed by the 
subsequent reaction with 5-bromovaleric acid to yield amide 220 in good yield. 
Finally, alkyl bromide displacement by morpholine in the presence of potassium 
iodide then furnished the desired ligand 206 (Scheme 25).  
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Scheme 25. Synthesis of compound 206. Reagents and conditions: (a) H2 (1 atm), cat. Pd/C, MeOH, 
18 h, rt, 87%; (b) (i) 5-bromovaleric acid, (COCl)2, rt, 1 h (ii) 219, NEt3, CH2Cl2, −78 °C to rt, 10 h, 
85%; (c) Morpholine, NaI, NEt3, THF, reflux, 16 h, 74%. 
The low yield of 218 precluded a similar strategy from being employed for 
compound 207 (as shown in Scheme 26).  
 
Scheme 26. Proposed synthesis of compound 207. Reagents and conditions: (a) H2, Pd/C, MeOH, 18 
h, rt, 63% 
When 4-pyridylboronic acid became commercially available, ligand 207 was instead 
synthesised in excellent yield by Suzuki coupling reaction of previously made amide 
68 and 4-pyridylboronic acid (Scheme 27).  
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Scheme 27. The synthesis of compound 207. Reagents and conditions: (a) Pd[(PPh3)4], pyridine-4-
boronic acid, MeCN-sat. aq. Na2CO3 (1:1), reflux, 18 h, 57%. 
With the synthesis of analogues 206 and 207 complete, we then turned our attention 
towards the synthesis of compound 208. 
5.3 The synthesis of compound 208 
Based upon the positive results exhibited by compound 194 (Table 19), the 
incorporation of a fluorine substituent onto the terminal ring of 45 was explored in 
analogue 208. The structural similarities of compound 208 to SEN12333 (45) and 
compound 194 can be seen in Figure 55. Compound 208 can be thought of as a 
hybrid of these two compounds.  
 
Figure 55 . Similarities of 208  with SEN12333 (45)  and 194 .  
The unique properties of fluorine have resulted in its extensive application in drug 
design as an isostere for hydrogen. Furthermore incorporation of this halogen can 
productively modulate multiple properties of interest to medicinal chemists.
328-330
 As 
the second smallest substituent, it closely mimics hydrogen with respect to the steric 
requirements at active sites. The presence of fluorine also often results in increased 
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lipid solubility and enhanced rates of absorption and drug transport in vivo.
331
 Whilst 
fluorine is sterically similar to hydrogen, its high electronegativity imparts different 
electronic effects and can result in altered ligand/receptor interactions.
331
 
Furthermore, fluorine imparts increased oxidative and thermal stability as a result of 
the enhanced strength of the C-F bond compared to the C-H bond.
332,333
  
The synthesis of ligand 208 is straightforward and is summarised in Scheme 28. 
Previously synthesised amide 68 was subjected to Suzuki coupling reaction 
conditions in the presence of readily available (2-fluoropyridin-3-yl)boronic acid to 
give the desired compound 208. 
 
Scheme 28. Synthesis of compound 208. Reagents and conditions: (a) Pd[(PPh3)4], (2-fluoropyridin-
3-yl)boronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 72%. 
With compound 208 in hand, we then focused our efforts on the synthesis of 
pyrazole analogues 209–211. 
5.4 The synthesis of pyrazole analogues 209–211  
5.4.1 Introductory remarks  
Based upon previous SAR work by Haydar and co-workers, the synthesis of 
compounds 209–211 containing the 3,5-dibsubstituted-1H-pyrazole core was 
proposed to examine the effect of substitution of this biaryl motif on SEN12333 (45) 
(Figure 56).
265
 As the previous SAR work by Haydar and co-workers was completed 
using piperidine as the acyclic heterocycle, the synthesis of piperidine compound 210 
was proposed. Piperazine 211 was similarly included to allow for further comparison 
with compounds synthesised in Chapter 4. Prior to discussing the synthesis of these 
compounds, it is worthwhile to examine the use of pyrazoles in medicinal chemistry.  
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Figure 56.  Pyrazole containing compounds  to be synthesised.  
5.4.2 Pyrazoles in medicinal chemistry  
The importance of pyrazoles in drug discovery is highlighted in the quantitative 
analysis of ring systems present within biologically active molecules. Of the 2509 
occurrences of 5-membered heterocyclic rings, pyrazoles account for 616 or 24.6% 
of these. Furthermore, they constitute 14.1% of all heteroaromatics reported within 
the data set.
255
 Derivatives of pyrazole are widely acknowledge to possess a variety 
of bioactivities including analgesic, anti-inflammatory, antipyretic, antiarrhythmic, 
antimicrobial and antitubercular properties.
334-336
  
The pyrazole ring is present in a variety of leading nonsteroidal anti-inflammatory 
drugs (NSAIDs) and antihypertensive drugs. The most prominent example of a 
pyrazole-containing drug is the cyclooxygenase-2 (COX-2) inhibitor, Celebrex™ 
(221, Figure 57), commonly administered for the treatment of osteoarthritic, 
rheumatoid arthritis, acute pain and menstrual pain.
337
 The investigation of pyrazole-
containing compounds having therapeutic value for the treatment of cancer has also 
recently been undertaken. One of the first pyrazole containing compounds to be 
studied was dichloro-bis(pyrazole)platinum(II) (222, Figure 57). Compound 222 has 
shown anticancer activity similar to that of cisplatin against a range of cell lines 
including the human colorectal cell lines, DLD-1, HCT15 and HT29 (IC50 = 2.31, 2.5 
and 1.2 µM respectively), and also the human gastric cell line (IC50 = 2.84 µM).
338
 
Compound 222 was additionally tested against L1210 murine leukaemia cells with 
an IC50 of 4.6 µM as compared to cisplatin (IC50 = 1.2 µM) and carboplatin (IC50 = 
11.2 µM).  
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Figure 57.  Biologically activity molecules containing the pyrazole ring . 
These examples of biologically active pyrazoles validate the incorporation of 
pyrazole into drug design exploration. A discussion of pyrazole-containing α7 
agonists was described in Sections 2.1, 4.2.1 and 5.1. Prior to discussing the 
synthesis of analogues 209–211, it is worthwhile to review the synthetic protocols 
employed for the synthesis of 3,5-disubstituted-1H-pyrazoles. 
5.4.3 The synthesis of 3,5-disubstituted-1H-pyrazoles  
The most common synthetic procedure for the formation of 3,5-disubstituted 
pyrazoles involves cyclocondensation of an appropriate hydrazine, which acts as a 
bidentate nucleophile, with three other carbon units containing two electrophilic 
carbons in a 1,3-relationship, such as 1,3-dicarbonyl (Scheme 29, A) or α,β-
unsaturated carbonyl compounds (Scheme 29, B, C and D).
339
 Unsymmetrical 
substrates which contain two electrophilic centres as in A, B, C and D (Scheme 29) 
often result in mixtures of regioisomers X and Y upon reaction with substituted 
hydrazines (R
3
 ≠ H). When R3 = H, the prototropic tautomerism of pyrazoles renders 
X and Y equivalent.
339
  
Chapter 5 The biaryl ring system 
 
127 
 
 
Scheme 29.  Synthetic pathways to 3,5 -disubstituted-pyrazoles.  
In terms of substrates, the majority of the 1,3-diketones (A) employed in pyrazole 
syntheses are the product of condensation reactions. They therefore must first be 
prepared and purified. Recently, the effective, one-pot synthesis of 3,5-disubstituted 
pyrazoles of general structure 223 has been reported starting from lithium enolates of 
the general structure 224 and acid chloride 225. The 1,3-diketones formed (226) 
were not isolated but were instead converted in situ into pyrazoles by the addition of 
hydrazine (Scheme 30).
340
  
 
Scheme 30. In situ preparation of 1,3-diketones for pyrazole synthesis. Reagents and conditions: (a) 
LiHMDS, PhMe, 0 °C, 2 min; (b) AcOH, EtOH, THF, reflux, 5 min, 43-89% R
1
 = aryl, heteroaryl; R
2
 
= H, n-propyl, Ph; R
3
 = Aryl, n-C5H11; R
4
 = H, Me, Ph. 
In terms of α,β-unsaturated ketones, the synthesis of various 3,5-1H-pyrazoles (227) 
from chalcone 228 has been recently reported by Bhat and co-workers.
341
 Chalcone 
228 was initially converted into epoxide 229 when treated with a mixture of 
hydrogen peroxide and hydroxide, which, in the presence of hydrazine hydrate, was 
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converted into the intermediate 230. Subsequent dehydration formed 227 (Scheme 
31). The epoxidation reaction was reported to proceed in good yields (85–94%) with 
the latter two steps completed as a one-pot reaction.
341
  
 
Scheme 31. Synthesis of pyrazole-containing 227. Reagents and conditions: (a) H2O2/OH
-
, 0 °C, 85–
94% (b) NH2NH2•H2O, reflux; (c) AcOH, H2SO4 (cat.), 71–83%.  
The synthesis of 3,5-1H-pyrazoles through 1,3-dipolar cycloaddition has also been 
reported by Aggarwal and co-workers.
342
 Addition of diazo compounds (232), 
synthesised from aldehyde 231, to phenyl- and 3-pyridylacetylenes reportedly 
afforded the 3,5-disubstituted pyrazoles (233) in excellent 3,5/3,4 regioselectivity 
(95:5 to 99.8:0.2) (Scheme 32).  
 
Scheme 32. 1,3-Dipolar cycloaddition for the synthesis of 3,5-1H-pyrazoles. Reagents and 
conditions: (a) (i) TsNHNH2, MeCN (ii) 5 M NaOH; (b) Phenylacetylene or 3-pyridylacetylene: R
1
 = 
R
2
 = Ph, 61%; R
1
 = Ph, R
2
 = 3-pyridyl, 36%. 
The practical, multi-gram synthesis of translocator protein ligand (TSPO) DPA713 
(234) containing a pyrazolopyrimidine core was recently reported (Scheme 33). A 
Claisen-type ester condensation between ester 235 and acetonitrile gave compound 
236 in good yield.
343
 Subsequent alkylation installed the required N,N-
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diethylacetamide side chain to give compound 237. Condensation of compound 237 
with hydrazine hydrate formed the desired amino pyrazole core of 238. This reaction 
was conducted on a 20 gram scale and in excellent yield.
343
 
Scheme 33. Synthesis of pyrazole core within DPA713 (234). Reagents and conditions: (a) NaH, 
MeCN, PhMe, 80 °C, 18 h, 67%; (b) NaH, BrCH2C(O)NEt2, THF, 0 °C to rt, 27 h; (c) NH2NH2•H2O, 
AcOH, EtOH, reflux, 13 h, 71% over two steps.  
The practical nature of the synthetic protocol described in Scheme 33, the 
commercial availability of the reagents required and our need for the generation of a 
3-amino pyrazole, prompted us to undertake an analogous synthesis of the pyrazole 
core contained within compounds 209–211. 
5.4.4 The synthesis of compounds 209–211 
Pyrazole containing analogues 209–211 were synthesised as depicted in Scheme 34. 
Methyl benzoate (239) was treated with the anion derived from acetonitrile to afford 
compound 240, which was subsequently reacted with hydrazine to form 3-amino 
pyrazole 241 in excellent yields. The primary amine contained within pyrazole 241 
was then used to form amide 242 (74%). Unfortunately, the reactive nature of 242 
resulted in it decomposing within 12 h. As such, amine displacement of the alkyl 
bromine, as utilised earlier, was conducted immediately and afforded analogues 209–
211 (56-62%).  
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Scheme 34. Synthesis of pyrazole containing analogues 209–211. Reagents and conditions: (a) NaH, 
MeCN, PhMe, reflux, 18 h, 63%; (b) 240, NH2NH2•H2O, AcOH, EtOH, reflux, 18 h, 80%; (c) (i) 5-
bromovaleric acid, (COCl)2, rt, 1 h (ii) 241, NEt3, CH2Cl2, –78 °C to rt, 10 h, 74%; (d) appropriate 
amine, NaI, NEt3, THF, reflux, 16 h, X = O: 59%, X = CH2: 56%, X = NMe: 62%. 
With the synthesis of pyrazole containing compounds 209–211 complete, we next 
turned our attention towards the synthesis of compound 212.   
5.5 The synthesis of compound 212  
As discussed in section 4.4.1, pyridazinyl compound 139 is a potent and selective 
agonist at α7 receptors (Ki = 9.3 nM, EC50 = 9.5 µM). Section 4.4.1 describes the 
replacement of the basic centre (morpholine ring) of SEN12333 (45) with the basic 
centre, azacyclic (1S,4S)-2,5-diazabicyclo[2.2.1]heptane functionality, contained in 
compound 139 (Figure 58).  
 
Figure 58.  Hybrid structure 108  previously synthesised in section 4.4.  
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The present section describes the transposition of the aromatic moiety – biaryl ring 
system of compound 139 onto the structure of SEN12333 (45) resulting in hybrid 
compound 212 (Figure 59).  
 
Figure 59.  Proposed hybrid compound 212 .  
Prior to discussing the synthesis of compound 212 it is worthwhile to examine the 
use and properties of pyridazines in medicinal chemistry.  
5.5.1 Pyridazines in medicinal chemistry 
Pyridazine is a privileged structure in medicinal chemistry and is commonly used as 
an isosteric replacement for phenyl and heteroaromatic rings. Pyridazines are 
reported to improve the physiochemical properties of drug molecules by enhancing 
their water solubility, and participate in additional hydrogen bond interactions 
compared to carbocycles.
344,345
 Pyridazines further possess the capacity to complex 
targets due to their dipole moment; studies of the dipole moments of unsubstituted 
diazines (Figure 60) have revealed that pyridazine (243) exhibits the most elevated 
dipolar moment of 3.9 Debye (D) units – the result of both electronegative nitrogen 
lone pairs residing on the same side of the ring.
346
 This value is in comparison to 
those of isomeric diazines pyrimidine (244, 2.42 D) and pyrazine (245, 0.6 D).
346
  
 
Figure 60.  Dipole moments of diazines .  
Chapter 5 The biaryl ring system 
 
 
132 
 
In terms of drugs on the market, the most prominent example of a pyridazine 
containing drug is hydralazine (Apresoline™, 246, Figure 61). Hydralazine (246) is 
a smooth muscle relaxant utilised in the treatment of hypertension, which exerts its 
peripheral vasodilating effect through a direct relaxation of vascular smooth 
muscle.
347
 Other biologically active pyridazine-containing molecules include the 
highly potent and selective antagonists of the GABA-A receptor, “pyridazinyl-
GABA’s” (247, Figure 61), generated by attachment of a butyric acid chain to the 
endo-amidino nitrogen of a 3-amino pyridazine.
348-350
 This has resulted in the 
development of Gabazine (SR-95531, 248), an allosteric inhibitor currently used in 
scientific research.
351
  
 
Figure 61.  Biologically active pyridazine containing compounds . 
In terms of α7 agonists, several pyridazine containing molecules have previously 
been discussed in Section 4.4.1.  
5.5.2 The synthesis of compound 212 
Pyridazine analogue 212 could be synthesised from starting material 249, which 
underwent mono-substitution to afford aniline 250 (66%, Scheme 35) followed by 
amide formation in a manner similar to that previously described. This provided 
compound 251 (20% over two steps).  
 
Scheme 35. Synthesis of compound 251. Reagents and conditions: (a) NH4OH, µwave, 120 °C, 
300 W, 30 min, 66%; (b) (i) 5-Bromovaleric acid, (COCl)2, rt, 1 h (ii) 250, NEt3, CH2Cl2, –78 °C to rt, 
10 h, 20% 
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It was postulated that the low yield seen in the amide coupling of compound 250 
with 5-bromovaleric acid (58) was a result of the limited solubility of amine 250 in 
CH2Cl2. The solubility of amine 250 has been reported in polar organic solvents such 
as ethanol, methanol, 2-propanone and ethyl acetate, however, the use of such 
solvents in amide coupling reactions is unsuitable.
352
 The formation of 251 was 
attempted in various other organic solvents as described in Table 22, unfortunately 
the highest yield ever obtained was that of 20% utilising CH2Cl2 as previously 
described in Scheme 35.  
 
Table 22.  Solvents trialled in the synthesi s of amide 251 .  
Reagents and conditions: (a) (i) 5-bromovaleric acid, (COCl)2, rt, 1 h (ii) 250, NEt3, solvent, –78 °C 
to rt, 10 h. 
Solvent Outcome 
MeCN 
complex mixture containing some 
unreacted starting material 
DMF no reaction 
 
An alternative synthesis of the amide bond contained within compound 251 was 
therefore proposed (Scheme 36). 5-Bromovaleric acid (58) was readily converted to 
its corresponding methyl ester (252). Subsequent alkylation of morpholine with 252 
gave the desired compound 253 in excellent yields. Ester 253 was not hydrolysed to 
its corresponding carboxylic acid due to its zwitterionic nature. Consequently a range 
of conditions were trialled to form the desired bond between ester 253 and aniline 
250 (Table 23). Unfortunately in no instance was the desired amide 254 formed. 
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Scheme 36. Alternative synthesis towards compound 254. Reagents and conditions: (a) SOCl2, 
MeOH, 0 °C to rt, 18 h, 91%; (b) Morpholine, NaI, NEt3, THF, reflux, 16 h, 77%; (c) see Table 23.  
Table 23.  Conditions trialled for aminolysis of 253 ,  (Scheme 36 , step c).  
Reagents Conditions Outcome 
250, BF3•OEt2 MeCN, reflux, 16 h,  no reaction 
250 MeOH, reflux, 18 h no reaction 
250, AlCl3 
CH2Cl2, 0 °C to rt,  
17 h
353
 
no reaction 
250, AlMe3 CH2Cl2, rt, 17 h
354
  no reaction 
250, AlMe3 PhMe, reflux, 18 h no reaction 
250, NaH DMSO, rt, 16 h no reaction 
 
An alternative to forming the problematic amide bond was proposed and is depicted 
in Scheme 37. Cyclopentanone (255) was subjected to Baeyer-Villiger oxidation 
conditions to give lactone 256 in acceptable yield.
355
 Initial attempts to open the 
lactone ring of 256 with amine 250 proved fruitless and instead lactone 256 was 
treated with sodium hydroxide to give carboxylic acid 257. It was thought that the 
absence of the alkyl bromide would render the amide formation more facile. 
Disappointingly, attempts to couple acid 257 with amine 250 to give amide 258, 
again proved unsuccessful.  
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Scheme 37. Alternative synthesis towards compound 212. Reagents and conditions: (a) m-CPBA, 
TFA, CH2Cl2, 0 °C to rt, 1 h, 55%; (b) 250, MeCN, reflux, 20 h, no reaction; (c) NaOH, MeOH:H2O 
(3:1), rt, 19 h, 73%; (d) (i) (COCl)2, rt, 1 h (ii) 250, NEt3, DMF, –78 °C to rt, 15 h, complex mixture.  
Due to the extensive number of synthetic protocols trialled for the synthesis of the 
amide bond within 251 and the unsuccessful outcome of each of these, the initial 
conditions described in Scheme 35 were adopted, albeit with a low yield of 20% 
(over two steps). Our attention was then re-focused upon completion of the synthesis 
of compound 212. Iodide assisted morpholine substitution provided amine 254. 
Suzuki cross-coupling with phenylboronic acid then afforded the target pyridazine 
containing analogue 212 in good yields (Scheme 38). 
 
Scheme 38. Synthesis of compound 153. Reagents and conditions: (a) Morpholine, NaI, NEt3, DMF, 
reflux, 16 h, 62%; (b) Pd(PPh3)4, phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 63%. 
With the synthesis of compound 212 complete, we next directed our efforts towards 
the synthesis of compound 213. 
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5.6 The synthesis of indole analogue 213  
5.6.1 The 5-indolyl motif in medicinal chemistry  
The 5-indolyl motif is previously described by Li and co-workers in the α7 agonist 
259 (Figure 62).
279
 The 5-indolyl motif was reported to exhibit excellent human liver 
microsome stability (>97% remaining after 30 min incubation). Incorporation of this 
motif into the aromatic moiety of SEN12333 (45) resulted in the development of 
compound 213. We hoped to potentially improve the biological properties of 
SEN12333 (45) and enhance the hydrogen bonding capacity of the terminal aromatic 
ring through incorporation of this motif.  
Substituted indoles have frequently been referred to as “privileged structures”. They 
are capable of binding to multiple receptors with high affinity, and therefore have 
applications across a wide range of therapeutic areas.
356,357
 Most notably, the indole 
ring is present as the key substructure in the amino acid tryptophan (260, Figure 62), 
and also the numerous molecules which contain this amino acid.
357
 Additionally, this 
prominent bicycle is found in a multitude of natural products, including serotonin (5-
hydroxytryptamine, 261), a key neurotransmitter within the CNS that is known to 
regulate smooth muscle function in the cardiovascular and gastrointestinal systems 
and is also involved in regulation of platelet function.
357
 In terms of drugs, the indole 
scaffold is found in NSAID indomethacin (262) and racemic etodolac (263) (Figure 
62).
357
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Figure 62.  Biologically active molecules containing the indole mot if.  
5.6.2 Synthesis of compound 213 
The synthesis of compound 213 was straight forward and involved the Suzuki cross-
coupling reaction between previously made amide 68 and 5-indolylboronic acid 
(Scheme 39), which proceeded in excellent yield.  
 
Scheme 39. Synthesis of compound 213. Reagents and conditions: (a) Pd[(PPh3)4], 5-indolylboronic 
acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 81%. 
With the synthesis of compound 213 complete, we next turned our attention towards 
investigation of the binding affinities of all newly synthesised compounds exploring 
variation of the aromatic moiety. 
Chapter 5 The biaryl ring system 
 
 
138 
 
5.7 The binding affinities and physicochemical 
properties of all aromatic moiety analogues of 
SEN12333   
All newly synthesised compounds were subjected to competition binding assays 
according to the procedures described in Section 11.9.1 The library displayed a range 
of affinities and all compounds were selective for the α7 subtype over the α4β2 and 
α3β4 subtypes (Table 24).  
 Compounds 206 and 207, containing the 2- and 4-position pyridine nitrogen 
both display a 2-fold increased potency over the lead compound SEN12333 
(45). Importantly they also display an increase in their LLE values. This 
indicates that the pyridine nitrogen of SEN12333 (45) is currently in the least 
favorable position within the terminal aromatic ring and suggests the 
potential of further development of compounds 206 and 207.  
 Gratifyingly, upon conserving the 3-position of the pyridine nitrogen and 
incorporating the electronegative 2-fluorine substituent as in compound 208, 
a dramatic increase in potency and LLE is seen compared to SEN12333 (45) 
(85 nM vs 670 nM respectively). This 8-fold increase in potency is a 
significant outcome and highlights the potential for further development. 
 Incorporation of the prominent 5-phenyl-1H-pyrazole moiety resulted in a 
severe loss of potency at α7 receptors evident by the direct comparison of 
compounds 209 and SEN12333 (45). This drop in potency was restored by 
incorporation of the previously identified aliphatic heterocycle, piperidine 
(210). Consistent with our SAR results from the basic centre exploration of 
SEN12333 (45), incorporation of the 1-methylpiperazine functionality was 
unfavorable and resulted in a loss of potency at α7 receptors (211). While 
compound 210 displayed a similar binding affinity to SEN12333 (45), its 
increased lipophilicity lowered its LLE value compared to SEN12333 (45) 
(2.29 vs 3.92 respectively) and suggests that it will not be successful in vivo.  
 Hybrid compound 212 containing the biaryl ring system of compound 139 
(Figure 59) exhibited a complete loss of potency at α7 receptors. This 
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indicates that the biaryl ring system of compound 139 cannot be incorporated 
into SEN12333 (45). The development of such hybrids is catastrophic for α7 
binding affinity.  
 Introduction of the 5-indolyl moiety (213) was well tolerated and increased 
potency 2-fold relative to SEN12333 (45). This suggests that the additional 
H-bonding capacity of indole 213 is favorable and that the biaryl moiety can 
be extended without sacrificing potency. However, the increased lipophilicity 
of compound 213 resulted in a somewhat diminished LLE value.  
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Table 24.  Binding affinities of aromatic moiety exploration analogues of SEN12333 
(45). 
Ligand 
Binding affinity Ki (nM)
a
 
Physicochemical 
properties 
 
Compound aromatic moiety α7 α4β2 α3β4 
cLogP
b
 
PSA LLE 
SEN12333 
(45) 
 
670 ± 
119 
>1000
0 
>1000
0 
2.25 
53.9
3 
3.92 
206 
 
330 ± 
80 
>1000
0 
>1000
0 
2.46 
53.9
3 
4.02 
207 
 
350 ± 
90 
>1000
0 
>1000
0 
2.25 
53.9
3 
4.21 
208 
 
85 ± 
10 
>1000
0 
>1000
0 
2.48 
53.9
3 
4.59 
209 
 
2600 ± 
300 
>1000
0 
>1000
0 
2.96 
65.9
6 
2.63 
210 
 
660 ± 
70 
>5000
0 
>1000
0 
3.89 
56.7
3 
2.29 
211 
 
26000 
± 6000 
>1000
0 
>1000
0 
1.74 
59.9
7 
2.85 
212 
 
92000 
>1000
00 
>1000
00 
2.39 
66.2
9 
1.65 
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213 
 
310 ± 
30
 
>1000
0 
>1000
0 
3.57 53.6 2.94 
a
 Competition curves were constructed in which 10 concentrations of a sample were included (n = 1), 
DNC = does not converge Ki values are the Mean ± SEM of three to six independent measurements. 
For low binding affinity compounds, estimated Ki value ranges were provided. 
b
 Calculated using 
ChemDraw12.0 
c
 calculated according to equation LLE = pIC50 (or pKi) – cLogP. 
5.8 Concluding remarks  
The work within the present chapter investigates the SAR of the biaryl rings 
contained within lead structure SEN12333 (45). The findings reveal that the 3-
position of the pyridine nitrogen within the terminal aromatic ring of compound 45 is 
the least favourable in terms of binding affinity at α7 receptors. Compounds 206 and 
207 bearing the pyridine nitrogen in the 2- and 4- positions respectively both exhibit 
a 2-fold increase in binding affinity at α7 receptors and also an increase in LLE value.  
Incorporation of the electronegative fluorine atom onto the structure of SEN12333 
(45) as in compound 49 resulted in an 8-fold increase of potency at α7 receptors. This 
significant outcome substantially increases our knowledge about α7 receptors and 
identifies the most potent compound of the present series. The desirable LLE value 
of compound 49 suggests its potential for in depth evaluation.  
Incorporation of the 5-substituted-1H-pyrazole motif, compound 209, a hybrid of 
Haydar’s work and SEN12333 (45), completely abolished affinity at α7 receptors. 
This loss of potency was restored through replacement of the morpholine ring with 
the azacyclic piperidine ring (compound 210). As previously shown in Chapter 4, 
this N-heterocycle enhances α7 affinity. Consistent with the results from Chapter 4, 
introduction of the 1-methylpiperazine functionality (211) was deleterious for α7 
affinity. Incorporation of the biaryl motif from known α7 agonist 139, to give the 
hybrid compound 212 also resulted in diminished affinity. Again this was consistent 
with our results from Chapter 4 and suggests substantially that the structural features 
of compound 212 cannot be transposed onto SEN12333 (45). Incorporation of the 5-
indolyl motif (compound 213) proved promising for α7 receptor affinity with a 2-fold 
increase in potency over the lead SEN12333 (45), however, its higher lipophilicity 
would have to be address in future explorations 
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Chapter 6 - Truncated hybrids 
6.1 Introductory remarks  
The work described in the previous chapter illustrates how modifications to the 
aromatic moiety of SEN12333 (45) affect the binding affinities of the compounds. 
This was accomplished by alteration of the biaryl ring system of SEN123333 (45). 
Minor structural adjustments, such as the position of the pyridine nitrogen within the 
terminal ring were investigated along with the direct transposition of biaryl motifs 
that occur in α7 agonists. Prominent in this respect, was compound 139. The focus of 
the present chapter is to investigate the development of truncated hybrid analogues of 
SEN12333 (45) through incorporation of structural motifs seen in agonist 139.  
The structural similarities of selective α7 agonists SEN12333 (45) and compound 139 
was noticed and it was postulated that compound 139 was somewhat of a truncated 
hybrid of SEN12333 (45), in which removal of the carbon chain linker and amide 
bond of SEN12333 (45) would result in a compound displaying similarity to 
compound 139 (Figure 63).  
 
Figure 63.  Similarities and general structures of SEN12333 ( 45) and compound 139 .  
Truncated hybrids of SEN12333 (45) would therefore be synthesised through the 
integration of functionalities present within compound 139. This would allow us to 
determine which pharmacophoric units were optimal for the binding of truncated 
SEN12333 analogues, and to concurrently identify the most important structural 
elements responsible for the point binding of compound 139. 
Chapter 6 Truncated hybrids 
 
143 
 
The most striking difference between SEN12333 (45) and compound 139 is the 
identity of the heterocycle comprising the basic centre of the molecules. Therefore 
this portion of the molecule was selected as the starting point for our SAR study. 
This was to be achieved by altering the heterocycle comprising the basic centre of 
compound 139 while still retaining the more truncated structure that distinguishes 
compound 139 from SEN12333 (45). Similar to the previous work in Chapter 4 on 
SEN12333 (45), (1S,4S)-2,5-diazabicyclo[2.2.1]heptane was to be replaced by the 
small azacycles morpholine, piperidine and 1-methylpiperazine. These azacycles 
were selected as they represent the stepwise degression from the (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane heterocycle contained within compound 139 to the 
morpholine ring contained within SEN12333 (45). Accordingly, the synthesis of 
compounds 264–266 and 139 was proposed. Compound 267 containing the 5-indolyl 
motif was included based upon previous work by Li and co-workers
279
 to further 
investigate the incorporation of this aromatic moiety and also morpholine onto a 
truncated structure (Table 25). 
Table 25.  Truncated analogues exploring basic centre of compound 139 .  
 
Compound basic centre 
264 
 
265 
 
266 
 
139 
 
267 
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The final set of hybrids to be synthesised in this study, investigate the necessity of 
the pyridazine moiety within compound 139 and the consequence of incorporating 
the phenyl-pyridyl or biphenyl motif originally associated with SEN12333 (45). The 
proposed analogues are summarised in Table 26.  
Table 26.  Truncated analogues exploring aromatic moiety of compound 139 .  
 
Compound basic centre X Compound 
basic 
centre 
X 
268 
 
N 272 
 
N 
269 CH 273 CH 
270 
 
N 274 
 
N 
271 CH 275 CH 
 
Prior to discussing the synthesis of these truncated hybrids it is worthwhile to look at 
the use of truncated hybrids within medicinal chemistry.  
6.2 The use of truncated scaffolds and hybrids within 
medicinal chemistry  
6.2.1 The use of truncated scaffolds within biologically active molecules 
Marine macrolides are commonly recognised for their intriguing molecular structure 
and potent anticancer activity.
358
 Superstolides A (276) and B (277) (Figure 64) 
represent two marine macrolides isolated in minute amounts from the deep-water 
marine sponge Neosiphonia superstes.
358
 Both compounds exhibit potent 
antiproliferative effects against several tumour cell lines (IC50 values ranging from 
4.8 to 64 nM).
359,360
 Unfortunately, yields of isolation for superstolides A (276) and 
B (277) are only 0.003% and 0.0003% respectively. In addition to this, the marine 
sponge from which they are isolated resides at depths of 500–515 metres off New 
Caledonia, rendering the collection of substantial quantities extremely difficult and 
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also potentially damaging to the surrounding marine habitat.
361
 As a result of their 
potent anticancer properties and unique molecular structure, the total synthesis of 
these compounds has generated a large amount of attention.
362-364
 However, due to 
the structural complexity of the target molecules, a practical total synthesis which 
provides adequate amounts of material for biological investigation has proved 
extremely challenging. Consequently, Jin and co-workers have investigated the 
design and synthesis of truncated superstolide A (278) in which the cis-fused decalin 
system is simplified to a cyclohexene ring.
361
  
 
Figure 64.  Structures of Superstolides A (276) and B (277) and truncated analogue 
278 .  
Such a modification maintained the general template of the lead molecule but 
simplified the synthesis significantly. Compound 278 was synthesised from 
commercially available starting materials in 15 steps and 6.2% overall yield.
361
 The 
antiproliferative effect of truncated analogue 278 was then evaluated in eight cancer 
cell lines utilising the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. Gratifyingly, compound 278 was shown to be seven times more 
potent in suppressing tumor cell proliferation in HT-29 cells than its parent natural 
product, superstolide A (276). Furthermore, analogue 278 exhibited potent activity in 
suppressing tumour cell proliferation in the additional seven cell lines tested with 
IC50 values ranging from 12–77 nM.
361
 Modification of the cis-decalin of compound 
276 to a cyclohexene ring as in truncated compound 278, does not appear to affect 
anticancer activity and the more straightforward synthesis of hybrid compound 278 
allows for the synthesis of more substantial quantities and further biological 
evaluation.  
Whilst the development of compound 278 represents an example of a truncated 
analogue derived from a single lead compound (276). There exist numerous 
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examples of the development of biologically active molecules from the incorporation 
and merging of structural motifs seen in two or more different lead compounds.  
6.2.2 The development of hybrid compounds with biological activity 
Geldanamycin (279) is an ansamycin antibiotic initially isolated from Streptomyces 
hygroscopicus which binds to the histone shock protein 90 (Hsp90) chaperone 
protein resulting in the downstream inactivation of multiple important signalling 
proteins (Figure 65).
365
 It was consequently postulated that a suitably designed 
hybrid drug of compound 279 and estradiol (280) would possess the ability to induce 
selective degradation of the estrogen receptor (ER), present at higher concentrations 
in breast cancer, ovarian adenocarcinoma, prostatic carcinoma and endometrial 
carcinoma than in normal tissues.
366
  
 
Figure 65.  Structures of geldanamycin (279  and estradiol (280).  
Through various functional group manipulations, a linker was attached to the 
cyclopentane ring of estradiol (280) and was connected to the amino functionality at 
C17 of geldanamycin (279). Two different linker-containing hybrids (281 and 282) 
were synthesised and their activity evaluated in the reduction of expression of 
different tumour relevant proteins in MCF7 breast cancer cells (HER2, ER and Raf-
1) (Table 27). A second assay on these proteins and IGF1R revealed hybrid 281 to 
be of enhanced selectivity compared to geldanamycin (279) and estradiol (280) for 
the degradation of HER2 and ER.
366,365
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Table 27 . Effects of hybrids 281  and 282 .  
Compound Linker HER2 (µM) 
IC50 (ER) 
(µM) 
(Raf-1) (µM) 
Geldanamycin 
(279) 
- 0.05 0.06 0.2 
281 
 
0.1 0.08 1.5 
282 
 
0.1 0.22 1.5 
 
The development of 281 highlights an example of a designed hybrid with biological 
activity exceeding that of the parent compounds and further emphasises the potential 
of hybrid development within medicinal chemistry and drug design.  
6.3 The synthesis of truncated pyridazine analogues 
264–266 and 139 
The synthesis of analogues 264–266 and 139 began with mono-chloride substitution 
of 3,6-dichloropyridazine (249) with an appropriate amine to afford compounds 283–
286 in moderate to excellent yields (Table 28).  
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Table 28.  Synthesis of compounds 283–286 .  
Compound basic centre
 
Yield (%) 
283 
 
83 
284 
 
72 
285 
 
62 
286 
 
37 
Reagents and conditions: (a) appropriate amine, DIPEA, DMF, reflux, 17 h. 
Subsequent Suzuki cross-coupling of the remaining chloride with phenylboronic acid 
afforded the desired analogues 264–266 and 287 in excellent yields (Table 29). 
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Table 29.  Suzuki coupling of compounds 283–286 .  
Compound basic centre Yield (%) 
264 
 
61 
265 
 
68 
266 
 
59 
287 
 
78 
Reagents and conditions: (a) Pd(PPh3)4, phenylboronic acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h 
In the case of compound 287 an additional deprotection and methylation step was 
required to furnish the desired (1S,4S)-2-methyl-2,5-diazabicyclo[2.2.1]heptane core 
contained within lead compound 139 (Scheme 40). 
 
Scheme 40. Deprotection and methylation to give compound 139. Reagents and conditions: (a) HCl 
(4 M in 1,4-dioxane), MeOH, rt, 2 h; (b) 37% aq. HCOH, NaBH(OAc)3, ClCH2CH2Cl, rt, 18 h, 66% 
over two steps.  
5-Indolyl analogue 267 was synthesised analogously from compound 283 in good 
yield, so as to draw comparisons with the previously synthesised SEN12333 hybrid 
213 (Scheme 41).  
 
Scheme 41. Synthesis of compound 267. Reagents and conditions: (a) Pd(PPh3)4, 5-indolylboronic 
acid, MeCN/sat. aq. Na2CO3 (1:1), reflux, 18 h, 74%. 
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With the synthesis of compounds 264–266 and 139 complete, we then turned our 
attention to the preparation of compounds 268–271 and 274–273. 
6.4 The synthesis of truncated phenyl analogues 268–
275  
It was envisioned that compounds 268–275 would be synthesised according to the 
general conditions shown in Scheme 42. A suitable 1,4-disubstituted benzene would 
serve as the starting material for C-N bond formation with the desired amines 
morpholine, piperidine, 1-methylpiperazine and previously made amine 157. 
Subsequent Suzuki cross-coupling reaction with either 3-pyridyl- or phenylboronic 
acid would furnish the desired ligands.  
 
Scheme 42.  Proposed synthesis for analogues 268–271  and 274–273 .  
Prior to discussing the synthesis of compounds 268–271 and 274–273, it is 
worthwhile to review the chemistry of C-N bond formation. 
6.4.1 C-N Bond formation  
Heteroatom alkylation and arylation are fundamental transformations within 
medicinal chemistry and are reported to account for 23% of the reactions commonly 
used by medicinal chemists.
255
 Within this subset, N-arylation with aryl halides is the 
most prevalently used reaction, accounting for 27% of this subtype. The formation of 
molecules containing the N-aryl moiety has garnered a large amount of attention as a 
result of their occurrence in a wide variety of areas such as natural product synthesis 
and materials, and also their prevalence in compounds with medicinally important 
properties.
367
 Despite the simplicity of the arylamine moiety, the synthesis of such 
compounds is often challenging and as a result a number of methods have been 
generated for aryl C-N bond construction. Methods involving nitration, reduction, or 
substitution are often incompatible with multiple functional groups and typically 
require protection and deprotection steps.
368
 Arylamine reductive amination involves 
imine formation and subsequent reduction. This requires multiple steps: preformation 
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of the C-N bond within the aniline, use of an excess of the amine, and the reactions 
are often sluggish.
369,370
 Alternatively, copper mediated (Ullmann) substitutions have 
been reported, however, they occur at high temperatures, are substrate specific, and 
often give rise to diarylation products.
371-374
 The addition of amines to benzyne 
intermediates commonly results in regioisomers and direct nucleophilic substitution 
of aryl halides typically require a large excess of reagent, highly polar solvents and 
either high reaction temperatures or highly activated aryl halides.
375,376
 A transition 
metal catalysed approach to C-N bond construction is therefore convenient in terms 
of directness and atom-economy, as it involves the direct cross-coupling of an amine 
with an aryl halide.  
6.4.2 Palladium catalysed amination 
The initial entry into the palladium-catalysed formation of aryl C-N bonds was 
provided by Migita and co-workers in 1983.
377
 The reaction of electronically neutral 
aryl bromides and N-N-diethylaminotributyltin in the presence of catalytic [(o-
tol)3P]2PdCl2 was reported to afford the corresponding N,N-diethylaniline, as well as 
tri-n-butyltin bromide as the stoichiometric by-product, in good to moderate yields 
(Scheme 43). Unfortunately, this pivotal discovery was limited as the procedure was 
not readily extendable to other amine types because amino stannanes are not 
commercially available and are both thermally and moisture-sensitive.
378
 
 
Scheme 43. Palladium-catalysed formation of C-N bonds. Reagents and conditions: (a) 1 mol% [(o-
tol)3P]2PdCl2, toluene, 100 °C, 3 h. 
This problem was somewhat circumvented by Buchwald and Guram, who exploited 
the ability of N-N-diethylaminostannane to endure transamination reactions.
379
 
Aminotin compounds were then able to be prepared in situ and were subsequently 
found to undergo cross-coupling reactions with various aryl bromides (Scheme 44).  
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Scheme 44.  Buchwald and Guram modifications . 
Despite the increased practicality and generality of this protocol, it was still 
undesirable due to the stoichiometric amounts of tin required. The limitations 
associated with the use of tin compounds were overcome concurrently by the 
Buchwald and Hartwig groups. By employing NaO
t
Bu as a base, Buchwald was 
effectively able to achieve catalytic C-N bond formation (Scheme 45).
380
 The 
sodium amide generated through in situ deprotonation of the reacting amine could be 
employed instead of the corresponding aminotin species. Buchwald reported that the 
isolate complex [(o-tol)3P]PdCl2 (or a catalyst generated from mixing Pd2dba3 and 
two equivalents of (o-tol)3P) achieved the C-N bond formation with comparable 
efficiency.
380
  
 
Scheme 45. Buchwald-Hartwig amination. Reagents and conditions: (a) 2 mol% Pd2(dba)3, 4 mol% 
(o-tol)3P or [(o-tol)3P]2PdCl2, NaO
t
Bu, toluene, 65 or 110 °C.  
Similarly, Hartwig reported that lithium hexamethyldisilazide (LiHMDS) could also 
be utilised as a base for such transformations (Scheme 46).
381
 They also reported the 
two different complexes [(o-tol)3P]2PdCl2 and [(o-tol)3P]2Pd to effectively catalyse 
the amine arylation reaction. The palladium catalysed synthesis of aryl amines then 
became known as the Buchwald-Hartwig amination. 
 
Scheme 46. Buchwald-Hartwig amination. Reagents and conditions: (a) 5 mol% [(o-tol)3P]2PdCl2 or 
[(o-tol)3P]2Pd, LiHMDS, toluene, 100 °C.  
While both of these reports have greatly expanded the scope and utility of the amine 
arylation reaction, which now encompasses various other nitrogen-containing species 
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and other aryl ‘halides’, these catalytic systems serve a relatively narrow substrate 
scope compared to subsequent generations of catalysts developed by the Buchwald 
and Hartwig groups. Through numerous progressions of ligand design, 
methodological studies and mechanistic investigations, highly active and broadly 
useful catalyst systems have been developed. The general mechanism for the amine 
arylation is summarised in Scheme 47. The catalytic cycle commences with the 
oxidative addition of the aryl halide (or sulfonate) by the active catalyst species, 
Pd(0). The palladium (II) aryl amide can be formed through either direct 
displacement of the halide (or sulfonate) by the amine or via the intermediary 
palladium (II) alkoxide.
382
 Reductive elimination of the C-N bond results in the 
formation of the desired arylamine and regeneration of the Pd(0) catalyst.
383
  
 
Scheme 47.  Catalytic cycle of the Buchwald-Hartwig amination reaction.  
A noteworthy side reaction occurs when instead of reductively eliminating the N-aryl 
product; the intermediate palladium amide undergoes β-hydride elimination to 
generate an imine and a palladium (II) aryl hydride (Scheme 48). Subsequent 
reductive elimination yields the reduced arene (Ar-H) and regenerates the Pd(0) 
catalyst.
384
 This side reaction generally becomes of increased importance when 
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electron-donating aryl halides or sulfonates are employed, as electron-deficient 
palladium species more readily undergo reductive elimination.
367
 One of the major 
challenges faced in the development of efficient amine arylation catalysts, was 
circumventing this unwanted side reaction.  
 
Scheme 48 .  β-hydride elimination side reaction . 
In terms of the cross-coupling of cyclic secondary amines with aryl bromides, these 
reactions generally tended to provide less of the reduced arene side product.
367
 
Presumably, the cyclic palladium (II) amide intermediate is less prone to β-H 
elimination compared to the acyclic counterpart. Although the arylation reaction 
could be achieved with (o-tol)3P as a ligand, Buchwald and co-workers have 
investigated the use of (±)-BINAP and other diphosphine ligands in the C-N bond 
forming reaction. (±)-BINAP is reported to often provided increased yields of the 
desired product for both cyclic and acyclic amines, and lower amounts of aryl 
bromide reduction is observed.
385,386
 For example, the coupling of 1-
methylpiperazine with 3,5-dimethylbromobenzene is reported to proceed in 47% 
yield utilising the (o-tol)3P based protocol; however, when the (±)-BINAP-derived 
catalyst is employed, the reaction proceeds in 98% yield (Scheme 49). Yields of 94% 
can even be obtained upon utilising the (±)-BINAP/Pd catalyst in only 0.05 mol% 
and in the absence of solvent.
378
  
 
Scheme 49. Buchwald-Hartwig amination with cyclic secondary amines. Reagents and conditions: (a) 
2 mol% ligand, Pd2(dba)3, NaO
t
Bu, toluene, 80 °C. 
The palladium catalysed Buchwald-Hartwig cross coupling reaction was therefore 
chosen as the preferred method to form the C-N bond for the synthesis of compounds 
268–271 and 274–273 (Scheme 42). 
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6.4.3 C-N bond formation in the synthesis of truncated phenyl analogues 
268–275  
Morpholine was selected as a starting point for investigations into determining the 
optimal conditions for the cross coupling of the desired cyclic, secondary amines and 
1,4-dibromobenzene (288). 1,4-Dibromo substitution was essential as the second 
halogen served as the coupling partner for the subsequent Suzuki cross-coupling 
reaction. The catalysts and ligands trialled are summarised in Table 30. 
 
Table 30.  Conditions trialled for Buchwald -Hartwig amination to give compound 289 .  
Entry 
Catalyst (% 
loading) 
Ligand (% 
loading) 
Reaction conditions 
Yield 
289 (%) 
1 - - 
KO
t
Bu, morpholine, 
toluene, reflux, 17 h 
no 
reaction 
2 Pd(PPh)4 (5) - 
KO
t
Bu, morpholine, 
toluene, reflux, 16 h 
15 
3* Pd2(dba)3 (2) XPhos (4) 
KO
t
Bu, morpholine, 
toluene, 60 °C, 1.5 h
387
  
28 
4 Pd2(dba)3 (4) 
(±)-BINAP 
(X302) (8) 
KO
t
Bu, morpholine, 
toluene, 110 °C, 5 h
388
  
47 
* 4-iodo-bromobenzene was used.  
Similar to the results previously reported by Buchwald and co-workers the most 
positive results and highest yields were evident in entry 4 (Table 30) utilising 
Pd2(dba)3 as a catalyst and (±)-BINAP as the ligand.
385,386
 These conditions were 
therefore employed for the cross coupling 1,4-dibromobenzene with the remaining 
amines piperidine, 1-methylpiperazine and previously synthesised amine 157. The 
yields obtained are summarised in Table 31.  
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Table 31.  Synthesis of compounds 290 ,  291  and 292.
388
  
Compound basic centre Yield 
290 
 
only di-substituted 
products isolated 
291 
 
51 
292 
 
82 
Reagents and conditions: (a) Pd2(dba)3 (4 mol%), (±)-BINAP (8 mol%), KO
t
-Bu, morpholine, 
toluene, 110 °C, 8-16 h. 
While the synthetic protocol worked well for the synthesis of 1-methylpiperazine- 
and (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-containing compounds (compounds 291 
and 292 respectively), in the case of piperidine-containing compound 290 only di-
substituted of 1,4-dibromobenzene was observed. Consequently, an alternative 
synthetic protocol was investigated for the synthesis of compound 290.  
Copper-mediated C-N bond formation via the cross-coupling of arylboronic acids 
and nitrogen-based nucleophiles has become an increasingly important synthetic 
strategy following their initial discovery by Chan and Lam.
389,390
 The reported 
conditions described N-arylation of nitrogen based nucleophiles by arylboronic acids 
occurring with a stoichiometric amount of Cu(II) salt, and several equivalents of a 
base/ligand. However, the amine substrate scope examined was largely confined to 
aromatic amines and limited examples of aliphatic amines have been reported.
389
 
Quach and Batey have since reported a set of reaction conditions optimised for the 
cross-coupling of primary and secondary amines with arylboron compounds.
391
 The 
process utilises catalytic copper(II) acetate monohydrate and 4 Å molecular sieves 
under an atmosphere of oxygen. Based upon the positive results described and the 
simplicity of the reaction conditions, this synthetic protocol was applied to the 
synthesis of compound 290 (Scheme 50).  
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Scheme 50. Synthesis of compound 290. Reagents and conditions: (a) CuOAc2•H2O, CH2Cl2, 4 Å 
MS, O2, rt, 20 h, 58%.  
With coupled amines 289–292 in hand, we now focused our attention on the final 
Suzuki coupling reactions to afford the desired hybrid ligands. 
6.4.4 Suzuki coupling reactions of compounds 289, 290, 291 and 292 
The final set of hybrids (compounds 268–275) investigate the incorporation of the 
biaryl ring system contained within SEN12333 (45) onto truncated lead 139. So as to 
continue our investigations from Chapters 3, 4 and 5; both the phenyl-pyridyl and 
biphenyl motifs were synthesised. The completion of the synthesis of hybrid 
compounds 268–275 involved the Suzuki coupling reaction of the aryl bromide 
contained within compounds 289, 290, 291 and 292 with either 3-pyridylboronic- or 
phenylboronic acid. The reactions were conducted under the conditions previously 
described and proceeded in excellent yield. The results are summarised in Table 32.  
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Table 32. Suzuki coupling of compounds  289, 290, 291 and  292 
Compound basic centre X Yield 
268 
 
N 56 
269 CH 72 
270 
 
N 72 
271 CH 71 
272 
 
N 63 
273 CH 74 
293 
 
N 52 
294 CH 58 
Reagents and conditions: (a) Pd(PPh3)4, appropriate boronic acid, MeCN/sat. aq. Na2CO3 (1:1), 
reflux, 18 h, 70–90%. 
In the case of compounds 293 and 294, the additional de-protection and methylation 
steps were required to provide the specific (1S,4S)-2-methyl-2,5-
diazabicyclo[2.2.1]heptane core contained within lead compound 139 (Scheme 51). 
 
Scheme 51. Deprotection and methylation to give compounds 274 and 275. Reagents and conditions: 
(a) HCl (4 M in 1,4-dioxane), MeOH, rt, 2 h; (b) 37% aq. HCOH, NaBH(OAc)3, ClCH2CH2Cl, rt, 18 
h, 274: 61%, 275: 54% over two steps.  
With the synthesis of analogues 268–275 complete, we then focused our efforts upon 
the biological evaluation of all newly synthesised truncated hybrids (139, 264–267, 
and 268–275). 
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6.5 The binding affinities of truncated hybrids  
All newly synthesised compounds were subjected to competition binding assays 
according to the procedures described in Section 11.9.1 and the results are 
summarised in Table 33 and Table 34.  
Table 33 describes the biological evaluation of compounds 264–266, 139 and hybrid 
compound 267, which respectively explore the effects of alteration to the basic centre 
of compound 139 and the incorporation of the 5-indolyl motif. It was immediately 
evident that the potency trend for the basic centre of compounds containing the 
truncated structure of lead 139, was in contradiction to that of SEN12333, 45 (Figure 
63). Aliphatic azacycles morpholine and piperidine which corresponded to increased 
potency and selectivity for SEN12333 (45) were the less active in the series of 
truncated hybrids (264 and 265). Incorporation of 1-methylpiperazine (266) 
marginally restored potency at α7 receptors. Interestingly, compound 266 was the 
only ligand to show any potency for the α4β2 nAChR. The most potent compound of 
the series for the α7 receptor, was compound 139. This suggests that the (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane functionality is the optimal heterocycle for the binding 
and selectivity of the synthesised truncated compounds. This is further highlighted 
by the excellent LLE value of compound 139. Incorporation of the 5-indolyl moiety 
previously improved the potency of SEN12333 hybrid 213 (Section 5.7, Table 24). 
However, in the case of hybrid 267, incorporation of the 5-indolyl motif onto a 
truncated scaffold resulted in a complete loss of potency at α7 receptors.  
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Table 33.  Binding affinities of basic centre exploration of truncated analogues . 
Ligand 
Binding affinity Ki (nM)
a
 
Physicochemical 
properties 
 
Compound basic centre α7 α4β2 α3β4 cLogP
b
 PSA LLE 
264 
 
358000 >10000 >100000 1.78 37.19 1.67 
265 
 
>100000 >10000 >100000 3.18 27.96 ND 
266 
 
4070 417 19700 2.36 31.20 ND 
139 
 
5.9 ± 0.6 >30000 >50000 2.50 31.20 5.73 
267 
 
>100000 >10000 >100000 1.79 49.22 ND 
a
 Competition curves were constructed in which 10 concentrations of a sample were included (n = 1), 
DNC = does not converge Ki values are the Mean ± SEM of three to six independent measurements. 
For low binding affinity compounds, estimated Ki value ranges were provided. 
b
 Calculated using 
ChemDraw12.0 
c
 calculated according to equation LLE = pIC50 (or pKi) – cLogP. 
In terms of binding affinities of truncated hybrids exploring biaryl alteration, the 
results are summarised in Table 34. In line with our results of the previous truncated 
series (Table 33), small unsubstituted azacycles morpholine and piperidine are not 
tolerated for compounds bearing the truncated scaffold of compound 139 (Figure 
63). This is evident in the dramatic loss of potency of compounds 268–271. Similar 
to the results of Table 33, introduction of the 4-methylpiperazine functionality (272 
and 273) marginally restored potency. The most potent compounds of this series 
were 274 and 275 containing the (1S,4S)-2,5-diazabicyclo[2.2.1]heptane 
functionality. Interestingly, in accordance with the results of Chapter 4, SEN12333-
hybrid compounds containing the biphenyl motif were of enhanced potency as 
compared to their corresponding phenyl-pyridyl counterparts. While compound 275 
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was considerably more potent than compound 274, the high cLogP value of 
compound 275 has resulted in its LLE value being below that of compound 274, 
suggesting compound 274 may be more effective in vivo. For compounds containing 
the truncated structure, it can be concluded that potency at α7 receptors is largely 
dependent on the basic centre. Alteration of this aliphatic heterocyclic ring to a 
smaller, unsubstituted heterocycle results in a striking loss of potency at α7 receptors 
irrespective of the biaryl ring system. Substitution of the biaryl ring system of 
compound 139 with that of SEN12333 (45) was well tolerated and suggests that 
these ring systems can be interchanged on these smaller truncated hybrids (Figure 
63).  
Table 34.  Binding affinities of SEN12333-hybrid-truncated analogues . 
Ligand 
Binding affinity Ki (nM)
a
 
Physicochemical 
properties  
 
Compound basic centre X α7 α4β2 α3β4 cLogP
b
 PSA LLE 
268 
 
N 254000 DNC >10000 2.10 24.83 1.50 
269 CH >100000 >10000 >10000 3.49 12.47 ND 
270 
 
N >100000 >10000 >10000 3.48 15.6 ND 
271 CH >100000 >100000 >100000 4.87 3.24 ND 
272 
 
N 
9400 ± 
1800 
>10000 >10000 2.66 
18.84 2.37 
273 CH 
7700 ± 
800 
>10000 >50000 4.05 
6.48 1.06 
274 
 
N 140 ±40 >10000 >50000 2.80 18.84 4.05 
275 CH 34 ± 10 >10000 >10000 4.19 6.48 3.28 
a
 Competition curves were constructed in which 10 concentrations of a sample were included (n = 1), 
DNC = does not converge Ki values are the Mean ± SEM of three to six independent measurements. 
For low binding affinity compounds, estimated Ki value ranges were provided. 
b
 Calculated using 
ChemDraw12.0 
c
 calculated according to equation LLE = pIC50 (or pKi) – cLogP. 
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6.6 Concluding remarks  
Whilst compound 139 represents a truncated version of SEN12333 (45) it appears 
that the functional groups of the two structures cannot be interchanged and maintain 
potency at α7 receptors. This is particularly evident in relation to the aliphatic 
heterocycle and suggests that the α7 binding of compounds with a truncated structure 
like compound 139, is largely dependent on the basic centre of the molecule. The 
structural differences are not likely a result of binding at different locations on the 
receptor due to the use of competitive binding studies to assay biological activity. 
Biaryl ring substitution of compound 139 with those present in SEN12333 (45) was 
the only functional group exchange tolerated, as evident in compounds 274 and 275 
and further highlights the fact that binding of these compounds is largely dependent 
upon the basic centre contained within the molecule. 
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Chapter 7 - Funtional activities of selected 
compounds 
7.1 The functional activities of selected compounds 
from Chapters 4, 5 and 6  
Several of the α7 receptor ligands described in Chapters 4, 5 and 6 were selected, 
based upon their binding profiles, for evaluation in functional activity studies. The 
aim of these studies was to determine the agonist activity of the selected synthesised 
ligands at the α7 receptor. 
The ligands included in the functional activity studies were compounds 207, 208, 
213, hybrid compounds 274 and 275. SEN12333 (45) and lead agonist 139 were also 
included as references to directly correlate SAR as a result of modifying these leads. 
To determine their agonistic activity at α7 receptors, the compounds were evaluated 
by Bionomics Ltd in a fluorescent calcium assay using a GH4C1 cell line expressing 
rat α7 receptors and in line with the conditions described in Section 11.9.3.  
The EC50 of SEN12333 (45) was determined to be 687 nM as shown in Figure 66 
which corresponds equally with its binding affinity (Ki = 670 nM). Compound 207 
which contains the pyridine nitrogen at the 4-position within the terminal aromatic 
ring, previously displayed a 2-fold increase in binding affinity compared to 
SEN12333 (45) (Ki = 350 vs 670 nM) (Figure 67). In the functional assay, 
compound 207 also exhibited an improved EC50 of 522 nM over SEN12333 (45). 
This suggests the 4-position of the pyridine nitrogen within the terminal aromatic 
ring to be favourable for both binding affinity and functional activity.  
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Figure 66.  Dose response curve of SEN12333 (45)  on rat α7 GH4C1 cells; EC5 0 = 687 
nM. 
 
Figure 67 . Dose response curve of compound 207  on rat α7 GH4C1 cells; EC5 0 = 522 
nM. 
Compound 208, incorporating the electronegative fluorine atom, previously 
displayed an 8-fold increase in binding affinity compared to SEN12333 (45) (Ki = 85 
nM vs 670 nM). Compound 208 additionally demonstrated an EC50 of 44 nM 
(Figure 68), a dramatic improvement in functional activity compared to SEN12333 
(45), highlighting the potential for further development of this compound. The 
functional EC50 of compound 208 (44 nM) is lower than its binding affinity (85 nM), 
it was concluded that due to the strong binding of this molecule, the concentration 
range examined did not encompass the full binding range. As a result this value had 
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to be extrapolated as its EC50 value falls just on the edge of this data.  The functional 
value is usually much higher than the binding data (as exemplified in the other 
structures) as the functional data is performed on whole cells where other process can 
complicate the activity.  This functional assay needs to be repeated at lower 
concentrations to obtain a more accurate EC50 value for compound 208, however, 
this curve still alludes a low EC50 value.   
 
Figure 68.  Dose response curve of compound 208  on rat α7 GH4C1 cells; EC5 0 = 44 
nM. 
Compound 213 containing the 5-indolyl motif, previously demonstrated a 2-fold 
improvement in binding affinity compared to SEN12333 (45) (Ki = 310 nM vs 670 
nM). However, in studies of functional activity, compared to SEN12333 (45), 
compound 213 displayed diminished agonist activity at the α7 receptor, with an EC50 
of 997 nM (Figure 69). This suggests that the binding affinity of these ligands does 
not always correlate with functional activity and that the extension of the indolyl 
motif into the hydrophobic pocket is not favourable for agonist activity.  
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Figure 69.  Dose response curve of compound 213  on rat α7 GH4C1 cells; EC5 0 = 997 
nM. 
Lead agonist 139 (Ki = 5.9 nM) was the most potent compound of the series with an 
EC50 of 25 nM (Figure 70).  
 
Figure 70 . Dose response curve of compound 139  on rat α7 GH4C1 cells; EC5 0 = 25 
nM. 
DBH-containing analogues 274 and 275 examined the incorporation of the biaryl 
motif initially associated with SEN12333 (45). These compounds maintained binding 
affinity at the α7 receptor (Ki = 140 and 34 nM respectively), however, this was 
diminished compared to the lead compound 139. These compounds additionally 
maintained agonist activity at the α7 receptor, albeit below that of lead agonist 139. 
Compound 274, containing the phenyl-pyridyl motif, displayed an EC50 of 126 nM 
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(Figure 71). Although this is diminished compared to the lead 139, this is still a 5-
fold increase in agonist activity compared to SEN12333 (45) (EC50 687 nM). 
Interestingly, biphenyl containing compound 275, displayed a much lower binding 
affinity than the related 274, but exhibited a somewhat diminished EC50 of 253 nM 
(Figure 72), again highlighting the fact that binding affinity does not always 
correlate with functional activity. 
 
Figure 71.  Dose response curve of compound 274  on rat α7 GH4C1 cells; EC5 0 = 126 
nM. 
 
Figure 72.  Dose response curve of compound 275  on rat α7 GH4C1 cells; EC5 0 = 253 
nM. 
In summary, α7 functional activity results highlight the potential for the further 
development of compound 208, which shows improvement in both binding affinity 
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and functional activity compared to SEN12333 (45). The favourable 
physicochemical properties of compound 208 additionally highlight its potential for 
further development and suggest its effectiveness in vivo. These studies additionally 
highlight the excellent binding affinity and agonist activity of lead compound 139. 
The results reveal the aromatic moiety of compound 139 can be substituted with that 
originally associated with SEN12333 (45) (as in compounds 274 and 275), while still 
maintaining potency and agonist activity at the α7 receptor.  
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Chapter 8 - The Blood brain barrier 
pearmeability of cubane 
8.1 Introductory remarks  
The work discussed throughout the thesis has so far examined a detailed analysis of 
the structural features of SEN12333 (45, Figure 73) and included variation of the 
basic centre, alkyl chain, amide bond and aromatic moiety, and the effect of each of 
these modifications upon the binding affinity, selectivity and in some instances 
functional activity at α7 receptors. The effect upon the drug-like properties was also 
simultaneously investigated. Structural motifs were incorporated from the known α7 
agonist 139 and also other previously reported agonists. A series of hybrids that 
relate to the truncated scaffold of compound 139 but incorporating functionalities 
present in SEN12333 (45) were then investigated for affinity at α7 receptors (Figure 
73).  
 
Figure 73.  Structural modifications examined in the previous chapters.  
While the work discussed thus far has provided both active and selective α7 agonists, 
however, for these compounds to be effective and successful drugs they must reach 
their site of action which means crossing the blood brain barrier (BBB). The 
remainder of this thesis will therefore adopt an alternative approach towards the 
improvement of α7 agonists as therapeutic agents and investigate the incorporation of 
polycyclic moieties as BBB-delivery agents to enhance the brain concentrations of 
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selective α7 agonists. The pharmacology of the BBB and validation of the use of 
some polycyclic moieties to traverse the BBB will first be discussed.  
8.2 The blood brain barrier 
The healthy functioning of the human brain is dependent on protective barriers which 
regulate the admission of compounds into the brain and which maintain brain 
homeostasis.
392
 The human BBB performs a critical role in this regard; it is 
comprised of an intricate network of capillaries which are estimated to span 
approximately 600 km in length and a surface area of roughly 12 m
2
 (Figure 74).
393
  
 
 
Figure 74.  The Blood-Brain Barrier .
393
 
These capillaries are lined with endothelial cells which possess various unique 
morphological and biochemical characteristics.
394,392
 The continuous tight junctions 
found between these cells effectively restrict the paracellular diffusion of molecules, 
thereby giving rise to the relatively impermeable nature of the BBB.
394,395
 Also 
present within these endothelial cells are alternate transport pathways such as the 
fenestra and transendothelial channels, and high levels of expression of active efflux 
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transport proteins including P-glycoprotein (P-gp) and multidrug resistance protein 
(MRP). Together, these elements help to create a formidable and complex barrier to 
small molecule entry into the brain.
396,395
 
In contrast, transport proteins simultaneously ensure the uptake of essential nutrients 
into the brain that would otherwise be unable to enter via passive diffusion.
393
 These 
transporters, present at the luminal (blood) and basolateral (brain) side of endothelial 
cells, are used to transport small, hydrophilic molecules including amino acids and 
glucose, necessary for brain survival.
397
 Vital larger and/or hydrophobic vital 
molecules such as insulin, hormones, transferrin for iron and lipoproteins similarly 
use specific receptors expressed on the luminal side of the endothelial cell.
396
 
Interestingly, a small selection of small molecules with the desired lipophilicity, 
molecular weight and charge may diffuse from the blood and into the CNS; the 
majority of small molecules (>98 %) and nearly all large molecules (such as proteins 
and peptides), however can not cross the BBB.
398
 The small percentage of lipophilic 
molecules that do successfully diffuse into the BBB will also be exposed to the 
previously described efflux pumps (P-gp), and multidrug resistance proteins (MRP), 
expressed on the luminal side of endothelial cells, and to the degrading enzymes 
localised in the cytoplasm of endothelial cells, before brain penetration can be 
achieved.
396
  
The extremely discriminatory nature of the BBB with respect to the passive diffusion 
of molecules therefore presents a formidable barrier to overcome when endeavouring 
to access targets located within the CNS.
393
 This effect is illustrated in Figure 75, 
which shows the whole-body autoradiography of an adult mouse radiolabelled with 
histamine. The study reveals the ready penetration of the small molecule into the post 
vascular space of all organs of the body excluding the brain and spinal cord.
398
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Figure 75.  Radiolabelled histamine distribution in an adult mouse.
3 98
 
8.3 The BBB and neurological disease 
The fact that such an extremely limited number of drugs can successfully cross the 
BBB poses a considerable problem in relation to the increasing number of 
individuals with a CNS condition within an aging population.
399
 As previously 
discussed in Section 1.1, neurodegenerative diseases such as AD, Huntingtin’s and 
PD and CNS disorders such as schizophrenia, epilepsy and bipolar disorder are all 
detrimental to human health and well-being and all require drug treatment of the 
brain.
400,401
 Consequently, the CNS pharmaceutical market is rapidly expanding, with 
one in every three individuals estimated to have a CNS condition at some stage in 
their lifetime.
402
 However, when attempting to successfully prevent and treat these 
diseases, the BBB stands as a major obstacle by prohibiting substances from entering 
the CNS.
401,399
 As a result, there is an increasing demand for BBB delivery 
technologies within the pharmaceutical industry, particularly given the limitations of 
previous brain-drug delivery methods.
399
  
8.4 Current methods used to cross the BBB 
Invasive approaches such as intracerebro-ventricular infusion (ICV) or convection 
enhanced diffusion (CED), or pharmacological approaches such as the lipidisation of 
small molecules, are strategies currently used to breach the human BBB.
398,403
 
Paradoxically, an ICV injection has been shown to be similar to a slow intravenous 
injection with the diffusion of the drug into the brain parenchyma being extremely 
low.
403
 The concentration of the drug in the brain is reported to be approximately 1–2 
% of the cerebrospinal fluid (CSF) concentration at only 1-2 mm from the surface. 
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Over time, the drug is distributed into general circulation, and it enters the brain 
parenchyma only post-transport across the BBB.  
The concept of CED involves the stereotactically guided insertion of a small-caliber 
catheter into the brain parenchyma.
396
 The infusate is then actively pumped into the 
brain parenchyma and penetrates the interstitial space. CED has been shown to 
deliver high molecular weight proteins up to 2 cm from the injection site in the brain 
parenchyma after as little as 2 h of continuous infusion.
404
,
403
 However, the success 
of CED is dependent on the exact location of catheter insertion and it is well known 
that certain areas of the brain are difficult to completely saturate with infusate, most 
notably infiltrated tissues surrounding a cavity.
405
  
The pharmacological approach to breaching the BBB is based on the fact that 
molecules such as benzodiazepine, alcohol and nicotine (4) freely enter the brain.
403
 
The ability of these molecules to diffuse across the BBB is dependent on factors such 
as molecule size being less than 500 Da, and appropriate hydrogen bonding 
capability and lipophilicity.
406
 This approach therefore involves the modification of 
molecules known to be active in the CNS into molecules better able to cross the 
BBB. Such modifications include the reduction in the number of polar groups to 
increase lipophilicity. Unsurprisingly, these modifications commonly result in 
diminished CNS activity, and increasing the lipophilicity of a molecule can further 
enhance its susceptibility as a substrate for the efflux pump P-gp.
396,403
 More 
recently, specifically engineered drugs have been developed to take advantage of the 
existing BBB nutrient transport systems.
407
 After the receptor mediated transcytosis, 
the such drugs are carried across the BBB. This physiological approach is regarded 
by the scientific community as the most probable chance of achieving therapeutic 
success.
407
 
8.5 The use of polycyclic moieties to enhance BBB 
permeability of drugs  
It has been recently described that the polycyclic structures, 
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane and adamantane readily penetrate the BBB 
and display favourable distribution to the brain.
408,409
 The introduction of the 
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adamantanyl moiety to azidothymidine (295 and 296, Figure 76), used in the 
treatment of the acquired immune deficient syndrome (AIDS) was previously shown 
to enhance the BBB penetration of this molecule, with the prodrug detected in brain 
tissues at 7–18 times higher concentration than unconjugated azidothymidine.408  
 
Figure 76.  Adamantane conjugates.
40 8
 
Similarly, conjugation of acetylsalicylic acid and ibuprofen through esterification to 
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane cores (297 and 298 respectively, Figure 77) 
substantially improved their BBB permeability and increased subsequent brain 
concentrations.
401
  
 
Figure 77.  Pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane conjugates.  
Lipophilic polycyclic amines such as amantadine (299) and racemic rimantadine

 
(300, Figure 78) have been reported to cross the BBB not only by passive diffusion, 
but also through an active transport process.
410
 The closely related molecules 299 and 
300 are effective prophylactic and therapeutic agents against viral influenza Type 
                                                 

 From here on, rimantadine (300) will refer to the racemic mixture. 
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A.
411,412
 Amantadine (299) has additionally shown effectiveness as an anti-
Parkinsonian drug.
413
 At similar doses, amantadine (299) is reported to result in 
greater CNS side effects such as dizziness, difficulty thinking, dysphoria and 
convulsions than rimantadine (300). Initially this was attributed to the observed 
higher plasma concentrations of amantadine (299) compared to rimantadine (300) 
following oral administration to humans with the assumption that the concentration 
of amantadine (299) in brain parenchyma also exceeded that of rimantadine (300).
414
 
This assumption has since been discounted as rat in situ perfusion studies have 
revealed both these compounds (299 and 300), exhibit saturable transport across the 
BBB, rimantadine (300) exhibits a 7.7-fold higher rate of BBB transport compared to 
amantadine (299).
410
 
 
Figure 78 . The structure of amantadine (299) and rimantadine (300).  
The brain uptake of amantadine (299) and rimantadine (300) have since been 
assessed in vivo, and the mechanisms responsible for their transport across the BBB 
elucidated using a human brain endothelial cell line.
415
 Following oral administration 
to mice, while the plasma exposure of rimantadine (300) was similar or lower to that 
of amantadine (299), rimantadine (300) exhibited a 2.4–3-fold greater brain 
exposure.
415
 It was postulated that amantadine (299) and rimantadine (300) were 
transported across the BBB via a transport-mediated process, given that their 
permeability coefficients were reduced with increasing concentration of unlabelled 
amantadine (299) or rimantadine (300).
420 
Additional evidence was obtained when 
diphenhydramine, a weak base known to cross the BBB by a saturable transport 
mechanism, was coadministered leading to a reduction in permeability coefficients of 
amantadine (299) or rimantadine (300).
415,416
 These results confirm that, upon 
administration to an intact physiological system, relative to plasma concentrations, 
the overall brain concentration of rimantadine (300) is substantially higher than that 
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of amantadine (299), and that this is not the result of differences in the extent of 
plasma protein binding.  
To elucidate which transporter may be implicated in the brain uptake of amantadine 
(299) and rimantadine (300), the cellular uptake of these two compounds were 
determined in a human immortalised brain endothelial cell line. The in vitro studies 
revealed that both amantadine (299) and rimantadine (300) exhibited saturable 
uptake suggesting the involvement of an active transport process.
415
 Consistent with 
the in vivo results, the brain endothelial cell uptake of rimantadine (300) was 
significantly higher than that of amantadine (299) and highlights the applicability of 
this in vitro human cell line in reflecting brain uptake in mice. Utilising this model, 
the affinity of rimantadine (300) for the putative transporter was found to be 38-fold 
higher than that of amantadine (299); much greater than initially expected based 
upon their structural similarities alone.
415
 Investigations were then conducted into the 
impact of extracellular pH on the uptake of these two compounds and reveal both 
amantadine (299) and rimantadine (300) to be translocated by a pH-sensitive 
transporter. The cellular uptake of amantadine (299) was seen to decrease as the 
fraction of non-ionised species decreases, suggesting uptake to be dependent on a 
process other than simple passive diffusion. This outcome is in line with the 
involvement of an active transport system. Similar results were seen for rimantadine 
(300) where the percentage of ionic form (protonated) is predicted to be 99.9% at 
physiological pH.
410
 This pH-sensitive transporter involved in the uptake of 
amantadine (299) and rimantadine (300) was inhibited by various organic cations, of 
which quinine appeared to be the most potent cationic inhibitor. Furthermore, the 
uptake of amantadine (299) and rimantadine (300) and the effect of inhibitors were 
shown to be dependent on the presence of Na ions, which suggests the involvement 
of a Na
+
 dependent organic cation transporter. While a member of the organic cation 
transporter (OCT) family could potentially be considered for the uptake of these 
compounds, they function in a Na
+
 independent manner and therefore must be 
discounted.
417
 Possible transporters which could mediate the uptake of amantadine 
(299) and rimantadine (300) include the OCTN2 (the polyspecific high affinity 
transporter for ʟ-carnitine)418,419, or ATB0,+ (the amino acid transporter affecting 
cationic and neutral mono-amines, but not anionic amino acids).
420
 Whilst OCTN2 
was seen to be functional in hCMEC/D2 cells and have been shown to be expressed 
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at the BBB
421
, amantadine (299) and rimantadine (300) did not seem to interact with 
this particular transporter.
415
 Conversely, amantadine (299) and rimantadine (300) 
both decreased the uptake of 
3
H-glycine, a substrate of the Na
+
/Cl
-
 dependent 
ATB
0,+
, which has been found to be expressed in rat, bovine and human brain 
endothelial cells.
422,423
 Further support for the involvement of ATB
0,+ 
in the 
hCMEM/D3 uptake of amantadine (299) and rimantadine (300) is the Cl
–
 
dependence of this uptake process and dependence on transmembrane potential, 
known characteristics of ATB
0,+
.
420,424
 The decrease in 
3
H-glycine uptake is therefore 
likely the result of an interaction of amantadine (299) and rimantadine (300) with 
ATB
0,+
.  
Though ATB
0,+ 
performs a significant role in the transport of amino acids across 
biological barriers, it has also been observed to facilitate the transport of various 
monoamine drugs across different membranes including the mammary epithelium 
and cornea.
425,426
 Accordingly, its potential for exploitation in drug delivery is also 
highlighted. For example, previous conjugation of amino acid moieties to the 
antiviral drugs Aciclovir and Ganciclovir has been shown to increase their transport 
into ATB
0,+
 transfected cells.
425,427,428
 Similarly, adamantane cations 299 and 300 can 
be used to facilitate drug transport into these cells and potentially across the BBB.  
While the adamantane-based molecules demonstrate affinity for an active transport 
process at the BBB which may be exploited for effective CNS drug delivery 
applications, their limited potential for chemical modification prevents a more 
systematic investigation of any relationship between structure and affinity for BBB 
transport. The analogous polycyclic hydrocarbon cubane (301, Figure 79), however, 
offers far greater scope and flexibility for chemical modification. 
 
Figure 79.  Cubane polycycle.  
Cubane (301) has a positive heat of formation and is an immensely strained 
molecule
429
, with the geometry of each carbon being far from tetrahedral.
430
 This 
unique molecular geometry confers unique electronic and structural properties that 
Chapter 8 The Blood brain barrier pearmeability of cubane Summary and future work 
 
178 
 
differ from other hydrocarbons.
430
 Functional group transformations on a cubane 
system have been extensively studiedand have revealed some unusual 
charcacteristics, such as the formation of a cubyl cation, previously anticipated to be 
highly disfavoured.
431,432
 Despite its unique and highly strained structure, cubane is 
remarkably stable to oxygen, water and light and has a melting point of just over 130 
°C.
432
 These favourable physical properties and the diverse chemistry of cubane 
make it a potential rigid scaffold for medicinal chemistry. Cubane (301) can be 
thought of as a biologically stable, lipophilic frame which can accomodate multiple 
functional groups in precise orientations in all three dimensions.
433
  
8.6 Aims of the Project 
The initial aim of the present work was directed towards the synthesis of a series of 
substituted cubylamines, (302–305, Figure 80) in order to assess the effect of 
substitution on BBB permeability by passive diffusion and/or active transport. These 
compounds were evaluated in an established mouse model and compared with the 
analogous and well-studied adamantylamines. Pending biological evaluation, the 
project then aimed to explore the incorporation of the cubane nucleus into previously 
identified α7 agonists in the hope that these molecules will show enhanced BBB 
permeability, whilst still maintaining the agonistic activity, selectivity and additional 
drug-like properties of the parent drug.  
 
Figure 80. Initial cubane targets (302–305).  
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Chapter 9 - Synthesis and evaluation of 
cubylamine analogues 
9.1 The Chemistry and Synthesis of Cubane 
The first synthesis of the cubane nucleus was reported by Eaton and Cole from 
cyclopent-2-en-1-one (306) (Scheme 52) where the key transformation was a double 
Favorskii-like rearrangement to give 1,4-cubanedicarboxylic acid (312).
434
 This was 
characterised as the corresponding dimethyl ester 313.
434
 
 
Scheme 52.  First reported synthesis of cubane .
43 4
 
Numerous difficulties have been encountered when following this initial synthesis, 
including the need to prepare cyclopent-2-en-1-one (306) on a large scale. Moreover, 
the unstable nature of compounds leading to formation of dione 310 results in 
complex reaction mixtures making product isolation difficult and decreasing 
yields.
429
 Significant improvements to this synthesis were introduced by Chapman 
and co-workers in 1970.
429
 The key dicyclopentadienone intermediate 310 was 
obtained by a more facile method starting from commercially available 
cyclopentanone 314. The most efficient synthesis to date (Scheme 53) of cubane-1,4-
dicarboxylate (313) is based on these modifications and follows the preparatively 
useful synthesis reported by Bliese and Tsanaktsidis.
435
 The dimethyl 1,4-cubane 
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dicarboxylate (313) is now easily accessible in multi-gram quantities, and is also 
commercially available. 
 
Scheme 53. Modified synthetic pathway to 313. Reagents and Conditions: a) ethane-1,2-diol, Dowex 
50W-8 (H), benzene, reflux, 30 h, 90%; b) Br2, 1,4-dioxane, RT, 3 d; c) NaOH, MeOH, reflux, 2 h, 
60% (over two steps); d) conc. H2SO4, RT, 30 h, 92%; e) hv, HCl, MeOH, RT, 17 h; f) HCl, H2O, 
reflux, 1 h; g) NaOH, H2O, reflux, 4 h; h) Dowex 50W-8 (H), MeOH, reflux, 24 h, 47% (over four 
steps). 
Interestingly, the C-C bonds of cubane are known to possess more p-character than 
the sp
3
 hybrid of typical tetravalent carbon molecules.
432
 As a result of this, the C-H 
bonds of cubane have approximately 31% of s-character (calculated from the 
observed 
13
C-
1
H coupling of 155 Hz).
436
 Compared to other hydrocarbons, such as 
cyclopropane, this renders cubane more acidic.
437
 Reports of synthesised cubane 
structures have described a variety of extreme molecules (Figure 81) and include the 
twisted alkene, 1-cubene (318), 1,9-homocubene (319) and the short-lived radical 
cubylarbinyl species 320 (k = 2 × 10
10
 s
-1
).
432,438
 The cubyl cation 321 and cubyl 
anion 322 have been precedented as intermediates of some cubane 
transformations.
437,431,439
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Figure 81.  Cubyl Intermediates.  
Though there has been considerable speculation about the use of cubane in drug 
discovery, there has been comparatively little attention. Specifically, in relation to its 
incorporation into biologically active molecules. It is worthwhile to review some 
representative examples of cubane in medicinal chemistry.  
9.2 Cubane in medicinal chemistry  
A small amount of cubane-containing molecules have been identified as biologically 
active and some illustrative examples are shown in Figure 82. 4-Methylcubylamine 
(323) has been identified as having antiviral properties and nitroalkylcubane (324) 
has displayed anti-ischemic properties.
440
 Cubyl glycine 325 was reported as an 
antagonist of metabotropic glutamate receptors and cubane 326 has identified 
antiulcer properties.
441,442
  
 
Figure 82. Biologically active cubane containing molecules .  
The introduction of the cubylmethyl moiety into morphine analogues has also been 
reported and is shown in Figure 83.
443
 Cubane analogues 328 and 330 (Figure 83) 
were found to enhance potency at all three opioid receptors compared to their 
corresponding parent compounds (morphine 327 and oxymorphone 329 
respectively). In vivo studies of compound 330 revealed that it contained moderate 
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narcotic antagonism effects, though it was less potent than naloxone, possibly the 
result of unfavourable steric interactions of the cubane moiety.
443
  
 
Figure 83. Cubylmethylmorphine and analogues. 
These representative examples highlight the incorporation of the cubane nucleus into 
biologically active molecules and further validate its use in drug design exploration. 
9.3 The synthesis of cubylamines 302–305 
9.3.1 The functionalisation of dimethyl cubane-1,4-dicarboxylate 
A generous donation of cubane diester 313 by colleagues at the CSIRO, enabled us 
to utilise this molecule as the starting material for our synthesis. It was envisioned 
that cubylamines 302–305 would be accessed from mono-substituted cubane 
carboxylic acid 331.  
In accordance with the procedure reported by Eaton and co-workers, anhydrous 
saponification of diester 313 produced the half ester 332 in an excellent yield of 88% 
(Scheme 54).
444
 The monohydrolysed product was obtained in a better than 
statistical yield most likely as a result of the precipitation of the sodium salt from the 
THF solution thereby precluding further hydrolysis.  
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Scheme 54. Synthesis of mono-acid 341. Reagents and Conditions: a) NaOH (1 equiv.), MeOH, THF, 
rt, 16 h, 85%; b) IBDA, I2, PhMe, reflux, 16 h; c) NaOH, MeOH, THF, RT, 16 h, 80% (over two 
steps); d) n-BuLi then MeOH, THF, -78 °C, 92%.  
Ester-acid 332 was then subjected to oxidative decarboxylative iodination by 
treatment with iodobenzenediacetate and molecular iodine.
445
 It is probable that the 
hypervalent [PhI(OAc)2] exchanges one or both of its acetoxy ligands with the 
carboxylic acid, generating the cubyl acyloxy hypervalent system which initiates 
subsequent decomposition (Scheme 55).
446
 This afforded 1,4-iodocubane methyl 
ester 333 in good yield. 
 
Scheme 55.  Mechanism of action of IBDA. 
Hydrolysis of ester 333 gave the corresponding iodocubane carboxylic acid 334 
(Scheme 54). Dehalogenation via treatment with n-butyllithium then gave cubane 
acid 331.
445
 It was found that the conditions reported for this dehalogenation were 
extremely impractical and prevented the preparation of acid 331 on a large scale. 
Due the insolubility of the dehalogenated intermediate, the reaction required dilute 
concentrations (0.0074 M) of acid substrate 334 in THF.
445
 The dilution of the 
reaction by hexanes from the addition of excess nBuLi solution did not assist in 
maintaining the charged intermediate in solution. Optimisation of these reaction 
conditions revealed concentrations of 0.01 M and 3 equivalents of nBuLi to optimal 
for yield and synthetic practicality (Table 35).  
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Table 35 . Various conditions for de -halogenation of compound 334 .  
Entry Concentration 
Equivalents of 
nBuLi 
Yield 
1 0.0074 5.7 88% 
2 0.001 3 92% 
3 0.005 3 
No product 
obtained 
 
Cubane carboxylic acid 331 was then used as a point of divergence for the synthesis 
of cubylamines 302–305. The mono-acid 331 was readily prepared from the 
dimethyl ester 313 in a four step synthetic sequence and overall yield of 63%.  
During the time of this work, a more convenient synthesis of cubanecarboxylic acid 
331 was reported (Scheme 56). It involved the Barton decarboxylation of the half 
ester 332 utilising a procedure reported by Tsanaktsidis and co-workers.
447
 The half-
ester 332 was transformed into the corresponding acid chloride (335) in situ and 
subsequently treated with the sodium salt of N-hydroxypyridine-2-thione and a 
catalytic amount of 4-dimethylaminopyridine (DMAP). Chloroform served 
simultaneously as a solvent, radical initiator and hydrogen atom donor. The solution 
was irradiated with a tungsten lamp to afford the decarboxylated methyl 
cubanecarboxylate (336). The Barton decarboxylation proved extremely robust, 
reproducible and could be conducted on a multiple gram scale. Subsequent ester 
hydrolysis provided the desired mono-acid 331 in 61% over three steps (Scheme 56). 
The relatively low molecular weight and compacted framework of cubanes renders 
them reasonably volatile and therefore required extreme care when removing 
reaction solvents in vacuo. Eaton and co-workers have previously reported several of 
the low molecular weight cubane derivatives to be heat-sensitive and potentially 
explosive; as such they mandated handling with care.
448
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Scheme 56. Alternative synthesis of acid 331. Reagents and conditions: (a) (COCl)2, cat. DMF, 
CHCl3, rt, 3 h; (b) Sodium 2-thioxopyridin-1(2H)-olate, DMAP, CHCl3, hv, reflux, 45 min, 80% over 
two steps; (c) NaOH, MeOH, reflux, 1.5 h, 76%. 
The mechanism for the Barton decarboxylation, illustrating the radical chain 
propagating steps is shown in Scheme 57. The sodium salt of N-hydroxypyridine-2-
thione is first acetylated with the acid chloride 335 in the presence of catalytic 
DMAP, resulting in the formation of thiohydroxamic ester 337.
447
 Subsequent direct 
H-transfer from chloroform to the alkyl radical (338) thus delivers the observed 
reaction product (336) and trichloromethyl radical (339), which next propagates the 
radical chain reaction by attack of the sulfor terminus to the thiohydroxamic ester 
(337) and furnishes the pyridyl sulfide coproduct (340) and a new alkyl radical 
(338).
449-451
 
 
Scheme 57.  Mechanism for Barton decarboxylation . 
With cubane carboxylic acid 331 in hand, we next turned our attention towards the 
synthesis of cubylamines 302–305. 
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9.4 The synthesis of cubylamine 302 
It was envisioned that amine 302 would be derived from isocyanate 341, obtained 
from the Curtius rearrangement of acid 331 (Scheme 58).  
 
Scheme 58.  Retrosynthetic analysis of amine 302 .  
Of the various methods employed for the synthesis of amines, the Curtius 
rearrangement is a highly popular and practical choice; it allows for the efficient and 
direct synthesis of an amine from the corresponding carboxylic acid.
452
 The reaction 
proceeds via the conversion of the starting carboxylic acid to the corresponding acyl 
azide. Subsequent rearrangement produces the corresponding isocyanate where the 
loss of N2 is a driving force in this reaction (Scheme 59).
453
 Trapping of the 
isocyanate can be achieved with a variety of nucleophiles. Carbobenzyloxy (Cbz) 
protected amines are formed when the reaction is carried out in the presence of 
benzyl alcohol.
454
 Conversely Boc protected amines are produced when the 
intermediate isocyanate is trapped with tert-butanol (Scheme 59).
455
 The primary 
amine can also be obtained by the direct hydrolysis of the isocyanate 
intermediate.
453,456 
However, due to the high reactivity of the isocyanate 
intermediate, contamination of the product with the corresponding urea is 
common.
457
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Scheme 59.  The Curtius Rearrangment.  
A simple one pot procedure for the conversion of carboxylic acids to various 
carbamates was reported utilising the reagent diphenylphosphoryl azide 
(DPPA).
458,459
 The reaction procedure involves refluxing an equimolar amount of a 
carboxylic acid, DPPA and triethylamine in the presence of a hydroxyl 
component.
459
 The conditions provided satisfactory yields in the rearrangement of 
various aromatic, aliphatic and heterocyclic carboxylic acids.
459
 The use of DPPA as 
a source of azide allows for mild reaction conditions and avoids the isolation of the 
unstable acyl azide and isocyanate intermediates, rendering it far less laborious than 
the classical Curtius reaction and therefore increasing synthetic utility.
460
 
The use of DPPA has been reported in the Curtius rearrangement of carboxylic acids 
containing a cubane nucleus.
461,462
 One of the key transformations in the synthesis of 
1,4-dinitrocubane involved treatment of cubane-1,4-dicarboxylic acid (312) with 
DPPA and tBuOH to give bis-Boc cubane-1,4-diamine (342) in near quantitative 
yield (Scheme 60).
461
 The product was precipitated from the reaction mixture with 
saturated, aqueous sodium bicarbonate.
462
 Subsequent hydrolysis and 
decarboxylation gave 1,4-diaminocubane dihydrochloride (343).
461
 This method 
avoids the formation of the diacyl azide, which is reported to be extremely unstable 
and shock sensitive.
461
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Scheme 60. The preparation of 1,4-bis[(tert-butoxycarbonyl)-amine]cubane (342).
461
 Reagents and 
conditions: (a) DPPA, NEt3, tBuOH, reflux, 12 h, 94%; (b) HCl, MeOH, −60 °C to rt, 67%. 
The synthesis amine 302 was based on this work (Scheme 61). Unfortunately, the 
product (344) could not be precipitated with saturated, aqueous sodium bicarbonate. 
It was hypothesised that the altered solubility of mono-substituted cubane (344) (as 
opposed to the previously discussed di-substituted cubane 312) prevented 
precipitation. Following aqueous workup, column chromatography was employed as 
an alternative purification procedure. Disappointingly, the desired carbamate 344 
could not be separated from the phosphorous containing compounds. The attempts to 
isolate compound 344 are summarised in Table 36. The impurity was suggested to 
be either unreacted DPPA or the resulting reduced form, based on the presence of 
aromatic peaks in the 
1
H NMR spectrum of compound 344. As a result, limiting 
DPPA was used (Table 36, entry 3), however, aromatic impurities still remained. 
Consequently, the crude mixture containing compound 344 was subjected to acid 
hydrolysis to liberate the primary amine of cubylamine 302 as the hydrochloride salt 
(Scheme 61). Following recrystalisation, the aromatic impurities, unfortunately, 
were still detected by 
1
H NMR. 
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Scheme 61. The synthesis of amine 302. Reagents and conditions: (a) DPPA, NEt3, tBuOH, reflux, 17 
h, see Table 36; (b) HCl, MeOH, rt, 6 h 
Table 36.  The various conditions employed in the Curtius rearrangement of acid 331 .  
Entry Reagent Equivalents Purification 
 
Cubane 
carboxylic 
acid (331) 
NEt3 DPPA  
1 1 2 2 
No precipitate formed on workup. 
Aromatic peaks detected by 
1
H NMR 
2 1 2 2 
No precipitate formed on workup. Flash  
chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia 
(95:4:1). Aromatic peaks detected by 
1
H 
NMR 
3 1 1 0.9 
No precipitate formed on workup. Flash  
chromatography on silica eluting with 
hexane-ethyl acetate (1:1). Aromatic peaks 
detected by 
1
H NMR 
 
As contamination of amine 302 is unacceptable for biological testing, a new 
synthetic procedure was devised.  
Cubane carboxylic acid 331 was converted into acid chloride 345, subsequent 
treatment with trimethylsilyl azide and TBAF then gave the desired acyl azide 346 
(Scheme 62). The displacement reaction was carried out at 0 °C due to the reactive 
nature of the acid chloride. It was noted that reaction times longer than one hour 
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resulted in hydrolysis of acyl azide 346 to give the starting carboxylic acid 331. This 
was assumed to be the result of disadventageous H2O present in the TBAF solution. 
Due to its reactive and sensitive nature, acyl azide 346 was not purified and instead 
the crude residue heated at 60 °C in tBuOH. The desired carbamate 344 was isolated 
in a modest, overall yield of 42% from carboxylic acid 331. Quantitative hydrolysis 
of the Boc group then gave amine hydrochloride salt 302, which was further purified 
by recrystallisation. 
 
Scheme 62. The synthesis of amine 302. Reagents and conditions: (a) (COCl)2, rt, 1 h; (b) 345, 
TMSN3, TBAF, THF, 0 °C, 1 h; (c) 346, tBuOH, 60 °C, 16 h, 42% over 3 steps; (d) HCl, MeOH, rt, 3 
h, 99% 
With the synthesis of cubylamine 302 complete, we next directed our efforts towards 
the synthesis of cubylamine 303. 
9.5 The synthesis of cubylamine 303 
The synthesis of amine 303 was straightforward and is depicted in Scheme 63. 
Carboxylic acid 331 was converted into acid chloride 338 via treatment with oxalyl 
chloride. Compound 338 was then treated with liquid ammonia to give cubylamide 
347. Lithium aluminium hydride reduction of amide 347 furnished the desired 
cubylamine 303 in a yield of 53% over three steps. This was converted to the 
corresponding hydrochloride salt (303•HCl) in quantitative yield. The synthesis of 1-
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cubanemethylamine (303) was completed in a yield of 29% over seven steps from 
dimethyl 1,4-cubanedicarboxylate 313, the synthetic sequence was found to be 
highly reliable and reproducible. 
 
Scheme 63. The synthesis of amine 303. Reagents and conditions: (a) (COCl)2, rt, 1 h; (b) 338, NH3 
(l), CH2Cl2, −78 °C to rt, 40 min; (c) LiAlH4, THF, 0 °C to reflux, 16 h, 53% over 3 steps; (d) HCl, 
MeOH, RT, 3 h, 100% 
Following completion of the synthesis of cubylamine 303, we next focused our 
attention upon the synthesis of amine 304. 
9.6 The synthesis of amine 304 
The proposed synthesis of amine 304 is summarised in Scheme 64 and involved the 
reduction amination of ketone 348, which could be derived from acid 331. 
 
Scheme 64.  Retrosynthetic analysis of compound 303 .  
9.6.1 The synthesis of methyl ketone 348 
The synthesis of amine 303 began with the conversion of carboxylic acid 331 to the 
corresponding methyl ketone 348 via treatment with methyl lithium (Scheme 65). 
Chapter 9 Synthesis and evaluation of cubylamine 
analogues 
 
192 
 
The reaction between alkyl or aryl lithium compounds and carboxylic acids or their 
lithium salts is reported to give good yields of the corresponding ketones and 
minimal to negligible amounts of the corresponding tertiary alcohol.
463
 The reaction 
of cubane carboxylic acid 331 with methyl lithium proceeded in acceptable yield 
with minimal amounts of the tertiary alcohol 349 isolated (Scheme 65).  
 
Scheme 65. The formation of methyl ketone 331. Reagents and conditions: (a) MeLi (3 eq), THF, -78 
°C, 1 h. 
With cubane methyl ketone 331 in hand, we then focussed on the reductive 
amination to give the desired cubylamine 304. 
9.6.2 The synthesis of amine 304 via Reductive Amination 
The next step in the synthesis of amine 304 involved the reductive amination of 
methyl ketone 348 (Scheme 66). Numerous conditions were trialed and are shown in 
Table 37. Initial attempts utilising sodium triacetoxyborohydride as the reducing 
reagent with variations in amine source and solvent, were unsuccessful and prompted 
us to consider an alternative reducing agent. The hydride reducing agent, sodium 
cyanoborohydride is recognised for its stability in relatively strong acid solutions (pH 
~ 3), selective reduction of the iminium ion and solubility in hydroxylic solvents 
such as methanol.
464
 At pH range 3-4 sodium cyanoborohydride effectively reduces 
aldehydes and ketones, however, this reduction becomes much slower at higher pH 
values.
464
 At pH range 6–8, protonation occurs preferentially at the more basic 
imines and reduction occurs at a much faster rate relative to aldehydes and 
ketones.
464
 Utilising ammonium acetate as the amine source, sodium 
cyanoborohydride as the reducing agent and methanol as the solvent (Table 37, entry 
5) the desired cubylamine 304 was obtained, albeit in low yield.
465
 Despite the low 
yield, the desired product was isolated in excellent purity, without the need for 
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further purification. It was subsequently converted to its hydrochloride salt, 
compound 304•HCl, in quantitative yield for ease of storage. 
 
Scheme 66.  Reductive amination of ketone 348 .  
Table 37.  Various conditions employed for the synthesis of primary amine 304 .  
Entry Conditions Observation 
1
466
 
Ti(OPr
i
)4, NH4Cl, NEt3, 
EtOH, Na(OAc)3BH, rt, 
14 h 
Complex mixture 
2 
NH4HCOO, AcOH, 
ClCH2CH2Cl, 
Na(OAc)3BH, rt, 14 h 
No product or recovered 
starting material isolated 
3 
NH4HCOO, AcOH, THF, 
Na(OAc)3BH, rt, 14 h 
No product or recovered 
starting material isolated 
4
467
 
NH4Cl, NEt3, Ti(OPr
i
)4, 
EtOH, NaBH4, MgSO4, rt, 
9 h 
Complex mixture 
5
465
 
NH4OAc (10 eq), 
NaBH3CN, MeOH, rt, 16 
h 
304 (31%) 
 
Although Table 37 successfully describes the synthesis of cubylamine 304, the low 
yield obtained, prompted us to devise an alternative synthetic strategy. 
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9.6.3 The use of protecting groups in the synthesis of amine 304 
In an attempt to increase the yield of amine 304, research was conducted and 
revealed that although various reductive amination protocols work well for the 
preparation of secondary tertiary amines, the synthesis of primary amines is 
compromised by the formation of over-alkylated products.
468
 To overcome this 
obstacle, protecting groups have commonly been utilised in the preparation of 
primary amines via metal hydride reductive aminations.
469
 While protecting groups 
have their disadvantages, such as an increase in total number of synthetic steps, the 
issue of overalkylation of the primary amine would be circumvented and the yield 
potentially increased. It was envisioned that cubylamine 304 would be synthesised 
by the reductive amination of methyl ketone 348 with a protected secondary amine. 
Subsequent removal of the protecting group would yield the desired cubylamine 304. 
Various benzyl containing cubylamines (350–352, Scheme 67) were synthesised 
according to the conditions described by Abdel-Magid and co-workers.
470
 The yields 
are shown in Table 38. The reaction proceeded well on all occasions, and gave the 
desired product in good to excellent yield.  
 
Scheme 67. Synthesis of amines 350–352. Reagents and conditions: (a) AcOH, NaBH(OAc)3, 
ClCH2CH2Cl, rt, 16 h, see Table 38. 
Table 38 .  Yields of benzyl protected amines 50-52 .  
Compound R Yield (%) 
350 H 86 
351 4-OMe 78 
352 2,4-(OMe)2 93 
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The various conditions attempted to remove the various protecting groups are 
summarised in Table 39. Unfortunately standard hydrogenation conditions 
commonly employed for the removal of benzyl protecting groups
471
 resulted in 
complete decomposition of compound 350 (entry 1). Treatment of para-
methoxybenzyl protected derivative 351 with oxidative conditions commonly used to 
cleave this protecting group, (2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)), 
resulted in the recovery of unchanged starting material. None of the desired product 
was detected. Compound 352 was synthesised in the expectation that under acidic 
conditions, protonation of the amine nitrogen would affect an E1 elimination of the 
benzyl group, where the carbocation formed is stabilised by the presence of the two 
methoxy substituents. Unfortunately, upon treatment with extremely forcing 
conditions (entries 3 and 4) only unchanged starting material was recovered. 
Compound 352 was additionally subjected to oxidative cleavage conditions, ceric 
ammonium nitrate (CAN) (entry 5). Disappointingly, only unchanged starting 
material was recovered.  
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Scheme 68.  Removal of various benzyl protecting groups . 
Table 39.  The conditions employed for the cleavage of various benzyl protecting 
groups.  
Entry Compound 
Cleavage 
Conditions 
Outcome 
1 350 
H2, Pd/C, MeOH, 
rt, 16 h 
Decomposition of 
starting material 
2 351 
DDQ, CH2Cl2:H2O 
(10:1), rt, 16 h 
Unchanged starting 
material 
3 352 
10 M HCl (aq), rt, 
16 h 
Unchanged starting 
material 
4 352 
10 M HCl (aq), 
reflux, 16 h 
Unchanged starting 
material 
5 352 
CAN, MeCN:H2O 
(9:1), rt, 16 h 
Unchanged starting 
material 
 
As a result of the difficulties encountered in the removal of the various protecting 
groups, it envisioned that a more efficient synthesis of cubylamine 304 would 
involve the incorporation of an oxime functionality. 
9.6.4 The synthesis of cubylamine 304 via the oxime 
Due to the lack of success in the removal of the amine protecting groups in 
compounds 350–352, it was proposed that cubylamine 304 could be synthesised via 
reduction of the oxime 353, which, in turn, could be derived from previously 
synthesised ketone 348 (Scheme 69). 
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Scheme 69 . Retrosynthetic analysis of cubylamine 304  via  the oxime.  
The synthesis of oxime 353 is depicted in Scheme 70. Oxime 353 was formed 
readily in moderate yield by treatment of ketone 348 with hydroxylamine 
hydrochloride in the presence of base. The common method of reducing an oxime 
functional group involves treatment with Raney nickel, as this was not readily 
available and due to the hazardous nature of Raney nickel, oxime 353 was instead 
treated with 6 equivalents of Ni(II)Cl2 and 6 equivalents of lithium aluminium 
hydride.
472,473
 The desired reduced product 304 was obtained in poor yield of 15%. 
 
Scheme 70. The formation and reduction of oxime 53. Reagents and conditions: (a) NH2OH•HCl, 
NEt3, CH2Cl2, reflux, 18 h, 57%; (b) Ni(II)Cl2, LiAlH4, Et2O, rt, 16 h, 15%. 
Due to the poor yield obtained and the extremely harsh conditions required for 
reduction of the oxime functional group, this synthetic pathway was deemed 
unacceptable.  
Despite our initial disappointment at the low yield (31%) in the synthesis of amine 
304 by treatment of ketone 348 with ammonium acetate and sodium 
cyanoborohydride in methanol, this synthetic pathway was now deemed the most 
appropriate and practical, especially in view of the difficulties encountered in 
attempting to remove the protecting groups. This reaction allowed for the synthesis 
of amine 304 from methyl ketone 348 in a single step, without the need for 
purification by column chromatography. The enantiomers of cubylamine 304 were 
not resolved. As the biological evaluations to be conducted were initially only 
preliminary and aimed at determining if cubylamine 304 traversed the BBB, this was 
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deemed unnecessary. In line with this, the enantiomers of rimantadine (300) were not 
resolved and its previous biological evaluation was conducted on a racemic mixture. 
If cubylamine 304 is shown to be a substrate of the ATB
0,+ 
transporter, the 
enantiomers of cubylamine 304 would be resolved via diastereomeric recrystalisation 
with tartaric acid or through employing chiral HPLC. This would enable us to 
determine if one enamtiomer of cubylamine 304 possessed greater affinity for the 
transporter in question. Therefore, with cubylamine 304 in hand, we turned our 
attention towards the synthesis of the remaining cubylamine 305. 
9.7 The synthesis of cubylamine 305 
The synthetic pathway for the synthesis of amine 305 is proposed in Scheme 71 and 
involved the formation of tosylate 355, which upon displacement with sodium 
cyanide, would give nitrile 354. The desired amine 305 could then be obtained via 
reduction of the nitrile using lithium aluminium hydride. 
 
Scheme 71.  Retrosynthetic analysis of amine 305 .  
In the forward sense, the synthesis of amine 305 began with the reduction of cubane 
carboxylic acid 331 to the corresponding alcohol 356 by treatment with borane 
dimethylsulfide complex (Scheme 72).
445
 The reaction proceeded cleanly and gave 
the desired product in excellent yield. Following treatment with tosyl chloride and 
pyridine, alcohol 356 was converted into tosylate 355 in exceptional yield (Scheme 
72).
474
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Scheme 72. The synthesis of amine 305 via tosylate precursor 355. Reagents and conditions: (a) (i) 
BH3•SMe2, THF, 0 °C to rt, 2 h (ii) H2O, rt, 16 h, 90%; (b) TsCl, Pyridine, CH2Cl2, rt, 2 d, 75%. 
Based on previous work in a related polycyclic system
460
, it was envisioned that 
tosylate 355 would be displaced with sodium cyanide to yield nitrile 354. 
Unfortunately under various reaction conditions (Table 40), none of the desired 
nitrile 354 was formed. It was hypothesised that the sp
3
 hybridised carbon adjacent to 
the tosylate group in structure 355 was too bulky for nucleophilic attack of the 
cyanide anion to occur, thereby preventing the desired SN2 displacement of the 
tosylate group. This is analogous to the neopentyl system, previous reports have 
described neopentyl chlorides failing to react with cuprous cyanide in a sealed tube 
following heating at 90 °C for 200 hours.
475
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Scheme 73.  The SN2  displacement of tosylate 355  with NaCN. 
Table 40 . Various conditions employed for the attempted synthesis of nitrile 354 .  
Entry Conditions Outcome 
1 
NaCN (10 eq), DMSO, rt, 
3 d 
No product detected, 
starting material recovered 
2 
NaCN (10 eq), DMSO, 
reflux, 3 d 
No product detected, 
starting material recovered 
3 
NaCN (10 eq), DMSO, 
sealed tube, 3 d 
No product detected, 
starting material recovered 
 
Due to the difficulties encountered in the displacement of tosylate 355 an alternative 
synthetic pathway for cubylamine 305 was proposed.  
9.7.1 The synthesis of amine 305 via a one carbon homologation 
The alternative synthetic pathway devised for the formation of cubylamine 305 is 
depicted in Scheme 74. It was postulated that cubylamine 305 would be derived 
from carboxylic acid 357, which could be obtained from the one carbon 
homologation of cubane ester 336. 
 
Scheme 74.  Modified retrosynthetic analysis of amine 305 .  
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Prior to discussing the synthesis of cubylamine 305, it is worthwhile to review the 
synthetic protocols commonly employed in the one carbon homologation of carbonyl 
compounds. 
9.7.2 One carbon homologations of carbonyl compounds  
The one carbon homologation of carboxylic acids is an important transformation in 
organic synthesis. Four general methods have been developed including: i) Arndt-
Eistert reaction (Scheme 75); ii) Barton radical homologation (Scheme 76); iii) 
Kowalski ester homologation (Scheme 77); and iv) Katritzky homologation (Scheme 
78) via 1-(trimethylsilylmethyl) benzotriazole (BtCH2TMS).  
 
Scheme 75.  Arndt-Eistert reaction.  
 
Scheme 76.  Barton radical homologation.   
 
Scheme 77.  Kowalski ester homologation. 
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Scheme 78.  Katritzy Homologation.  
The use of the extremely sensitive reagent diazomethane, which requires specialised 
equipment for preparation is utilised in the Arndt-Eistert reaction. In most examples, 
the Arndt-Eistert reaction also demands the use of freshly prepared silver solution for 
the rearrangement step. The Barton radical homologation utilises a photoreacter and 
contains a relatively lengthy procedure. The Katritzy and Kowalski homologations 
therefore appeared to be the most ideal and practical. Due to the ready availability of 
reagents required for the Kowalski homologation, it was selected for the synthesis of 
homologated acid 357. 
9.7.3 The synthesis of homologated acid 357 
Based on the previous work by Smith and co-workers
476
, methyl ester 336 was 
converted into α,α-dibromoketone 358 by treatment with dibromomethyllithium, 
prepared freshly from lithium tetramethylpiperidine and dibromomethane (Scheme 
79). In contrast to the original Kowalski procedure, the α,α-dibromoketone precursor 
was isolated and purified prior to the homologation step.
477,478
 
 
Scheme 79. The synthesis of α,α-dibromoketone 358. Reagents and conditions: (a) LTMP, CH2Br2, 
THF, −78 °C, 30 min, 64%. 
The α,α-dibromoketone 358 was then subjected to the homologation conditions. This 
involved a three step, one-pot reaction and produced the desired homologated ester 
359 and allene by-product 360 in a 3:1 ratio (Scheme 80). Unfortunately, these 
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products could not be separated by column chromatography. The mixture was 
therefore subjected to basic hydrolysis which, upon acidification, yielded 
homologated acid 357 in 53% yield over two steps.  
 
Scheme 80. The Kowalski ester homologation. Reagents and conditions: (a) (i) LHMDS, THF, −78 
°C, 30 min (ii) nBuLi, −78 °C, 30 min (iii) EtOH, AcCl, 0 °C, 20 min; (b) LiOH, THF, H2O, reflux, 
12 h, 53% over 2 steps. 
The mechanism of the Kowalski homologation is outlined in Scheme 81. Exposure 
of α,α-dibromoketone 358 to LHMDS results in the formation of enolate 361, which 
upon treatment with nBuLi forms the carbenoid intermediate 363. Ynolate 364 is 
formed by a Fritsch-Buttenberg-Wiechell rearrangement which is subsequently 
quenched by acidic ethanol, initially forming ketene intermediate 365, which is then 
trapped as the homologated ester 359. In order to avoid the formation of complex, 
polymer-containing mixtures, the reaction mixture was poured onto a solution of 
acidic ethanol as opposed to the addition of acidic ethanol to the reaction mixture.  
 
Scheme 81 . The mechanism of Kowalski ester homologation.  
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The formation of the unwanted allene by-product 360 is depicted in Scheme 82, and 
begins with the interaction of ynolate 364 with ketene 365.  
 
Scheme 82.  Formation of unwanted allene byproduct 360 .  
With homologated cubane carboxylic acid 357 in hand, the corresponding amide 367 
was synthesised via treatment with oxalyl chloride and liquid ammonia (Scheme 83). 
Unexpectedly, when amide 367 was treated with lithium aluminium hydride (to 
effect reduction to cubylamine 305), complete decomposition occurred. Upon 
heating the reaction mixture, a dark brown to green colour was formed and following 
standard work up and purification procedures none of the desired amine 305 could be 
detected. The issue of decomposition could potentially be the result of deprotonation 
of 367, the corresponding anion would undergo rapid ring opening and explain the 
observed decomposition. The use of an alternative, milder reducing agent, such as 
borane dimethyl sulfide, was proposed for the reduction of cubylamide 367 to 
cubylamine 305. Unfortunately, due to the unexpected decomposition, this 
necessitated the synthesis of additional quantities of amide 367.  
 
Scheme 83. Attempted synthesis of amine 305. Reagents and conditions: (a) (COCl)2, rt, 1 h; (b) 366, 
NH3 (l), CH2Cl2, −78 °C to rt, 40 min; (c) LiAlH4, THF, 0 °C to reflux, decomposition. 
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An alternative synthetic pathway, avoiding the necessity to reduce amide 367, is 
depicted in Scheme 84. The proposed synthesis involves conversion of homologated 
acid 357 to ester 359. Subsequent Kowalski homologation of ester 359 would yield 
propanoate 368¸ which, upon hydrolysis could be converted into carboxylic acid 369. 
Subjecting acid 369 to the Curtius rearrangement conditions previously utilised in 
Section 8.4, Boc-propected amine 372 could be obtained. Acidic hydrolysis would 
yield the desired cubylamine 305. 
Scheme 84.  An alternative synthetic pathway for the synthesis of cubylamine 305 .  
Due to time constraints, the biological evaluation of cubylamines 302–305 was 
commenced. The extensive number of synthetic steps required for the synthesis of 
additional quantities cubylamide 367 and the large amount of transformations 
involved in Scheme 84 prompted us to commence preliminary biological testing for 
proof of concept. Cubylamines 303 and 304, bearing structural similarities to 
amantadine (299) and rimantadine (300) respectively, were deemed the most 
important for this proof of concept trial.  
9.8 Summary of synthesised cubylamines 
In summary, three mono-substituted cubylamine hydrochloride salts (302–304) have 
been synthesised in moderate to good yields and excellent purity. It is interesting to 
note that without conversion to the hydrochloride salt, complete decomposition of 
cubylamines 302–304 occurred after 12 h at 4 °C, and in the absence of oxygen. 
Conversion to the hydrochloride salts additionally allowed for ease of storage and 
characterisation, without the problem of decomposition.  
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Cubanecarboxylic acid 331 was successfully homologated utilising Kowalski 
homologation conditions to give acid 357. Unfortunately, the target amine 305 could 
not be synthesised from this acid 357 due to unexpected decomposition.  
It was envisioned that the biological evaluation of cubylamines 302–304 in a known 
mouse model would potentially provide the proof of concept for the use of 
cubylamines as BBB permeability agents. It would also allow for direct comparison 
to the previously well-studied adamantanes, amantadine (299) and rimantadine (300). 
9.9 Biological evaluation of compounds 302–304  
All newly synthesised cubylamines 302–304 were evaluated by collaborator’s at 
Monash University in an established mouse model (full experimental detailes are 
provided in Section 11.9.4) in order to assess their in vivo brain exposure following 
oral administration to rodents at therapeutically relevant doses and therefore gain 
insight into their BBB permeability.
415
 Following administration of a solution of 
amine 302, 303 or 304, blood and brain samples were then obtained at 0.25, 0.5, 1, 2, 
4, 6, and 8 h (n= 5 mice at each time point) from individual animals under 
anaesthesia. The results are summarised in Table 41. 
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Table 41 . Concentrations of cubylamines 302–304  in mouse plasma and brain samples 
Cubylamine 
Plasma 
concentration 
(ng/mL)
a 
Brain 
concentration 
(ng/g)
a 
Brain/Plasma 
ratio
a 
 
521.5 2491.4 4.7 
 
263.9 1338.4 4.9 
 
547.1 5450.9 10.0 
a
 Values represent the mean of 5 sample measurements, full experimental procedures and 
measurements are provided in Section 11.9.4. 
The results reveal a similar trend to the corresponding adamantane analogues, 
amantadine (299) and rimantadine (300).
415
 Branched cubylamine (304), which bears 
structural similarities to rimantadine (300), exhibited the greatest brain:plasma (B:P) 
ratio with an average of 10.0. This ratio was substantially higher than that of 
cubylamine 302, which exhibited a B:P ratio of 4.7 and bears structural similarities to 
amantadine (299). Albeit the difference in the brain uptake is not as great (i.e. 
amantadine (299) exhibited a 5 min post-dose B:P ratio of 5.3 ± 0.9 whereas 
rimantadine exhibited a B:P ratio of 17.4 ± 1.2). Interestingly, the modification made 
for 303 does not appear to have any effect on B:P ratio with brain concentrations 
similar to that of amine 302. The similar uptake trends of cubylamines 302 and 304, 
to amantadine (299) and rimantadine (300), suggest these cubylamines traverse the 
BBB in a similar mechanism to that of the adamantane amines. Further biological 
evaluations are warranted.  
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9.10 Concluding remarks  
The present results are promising and reveal the newly synthesised cubylamines 
(302–304) to show similar trends in brain uptake to the corresponding adamantane 
derivatives. Cubylamine 304, bearing structural similaritites to rimantadine (300), 
displayed the greatest B:P ratio (10.0) and was significantly increased with respect to 
cubylamine 302 (which bears similarities to amantadine, 299). To further confirm the 
validity of using cubylamines as BBB permeability agents, further biological 
evaluation must be undertaken. In vitro cellular uptake must be assessed utilising 
immortalised brain endothelial cell lines to establish whether the difference in in vivo 
brain uptake observed in mice would correspond to a human setting and to further 
characterise the transport system involved in the mediation of brain uptake. The 
impact of known inhibitors of organic cation transporters, ʟ-carnitine and 3H-glycine 
can be further examined to determine more specifically if the synthesised 
cubylamines (302–304) are a substrate of the same transporter (ATB0,+), as 
rimantadine (300) and amantadine (299). Providing the further results demonstrate 
the involvement of ATB
0,+
 in mediating the transport of these cationic amines, this 
can potentially allow for a novel targeted approach to enhance drug delivery to the 
CNS. For the present project, this specifically involves further enhancement of the 
levels of α7 agonists reaching the brain, and will be discussed in Section 10.2. 
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Chapter 10 - Summary and future work 
10.1 Summary and conclusions   
In the current work, a small library of compounds have been synthesised based upon 
structural modifiations to lead compound SEN12333 (45). The investigations 
systematically investigated the structural features of SEN12333 (45): 
 The alkyl chain linker 
 The amide bond 
 The basic centre comprised of the heterocyclic morpholine ring 
 The aromatic moiety containing the biaryl ring system 
 The development of hybrid compounds incorporating features from known α7 
agonist, compound 139 
 Finally, the use of mono-substituted cubylamines were investigated in the 
hope of incorporating them into an α7 agonist in the futre. 
All compounds were evaluated for binding affinity at α7 receptors and for selectivity 
over other common subtypes α4β2 and α3β4. In some instances functional activity was 
additionally evaluated. The drug like properties – cLogP, PSA and LLE were 
calculated for all ligands investigated to provide an indication of their success in 
vivo. 
In terms of the alkyl chain linker, investigations have revealed the 4-carbon chain 
linker of SEN12333 (45) to be optimal for binding affinity and functional activity at 
α7 receptors. Contraction (51–53) or elongation (54) of this linker resulted in a 
complete loss of affinity and agonist activity. In relation to the amide bond, the 
connectivity of the amide bond in SEN12333 (45) was shown to be ideal. Its reversal 
resulted in a decrease in binding affinity at α7 receptors. The incorporation of the 
tetrazole functionality, a known isostere of cis amides, resulted in a dramatic loss of 
potency and agonist activity for all synthesised analogues (75–78). This suggests that 
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the amide bond of SEN12333 (45) adopts a trans conformation while interacting 
with the α7 receptor. 
The nature of the heterocyclic ring of SEN12333 (45) was found to be essential for 
binding affinity at α7 receptors. Replacement of the morpholine ring of SEN12333 
(45) with a piperidine functionality resulted in an increase in potency at α7 receptors. 
This is evident in the direct comparison of SEN12333 (45) and piperidine analogue 
100 (Ki: 670 vs 220 nM). Removal of the pyridine nitrogen within the terminal 
aromatic ring of SEN12333 (45) and related compounds, gave the corresponding 
biphenyl analogues. This structural modification consistently resulted in an 
improvement in binding affinity. The effect of these modifications is highlighted in 
the piperidine, biphenyl compound 101, which displayed a 3.5 fold improvement in 
binding affinity over lead compound SEN12333 (45) (Ki: 670 vs 190 nM). Though 
these structural modifications result in improved binding affinity, they increase the 
lipophilicity of the molecule (evident in the increased cLogP values of 100 and 101). 
Accordingly, the LLE values of these compounds are below that of SEN12333 (45), 
suggesting they may not be as successful in vivo. Incorporation of slightly branched 
or bicyclic amines namely 1-methyl piperazine or (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane resulted in a complete loss of affinity at α7 receptors and 
highlights the importance of the heterocyclic ring within this structural class of 
compounds.  
Exploration of the nature of the biaryl ring system of SEN12333 (45) revealed 
various modifications and substitutions to be tolerated. Repositioning the pyridine 
nitrogen within the terminal aromatic ring to either the 2- or 4- position, as in 
compounds 206 and 207 respectively, resulted in a two fold increase in binding 
affinity at α7 receptors (Ki: 330 and 350 nM respectively) and improved LLE values. 
Fluorine containing compound 208 represents the most potent congener of 
SEN12333 (45) (Ki = 85 nM) and displays a highly optimised LLE value of 4.59. 
This is a noteworthy result, highlighting its in vivo potential and warranting the 
further development of compound 208. Incorporation of biaryl ring systems from 
known α7 agonists gave pyrazole analogues (209–211), pyridazine containing 212 
and indolyl 213. The diverse results highlight the vast array of biaryl ring systems 
tolerated on the aromatic moiety of the SEN12333 (45) scaffold.   
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The development of truncated hybrids of SEN12333 (45) was based upon the 
scaffold of previously identified α7 agonist 139. Binding affinity was observed to be 
contingent on the basic centre of the molecule. The (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane was deemed optimal and it was evident that it could not 
be substituted with the basic centre (morpholine) of SEN12333 (45). In terms of the 
aromatic moiety of the truncated hybrids, the biaryl ring systems of SEN12333 (45) 
and compound 139 could be interchanged with potency maintained (provided the 
basic centre of the ligand consisted of the previously optimised (1S,4S)-2,5-
diazabicyclo[2.2.1]heptane). The phenyl-pyridyl and biphenyl motifs originally 
associated with SEN12333 (45) were incorporated into truncated hybrids 274 and 
275 respectively. These compounds maintained affinity at α7 receptors (Ki: 140 and 
34 nM respectively), albeit lower than lead compound 139 (Ki = 5.9 nM). Whilst 
compound 275 diplays high potency at α7 receptors, its high lipophilicity diminishes 
its LLE value. This suggests it may be not as successful in vivo compared to the 
related phenyl-pyridyl 274.  
The functional activities of selected compounds were then investigated, all 
compounds tested displayed agonist activity at the α7 receptor. The low EC50 of 
compound 208 highlights its potential for further development. Compounds 274 and 
275 both retain agonist activity at the α7 receptor and suggest the aromatic moiety of 
lead agonist 139 can be modified, with binding affinity and functional activity still 
maintained.  
Following an exhaustive investigation into the effects of the structural features of 
SEN12333 (45) for binding affinity and functional activity at α7 receptors – the final 
section of the present body of work investigated an alternative method of improving 
α7 agonists. Studies were conducted into the use of mono-substituted cubylamines as 
BBB permeability agents, in the hope that in the future these can be utilised to 
further enhance the brain levels of selected α7 agonists. The preliminary results have 
revealed the cubylamines 302–304 to display a similar trend to the corresponding, 
established adamantane amines, amantadine (299) and rimantadine (300). The results 
suggest cubylamines 302–304 to be substrates for the same ATB0,+ transporter, 
similar to their corresponding adamantane analogues. The promising results of this 
pilot study warrants further investigation of cubylamines 302–304.  
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10.2 Future work  
The future work of this project involves further biological evaluation of the 
cubylamines synthesised in Chapter 9, specifically cubylamine 304, which displayed 
the greatest B:P ratio. The synthesis of cubylamine 305 had previously proven 
difficult. However, given the similar trend in the B:P ratios of cubylamines 302 and 
304 to the related adamantane amines, and the negligible effect of the modification in 
cubylamine 303, the completion and evaluation of cubylamine 305 would likely 
yield little information relating to brain uptake.  
Though the results suggest cubylamines 302–304 to be substrates for the ATB0,+ 
transporter, further biological evaluation is required. To elucidate if cubylamines 
302–304 are indeed substrates for the ATB0,+ transporter, their brain uptake must be 
investigated in the presence of 
3
H-glycine, a known substrate of the ATB
0,+
 
transporter. To confirm the affinity of cubylamines 302–304 for the ATB0,+ 
transporter, further uptake studies are necessitated. These can be conducted in 
ATB
0,+
 transfected cells, utilising the previously described Xenopus laevis oocyte 
expression system.
426,428,479
  
To evaluate whether one enantiomer of cubylamine 304 possesses greater affinity for 
the ATB
0,+
 transporter, the enantiomers must be resolved. This could be achieved 
through diastereomeric recrystalisation utilising tartaric acid or alternatively, with 
chiral HPLC. Subsequent evaluation in the previously mentioned ATB
0,+
 transfected 
cells, would determine if one enantiomer is preferentially transported over the other. 
Assuming that cubylamine 304 displays the greatest affinity for the ATB
0,+
 
transporter, the substitution of the 4-position of cubylamine 304 must subsequently 
be explored to determine the amount of steric bulk tolerated by the ATB
0,+
 
transporter (assuming this is the method of BBB penetration) (Figure 84). If 
substitution at the 4-position is tolerated by the ATB
0,+
 transporter, this would 
provide further rationale to exploit cubanes uptake across the BBB and the 
development of cubanyl bearing α7 ligand.  
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Figure 84.  Substitution patterns to be examined for cubylamine 304 .  
The proposed incorporation of the cubane nucleus into various α7 agonists is depicted 
in Figure 85. In terms of SEN12333 (45), structures 373 and 374 explore the 
replacement of the basic centre with cubyl amines 304 and 302 respectively. These 
cubylamines can be viewed as a three dimensional isostere of piperidine, which was 
previously shown in Chapter 4 to improve the affinity of these compunds at α7 
receptors. The incorporation of these cubylamines as the basic centre in SEN12333 
(45) would also provide additional information into the amount of steric bulk 
tolerated at the basic centre for binding at the α7 receptor. The use of branched 
heterocyclic amines 1-methylpiperazine and (1S,4S)-2,5-diazabicyclo[2.2.1]heptane 
corresponded to decreased affinity at α7 receptors in Chapter 4, it was hypothesised 
that was either the result of increased steric bulk or the additional site of protonation 
present within the basic centre. The incorporation of cubylamines 302 and 304 would 
help to further elucidate this. The basicitiy of structures 373 and 374 can additionally 
be explored through methylation of the cubane nitrogen comprising the basic centre. 
Structure 375 investigates the replacement of the alkyl chain of SEN12333 (45) with 
either cubylamine 302 or 304. This modification would further rigidify the structure 
of SEN12333 (45) and reduce the number of rotatable bonds. The incorporation of 
cubylamine 304 into truncated lead 139 is illustrated in structure 376. This would 
also provide additional information about the amount of steric bulk tolerated at the 
basic centre of compound 139 for binding affinity at α7 receptors. 
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Figure 85.  The proposed incorporation of the cubane nucleus into α 7 agonists.  
For structures 373–376 to be effective α7 agonists and successfully cross the BBB via 
a transport-mediated process, the multiple biological evaluations must be completed. 
Investigations of the binding affinity and agonistic activity of structures 373–376 at 
α7 receptors will provide insight into their therapeutic effectiveness. While their 
evaluation in the previously discussed established mouse model will investigate their 
ability to traverse the BBB. Further evaluation in ATB
0,+
 transfected cells will 
ultimately determine their affinity for the ATB
0,+
 transporter and elucidate if 
cubylamines can be employed to enhance drug delivery to the CNS. 
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Chapter 11 - Experimental 
11.1 General synthetic details 
Reactions were conducted under a positive pressure of dry nitrogen or argon, unless 
otherwise stated. Temperatures quoted as 0 °C and –78 °C were achieved with 
cooling baths of ice-water and dry ice-acetone, respectively. Acetronitrile, 
dichloromethane, 1,2-dichloroethane, methanol, and triethylamine were distilled 
from calcium hydride. Tetrahydrofuran and diethyl ether were dried over sodium 
wire and distilled from sodium benzophenone ketyl. Ethanol, n-propanol and 
pyridine were distilled from calcium hydride and stored over activated 3 Å molecular 
sieves. Crude tosyl chloride (~ 10 g) was dissolved in chloroform (25 mL), filtered 
and diluted with hexanes (125 mL) to precipitate impurities. The solution was then 
filtered, clarified with activated charcoal and concentrated under reduced pressure to 
give analytically pure material (~7 g).  All reagents were purchased from either 
Sigma Aldrich Chemical Company, Matrix Scientific, Boron Molecular, or Tokyo 
Chemical Industry Co and used without further purification. Melting point 
determinations were measured on either a Gallenkamp melting point apparatus or 
Optimelt Automated Melting Point System and are recorded uncorrected. Infrared 
absorption spectra were run as Nujol (KBr) mulls for solids using a BIO-RAD FT-IR 
spectrophotometer/DRIFTS A 4000-400 cm
-1
 or as thin films on sodium chloride 
(NaCl) plates for oils using either Shimadzu FTIR-8400S Bruker Alpha-E FT-IR 
spectrometers. 
1
H and 
13
C NMR spectra were acquired at 300 ± 1 K using either a 
Bruker Avance DP 282 (300 MHz), DP X400 (400 MHz) or DPX500 (500 MHz). 
1
H 
chemical shifts are reported relative to residual non-deuterated solvent resonance or 
tetramethylsilane. Data are reported as chemical shifts (δH ppm), relative integral, 
multiplicity (s = singlet; br s = broad singlet; app. br s = apparent broad singlet; d = 
doublet; dd = doublet of doublets; t = triplet; dt = doublet of triplets; q = quartet; quin 
= quintet; m = multiplet range), coupling constants (J, Hz) and assignments are made 
where unambiguous. 
13
C chemical shifts are reported relative to the internal 
perdeuterated solvent resonance and are specified as quaternary (C), methine (aryl or 
CH), methylene (CH2) or methyl (CH3). Residual acid in deuterated chloroform was 
removed prior to use by filtering through a pad of basic alumina. Low-resolution 
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mass spectra were recorded on a Finnigan LCQ mass spectrometer. High-resolution 
mass spectra were recorded by the Mass Spectrometry Unit of the School of 
Chemistry, University of Sydney. Positive electrospray ionisation (ESI) and 
atmospheric pressure chemical ionisation (APCI) utilised methanol and/or 
dichloromethane. The purity of all new compounds was ≥95% based on C, H and N 
analyses conducted at the Department of Chemistry and Biomolecular Sciences, 
Macquarie University, Sydney, Australia. Analytical thin layer chromatography was 
carried out using aluminium backed silica gel 60 F254 (0.2 mm) Merck KGaA sheets 
and plates were visualised under a UV lamp at  = 254 nm. Plates were routinely 
stained with phosphomolybdic acid (5% solution in absolute ethanol). Flash column 
chromatography employed Merck Kieselgel 60 (230–400 mesh) silica gel. Solvents 
for flash column chromatography were distilled prior to use and are quoted as 
volume/volume mixtures where applicable.  
11.2 The synthesis of compounds from Chapter 2 
11.2.1 General procedure 1 for the synthesis of ω-bromo-N-(4-
bromophenyl)alkanamides
204
  
The appropriate ω-bromoalkanoic acid (1 mmol) was suspended in oxalyl chloride 
(ca. 2 mL), stirred at ambient temperature for 45 min, and the excess oxalyl chloride 
evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (10 mL), 
cooled to –78 °C, and treated dropwise with a solution of 4-bromoaniline (1.1 mmol) 
and triethylamine (1.1 mmol) in CH2Cl2 (11 mL). The mixture was warmed to 
ambient temperature, stirred for 4 h, and CH2Cl2 (50 mL) was added. The solution 
was washed with H2O (50 mL), hydrochloric acid (1M; 50 mL), saturated aqueous 
sodium hydrogencarbonate (50 mL), brine (50 mL), dried (MgSO4), filtered, and the 
solvent evaporated under reduced pressure to give crude amides 60-64. 
2-Bromo-N-(4-bromophenyl)acetamide (60)
204
 
 
Subjecting 2-bromoacetic acid to general procedure 1 gave amide 60 (0.94 mmol, 
94%) as a colourless solid; mp 163–165 °C; νmax/cm-1 3292, 3131, 1650, 1611, 
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1547, 1487, 1430, 1397, 1330, 1106, 1071, 1008, 824, 700; δH (300 MHz, CDCl3) 
8.14 (1 H, br s), 7.47 (2 H, d, J 9.0 Hz), 7.42 (2 H, d, J 9.0 Hz), 4.01 (2 H, s); δC (75 
MHz, CDCl3) 163.5, 136.1, 132.2, 121.7, 118.1, 29.5; m/z (+ESI) 291 ([M + H]
+
, 
100). Found: C, 32.91; H, 2.38; N, 4.76. Calc for C8H7Br2NO: C, 32.80; H, 2.41; N, 
4.78% 
3-Bromo-N-(4-bromophenyl)propanamide (61)
204
 
 
Subjecting 3-bromopropanoic acid to general procedure 1, using potassium carbonate 
as a base instead of triethylamine, gave after purification by flash chromatography on 
silica eluting with hexane-ethyl acetate (70:30), amide 61 (0.67 mmol, 67%) as a 
colourless solid; mp 164–166 °C; νmax/cm-1 3280, 1655, 1589, 1530, 1396, 819; δH 
(300 MHz, CDCl3) 7.43 (5 H, m), 3.70 (2 H, t, J 6.3 Hz), 2.93 (2 H, t, J 6.3 Hz); δC 
(75 MHz, CDCl3) 168.3, 136.6, 132.2, 122.0, 117.6, 41.0, 27.3; m/z (APCI) 227 ([M 
– Br]−, 100). Found: C, 35.49; H, 2.94; N, 4.46. Calc for C9H9Br2NO: C, 35.21; H, 
2.96; N, 4.56% 
4-bromo-N-(4-bromophenyl)butanamide (62)
204
 
 
Subjecting 4-bromobutanoic acid to general procedure 1 gave, after purification by 
flash chromatography on silica eluting with hexane-ethyl acetate (70:30), amide 62 
(0.75 mmol, 75%) as a colourless solid; mp 158–160 °C; νmax/cm-1 3287, 1654, 
1590, 1528, 1487, 1395, 1247, 1072, 1011, 827; δH (300 MHz, CDCl3) 7.82 (1 H, br 
s), 7.39 (4 H, m), 3.49 (2 H, t, J 6.3 Hz), 2.53 (2 H, t, J 6.3 Hz), 2.24 (2 H, m); δC (75 
MHz, CDCl3) 170.4, 136.8, 131.7, 121.8, 117.1, 35.4, 33.3, 28.0; m/z (APCI) 241 
([M – Br]−, 100). Found: C, 37.54; H, 3.43; N, 4.27. Calc for C10H11Br2NO: C, 
37.42; H, 3.45; N, 4.36% 
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5-Bromo-N-(4-bromophenyl)pentanamide (63)
204
  
 
Subjecting 5-bromopentanoic acid to general procedure 1 gave, after purification by 
flash chromatography on silica eluting with hexane-ethyl acetate (70:30), amide 63 
(0.91 mmol, 91%) as a colourless solid; mp 165–167 °C; νmax/cm-1 3303, 1660, 
1591, 1522, 1394, 818; δH (300 MHz, CDCl3) 7.41 (4 H, m), 7.22 (1 H, br s), 3.43 (2 
H, t, J 9.2 Hz), 2.38 (2 H, t, J 9.2 Hz), 1.91–1.84 (4 H, m); δC (75 MHz, CDCl3) 
171.2, 137.5, 132.1, 121.3, 116.4, 58.2, 37.0, 25.4, 23.2; m/z (APCI) 255 ([M – Br]−, 
100). 
6-Bromo-N-(4-bromophenyl)hexanamide (64)
204
 
 
Subjecting 6-bromohexanoic acid to general procedure 1 gave, after purification by 
flash chromatography on silica eluting with hexane-ethyl acetate (70:30), amide 64 
(0.64 mmol, 64%) as a colourless solid; mp 157–159 °C; νmax/cm-1 3291, 1655, 
1525, 1395, 814; δH (300 MHz, CDCl3) 7.42 (4 H, m), 7.17 (1 H, br s), 3.42 (2 H, t, J 
6.6 Hz), 2.37 (2 H, t, J 6.6 Hz), 1.90 (2 H, m), 1.76 (2 H, m), 1.55 (2 H, m); δC (75 
MHz, CDCl3) 171.0, 137.0, 132.1, 121.4, 116.9, 37.5, 33.6, 32.5, 27.8, 24.6; m/z 
(APCI) 268 ([M – Br]−, 100). Found: C, 41.22; H, 4.36; N, 3.99. Calc for 
C12H15Br2NO: C, 41.29; H, 4.33; N, 4.01% 
11.2.2 General procedure 2 for the synthesis of N-(4-bromophenyl)-ω-
morpholinoalkanamides
204
 
A solution of amide 60–64 (1.0 mmol) in DMF (10 mL) was treated with sodium 
iodide (1.0 mmol), triethylamine (1.0 mmol) and morpholine (1.1 mmol), and heated 
at reflux for 16 h. After cooling to ambient temperature, the solution was partitioned 
between H2O (100 mL) and ethyl acetate (100 mL), the layers separated, and the 
aqueous layer extracted with ethyl acetate (2 × 100 mL). The combined organic 
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extracts were washed with H2O (100 mL), brine (100 mL), dried (MgSO4), filtered, 
and the solvent evaporated under reduced pressure to give crude amides 65–69. 
N-(4-Bromophenyl)-2-morpholinoacetamide (65)
204
 
 
Subjecting compound 60 to general procedure 2 gave, after purification by flash 
chromatography on silica eluting with ethyl acetate, compound 65 (0.79 mmol, 79%) 
as a colourless solid; mp 134–136 °C; νmax/cm-1 2824, 1685, 1587, 1510, 1395, 
1303, 1113, 1070, 1008, 910, 868, 823, 709; δH (500 MHz, CDCl3) 9.06 (1 H, br s), 
7.46 (2 H, d, J 9.0 Hz), 7.43 (2 H, d, J 9.0 Hz), 3.77 (4 H, t, J 4.5 Hz), 3.13 (2 H, s), 
2.61 (4 H, t, J 4.5 Hz); δC (125 MHz, CDCl3) 168.1, 136.7, 132.1, 121.1, 116.9, 67.1, 
62.6, 53.9; m/z (+ESI) 299 ([M + H]
+
, 100). 
N-(4-Bromophenyl)-3-morpholinopropanamide (66)
204
 
 
Subjecting compound 61 to general procedure 2 gave, after purification by flash 
chromatography on silica eluting with ethyl acetate, compound 66 (0.72 mmol, 72%) 
as a colourless solid; mp 138–139 °C; νmax/cm-1 2820, 1666, 1588, 1536, 1487, 
1395, 1304, 1248, 1114, 1070, 1006, 925, 823, 767; δH (300 MHz, CDCl3) 10.8 (1 H, 
br s), 7.40 (4 H, m) 3.79 (4 H, t, J 4.5 Hz), 2.71 (2 H, t, J 5.4 Hz), 2.60 (4 H, t, J 4.5 
Hz), 2.51 (2 H, t, J 5.4 Hz); δC (75 MHz, CDCl3) 170.4, 137.8, 132.0, 121.1, 116.2, 
67.1, 54.1, 52.9, 32.3; m/z (+ESI) 313 ([M + H]
+
, 100). Found: C, 49.87; H, 5.57; N, 
8.91. Calc for C13H17BrN2O2: C, 49.85, H, 5.47, N, 8.94% 
N-(4-Bromophenyl)-4-morpholinobutanamide (67)
204
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Subjecting compound 62 to general procedure 2 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 67 (0.69 mmol, 69%) as a colourless solid; mp 142–143 °C; νmax/cm-1 
3822, 3639, 2962, 1666, 1590, 1535, 1395, 1115, 1070, 1007, 825; δH (300 MHz, 
CDCl3) 8.30 (1 H, br s), 7.41 (4 H, m) 3.71 (4 H, t, J 4.8 Hz), 2.47–2.40 (6 H, m), 
1.90 (2 H, m), 1.85 (2 H, m) δC (75 MHz, CDCl3) 171.8, 137.3, 132.1, 121.4, 116.7, 
67.0, 57.6, 53.6, 35.7, 21.9; m/z (+ESI) 241 ([M – C4H8NO], 100); Found: M
+
, 
327.07028. C14H19BrN2O3 requires 327.07082. 
N-(4-Bromophenyl)-5-morpholinopentanamide (68)
204
 
 
Subjecting compound 63 to general procedure 2 gave, after purification by flash 
chromatography on silica eluting with ethyl acetate, compound 68 (0.85 mmol, 85%) 
as a colourless solid; mp 147-148 °C; νmax/cm-1 2939, 1665, 1590, 1531, 1488, 
1395, 1302, 1246, 1114, 1070, 1007, 825; δH (300 MHz, CDCl3) 7.54 (1 H, br s), 
7.42 (4 H, m), 3.74 (4 H, t, J 4.4 Hz), 2.51–2.36 (8 H, m), 1.77 (2 H, m), 1.61 (2 H, 
m); δC (75 MHz, CDCl3) 171.4, 137.2, 132.0, 121.5, 116.7, 66.7, 58.4, 53.7, 37.4, 
25.8, 23.3; m/z (+ESI) 341 ([M + H]
+
, 100). 
N-(4-Bromophenyl)-6-morpholinohexanamide (69)
204
 
 
Subjecting compound 64 to general procedure 2 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 69 (0.64 mmol, 64%) as a colourless solid; mp 148–149 °C; νmax/cm-1 
3649, 3294, 2943, 1664, 1590, 1534, 1489, 1395, 1116, 826; δH (300 MHz, CDCl3) 
7.53 (1 H, br s), 7.41 (4 H, m) 3.71 (4 H, t, J 4.5 Hz), 2.40 (4 H, m), 2.32 (4 H, m), 
1.72 (2 H, m), 1.51 (2 H, m), 1.38 (2 H, m); δC (75 MHz, CDCl3) 171.5, 137.1, 
132.0, 121.5, 116.8, 67.1, 58.9, 53.9, 37.6, 27.2, 26.4, 25.5; m/z (+ESI) 355 ([M + 
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H]
+
, 100). Found: C, 54.09; H, 6.56; N, 7.83. Calc for C16H23BrN2O2: C, 54.09; H, 
6.53; N, 7.89% 
11.2.3 General procedure 3 for the synthesis of morpholino-N-(4-(pyridin-
3-yl)phenyl)alkanamides
204
 
A suspension of the appropriate amide 65–69 (1.0 mmol) and pyridine-3-boronic 
acid (1.1 mmol) were suspended in acetonitrile-aqueous sodium carbonate (1:1, 0.4 
M, 10 mL) and deoxygenated with bubbling argon at ambient temperature. A 
catalytic amount of Pd(PPh3)4 (0.05 mmol, 5 mol%) was added, and the mixture 
heated at reflux for 18 h. The reaction was partitioned between ethyl acetate (30 mL) 
and saturated aqueous sodium carbonate (30 mL), the layers separated, and the 
aqueous layer extracted with ethyl acetate (2 × 30 mL). The combined organic 
extracts were washed with brine (40 mL), dried (MgSO4), filtered, and the solvent 
evaporated under reduced pressure to give the crude product. 
2-Morpholino-N-(4-(pyridin-3-yl)phenyl)acetamide (51)
204
 
 
Subjecting compound 65 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 51 (0.75 mmol, 75%) as an off-white solid; mp 112–114 °C; νmax/cm-1 
3289, 1681, 1587, 1520, 1395, 1315, 1112, 910, 802; δH (300 MHz, CDCl3) 9.15 (1 
H, br s), 8.82 (1 H, d, J 1.6 Hz), 8.56 (1 H, dd, J 4.7, 1.6 Hz), 7.84 (1 H, dt, J 7.8, 1.6 
Hz), 7.69 (2 H, d, J 8.7 Hz), 7.55 (2 H, d, J 8.7 Hz), 7.34 (1 H, dd, J 7.8, 4.7 Hz), 
3.79 (4 H, t, J 4.8 Hz), 3.16 (2 H, s), 2.64 (4 H, t, J 4.8 Hz); δC (75 MHz, CDCl3) 
168.2, 148.4, 148.2, 137.7, 136.1, 134.1, 132.3, 127.9, 123.7, 120.1, 67.2, 62.6, 54.0; 
m/z (+ESI) 298 ([M + H]
+
, 100). Found: C, 68.60; H, 6.44; N, 13.94. Calc for 
C17H19N3O2: C, 68.67; H, 6.44; N, 14.13%  
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3-Morpholino-N-(4-(pyridin-3-yl)phenyl)propanamide (52)
204
 
 
Subjecting compound 66 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(95:4.5:0.5) compound 52 (0.67 mmol, 67%) as an off-white solid; mp 114–115°C; 
νmax/cm-1 2928, 1677, 1597, 1530, 1425, 1290, 1183, 1114, 844, 803, 711; δH (300 
MHz, CDCl3) 10.90 (1 H, br s), 8.82 (1 H, d, J 1.5 Hz), 8.54 (1 H, dd, J 4.8, 1.5 Hz), 
7.82 (1 H, dt, J 8.5, 1.5 Hz), 7.65 (2 H, d, J 2.1 Hz), 7.54 (2 H, d, J 2.1 Hz), 7.34 (1 
H, m), 3.82 (4 H, t, J 4.5 Hz), 2.75 (2 H, t, J 6.3 Hz), 2.62 (4 H, t, J 4.5 Hz), 2.56 (2 
H, t, J 6.3 Hz); δC (75 MHz, CDCl3) 170.5, 148.2, 148.1, 138.8, 136.1, 134.0, 133.2, 
127.8, 123.6, 120.1, 67.1, 54.2, 52.9, 32.4; m/z (+ESI) 312 ([M + H]
+
, 100). Found: 
C, 69.53; H, 6.83 N, 13.19. Calc for C18H21N3O2: C, 69.43; H, 6.80; N, 13.49% 
4-Morpholino-N-(4-(pyridin-3-yl)phenyl)butanamide (53)
204
 
 
Subjecting compound 67 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 53 (0.72 mmol, 72%) as an off-white solid; mp 121–123°C; νmax/cm-1 
2966, 1670, 1598, 1531, 1474, 1290, 1115, 802; δH (300 MHz, CDCl3) 8.82 (1 H, s), 
8.65 (1 H, br s), 8.56 (1 H, d, J 4.5 Hz), 7.85 (1 H, d, J 7.8 Hz), 7.65 (2 H, d, J 8.1 
Hz), 7.54 (2 H, d, J 8.1 Hz), 7.35 (1 H, m), 3.73 (4 H, t, J 4.5 Hz), 2.46 (8 H, m), 
1.94 (2 H, m); δC (75 MHz, CDCl3) 171.5, 148.2, 148.0, 138.5, 136.1, 134.1, 133.3, 
127.7, 123.7, 120.3, 67.0, 57.7, 53.6, 35.6, 22.0; m/z (+ESI) 326 ([M + H]
+
, 100). 
Found: C, 69.93; H, 7.22 N, 12.23. Calc for C19H23N3O2: C, 70.13; H, 7.12; N, 
12.91% 
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5-Morpholino-N-(4-(pyridin-3-yl)phenyl)pentanamide (45, SEN12333)
204
  
 
Subjecting compound 68 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 45 (0.83 mmol, 83%) as an off-white solid; mp 112–114 °C; νmax/cm-1 
2954, 1669, 1599, 1532, 1474, 1289, 1184, 1115, 805, 711; δH (300 MHz, CDCl3) 
8.79 (1 H, s), 8.54 (1 H, d, J 4.6 Hz), 8.20 (1 H, br s), 7.83 (1 H, d, J 7.9 Hz), 7.65 (2 
H, d, J 8.5 Hz), 7.50 (2 H, d, J 8.5 Hz), 7.33 (1 H, m), 3.69 (4 H, t, J 6.0 Hz), 2.45–
2.35 (8 H, m), 1.76 (2 H, m), 1.58 (2 H, m); δC (75 MHz, CDCl3) 171.6, 148.2, 
148.2, 138.5, 136.2, 134.2, 133.3, 127.7, 123.8, 120.5, 66.8, 58.5, 53.7, 37.4, 25.9, 
23.5; m/z (+ESI) 340 ([M + H]
+
, 100). 
6-Morpholino-N-(4-(pyridin-3-yl)phenyl)hexanamide (54)
204
 
 
Subjecting compound 69 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1), 
compound 54 (0.80 mmol, 80%) as an off-white solid; mp 119–121°C; νmax/cm-1 
2951, 2858, 1666, 1598, 1527, 1473, 1290, 1182, 1116, 803, 710; δH (300 MHz, 
CDCl3) 8.80 (1 H, d, J 1.9 Hz), 8.54 (1 H, dd, J 4.8, 1.9 Hz), 7.90 (1 H, br s), 7.83 (1 
H, dt, J 7.8, 1.9 Hz), 7.65 (2 H, d, J 7.2 Hz), 7.51 (2 H, d, J 7.2 Hz), 7.32 (1 H, dd, J 
7.8, 4.8 Hz), 3.69 (4 H, t, J 4.5 Hz), 2.42–2.30 (8 H, m), 1.75 (2 H, m), 1.52 (2 H, 
m), 1.38 (2 H, m); δC (75 MHz, CDCl3) 171.6, 148.2, 148.0, 138.4, 136.2, 134.2, 
132.2, 127.7, 123.7, 120.4, 67.0, 58.9, 53.8, 37.7, 27.2, 26.4, 25.5; m/z (+ESI) 354 
([M + H]
+
, 100). Found: C, 71.34; H, 7.74 N, 11.49. Calc for C21H27N3O2: C, 71.36; 
H, 7.70; N, 11.89% 
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11.3 The synthesis of compounds from Chapter 3 
2-(4-Morpholinobutyl)isoindoline-1,3-dione (89)  
 
N-(4-Bromobutyl)phthalimide (1.5 g, 5.32 mmol) was suspended in THF (48 mL) 
and treated with sodium iodide (0.80 g, 5.32 mmol), triethylamine (0.74 mL, 5.32 
mmol) and morpholine (0.51 mL, 5.85 mmol). The mixture was then heated at reflux 
for 16 h. After cooling to ambient temperature, the solvent was removed in vacuo 
and the residue partitioned between H2O (100 mL) and CHCl3 (100 mL). The 
aqueous layer was further extracted with CHCl3 (100 mL) and the organic extracts 
combined, dried (MgSO4), filtered, and the solvent removed under reduced pressure. 
The crude product was purified by flash chromatography on silica eluting with ethyl 
acetate to give phthalimide 89 (1.02 g, 66%) as a pale yellow oil; νmax/cm-1 2942, 
2855, 2807, 1703, 1393, 1359, 1333, 1114, 1069, 1011, 862, 716, 528; δH (300 MHz, 
CDCl3) 7.86–7.77 (2 H, m), 7.73–7.67 (2 H, m), 3.69 (6 H, m), 2.40 (6 H, m), 1.71 (2 
H, m), 1.50 (2 H, m); δC (75 MHz, CDCl3) 168.5, 134.0, 132.2, 123.3, 66.9, 58.4, 
53.7, 37.9, 26.6, 23.8; m/z (+ESI) 289 ([M + H]
+
, 100); Found: M
+
, 289.15493. 
C16H20N2O3 requires 289.15467. 
4-Morpholinobutan-1-amine (90)  
 
Phthalimide 89 (0.96 g, 3.35 mmol) was suspended in anhydrous ethanol (34 mL) 
and treated with hydrazine monohydrate (0.8 mL, 16.8 mmol). The mixture was 
heated under reflux for 2 h and then cooled to room temperature, filtered, and the 
filtrate evaporated under reduced pressure. The remaining residue was suspended in 
hydrochloric acid (1M; 50 mL) and heated under reflux for 1 h. After cooling to 
room temperature, the mixture was filtered and the filtrate washed with CH2Cl2 (50 
mL). The aqueous layer was basified to pH 14 with addition of aqueous sodium 
hydroxide (3M), and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
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layers were dried (MgSO4), filtered, and the solvent removed in vacuo to give the 
amine 90 (0.20 g, 39%) as a pale yellow oil; νmax/cm-1 3397, 2954, 1655, 1115, 864, 
506; δH (300 MHz, CDCl3) 3.7 (4 H, t, J 6.0 Hz), 2.71 (2 H, t, J 9.0 Hz), 2.43 (4 H, t, 
J 6.0 Hz), 2.33 (2 H, t, J 9.0 Hz), 2.08 (2 H, br s), 1.50 (4 H, m); δC (75 MHz, 
CDCl3) 67.0, 58.9, 53.8, 42.0, 31.4, 24.1; m/z (+ESI) 159 ([M + H]
+
, 100). 
4-bromo-N-(4-morpholinobutyl)benzamide (91)  
 
4-Bromobenzoyl chloride (0.41 g, 1.85 mmol) was suspended in CH2Cl2 (20 mL) and 
cooled to 0 °C. A solution of amine 90 (0.32 g, 2.03 mmol) and triethylamine (0.28 
mL, 2.03 mmol) in CH2Cl2 (10 mL) was added dropwise and stirring continued at 0 
°C for 0.5 h. The mixture was then allowed to reach room temperature and stirring 
continued for a further 2 h. CH2Cl2 (50 mL) was added and the solution sequentially 
washed with saturated aqueous sodium carbonate (50 mL), saturated aqueous 
ammonium chloride (50 mL), H2O (50 mL) and brine (50 mL). The organic layer 
was then dried (MgSO4), filtered and the solvent removed under reduced pressure to 
give the crude residue. Purification by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (90:9:1), gave amide 91 (0.4 g, 64%, over 2 
steps without isolation of amine 90) as a colourless solid; mp 148–149 °C; νmax/cm-
1 
2950, 1670, 1600, 1490, 1385, 1302, 1240, 1072, 1008, 825; δH (300 MHz, CDCl3) 
7.64 (2 H, d, J 9.0 Hz), 7.55 (2 H, d, J 9.0 Hz), 3.72 (4 H, t, J 3.0 Hz), 3.45 (2 H, m), 
2.48 (6 H, m), 1.66 (4 H, m), NH proton not observed; δC (75 MHz, CDCl3) 166.8, 
133.7, 131.8, 128.7, 126.1, 66.6, 58.2, 53.6, 39.8, 27.2, 23.7; m/z (+ESI) 341 ([M + 
H]
+
, 100); Found: C, 52.75; H, 6.29; N, 8.10. Calc for C15H21BrN2O2: C, 52.8; H, 
6.20; N, 8.21% 
N-(4-morpholinobutyl)-4-(pyridin-3-yl)benzamide (72)  
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Subjecting compound 91 to the general procedure 3 gave the crude residue which 
was purified by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (90:9:1) to give pentanamide 72 (0.29 g, 70%) an off white solid; 
mp 142–143 °C; νmax/cm-1 3308, 2943, 1629, 1532, 1473, 1295, 1115, 999, 863, 
766, 710; δH (300 MHz, CDCl3) 8.85 (1 H, s), 8.62 (1 H, dd, J 3.0, 6.0 Hz), 7.89 (2 
H, d, J 9.0 Hz), 7.64 (2 H, d, J 9.0 Hz), 7.38 (1 H, m), 6.77 (1 H, s), 3.71 (4 H, t, J 
6.0 Hz), 3.50 (2 H, q, J 6.0 Hz), 2.47 (6 H, m), 1.69 (4 H, m), NH proton not 
observed; δC (75 MHz, CDCl3) 167.2, 149.2, 148.4, 140.8, 138.0, 135.7, 134.5, 
127.9, 127.3, 123.8, 66.7, 58.3, 53.7, 39.9, 27.4, 23.8; m/z (+ESI) 339.87 ([M + H]
+
, 
100); Found: C, 70.78; H, 7.45; N, 12.45. Calc for C20H25N3O2: C, 70.77; H, 7.42; N, 
12.38% 
N-(4-morpholinobutyl)-[1,1'-biphenyl]-4-carboxamide (74)  
 
Subjecting compound 91 to the general procedure 3 using phenyl boronic acid gave 
the crude residue which was purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (90:9:1) to give pentanamide 74 (0.34 g, 91%) 
as an off-white solid; mp 147–149 °C; νmax/cm-1 3734, 3317, 2932, 1631, 1549, 
1117, 747, 587; δH (500 MHz, CDCl3) 7.83 (2 H d, J 8.0 Hz), 7.65 (2 H d, J 8.0 Hz), 
7.61 (2 H d, J 7.5 Hz), 7.46 (2 H, t, J 7.5 Hz), 7.39 (1 H, t, J 7.5 Hz), 6.57 (1 H, br s), 
3.70 (4 H, t, J 4.5 Hz), 3.5 (2 H, q, J 7.0 Hz), 2.43–2.38 (6 H, m), 1.73–1.60 (4 H, 
m); δC (125 MHz, CDCl3) 167.5, 144.3, 140.2, 133.7, 129.1, 128.1, 127.5, 127.3, 
127.2, 67.1, 58.5, 53.9, 40.1, 27.6, 24.3; m/z (+ESI) 339 ([M + H]
+
, 100); Found: C, 
74.07; H, 7.72; N, 8.23. Calc for C21H26N2O2: C, 74.53; H, 7.74; N, 8.28% 
N-([1,1'-biphenyl]-4-yl)-5-morpholinopentanamide (73)   
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Subjecting compound 68 to general procedure 3 using phenylboronic acid, the crude 
residue was obtained and purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (90:9:1) to give pentanamide 73 (0.19 g, 68%) 
as a colourless solid; mp 146–147 °C; νmax/cm-1 3302, 2941, 1655, 1596, 1533, 
1117, 763; δH (300 MHz, CDCl3) 7.56 (6 H, m), 7.42 (2 H, t, J 6.0 Hz), 7.33 (1 H, d, 
J 6.0 Hz), 3.71 (4 H, t, J 6.0 Hz), 2.42 (8 H, m), 1.77 (2 H, m), 1.61 (2 H, m) NH 
proton not observed; δC (75 MHz, CDCl3) 171.3, 140.6, 137.4, 137.3, 128.9, 127.7, 
127.2, 126.9, 120.3, 67.0, 58.6, 53.8, 37.5, 26.1, 23.5; m/z (+ESI) 339 ([M + H]
+
, 
100); Found: C, 74.36; H, 7.77; N, 8.32. Calc for C21H26N2O2: C, 74.53; H, 7.74; N, 
8.28% 
11.3.1 General Procedure 4 for synthesis of tetrazoles  
Phosporous pentachloride (1.3 mmol) was added in one portion to a solution of 
amides 45, 72–73 (1.0 mmol) in CH2Cl2 (5 mL) at ambient temperature. The reaction 
mixture was stirred for 2 h and then cooled to 0 °C. Trimethylsilyl azide (1.6 mmol) 
was added dropwise and the solution stirred at ambient temperature for 16 h before 
being quenched with saturated aqueous hydrogen carbonate (20 mL). The reaction 
mixture was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
layers washed wit H2O (50 mL), dried (MgSO4), filtered, and the solvent removed in 
vacuo to give crude tetrazoles (75–78). 
4-(4-(1-(4-(Pyridin-3-yl)phenyl)-1H-tetrazol-5-yl)butyl)morpholine (75) 
 
Subjecting amide 45 to general procedure 4, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9:1) to give tetrazole 75 (0.069g, 40%) as a colourless solid; mp 88–89 
°C; νmax/cm-1 2945, 1477, 1115, 852, 807, 712, 577; δH (300 MHz, CDCl3) 8.85 (1 
H, s), 8.63 (1 H, s), 7.89 (1 H, m), 7.76 (2 H, d, J 6.0 Hz), 7.54 (2 H, d, J 6.0 Hz), 
7.40 (1 H, m), 3.60 (4 H, t, J 6.0 Hz), 2.93 (2 H, t, J 6.0 Hz), 2.33 (6 H, m), 1.82 (2 
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H, m), 1.55 (2 H, m); δC (75 MHz, CDCl3) 155.0, 149.7, 148.4, 140.3, 134.7, 134.6, 
133.7, 128.7, 125.6, 123.9, 66.6, 58.1, 53.6, 25.5, 25.0, 23.7; m/z (+ESI) 365 ([M + 
H]
+
, 100). Found: C, 65.48; H, 6.65; N, 22.85. Calc for C20H24N6O: C, 65.91; H, 
6.64; N, 23.06% 
4-(4-(1-([1,1'-Biphenyl]-4-yl)-1H-tetrazol-5-yl)butyl)morpholine (76)  
 
Subjecting amide 73 to general procedure 4, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (95:4.5:0.5) to give tetrazole 76 (0.075 g, 71%) as a colourless solid; mp 
113–114 °C; νmax/cm-1 2949, 1488, 1116, 846, 766, 698; δH (300 MHz, CDCl3) 7.77 
(2H, d, J 9.0 Hz), 7.61 (2H, d, J 9.0 Hz), 7.51-7.40 (5H, m), 3.64 (4H, t, J 3.0 Hz), 
2.94 (2H, t, J 6.0 Hz), 2.37–2.28 (6H, m), 1.84 (2H, m), 1.54 (2H, m); δC (75 MHz, 
CDCl3) 155.1, 143.5, 139.2, 132.8, 129.2, 128.5, 128.4, 127.2, 125.3, 66.9, 58.1, 
53.7, 25.8, 25.1, 23.6; m/z (+ESI) 364 ([M + H]
+
, 48), 249 (100); Found: C, 69.06; H, 
6.90; N, 19.25. Calc for C21H25N5O: C, 69.40; H, 6.93; N, 19.27% 
4-(4-(5-(4-(Pyridin-3-yl)phenyl)-1H-tetrazol-1-yl)butyl)morpholine (77) 
 
Subjecting amide 72 to general procedure 4, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9:1) to give tetrazole 77 (0.069 g, 78%) as a colourless solid; mp 82–84 
°C; νmax/cm-1 3462, 2952, 1471, 1115, 864, 808, 601, 573, 523, 508; δH (300 MHz, 
CDCl3) 8.85 (1 H, s), 8.62 (1 H, m), 7.90 (1 H, d, J 6.0 Hz), 7.79 (2 H, d, J 6.0 Hz), 
7.74 (2 H, d, J 6.0 Hz), 7.39 (1 H, m), 4.48 (2 H, t, J 6.0 Hz), 3.61 (4 H, t, J 6.0 Hz), 
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2.33 (6 H, m), 1.98 (2 H, m), 1.50 (2 H, m); δC (75 MHz, CDCl3) 153.8, 149.5, 
148.3, 140.8, 135.1, 134.5, 129.5, 129.4 128.0, 123.8, 66.9, 57.7, 53.6, 48.1, 27.6, 
23.2; m/z (+ESI) 365 ([M + H]
+
, 100). Found: C, 65.76; H, 6.66; N, 23.20. Calc for 
C20H24N6O: C, 65.91; H, 6.64; N, 23.06% 
4-(4-(5-([1,1'-Biphenyl]-4-yl)-1H-tetrazol-1-yl)butyl)morpholine (78)  
 
Subjecting amide 74 to general procedure 4, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9:1) to give tetrazole 78 (0.075 g, 57%) as a colourless solid; mp 83–85 
°C; νmax/cm-1 2945, 1474, 1116, 847, 746, 698; δH (500 MHz, CDCl3) 7.74 (4 H, s), 
7.60 (2 H, d, J 4.5 Hz), 7.45 (2 H, t, J 4.5 Hz), 7.38 (1 H, m), 4.48 (2 H, t, J 4.5 Hz), 
3.61 (4 H, t, J 2.7 Hz), 2.28 (6 H, m), 1.98 (2 H, m), 1.49 (2 H, m); δC (125 MHz, 
CDCl3) 154.0, 144.0, 139.5, 129.1, 129.0, 128.3, 127.8, 127.1, 122.8, 66.9, 57.7, 
53.6, 48.0, 27.5, 23.2; m/z (+ESI) 364 ([M + H]
+
, 100), 386 ([M + Na], 78), 749 
([2M + Na], 90); Found: C, 69.91; H, 7.0; N, 19.25. Calc for C21H25N5O: C, 69.40, 
H, 6.93; N, 19.27% 
11.4 The synthesis of compounds from Chapter 4 
N-(4-Bromophenyl)-5-(piperidin-1-yl)pentanamide (121)  
 
Subjecting amide 63 to general prodecure 2 using THF as the solvent and piperdine 
as the amine source, the crude amide was obtained and purified by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1) 
to give compound 121 (1.0 g, 82%) as a colourless solid; mp 123–124 °C; νmax/cm-1 
2934, 1739, 1665, 1592, 1535, 1489, 1394, 824; δH (300 MHz, CDCl3) 8.09 (1 H, br 
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s), 7.38 (4 H, m), 2.36–2.27 (8 H, m), 1.69 (2 H, m), 1.58–1.51 (6 H, m), 1.41 (2 H, 
m); δC (75 MHz, CDCl3) 171.8, 137.2, 131.9, 121.8, 116.8, 58.8, 54.7, 37.3, 26.2, 
25.9, 24.3, 23.7; m/z (+ESI) 339 ([M + H]
+
, 80); Found: C, 56.67; H, 7.04; N, 8.22. 
Calc for C16H23BrN2O: C, 56.64, H, 6.83; N, 8.26% 
5-(Piperidin-1-yl)-N-(4-(pyridin-3-yl)phenyl)pentanamide (100)  
 
Subjecting compound 121 to general procedure 3, the crude amide was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (93:6.5:0.5) to give compound 100 (0.12 g, 71%) as a colourless solid; mp 
117–118 °C; νmax/cm-1 2932, 1668, 1599, 1530, 1473, 1375, 1116; δH (500 MHz, 
CDCl3) 8.82 (1 H, d, J 2.0 Hz), 8.56 (1 H, dd, J 1.0, 4.5 Hz), 7.88 (1 H, br s), 7.84 (1 
H, dt, J 1.5, 8.0 Hz), 7.64 (2 H, d, J 8.5 Hz), 7.5 (2 H, d, J 8.5 Hz), 7.34 (1 H, dd, J 
5.0, 8.0 Hz), 2.43–2.32 (8 H, m), 1.76 (2 H, m), 1.62–1.55 (6 H, m), 1.42 (2 H, m); 
δC (125 MHz, CDCl3) 171.7, 148.3, 148.2, 138.4, 136.2, 134.2, 133.6, 127.8, 123.7, 
120.7, 59.0, 54.8, 37.6, 26.5, 26.1, 24.5, 23.9; m/z (+ESI) 169 ([M – C11H9N2], 100); 
(APCI) 253 ([M – C5H10N]
+
, 100); Found: C, 74.66; H, 8.24; N, 12.29. Calc for 
C21H27N3O: C, 74.74, H, 8.06; N, 12.45% 
N-([1,1'-Biphenyl]-4-yl)-5-(piperidin-1-yl)pentanamide (101)  
 
Subjecting compound 121 to general procedure 3 using phenylboronic acid, the 
crude amide was obtained and purified by flash chromatography on silica eluting 
with CH2Cl2-methanol-aqueous ammonia (90:9:1) to give compound 101 (0.15 g, 
52%) as a colourless solid; mp 109–111 °C; νmax/cm-1 2933, 1654, 1596, 1532, 
1488, 1395, 826; δH (500 MHz, CDCl3) 7.58–7.53 (4 H, m), 7.42–7.39 (4 H, m), 7.31 
(1 H, m), 2.44–2.37 (8 H, m), 1.78 (2 H, m), 1.65–1.59 (6 H, m), 1.45 (2 H, m) NH 
Chapter 11 Experimental 
 
231 
 
proton not observed; δC (125 MHz, CDCl3) 171.5, 140.9, 137.5, 132.1, 128.9, 127.7, 
127.2, 127.0, 120.7, 58.9, 54.8, 37.5, 26.4, 26.0, 24.5, 23.9; m/z (APCI) 252 ([M – 
C5H10N], 100), 168 ([M – C11H9N2]
+
, 95, 337 ([M + H], 80); Found: C, 78.74; H, 
8.01; N, 8.23. Calc for C22H28N2O: C, 78.53, H, 8.39; N, 8.33% 
2-(4-(Piperidin-1-yl)butyl)isoindoline-1,3-dione (122)  
 
N-(4-Bromobutyl)phthalimide (2.0 g, 7.09 mmol) was suspended in THF (64 mL) 
and treated with sodium iodide (1.06 g, 7.09 mmol), triethylamine (0.99 mL, 7.09 
mmol) and piperidine (0.77 mL, 7.79 mmol). The mixture was then heated at reflux 
for 16 h. After cooling to ambient temperature, the solvent was removed in vacuo 
and the residue partitioned between H2O (100 mL) and CHCl3 (100 mL). The 
aqueous layer was further extracted with CHCl3 (100 mL) and the organic extracts 
combined, dried (MgSO4), filtered, and the solvent removed under reduced pressure. 
The crude product was purified by flash chromatography on silica eluting with ethyl 
acetate to give phthalimide 122 (1.52 g, 74%) as a colourless solid; mp 73–74 °C; 
νmax/cm-1 2933, 2765, 1711, 1395, 1367, 1215, 1040; δH (300 MHz, CDCl3) 7.82–
7.80 (2 H, m), 7.70–7.67 (2 H, m), 3.68 (2 H, t, J 6.9 Hz), 2.32–2.26 (6 H, m), 1.66 
(2 H, m), 1.56–1.46 (6 H, m), 1.39 (2 H, m); δC (75 MHz, CDCl3) 168.5, 133.9, 
132.2, 123.2, 59.0, 54.7, 38.0, 26.8, 26.1, 24.5, 24.4; m/z (APCI) 287 ([M + H]
+
, 83); 
Found: C, 71.42; H, 8.06; N, 9.78. Calc for C17H22N2O: C, 71.30, H, 7.74; N, 9.78% 
4-(Piperidin-1-yl)butan-1-amine (123)  
 
Phthalimide 122 (0.85 g, 2.97 mmol) was suspended in anhydrous ethanol (30 mL) 
and treated with hydrazine monohydrate (0.72 mL, 14.85 mmol). The mixture was 
heated under reflux for 2 h and then cooled to room temperature, filtered, and the 
filtrate evaporated under reduced pressure. The remaining residue was suspended in 
hydrochloric acid (1M; 50 mL) and heated under reflux for 1 h. After cooling to 
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room temperature, the mixture was filtered and the filtrate washed with CH2Cl2 (50 
mL). The aqueous layer was basified to pH 14 with addition of aqueous sodium 
hydroxide (3 M), and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were dried (MgSO4), filtered, and the solvent removed in vacuo to give amine 
123 which was used directly in the next step without further purification or 
characterization due to its volatile nature.  
4-Bromo-N-(4-(piperidin-1-yl)butyl)benzamide (124)  
  
4-Bromobenzoyl chloride (0.52 g, 2.39 mmol) was suspended in CH2Cl2 (15 mL) and 
cooled to 0 °C. A solution of crude amine 123 (2.97 mmol) and triethylamine (0.33 
mL, 2.39 mmol) in CH2Cl2 (15 mL) was added dropwise and stirring continued at 0 
°C for 0.5 h. The mixture was then allowed to reach room temperature and stirring 
continued for a further 2 h. CH2Cl2 (50 mL) was added and the solution washed with 
saturated aqueous sodium carbonate (50 mL), saturated aqueous ammonium chloride 
(50 mL), H2O (50 mL) then brine (50 mL). The organic layer was then dried 
(MgSO4), filtered, and the solvent removed under reduced pressure to give the crude 
residue. Purification by flash chromatography on silica eluting with CH2Cl2-
methanol-aqueous ammonia (90:9:1), gave amide 124 (0.99 g, 50% over two steps) 
as a colourless solid; mp 112–113 °C; νmax/cm-1 3316, 2932, 1742, 1632, 1536; δH 
(300 MHz, CDCl3) 7.62 (2 H, d, J 8.4 Hz), 7.53 (2 H, d, J 8.4 Hz), 3.43 (2 H, q, J 5.4 
Hz), 2.34–2.30 (6 H, m), 1.66–1.50 (8 H, m), 1.40 (2 H, m); δC (75 MHz, CDCl3) 
166.9, 134.1, 131.8, 128.8, 125.9, 58.7, 54.7, 40.2, 27.5, 25.9, 24.7, 24.5; m/z (APCI) 
185 ([M – C9H19N2]
+
, 100), 339 ([M + H], 42); Found: C, 56.69; H, 6.97; N, 8.25. 
Calc for C16H23BrN2O: C, 56.64, H, 6.83; N, 8.26% 
N-(4-(Piperidin-1-yl)butyl)-4-(pyridin-3-yl)benzamide (102)  
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Subjecting compound 124 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(95:4.5:0.5) compound 102 (0.126 g, 63%) as a colourless solid; mp 115–117 °C; 
νmax/cm-1 3315, 2932, 1739, 1639, 1546, 1366, 1305, 1216; δH (300 MHz, CDCl3) 
8.87 (1 H, d, J 2.1 Hz), 8.62 (1 H, dd, J 1.5, 4.8 Hz), 7.91 (1 H, t, J 2.1 Hz), 7.87 (2 
H, d, J 8.4 Hz), 7.64 (2 H, d, J 8.4 Hz), 7.39 (1 H, dd, J 4.8, 8.78 Hz), 6.95 (1 H, br 
s), 3.50 (2 H, q, J 6.0 Hz), 2.37–2.32 (6 H, m), 1.69–1.51 (8 H, m), 1.42 (2 H, m); δC 
(75 MHz, CDCl3) 167.3, 149.2, 148.5, 140.7, 135.8, 134.8, 134.5, 128.0, 127.3, 
123.8, 58.8, 54.7, 40.1, 27.6, 25.9, 24.7, 24.5; m/z (APCI) 182 ([M – C11H8N]
+
, 100), 
253 ([M – C5H10N]
+
, 35); Found: C, 74.38; H, 8.37; N, 12.41. Calc for C21H27N3O: 
C, 74.74, H, 8.06; N, 12.45% 
N-(4-(Piperidin-1-yl)butyl)-[1,1'-biphenyl]-4-carboxamide (103)  
 
Subjecting compound 124 to general procedure 3 using phenylboronic acid gave, 
after purification by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (95:4.5:0.5) compound 103 (0.19 g, 67%) as a colourless solid; 
mp 129–131 °C; νmax/cm-1 3327, 2932, 1632, 1541, 1304, 852; δH (400 MHz, 
CDCl3) 7.83 (2 H, d, J 8.8 Hz), 7.64 (2 H, d, J 8.8 Hz), 7.61 (2 H, d, J 7.2 Hz), 7.46 
(2 H, t, J 7.2 Hz), 7.36 (1 H, m), 3.49 (2 H, q, J 6.4 Hz), 2.37–2.34 (6 H, m), 1.70–
1.62 (4 H, m), 1.58–1.53 (4 H, m), 1.41 (2 H, m), NH proton not observed; δC (100 
MHz, CDCl3) 167.5, 144.1, 140.3, 133.8, 129.0, 128.0 127.6, 127.3, 127.2, 58.7, 
54.7, 40.0, 27.6, 25.8, 24.5, 24.4; m/z (APCI) 181 ([M – C12H9]
+
, 100), 252 ([M – 
C5H10N]
+
, 38); Found: C, 78.01; H, 8.68; N, 8.32. Calc for C22H28N2O: C, 78.53, H, 
8.39; N, 8.33% 
N-(4-Bromophenyl)-5-(4-methylpiperazin-1-yl)pentanamide (127)
189
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Subjecting compound 63 to general procedure 2 using THF as the solvent and N-
methyl piperazine as the amine source, the crude amide was obtained and purified by 
flash chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(90:9:1) to give compound 121 (1.84 g, 51%) as a colourless solid; mp 99–100 °C; 
νmax/cm-1 2933, 1738, 1665, 1587, 1529, 1499, 1387, 824; δH (200 MHz, CDCl3) 
7.56 (1 H, br s), 7.41 (4 H, br m), 2.49–2.33 (12 H, m), 2.29 (3 H, s), 1.80–1.57 (4 H, 
m); δC (125 MHz, CDCl3) 171.4, 137.2, 132.0, 121.6, 116.8, 57.0, 54.9, 53.1, 46.0, 
37.4, 26.2, 23.5; m/z (+ESI) 355 ([M + H]
+
, 100).  
5-(4-Methylpiperazin-1-yl)-N-(4-(pyridin-3-yl)phenyl)pentanamide (104)
189
  
 
Subjecting compound 127 to the general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1) 
compound 104 (0.28 g, 57%) as a colourless solid; mp 144–146 °C; νmax/cm-1 3551, 
2945, 2803, 1740, 1653, 1532, 1425, 1289, 843; δH (500 MHz, CDCl3) 8.82 (1 H, d, 
J 1.5 Hz), 8.56 (1 H, dd, J 1.5, 4.5 Hz), 7.84 (1 H, dt, J 2.0, 8.0 Hz), 7.63 (2 H, d, J 
8.5 Hz), 7.54 (2 H, d, J 8.5 Hz), 7.35 (1 H, dd, J 5.0, 8.0 Hz), 2.43–2.34 (12 H, m), 
2.27 (3 H, s), 1.80–1.74 (2 H, m), 1.62–1.56 (2 H, m) NH proton not observed; δC 
(125 MHz, CDCl3) 171.3, 148.3, 148.0, 138.1, 136.0, 134.0, 132.1, 127.7, 123.6, 
120.4, 58.1, 55.1, 53.3, 46.1, 37.5, 26.4, 23.6; m/z (+ESI) 353 ([M + H]
+
, 100). 
N-([1,1'-Biphenyl]-4-yl)-5-(4-methylpiperazin-1-yl)pentanamide (105)  
 
 
Subjecting 127 to the general procedure 3 using phenylboronic acid gave, after 
purification by flash chromatography on silica eluting with CH2Cl2-methanol-
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aqueous ammonia (85:13.5:1.5) 105 (0.34 mmol, 68%) as a colourless solid; mp 
147.5–148.9 °C; νmax/cm-1 3552, 2942, 2805, 1738, 1656, 1596, 1532, 1372, 1216, 
834, 762; δH (500 MHz, CDCl3) 7.59 (2 H, d, J 8.5 Hz), 7.56–7.53 (4 H, m), 7.42 (2 
H, t, J 6.0 Hz), 7.32 (1 H, t, J 6.0 Hz), 2.47–2.38 (12 H, m), 2.28 (3 H, s), 1.78–1.74 
(2 H, m), 1.63–1.58 (2 H, m); δC (125 MHz, CDCl3) 171.4, 140.6, 137.4, 137.2, 
128.9, 127.7, 127.2, 127.0, 120.4, 58.1, 55.1, 53.3, 46.1, 37.6, 26.4, 23.7; m/z (+ESI) 
352 ([M + H]
+
, 100); Found: C, 75.10; H, 8.37; N, 11.86. Calc for C22H29N3O: C, 
75.18, H, 8.32; N, 11.96% 
2-(4-(4-Methylpiperazin-1-yl)butyl)isoindoline-1,3-dione (128)  
 
N-(4-Bromobutyl)phthalimide (2.0 g, 7.09 mmol) was suspended in THF (64 mL) 
and treated with sodium iodide (1.06 g, 7.09 mmol), triethylamine (0.99 mL, 7.09 
mmol) and N-methyl piperazine (0.86 mL, 7.09 mmol). The mixture was then heated 
at reflux for 16 h. After cooling to ambient temperature, the solvent was removed in 
vacuo and the residue partitioned between H2O (100 mL) and CHCl3 (100 mL). The 
aqueous layer was further extracted with CHCl3 (100 mL) and the organic extracts 
combined, dried (MgSO4), filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash chromatography on silica eluting with ethyl 
acetate to give phthalimide 128 (1.94 g, 91%) as a colourless solid; mp 71–72 °C; 
νmax/cm-1 2794, 1707, 1394, 1164, 1041; δH (300 MHz, CDCl3) 7.83–7.81 (2 H, m), 
7.72–7.69 (2 H, m), 3.70 (2 H, t, J 6.4 Hz), 2.43–2.33 (10 H, m), 2.26 (3 H, s), 1.69 
(2 H, m), 1.52 (2 H, s); δC (75 MHz, CDCl3) 168.6, 134.0, 132.2, 123.3, 58.1, 55.2, 
53.3, 46.2, 38.0, 26.7, 24.4; m/z (APCI) 302 ([M + H]
+
, 100); Found: C, 67.82; H, 
7.64; N, 13.84. Calc for C17H23N3O2: C, 67.75, H, 7.69; N, 13.94% 
4-(4-Methylpiperazin-1-yl)butan-1-amine (129) 
 
Phthalimide 128 (1.20 g, 3.98 mmol) was suspended in anhydrous ethanol (40 mL) 
and treated with hydrazine monohydrate (0.97 mL, 19.9 mmol). The mixture was 
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heated under reflux for 2 h and then cooled to room temperature, filtered, and the 
filtrate evaporated under reduced pressure. The resulting residue was suspended in 
hydrochloric acid (1 M; 50 mL) and heated under reflux for 1 h. After cooling to 
room temperature, the mixture was filtered and the filtrate washed with CH2Cl2 (50 
mL). The aqueous layer was basified to pH 14 with addition of aqueous sodium 
hydroxide (3 M), and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were dried (MgSO4), filtered and the solvent removed in vacuo to give amine 
129 which was used directly in the next step without further purification or 
characterization due to its volatile nature.  
4-Bromo-N-(4-(4-methylpiperazin-1-yl)butyl)benzamide (130)  
 
4-Bromobenzoyl chloride (0.18 g, 0.8 mmol) was suspended in CH2Cl2 (10 mL) and 
cooled to 0 °C. A solution of crude amine 129 (0.87 mmol) and triethylamine (0.11 
mL, 0.8 mmol) in CH2Cl2 (10 mL) was added dropwise and stirring continued at 0 °C 
for 0.5 h. The mixture was then allowed to reach room temperature and stirring 
continued for a further 2 h. CH2Cl2 (50 mL) was added and the solution washed with 
saturated aqueous sodium carbonate (50 mL), saturated aqueous ammonium chloride 
(50 mL), H2O (50 mL) then brine (50 mL). The organic layer was then dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the crude 
residue. Purification by flash chromatography on silica eluting with CH2Cl2-
methanol-aqueous ammonia (90:9:1), gave amide 130 (0.3 g, 35%) as a colourless 
solid; mp 121–123 °C; νmax/cm-1 2940, 2794, 1636, 1590, 1544, 1482, 1284, 1164, 
1011; δH (300 MHz, CDCl3) 7.61 (2 H, d, J 8.1 Hz), 7.54 (2 H, d, J 8.1 Hz), 3.43 (2 
H, t, J 6.0 Hz), 2.39–2.35 (10 H, m), 2.42 (3 H, s), 1.65–1.59 (4 H, m), NH proton 
not observed; δC (75 MHz, CDCl3) 166.8, 134.0, 131.8, 128.7, 125.9, 58.0, 55.1, 
53.3, 46.1, 40.2, 27.5, 24.6; m/z (APCI) 354 ([M + H]
+
, 100); Found: C, 54.18; H, 
7.06; N, 11.56. Calc for C16H24BrN3O: C, 54.24, H, 6.83; N, 11.86% 
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N-(4-(4-Methylpiperazin-1-yl)butyl)-4-(pyridin-3-yl)benzamide (106)  
 
Subjecting compound 130 to the general procedure 3 gave, after purification by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(95:4.5:0.5) compound 106 (0.05 mmol, 55%) as a colourless solid; mp 113–115 °C; 
νmax/cm-1 3295, 2939, 2798, 1737, 1638, 1545, 1458, 1371, 1301, 1216, 1164, 
1012; δH (500 MHz, CDCl3) 8.82 (1 H, d, J 2.0 Hz), 8.60 (1 H, dd, J 1.5, 5.0 Hz), 
7.87–7.83 (3 H, m), 7.60 (2 H, d, J 8.0 Hz), 7.36 (1 H, dd, J 5.0, 8.0 Hz), 6.89 (1 H, 
br s), 3.46 (2 H, q J 6.5 Hz), 2.38–2.35 (10 H, m), 2.22 (3 H, s), 1.68–1.58 (4 H, m); 
δC (125 MHz, CDCl3) 167.3, 149.2, 148.4, 140.8, 135.7, 134.7, 134.5, 127.9, 127.3, 
123.8, 58.1, 55.1, 53.3, 46.2, 40.2, 27.6, 24.7; m/z (APCI) 182 ([M – C9H20N3]
+
, 
100), 253 ([M – C5H11N2]
+
, 37); Found: C, 71.49; H, 8.31; N, 15.81. Calc for 
C21H28N4O: C, 71.56, H, 8.01; N, 15.9% 
N-(4-(4-Methylpiperazin-1-yl)butyl)-[1,1'-biphenyl]-4-carboxamide (107)  
 
Subjecting compound 130 to the general procedure 3 using phenylboronic acid gave, 
after purification by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (95:4.5:0.5) compound 107 (0.057 mmol, 71%) as a colourless 
solid; mp 132–133 °C; νmax/cm-1 3320, 2932, 2791, 1741, 1632, 1543, 1485, 1372, 
1166; δH (500 MHz, CDCl3) 7.82 (2 H, d, J 8.0 Hz), 7.62 (2 H, d, J 8.0 Hz), 7.58 (2 
H, d, J 7.5 Hz), 7.44 (2 H, t, J 7.5 Hz), 7.37 (1 H, t, J 7.5 Hz), 6.79 (1 H, br s), 3.47 
(2 H, q, J 6.5 Hz), 2.60–2.36 (10 H, m), 2.25 (3 H, s), 1.68–1.59 (4 H, m); δC (125 
MHz, CDCl3) 167.6, 144.2, 140.2, 133.8, 129.0, 128.1, 127.6, 127.30, 127.29, 58.1, 
55.1, 53.2, 46.0, 40.1, 27.6, 24.6; m/z (APCI) 181 ([M – C9H20N3]
+
, 100), 252 ([M – 
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C5H11N2]
+
, 37); Found: C, 75.17; H, 8.36; N, 11.87. Calc for C22H29N3O: C, 75.18, 
H, 8.32; N, 11.95%  
(2S,4R)-4-Hydroxy-2-(methoxycarbonyl)pyrrolidine hydrochloride 
(150·HCl)
285,480
 
 
A solution of trans-4-hydroxy-ι-proline (10.0 g, 76.3 mmol) in MeOH (80 mL) was 
cooled to 0 °C and thionyl chloride (11.1 mL, 152 mmol) was added dropwise. The 
mixture was allowed to stir at room temperature for 1 h before being heated under 
reflux for a further 17 h. The resulting solution was concentrated and the residue 
azeotroped with MeOH (3 × 200 mL) to give the desired compound 150·HCl (13.6 g, 
100%) as a colourless solid; mp 169–171 °C (lit mp 168–170 °C);     
   −21.6 (c 1.0, 
EtOH), (lit     
   −67.0 (c 0.75, CHCl3)); νmax/cm
-1
 3317, 2952, 2707, 1740, 1439, 
1240, 1074, 1025, 956, 901, 625; δH (500 MHz, CD3OD) 4.63–4.59 (2 H, m), 3.86 (3 
H, s), 3.46 (1 H, dd, J 3.2, 10.0 Hz), 3.34–3.30 (1 H, m), 2.45–2.41 (1 H, m), 2.21 (1 
H, ddd, J 2.4, 8.0, 11.2 Hz); δC (125 MHz, CDCl3) 170.6, 70.6, 59.4, 55.0, 54.0, 
38.6; m/z (+ESI) 146 ([M - Cl]
+
, 100). 
(2S,4R)-1-(tert-Butoxycarbonyl)- 4-hydroxy-2-(methoxycarbonyl)pyrrolidine 
(151)
285,481
 
 
A solution of 150·HCl (13.3 g, 73.9 mmol) and NEt3 (26.0 mL, 192 mmol) in 
CH2Cl2 (160 mL) was cooled to 0 °C and di-tert-butyl dicarbonate (17.7 g, 81.3 
mmol) was added portion-wise. The ice bath was allowed to expire and stirring was 
continued for 17 h. The reaction mixture was diluted with CH2Cl2 (100 mL) and 
washed with hydrochloric acid (1M; 100 mL). The organic extract was further 
washed with H2O (100 mL), saturated aqueous sodium hydrogencarbonate (100 mL), 
brine (100 mL) and then dried (MgSO4), filtered and the solvent removed under 
reduced pressure to yield the alcohol 151 (17.8 g, 72.9 mmol, 97%) as a yellow oil; 
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   −60.4 (0.98, CHCl3); νmax/cm
-1
 3431, 2978, 1748, 1677, 1411, 1367, 1158, 894, 
733, 551; δH (500 MHz, CDCl3) 4.38–4.46 (2 H, m), 3.71 (3 H, s), 3.42–3.59 (2 H, 
m), 2.24–2.47 (2 H, m), 2.04–2.10 (1 H, m), 1.39–1.43 (9 H, m); δC (125 MHz, 
CDCl3) 173.8, 154.1, 80.4, 69.9, 69.2, 58.0, 54.7, 52.0, 39.1, 38.4, 28.4, 28.3 
(mixture of rotamers); m/z (+ESI) 289 ([M + Na]
+
, 100). 
(2S,4R)-1-(tert-Butoxycarbonyl)-2-(hydroxymethyl)-4-hydroxypyrrolidine 
(152)
285
 
 
(2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxy-2-(methoxycarbonyl)pyrrolidine (151) 
(16.0 g, 65.5 mmol) was suspended in anhydrous THF (260 mL) and cooled to 0 °C. 
LiBH4 (6.0 g, 275.1 mmol) was added and stirring continued at 0 °C for 2 h. The 
mixture was then allowed to warm to room temperature and stirring continued for a 
further 24 h. The reaction mixture was then cooled to 0 °C and quenched by the 
addition of saturated aqueous ammonium chloride (40 mL). The resulting suspension 
was stirred for a further 2 h and the solvent then removed under reduced pressure. 
The residue was then partitioned between CHCl3 (200 mL) and H2O (150 mL), the 
aqueous layer was further extracted with CHCl3 (100 mL). The combined organic 
extracts were washed with brine (150 mL), dried (MgSO4), filtered and the solvent 
removed under reduced pressure to give diol 152 (13.5 g, 61.7 mmol, 94%) as a 
colourless oil;     
   −58.2 (1.0, EtOH) (lit     
   −58.9 (1.0, EtOH)); νmax/cm
-1
 3368, 
2976, 1666, 1412, 1366, 1163; δH (500 MHz, CDCl3) 5.13 (1 H, br. s), 4.33 (1 H, br. 
s), 4.12–4.11 (1 H, br. m), 3.65 (1 H, br. s), 3.57–3.48 (2 H, m), 3.42–3.4 (1 H, br. 
m), 2.71 (1 H, br. s), 2.04–2.0 (1 H, br. m), 1.66 (1 H, br. s), 1.45 (9 H, s); δC (125 
MHz, CDCl3) 157.2, 80.7, 69.3, 67.0, 58.9, 55.9, 37.6, 28.5; m/z (+ESI) 240 ([M + 
Na]
+
, 100). 
(2S,4R)-1-(tert-Butoxycarbonyl)-2-(4-toluensulfonyloxymethyl)-4-
hydroxypyrrolidine (153)
285
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Diol 152 (4.5 g, 20.7 mmol) was suspended in anhydrous CH2Cl2 (207 mL) and 
treated with pyridine (3.34 mL, 41.4 mmol). The mixture was then heated to 40 °C 
and a solution of para-toluenesulfonyl chloride (4.7 g, 24.85 mmol) in CH2Cl2 (10 
mL) was added via syringe pump over a period of 10 h. The mixture was heated for a 
further 8 h and then diluted with CH2Cl2 (100 mL) and washed with H2O (200 mL). 
The organic layer was then washed with hydrochloric acid (1 M; 150 mL) and brine 
(150 mL), dried (MgSO4), filtered and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography on silica eluting with 
hexane-ethyl acetate (1:1), to give the tosylate 153 (5.3 g, 69%) as a colourless solid; 
    
   −32.5 (1.0, CHCl3); mp 82.5–84.0 °C; νmax/cm
-1
 3407, 2977, 1689, 1400, 1364, 
1188, 1174, 1096, 968, 815; δH (500 MHz, CDCl3) 7.76 (2 H, d, J 8.0), 7.33 (2 H, d, 
J 8.0), 4.44–4.40 (1 H, m), 4.23–4.1 (2 H, m), 3.46–3.36 (2 H, m), 2.43 (3 H, s), 
2.09–2.02 (2 H, m), 2.02 (1 H, br.s), 1.40 (9 H, s); δC (125 MHz, CDCl3) 154.7, 
144.9, 133.6, 130.0, 128.0, 80.3, 70.5, 69.7, 55.2, 55.0, 28.5, 24.1, 21.7; m/z (+ESI) 
372 ([M + H]
+
, 100).  
(2S,4R)-1-(tert-Butoxycarbonyl)-2-(azidomethyl)-4-hydroxypyrrolidine (155)
285
 
 
(2S,4R)-1-(tert-Butoxycarbonyl)-2-(tosylmethyl)-4-hydroxypyrrolidine (153) (4.7 g, 
12.6 mmol) was suspended in anhydrous THF (126 mL) and treated with 
azidotrimethylsilane (2.5 mL, 19.0 mmol) and tetrabutylammonium fluoride in THF 
(1.0 M, 19.0 mL, 19.0 mmol). The resulting mixture was heated at 70 °C for 18 h. 
The solvent was then removed and the resulting residue partitioned between CH2Cl2 
(200 mL) and H2O (150 mL), the aqueous layer was then further extracted with 
CH2Cl2 (100 mL) and the combined organic layers washed with brine (100 mL), 
dried (MgSO4), filtered and the solvent removed under reduced pressure. The crude 
residue was then purified by flash chromatography on silica eluting with hexane-
ethyl acetate (2:1) to yield azide 155 (2.4 g, 79%) as a colourless oil;     
   −29.6 
(1.0, CHCl3); νmax/cm
-1
 3419, 2976, 2100, 1671, 1395, 1366, 1161, 1120; δH (500 
MHz, CDCl3) 4.44 (1 H, br s), 4.13-4.07 (1 H, m), 3.97 (0.5 H, dd, J 4.5, 12.5), 3.67 
(0.5 H, dd, J 5.5, 12.5), 3.64 (0.5 H, d, J 14.5), 3.50 (0.5 H, d, J 14.5), 3.43 (1 H, 
Chapter 11 Experimental 
 
241 
 
ddd, J 4.5, 9.6, 17.6), 3.28 (0.5 H, d, J 12.5), 3.19 (0.5 H, d, J 12.5), 2.45 (0.5 H, br 
s), 2.23 (0.5 H, br s) 2.04 ( 2H, m) 1.48–1.45 (9 H, m) (mixture of rotamers); δC (125 
MHz, CDCl3) 154.8, 80.5, 80.2, 69.9, 69.4, 55.7, 53.9, 52.6, 38.4, 37.7, 28.6 (mixture 
of rotamers); m/z (ESI) 265 ([M + Na]
+
, 100), 507 ([2M + Na]
+
, 42). Found: MNa
+ 
265.12711. C10H18N4O3 + Na requires 265.12766. 
(2S,4R)-1-(tert-Butoxycarbonyl)-2-(azidomethyl)-4-
methylsulfonyloxypyrrolidine (156)
285
 
 
Azide 155 (1.2 g, 5.0 mmol) was suspended in anhydrous CH2Cl2 (50 mL), 
triethylamine (1.38 mL, 10.0 mmol) was added and the mixture cooled to 0 °C. 
Methanesulfonyl chloride (1.16 mL, 15.0 mmol) in CH2Cl2 (15 mL) was added 
dropwise and the mixture stirred at 0 °C for 30 min. Excess methanesulfonyl chloride 
was then quenched with the addition of H2O (ca. 2 mL) followed by further dilution 
with H2O (50 mL) and extraction with CH2Cl2 (3 × 50 mL). The organic extracts 
were then combined, dried (MgSO4), filtered and the solvent removed under reduced 
pressure. The residue was then purified by flash chromatography on silica eluting 
with hexane-ethyl acetate (2:1) to give mesylate 156 (1.51 g, 95%) as a colourless 
oil;     
   −26.4 (0.5, CHCl3); νmax/cm
-1
 2977, 2105, 1691, 1397, 1355, 1167, 962, 
906; δH (500 MHz, CDCl3, 330K) 5.23 (1 H, br s), 4.15 (1 H, br s), 3.88 (2 H, br s), 
3.58 (1 H, d, J 10.7), 3.31 (1 H, d, J 12.3), 3.02 (3 H, s), 2.37 (1 H, br s) 2.24–2.19 (1 
H, m), 1.50 (9 H, s); δC (125 MHz, CDCl3) 154.3, 81.2, 80.9, 78.6, 55.4, 53.6, 53.4, 
52.8, 52.3, 38.9, 36.7, 35.4, 28.6 (mixture of rotamers); m/z 343 ([M + Na]
+
, 100), 
663 ([2M + Na]
+
, 87). Found: MNa
+ 
343.10466 C11H20N4O5S + Na requires 
343.10521 
(1S,4S)-tert-Butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (157)
285
 
 
Mesylate 156 (1.2 g, 3.78 mmol) was suspended in anhydrous THF (38 mL), 
triphenylphosphine (1.48 g, 5.66 mmol) added and the mixture stirred at room 
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temperature for 2 h. H2O (0.5 mL) was then added and stirring continued for a 
further 18 h. The solvent was then removed under reduced pressure and the residue 
suspended in hydrochloric acid (1M; 150 mL) and extracted with CH2Cl2 (2 × 70 
mL). The aqueous layer was then basified to pH 14 and extracted with CH2Cl2 (3 × 
70 mL), the combined organic extracts were washed with brine (100 mL), dried 
(MgSO4), filtered and the solvent removed under reduced pressure. Purification of 
the residue by flash chromatography on silicia eluting with, CH2Cl2-methanol-
aqueous ammonia (90:9:1) afforded the amine 157 (0.52 g, 2.62 mmol, 71%) as a 
colourless solid; mp 76.8–77.9 °C;     
   −47.6 (1.0, CHCl3); νmax/cm
-1
 2975 1688, 
1408, 1170; δH (500 MHz, CDCl3) 4.43 (0.5 H, s), 4.30 (0.5 H, s), 3.69 (1 H, s), 
3.38–3.32 (1 H, m), 3.19–3.13 (1 H, m), 3.06–2.97 (2 H, m), 1.75–1.65 (2 H, m), 
1.45–1.43 (9 H, m) (mixture of rotamers); δC (125 MHz, CDCl3) 154.6, 154.3, 79.6, 
79.5, 57.3, 56.6, 56.5, 56.3, 56.1, 52.8, 52.7, 37.2, 37.0, 28.66 (mixture of rotamers); 
m/z (APCI) 199 ([M + H]
+
, 100). 
4-Bromo-N-((1S,4S)-tert-butyl5-(2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate)butyl)benzamide (163)  
 
Subjecting compound 63 to general procedure 2 using THF as the solvent and 157 as 
the amine source, the crude amide was obtained and purified by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1) 
to give compound 163 (0.19 g, 84%) as a tan oil;     
   −19.4 (0.7, CHCl3); νmax/cm
-1
 
2931, 1666, 1590, 1531, 1488, 1393, 1364, 1328, 1246, 1100, 1007, 826; δH (500 
MHz, CDCl3) 8.06 (1 H, br s), 7.42 (2 H, d, J 8.5 Hz), 7.37 (2 H, d, J 8.5 Hz), 4.29 
(0.5 H, br s), 4.19 (0.5 H, br s), 3.74–3.40 (2 H, m, ), 3.10 (1 H, d, J 9.0 Hz), 2.88 
(0.5 H, d, J 9.5 Hz), 2.81 (0.5 H, d, J 9.0 Hz), 2.57–2.43 (3 H, m, ), 2.33 (2 H, t, J 7.5 
Hz), 1.78–1.61 (4 H, m), 1.50–1.43 (11 H, m) (mixture of rotamers); δC (125 MHz, 
CDCl3) 171.6, 154.5, 154.3, 137.4, 131.9, 121.5, 116.6, 79.6, 79.5, 61.4, 60.8, 60.3, 
60.1, 57.8, 56.8, 54.2, 53.6, 49.8, 48.9, 37.3, 36.2, 35.5, 28.79, 28.73, 28.6, 23.4 
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(mixture of rotamers); m/z (APCI) 396 ([M – C4H9]
+
, 100) 254 ([M – C10H17N2O2]
+
, 
80) 452 ([M + H]
+
, 100); Found: MH
+ 
452.15389 C21H36BrN3O3 + H requires 
452.15488. 
5-((1S,4S)-tert-Butyl5-(2,5-diazabicyclo[2.2.1]heptane-2-carboxylate)-N-(4-
(pyridin-3-yl)phenyl)pentanamide (164)  
 
Subjecting compound 163 to general procedure 3 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9.5:0.5) to give compound 164 (0.17 g, 93%) as a colourless oil;     
   
−25.1 (1.0, CHCl3); νmax/cm
-1 
2974, 1687, 1598, 1529, 1474, 1397, 1328, 1250, 
1103; δH (400 MHz, CDCl3) 8.81 (1 H, br s), 8.56 (1 H, d, J 4.8 Hz), 7.84 (1 H, d, J 
7.6 Hz), 7.65 (2 H, d, J 8.4 Hz), 7.53 (2 H, d, J 8.4 Hz), 7.34 (1 H, dd, J 4.8, 7.6 Hz), 
4.34 (0.5 H, s), 4.22 (0.5 H, s), 3.54–3.44 (2 H, m), 3.14 (1 H, d, J 6.8 Hz), 2.95 (0.5 
H, d, J 9.2 Hz), 2.88 (0.5 H, d, J 9.2 Hz), 2.63–2.56 (2 H, m), 2.42 (2 H, t, J 7.6 Hz), 
1.83–1.76 (4 H, m), 1.68 (1 H, m), 1.54 (2 H, quin, J 7.6 Hz), 1.45 (9 H, s) (mixture 
of rotamers); δC (100 MHz, CDCl3) 171.5, 154.3, 148.4, 148.2, 138.4, 136.2, 134.2, 
133.5, 127.8, 123.7, 120.5, 79.6, 79.5, 61.6, 60.9, 60.4, 60.3, 57.8, 56.8, 54.2, 53.6, 
49.7, 48.7, 37.6, 36.4, 35.6, 28.7, 23.5 (mixture of rotamers); m/z (ESI) 451 ([M + 
H]
+
, 100), 253 ([M – C10H17N2O2]
+
, 63, 395 ([M – C4H9]
+
, 34); Found: MH
+ 
451.27040 C26H34N4O3 + H requires 451.27092.  
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5-((1S,4S)-tert-Butyl5-(2,5-diazabicyclo[2.2.1]heptane-2-carboxylate)-N-[1,1'-
biphenyl]-4-carboxamide (165)  
 
Subjecting compound 163 to general procedure 3 using phenylboronic acid the crude 
residue was obtained and purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (92:7.5:0.5) to give compound 165 (0.1 g, 59%) 
as a colourless oil;     
   −22.3 (1.0, CHCl3); νmax/cm
-1 
2916, 1668, 1598, 1529, 
1486, 1405, 1165; δH (500 MHz, CDCl3) 7.60–7.54 (6 H, m), 7.42 (2 H, d, J 7.5 Hz), 
7.32 (1 H, d, J 7.5 Hz), 4.34 (0.5 H, s), 4.21 (0.5 H, s), 3.54 (0.5 H, d, J 10.0 Hz), 
3.48–3.44 (1.5 H, m), 3.14 (1 H, t, J 9.0 Hz), 2.94 (0.5 H, d, J 9.5 Hz), 2.89 (0.5 H, d, 
J 9.5 Hz), 2.62–2.55 (1.5 H, m), 2.47 (0.5 H, d, J 9.5 Hz), 2.40 (2 H, t, J 7.5 Hz), 
1.83–1.76 (4 H, m), 1.70 (0.5 H, d, J 9.0 Hz), 1.54 (0.5 H, d, J 9.5 Hz), 1.54 (2 H, 
quin, J 7.5 Hz), 1.45 (9 H, s), NH proton not observed (mixture of rotamers); δC (100 
MHz, CDCl3) 171.4, 154.5, 154.4, 140.7, 137.4, 137.2, 128.9, 127.7, 127.2, 127.0, 
120.3, 79.6, 79.5, 61.5, 60.9, 60.4, 60.2, 57.9, 56.8, 54.2, 53.6, 49.7, 48.7, 37.6, 36.4, 
35.6, 28.8, 28.7, 23.5 (mixture of rotamers); m/z (ESI) 472 ([M + Na]
+
, 100), 252 
([M – C10H17N2O2]
+
, 85), 394 ([M – C4H9]
+
, 34); Found: MNa
+ 
472.25675 
C27H35N3O3 + Na requires 472.25761. 
11.4.1 General procedure 5 for N-methylation of ((1S,4S)-5-methyl-2,5-
diazabicyclo[2.2.1]heptan-2-yl)pentanamides  
A solution of the appropriate N-Boc protected pentanamide (1.0 mmol) in methanol 
(0.1 M) was treated with hydrogen chloride gas in dioxane (5.0 mmol) and stirred at 
room temperature for 2 h. The solvent was then removed under a steam of nitrogen 
gas and the residue partitioned between hydrochloric acid (1M, 20 mL) and CH2Cl2 
(50 mL), the aqueous layer was further extracted with CH2Cl2 (20 mL) and then 
basified to pH 14 with addition of aqueous sodium hydroxide (3M, ca 10 mL). The 
aqueous layer was then extracted with CH2Cl2 (3 × 50 mL) and the combined organic 
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extracts dried (MgSO4), filtered and the solvent removed under reduced pressure. 
The free amine was then suspended in ClCH2CH2Cl (0.1 M) and treated with 
aqueous formaldehyde (37%, 1.5 mmol) and NaBH(OAc)3 (5 mmol) and the 
resulting mixture stirred at ambient temperature for 17–20 h. The reaction was 
quenched with addition of aqueous sodium hydroxide (3M, 5 mL) and the layers 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 30 mL) and the 
combined organic layers were washed with brine (30 mL), dried (MgSO4), filtered 
and the solvent evaporated to give the crude residue. 
5-((1S,4S)-5-Methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(4-(pyridin-3-
yl)phenyl)pentanamide (108)  
 
Subjecting compound 164 to general procedure 5 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (88:11.5:0.5) to give methylated amine 108 (0.05 g, 48% over two steps) as 
a colourless oil;     
   −21.5 (1.0, CHCl3); νmax/cm
-1
 2929, 1668, 1597, 1525, 1473, 
1425, 1288, 1250, 1182, 1001, 845; δH (500 MHz, CDCl3) 8.81 (1 H, d, J 1.5 Hz), 
8.55 (1 H, dd, J 1.5, 4.5 Hz), 7.99 (1 H, br s), 7.84 (1 H, dt, J 2.0, 8.0 Hz), 7.66 (2 H, 
d, J 8.5 Hz), 7.52 (2 H, d, J 8.5 Hz), 7.34 (1 H, dd, J 5.0, 8.0 Hz), 3.23 (1 H, s), 3.17 
(1 H, s), 2.82 (1 H, d J 10.0 Hz), 2.71 (1 H, dd, J 2.5, 10.0 Hz), 2.66–2.60 (2 H, m), 
2.51 (2 H, m), 2.42 (2 H, t, J 7.5 Hz), 2.36 (3 H, s), 1.79 (2 H, quin, J 7.5 Hz), 1.69 
(2 H, m), 1.54 (2 H, quin, J 7.5 H); δC (125 MHz, CDCl3) 171.7, 148.4, 148.2, 138.4, 
136.2, 134.2, 133.5, 127.8, 123.7, 120.5, 63.7, 62.4, 57.1, 56.6, 53.5, 41.6, 37.5, 33.6, 
28.5, 23.6; m/z (APCI) 253 ([M – C6H11N2]
+
, 100), 169 ([M – C11H19N2O]
+
, 68), 365 
([M + H]
+
, 24); Found: MH
+ 
365.23377 C22H28N4O + H requires 365.23414. 
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N-([1,1'-Biphenyl]-4-yl)-5-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-
yl)pentanamide (109)  
 
Subjecting compound 165 to general procedure 5 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (85:14:1) to give methylated amine 109 (0.06 g, 50% over two steps) as a 
colourless oil;     
   −24.7 (1.0, CHCl3); νmax/cm
-1 
2910, 1670, 1587, 1529, 1480, 
1428, 1165, 809; δH (500 MHz, CDCl3) 8.32 (1 H, br s), 7.62 (2 H, d, J 8.5 Hz), 7.54 
(4 H, t, J 9.0 Hz), 7.40 (2 H, t, J 7.5 Hz), 7.3 (1 H, t, J 7.5 Hz), 3.32 (1 H, s), 3.18 (1 
H, s), 2.92 (1 H, d, J 10.0 Hz), 2.72–2.60 (3 H, m), 2.49 (2 H, m), 2.40 (2 H, t, J 7.5 
Hz), 2.36 (3 H, s), 1.79–1.69 (4 H, m), 1.54 (2 H, m); δC (125 MHz, CDCl3) 171.9, 
140.7, 137.8, 136.9, 128.9, 127.6, 127.1, 126.9, 120.3, 63.6, 62.1, 57.0, 56.7, 53.4, 
41.8, 37.3, 33.1, 28.2, 23.6; m/z (ESI) 364 ([M + H]
+
, 100); Found: MH
+ 
364.23859 
C23H29N3O + H requires 364.23889. 
(1S,4S)-tert-Butyl-5-(4-(1,3-dioxoisoindolin-2-yl)butyl)-2,5-
diazabicyclo[2.2.1]heptane-2-carboxylate (166)  
 
N-(4-Bromobutyl)phthalimide (0.32 g, 1.15 mmol) was suspended in THF (11 mL) 
and treated with sodium iodide (0.17 g, 1.15 mmol), triethylamine (160 µL, 1.15 
mmol) and 157 (0.25 g, 1.26 mmol). The mixture was then heated at reflux for 16 h. 
After cooling to ambient temperature, the solvent was removed in vacuo and the 
residue partitioned between H2O (100 mL) and CHCl3 (100 mL). The aqueous layer 
was further extracted with CHCl3 (100 mL) and the organic extracts combined, dried 
(MgSO4), filtered and the solvent removed under reduced pressure. The crude 
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product was purified by flash chromatography on silica eluting with ethyl acetate to 
give phthalimide 166 (0.35 g, 76%) as an off-white solid;     
   −22.8 (0.9, CHCl3); 
νmax/cm-1 3129, 1689, 1419, 1320, 890; δH (500 MHz, CDCl3) 7.83–7.82 (2 H, m), 
7.71–7.69 (2 H, m), 4.31 (0.5 H, s), 4.19 (0.5 H, s), 3.69 (2 H, t, J 7.0 Hz), 3.50 (0.5 
H, d, J 10.0 Hz), 3.45–3.41 (1.5 H, m), 3.41 (1 H, t, J 10.0 Hz), 2.92 (0.5 H, d, J 9.5 
Hz), 2.85 (0.5 H, d, J 9.5 Hz), 2.58–2.52 (2.5 H, m), 2.43 (0.5 H, d, J 9.5 Hz), 1.78–
1.63 (4 H, m), 1.51–1.41 (11 H, m) (mixture of rotamers); δC (125 MHz, CDCl3) 
168.6, 154.4, 154.3, 134.0, 132.3, 123.3, 79.4, 79.3, 61.4, 60.9, 60.21, 60.16, 57.9, 
56.9, 54.0, 53.4, 49.8, 48.7, 38.0, 36.5, 35.6, 28.7, 26.7, 26.6 (mixture of rotamers); 
m/z (ESI) 400 ([M + H]
+
, 100); Found: MH
+ 
400.22329 C22H29N3O4 + H requires 
400.22363 
(1S,4S)-tert-butyl 5-(4-aminobutyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 
(167) 
 
Phthalimide 166 (0.40 g, 1.12 mmol) was suspended in anhydrous ethanol (12 mL) 
and treated with hydrazine monohydrate (273 µL, 5.62 mmol). The mixture was 
heated under reflux for 2 h and then cooled to room temperature, filtered, and the 
filtrate evaporated under reduced pressure. The remaining residue was suspended in 
hydrochloric acid (1 M; 50 mL) and heated under reflux for 1 h. After cooling to 
room temperature, the mixture was filtered and the filtrate washed with CH2Cl2 (50 
mL). The aqueous layer was basified to pH 14 with addition of aqueous sodium 
hydroxide (3 M), and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were dried (MgSO4), filtered and the solvent removed in vacuo to give amine 
167 which was used directly in the next step without further purification or 
characterization.  
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(1S,4S)-tert-Butyl 5-(4-(4-bromobenzamido)butyl)-2,5-
diazabicyclo[2.2.1]heptane-2-carboxylate (168)  
 
4-Bromobenzoyl chloride (0.25 g, 1.12 mmol) was suspended in CH2Cl2 (10 mL) and 
cooled to 0 °C. A solution of amine 167 (1.12 mmol) and triethylamine (156 µL, 0.8 
mmol) in CH2Cl2 (10 mL) was added dropwise and stirring continued at 0 °C for 0.5 
h. The mixture was then allowed to reach room temperature and stirring continued 
for a further 2 h. CH2Cl2 (50 mL) was added and the solution washed with saturated 
aqueous sodium carbonate (50 mL), saturated aqueous ammonium chloride (50 mL), 
H2O (50 mL) and brine (50 mL). The organic layer was then dried (MgSO4), filtered 
and the solvent removed under reduced pressure to give the crude residue. 
Purification by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (93:6.5:0.5), gave amide 168 (0.33 g, 66% over two steps) as a tan 
oil;     
   −22.6 (1.0, CHCl3); νmax/cm
-1 
2938, 1678, 1591, 1531, 1492, 1387, 1330, 
1245, 1105, 1010, 826; δH (500 MHz, CDCl3) 7.61 (2 H, d, J 8.5 Hz), 7.53 (2 H, d, J 
8.5 Hz), 4.31 (0.5 H, s), 4.19 (0.5 H, s), 3.5 (0.5 H, d, J 10.5 Hz), 3.44–3.40 (3.5 H, 
m), 3.12 (1 H, t, J 8.0 Hz), 2.88 (0.5 H, d, J 9.5 Hz), 2.83 (0.5 H, d, J 9.5 Hz), 2.60–
2.52 (2.5 H, m), 2.43 (0.5 H, d, J 9.5 Hz), 1.71 (1 H, d, J 9.5 Hz), 1.68–1.64 (3 H, 
m), 1.53 (2 H, m), 1.44 (9 H, s), NH peak not observed (mixture of rotamers); δC 
(125 MHz, CDCl3) 166.8, 154.4, 154.3, 134.0, 131.8, 128.7, 126.0, 61.3, 60.7, 60.2, 
60.1, 57.7, 56.7, 53.8, 53.3, 49.6, 48.6, 40.1, 36.4, 35.6, 28.7, 27.5, 27.4, 26.9 
(mixture of rotamers); m/z (ESI) 454, 452 ([M + H]
+
, 100); Found: MH
+ 
452.15429 
C21H30BrN3O3 + H requires 452.15429. 
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(1S,4S)-tert-Butyl-5-(4-(4-(pyridin-3-yl)benzamido)butyl)-2,5-diazabicyclo[2.2.1] 
heptane-2-carboxylate (169)  
 
Subjecting compound 168 to general procedure 3 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (95:4.5:0.5) to give the desired amide 169 (0.12 g, 89%) as a colourless oil; 
    
   −20.3 (1.0, CHCl3); νmax/cm
-1 
2935, 1688, 1547, 1409, 1103, 859; δH (500 
MHz, CDCl3) 8.84 (1 H, d, J 2.0 Hz), 8.6 (1 H, dd, J 1.5, 4.5 Hz), 7.89 (1 H, t, J 2.0 
Hz), 7.89 (2 H, d, J 8.5 Hz), 7.86 (2 H, d, J 8.5 Hz), 7.37 (1 H, dd, J 4.5, 8.0 Hz), 
6.93 (1 H, br s), 4.31 (0.5 H, s), 4.19 (0.5 H, s), 3.49–3.45 (4 H, m), 3.13 (1 H, m), 
2.91 (0.5 H, d, J 9.0 Hz), 2.84 (0.5 H, d, J 9.0 Hz), 2.62–2.54 (2.5 H, m), 2.45 (0.5 H, 
d, J 0.5 H), 1.74–1.68 (4 H, m), 1.56 (2 H, m), 1.43 (9 H, s) (mixture of rotamers); δC 
(125 MHz, CDCl3) 167.2, 154.4 154.3, 149.2, 148.4, 140.8, 135.7, 134.64, 134.55, 
127.9, 127.3, 123.77, 79.6, 79.5, 61.3, 60.7, 60.19, 60.10, 57.8, 56.7, 53.8, 53.4, 49.7, 
48.6, 40.1, 36.4, 35.6, 28.6, 27.5, 26.9 (mixture of rotamers); m/z (ESI) 923 ([2M + 
Na]
+
, 100); Found: MH
+ 
451.27035 C26H34N4O3 + Na requires 451.27092. 
(1S,4S)-tert-butyl-5-(4-([1,1'-biphenyl]-4-ylcarboxamido)butyl)-2,5-
diazabicyclo[2.2.1]heptane-2-carboxylate (170)  
 
Subjecting compound 168 to general procedure 3 using phenylboronic acid the crude 
amide was obtained and purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (95:4.5:0.5) to give the desired amide 170 (0.11 
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g, 80%) as a colourless oil;     
   −17.5 (1.0, CHCl3); νmax/cm
-1
 3279, 2914, 1689, 
1546, 1486, 1408, 1327, 1105, 858; δH (500 MHz, CDCl3) 7.82 (2 H, d, J 8.5 Hz), 
7.63 (2 H, d, J 8.5 Hz), 7.59 (2 H, d, J 7.5 Hz), 7.44 (2 H, t, J 7.5 Hz), 7.37 (1 H, t, J 
7.5 Hz), 6.86 (1 H, br s), 4.32 (0.5 H, s), 4.19 (0.5 H, s), 3.53–3.43 (4 H, m), 3.12 (1 
H, t, J 8.5 Hz), 2.91 (0.5 H, d, J 9.5 Hz), 2.85 (0.5 H, d, J 9.5 Hz), 2.62–2.54 (2.5 H, 
m), 2.45 (0.5 H, d, J 9.5 Hz), 1.75 (1 H, d, J 9.5 Hz), 1.70–1.62 (3 H, m), 1.56 (2 H, 
br s), 1.44 (9 H, s) (mixture of rotamers); δC (125 MHz, CDCl3) 167.5, 154.4, 154.3, 
144.2, 140.2, 133.7, 129.0, 128.1, 127.5, 127.28, 127.25, 79.6, 79.4, 61.2, 60.7, 60.2, 
60.1, 57.8, 56.7, 53.8, 53.3, 49.6, 48.6, 40.1, 36.4, 35.6, 28.6, 27.5, 26.9 (mixture of 
rotamers); m/z (ESI) 921 ([2M + Na]
+
, 100); Found: MH
+ 
450.27531 C27H35N3O3 + 
Na requires 450.27567. 
N-(4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)butyl)-4-(pyridin-3-
yl)benzamide (110)  
 
Subjecting compound 169 to general procedure 5 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (88:11:1) to give methylated amine 110 (0.08 g, 58% over two steps) as a 
colourless oil;     
   −17.6 (1.0, CHCl3); νmax/cm
-1
 2930, 1665, 1582, 1525, 1425, 
1289, 1250, 1184, 1005, 845; δH (500 MHz, CDCl3) 8.85 (1 H, d, J 2.0 Hz), 8.61 (1 
H, dd, J 1.5, 5.0 Hz), 7.98 (2 H, d, J 8.5 Hz), 7.89 (1 H, dt, J 1.5, 8.0 Hz), 7.64 (2 H, 
d, J 8.5 Hz), 7.38 (1 H, dd, J 4.0, 8.0 Hz), 3.63 (1 H, s), 3.51 (2 H, m), 3.47 (1 H, s), 
3.22 (1 H, d, J 11.0 Hz), 3.08 (1 H, d, J 11.0 Hz), 2.96 (1 H, dd, J 2.5, 11.0 Hz), 2.89 
(2 H, m), 2.76–2.70 (3 H, m), 2.51 (3 H, s), 1.71 (4 H, m), NH proton not observed; 
δC (125 MHz, CDCl3) 167.3, 149.2, 148.2, 140.8, 135.8, 134.6, 134.3, 128.1, 127.3, 
123.8, 63.6, 62.5, 56.5, 55.8, 52.7, 41.1, 39.3, 33.6, 26.9, 25.0; m/z (ESI) 365 ([M + 
H]
+
, 100); Found: MH
+ 
365.23366 C22H28N4O + H requires 365.23414. 
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N-(4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)butyl)-[1,1'-biphenyl]-
4-carboxamide (111) 
 
Subjecting compound 170 to general procedure 5 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (88:11:1) to give methylated amine 111 (0.075 g, 62% over two steps) as a 
colourless oil;     
   −25.8 (1.0, CHCl3); νmax/cm
-1
 3306, 2910, 1710, 1509, 1462, 
1408, 1318, 1106, 923; δH (500 MHz, CDCl3) 7.84 (2 H, d, J 8.5 Hz), 7.64 (2 H, d, J 
8.5 Hz), 7.60 (2 H, d, J 7.5 Hz), 7.45 (2 H, t, J 7.5 Hz), 7.37 (1 H, t, J 7.5 Hz), 7.05 
(1 H, br s), 3.48 (2 H, m), 3.33 (1 H, s,), 3.20 (1 H, s), 2.88 (1 H, d, J 10.0 Hz), 2.76–
2.64 (3 H, m), 2.57–2.52 (2 H, m), 2.37 (3 H, s), 1.74–1.66 (4 H, m), 1.59 (2 H, m); 
δC (125 MHz, CDCl3) 167.6, 144.2, 140.2, 133.8, 129.0, 128.1, 127.6, 127.31, 
127.25, 63.6, 62.2, 56.7, 56.2, 53.1, 41.4, 40.0, 33.7, 27.5, 26.7; m/z (ESI) 364 ([M + 
H]
+
, 100); Found: MH
+ 
364.23840 C23H29N3O + H requires 364.23889. 
6-tosyl-2-oxa-6-azaspiro[3.3]heptane (184)
293
  
 
A solution of potassium hydroxide (8.3 g, 147.8 mmol) and 4-toluenesulfonamide 
(9.5 g, 55.4 mmol) in ethanol (150 mL) was treated with 3-bromo-2,2-
bis(bromomethyl)propan-1-ol (15 g, 46.2 mmol) and heated at reflux for 90 h. The 
solvent was removed under reduced pressure and aqueous potassium hydroxide (1 
M; 125 mL) was added and the mixture stirred at ambient temperature for a further 2 
h. The mixture was filtered and the filter cake washed with H2O until the washing 
water was neutral. The filter cake was collected to give 184 (7.0 g, 60%) as a 
colourless solid; mp 93–94 °C; νmax/cm
-1 
2930, 2865, 1958, 1846, 1687, 1595, 1459, 
1442, 1335, 1292, 1209, 1165, 1039, 973, 890, 683, 542; δH (500 MHz, CDCl3) 7.70 
(2 H, d, J 8.0 Hz), 7.36 (2 H, d, J 8.0 Hz), 4.58 (4 H, s), 3.90 (4 H, s), 2.45 (3 H, s); 
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δC (125 MHz, CDCl3) 144.5, 131.6, 130.0, 128.4, 80.4, 59.6, 37.7, 21.7; m/z (APCI) 
254 ([M + H]
+
, 100). 
2-oxa-6-azaspiro[3.3]heptane oxalate salt (185)
293
  
 
Compound 184 (1.0 g, 3.95 mmol) and magnesium granulate (0.66 g, 27.7 mmol) 
were sonicated for 3 h in methanol (70 mL). Almost all solvent was removed from 
the grey reaction mixture under reduced pressure to give a viscous grey residue. 
Ether (100 mL) and sodium sulfate decahydrate (2 g) were added and the resulting 
light grey mixture was stirred vigorously for 1 h before filtration. The filtrate was 
dried (MgSO4), filtered and anhydrous oxalic acid (0.18 g, 1.98 mmol) dissolved in 
ethanol (1 mL) was added to the organic phase. A thick white precipitate formed 
instantly. It was filtered off and dried under vacuum to give 185 (0.52 g, 70%) as a 
colourless solid; mp 116–118 °C; νmax/cm
-1 
3400, 2953, 2875, 1653, 1556, 1431, 
1352, 1315, 1250, 963, 829, 774; δH (500 MHz, CDCl3) 4.81 (4 H, s), 4.29 (4 H, s), 
2.19 (2 H, m); δC (125 MHz, CDCl3) 167.2, 79.4, 54.9, 40.0; m/z (APCI) 100 ([M – 
C2O4]
+
, 100). 
N-(4-bromophenyl)-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pentanamide (186)  
 
A solution of amide 63 (0.8 g, 2.4 mmol) in DMF (24 mL) was treated with sodium 
iodide (0.36 g, 2.4 mmol), triethylamine (668 µL, 4.8 mmol) and compound 185 
(0.26 g, 2.6 mmol), and heated at reflux for 19 h. After cooling to ambient 
temperature, the solution was partitioned between H2O (70 mL) and ethyl acetate 
(100 mL), the layers separated, and the aqueous layer extracted with ethyl acetate (2 
× 50 mL). The combined organic extracts were washed with H2O (100 mL), brine 
(100 mL), dried (MgSO4), filtered, and the solvent evaporated under pressure to give 
the crude residue which was purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (92:8.5:0.5) to give amide 186 (0.63 g, 74%) as 
a colourless solid; mp 125–127 °C; νmax/cm
-1 
2937, 1734, 1690, 1524, 1502, 1475, 
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1248, 1106, 892; δH (500 MHz, CDCl3) 7.48 (1 H, br s), 7.43–7.39 (4 H, m), 4.72 (4 
H, s), 3.32 (4 H, s), 2.39 (2 H, t, J 7.5 Hz), 2.34 (2 H, t, J 7.5 Hz), 1.72 (2 H, quin, J 
7.5 Hz), 1.4 (2 H, quin, J 7.5 Hz); δC (125 MHz, CDCl3) 171.2, 137.2, 132.1, 121.5, 
116.9, 81.5, 64.0, 59.2, 39.2, 37.5, 27.2, 23.2; m/z (ESI) 353, 355 ([M + H]
+
, 100); 
Found: C, 54.11; H, 5.55; N, 7.80. Calc for C16H21BrN2O2: C, 54.40, H, 5.99; N, 
7.93% 
N-(4-(pyridin-3-yl)phenyl)-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pentanamide 
(112)  
 
Subjecting amide 186 to the general procedure 3 gave the crude residue which was 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9:1) to give pentanamide 112 (0.29 g, 70%) as a yellow oil; νmax/cm-1 
3673, 2925, 1738, 1598, 1535, 1365, 1215; δH (400 MHz, CDCl3) 8.78 (1 H, d, J 1.6 
Hz), 8.53 (1 H, dd, J 1.6, 4.8 Hz), 8.39 (1 H, br s), 7.81 (1 H, m), 7.62 (2 H, d, J 8.4 
Hz), 7.49 (2 H, d, J 8.4 Hz), 7.32 (1 H, dd, J 4.8, 7.6 Hz), 4.68 (4 H, s), 3.27 (4 H, s), 
2.37–2.33 (4 H, m), 1.70 (2 H, quin, J 7.6 Hz), 1.36 (2 H, quin, J 7.6 Hz); δC (100 
MHz, CDCl3) 171.6, 148.1, 147.9, 138.6, 136.2, 134.2, 133.3, 127.6, 123.7, 120.5, 
81.4, 63.9, 59.2, 39.1, 37.3, 27.2, 23.3; m/z (ESI) 352 ([M + H]
+
, 100), 725 ([2M + 
Na]
+
, 43); Found: MH
+
 352.01969. C21H25N3O + H requires 352.20250. 
N-([1,1'-biphenyl]-4-yl)-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pentanamide (113)  
 
Subjecting amide 186 to the general procedure 3 using phenylboronic acid gave the 
crude residue which was purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (92:7.5:0.5) to give pentanamide 113 (0.088 g, 
90%) as a colourless solid; mp 1089–111; νmax/cm-1 3729, 2927, 1740, 1662, 1597, 
1531, 1408, 1355, 1331, 1237; δH (500 MHz, CDCl3) 7.75 (1 H, br s), 7.58–7.53 (4 
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H, m), 7.43–7.37 (4 H, m), 7.32 (1 H, t, J 7.5 Hz), 4.70 (4 H, s), 3.38 (4 H, s), 2.42 (2 
H, t, J 7.5 Hz), 2.35 (2 H, t, J 7.5 Hz), 1.72 (2 H, quin, J 7.5 Hz), 1.45 (2 H, quin, J 
7.5 Hz); δC (125 MHz, CDCl3) 171.3, 140.6, 137.4, 137.2, 128.9, 127.7, 127.2, 
126.9, 120.3, 81.4, 63.7, 59.0, 38.8, 37.4, 26.8, 23.3; m/z (ESI) 351 ([M + H]
+
, 100), 
723 ([2M + Na]
+
, 33); Found: C, 75.92; H, 7.39 N, 7.33. Calc for C22H26N2O2: C, 
75.40; H, 7.48; N, 7.99% 
11.5 The synthesis of compounds from Chapter 5 
2-(4-Nitrophenyl)-pyridine (217)
482
 
 
4-(4-Nitrophenyl)-pyridine (218)
483
 
To a solution of pyridine (323 µL, 4.0 mmol) in dichloromethane (20 mL) was added 
trifluoroacetic acid (308 µL, 4.0 mmol) followed by 4-nitrophenylboronic acid (2.0 
g, 12.0 mmol). Water (12 mL) was then added, followed by silver(I) nitrate (0.14 g, 
0.8 mmol) in water (8 mL). Potassium persulfate (3.2 g, 12.0 mmol) was then added 
and the solution was stirred vigorously at room temperature and monitored by thin-
layer chromatography analysis of the organic layer. After 3 hours, a second addition 
of solid silver(I) nitrate (0.14 g, 0.8 mmol) and potassium persulfate (3.2 g, 12.0 
mmol) was added. After stirring for 24 h, the reaction was diluted with 
dichloromethane (70 mL) and washed with aqueous sodium hyrdoxide (2 M; 50 mL). 
The layers were separated, and the aqueous layer was extracted with 
dichloromethane (2 × 50 mL), the organic extracts were combined, dried (MgSO4), 
filtered, and evaporated in vacuo. Purification by flash chromatography on silica 
eluting with hexane-ethyl acetate (1:1) gave compound 217 (0.22 g, 27%) and 
compound 218 (0.088 g, 11%) both as yellow solids.  
217; mp 131–133 °C (lit mp 131–132 °C); νmax/cm
-1
 1583, 1516, 1435, 1347, 856; δH 
(500 MHz, CDCl3) 8.75 (1 H, d, J 4.5 Hz), 8.32 (2 H, d, J 8.5 Hz), 8.18 (2 H, d, J 8.5 
Hz), 7.84–7.81 (2 H, m), 7.34 (1 H, m); δC (125 MHz, CDCl3) 155.0, 150.3, 148.3, 
145.4, 137.3, 127.8, 124.3, 123.7, 121.4; m/z (ESI) 154 ([M – NO2]
+
, 100). 
218; mp 128–130 °C (lit mp 128–129 °C); νmax/cm
-1
 1593, 1514, 1347, 855, 815; δH 
(500 MHz, CDCl3) 8.74 (2 H, d, J 4.5 Hz), 8.34 (2 H, d, J 8.5 Hz), 7.79 (2 H, d, J 8.5 
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Hz), 7.53 (2 H, dd, J 1.5, 4.5 Hz); δC (125 MHz, CDCl3) 150.8, 150.7, 146.1, 144.6, 
128.1, 124.5, 121.9; m/z (ESI) 154 ([M – NO2]
+
, 100). 
4-(Pyridin-2-yl)aniline (219)
484,485
  
 
A solution of compound 217 (0.2 g, 1.03 mmol) in methanol (10 mL) was treated 
with 10% palladium on carbon (20 mg) and subjected to a hydrogen atmosphere. The 
mixture was stirred for a further 18 h and then filtered through a pad of Celite
®
. The 
pad was washed with methanol (50 mL) and the combined filtrates evaporated in 
vacuo to give the crude residue which was purified by flash chromatography on silica 
eluting with CH2Cl2-methanol-aqueous ammonia (95:4.5:0.5) to give amine 219 
(0.15 g, 87%) as a brown solid; mp 89–92 °C (lit mp 94–95 °C); νmax/cm
-1
 3333, 
3210, 1606, 1586, 1519, 1294, 1181; δH (500 MHz, CDCl3) 8.62 (1 H, dt, J 1.0, 5.0 
Hz), 7.83 (2 H, d, J 8.5 Hz), 7.68–7.61 (2 H, m), 7.11 (1 H, m) 6.75 (2 H, d, J 8.5 
Hz), 3.83 (2 H, br s); δC (125 MHz, CDCl3) 157.6, 149.5, 147.5, 136.6, 129.8, 128.1, 
121.0, 119.4, 115.2; m/z (ESI) 171 ([M + H]
+
, 100). 
5-Bromo-N-(4-(pyridin-2-yl)phenyl)pentanamide (220)  
 
5-bromovaleric acid (0.14 g, 0.75 mmol) was suspended in oxalyl chloride (ca. 2 
mL), stirred at ambient temperature for 45 min, and the excess oxalyl chloride 
evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (10 mL), 
cooled to –78 °C, and treated dropwise with a solution of amine 219 (0.14 g, 0.82 
mmol) and triethylamine (115 µL, 0.82 mmol) in CH2Cl2 (10 mL). The mixture was 
warmed to ambient temperature, stirred for 10 h, and CH2Cl2 (70 mL) was added. 
The solution was washed with H2O (50 mL), hydrochloric acid (1 M; 50 mL), 
saturated aqueous sodium hydrogencarbonate (50 mL), brine (50 mL), dried 
(MgSO4), filtered, and the solvent evaporated under reduced pressure to give the 
crude amide which was purified by flash chromatography on silica eluting with 
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CH2Cl2-methanol-aqueous ammonia (98:1.5:0.5) to give amide 220 (0.21 g, 85%) as 
a colourless solid; mp 97–98 °C; νmax/cm
-1
 3230, 1718, 1543, 1418, 1375, 1214, 907, 
814; δH (500 MHz, CDCl3) 8.67 (1 H, d, J 5.0 Hz), 7.98 (2 H, d, J 8.5 Hz), 7.76–7.70 
(2 H, m), 7.64 (2 H, d, J 8.5 Hz), 7.21 (1 H, t, J 5.5 Hz), 3.46 (2 H, t, J 7.0 Hz), 2.43 
(2 H, t, J 7.0 Hz), 2.01–1.87 (4 H, m), NH proton not observed; δC (125 MHz, 
CDCl3) 170.6, 156.9, 149.8, 138.7, 137.7, 127.6, 120.1, 120.3, 119.9, 115.3, 36.8, 
33.3, 32.2, 24.1; m/z (ESI) 333, 335 ([M + H]
+
, 100); Found: C, 57.74; H, 5.29; N, 
8.43. Calc for C16H17BrN2O: C, 57.67, H, 5.14; N, 8.41%  
5-morpholino-N-(4-(pyridin-2-yl)phenyl)pentanamide (206)  
 
A solution of amide 206 (0.1 g, 0.3 mmol) in THF (5 mL) was treated with sodium 
iodide (0.046 g, 0.3 mmol), triethylamine (42 µL, 0.3 mmol) and morpholine (64 µL, 
0.34 mmol), and heated at reflux for 16 h. After cooling to ambient temperature, the 
solvent was removed under reduced pressure and the residue partitioned between 
H2O (50 mL) and ethyl acetate (70 mL). The layers were separated, and the aqueous 
layer extracted with ethyl acetate (2 × 50 mL). The combined organic extracts were 
washed with brine (100 mL), dried (MgSO4), filtered, and the solvent evaporated 
under reduced pressure to give the crude residue which was purified by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1) 
to give amide 207 (0.073 g, 74%) as a colourless solid; mp 155–156.0 °C; νmax/cm
-1
 
3302, 2915, 1658, 1598, 1466, 1118, 782; δH (500 MHz, CDCl3) 8.65 (1 H, d, J 5.0 
Hz), 7.96 (2 H, d, J 8.5 Hz), 7.74–7.68 (2 H, m), 7.62 (2 H, d, J 8.5 Hz), 7.58 (1 H, 
br s), 7.19 (1 H, t, J 6.5 Hz), 3.69 (4 H, t, J 4.5 Hz), 2.42–2.34 (8 H, m), 1.77 (2 H, 
quin, J 7.5 Hz), 1.59 (2 H, quin, J 7.5 Hz); δC (125 MHz, CDCl3) 171.3, 156.9, 
149.7, 138.9, 136.9, 135.3, 127.7, 122.0, 120.3, 119.9, 67.1, 58.7, 53.9, 37.6, 26.2, 
23.5; m/z (ESI) 340 ([M + H]
+
, 100); Found: C, 70.74; H, 7.37; N, 12.37. Calc for 
C20H25N3O2: C, 70.77, H, 7.42; N, 12.38% 
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5-morpholino-N-(4-(pyridin-4-yl)phenyl)pentanamide (207)  
 
Subjecting compound 68 to general procedure 3 using 4-pyridineboronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with CH2Cl2-methanol-aqueous ammonia (92:7.5:0.5) to give pentanamide 207 
(0.067 g, 57%) as a colourless solid; mp 103–104 °C; νmax/cm
-1
 2949, 1689, 1596, 
1525, 1292, 1116, 814; δH (400 MHz, CDCl3) 8.64 (1 H, br s), 7.67–7.59 (6 H, m), 
7.49 (2 H, d, J 4.4 Hz), 3.71 (4 H, t, J 4.4 Hz), 2.44–2.36 (8 H, m), 1.79 (2 H, quin, J 
7.6 Hz), 1.60 (2 H, quin, J 7.6 Hz); δC (100 MHz, CDCl3) 171.4, 150.3, 147.7, 139.1, 
133.8, 127.8, 121.4, 120.3, 67.1, 58.6, 53.9, 37.6, 26.1, 23.5; m/z (ESI) 340 ([M + 
H]
+
, 100); Found: C, 63.74; H, 7.87; N, 11.39. Calc for C20H25N3O2 + 2H2O: C, 
63.98, H, 7.79; N, 11.19% 
N-(4-(2-fluoropyridin-3-yl)phenyl)-5-morpholinopentanamide (208)  
 
Subjecting amide 68 to general procedure 3 using 2-fluoro-3-pyridineboronic acid, 
the crude residue was obtained and purified by flash chromatography on silica 
eluting with CH2Cl2-methanol-aqueous ammonia (92:7.5:0.5) to give pentanamide 
208 (0.12 g, 72%) as a colourless solid; mp 129–130 °C; νmax/cm
-1 
2953, 1664, 1599, 
1527, 1437, 1397, 1249, 1116; δH (500 MHz, CDCl3) 8.17 (1 H, d, J 5.0 Hz), 7.85 (1 
H, m), 7.63 (2 H, d, J 8.5 Hz), 7.54 (2 H, d, J 8.5 Hz), 7.41 (1 H, br s), 7.26 (1 H, m), 
3.71 (4 H, t, J 4.5 Hz), 2.44–2.37 (8 H, m), 1.77 (2 H, quin, J 8.0 Hz), 1.61 (2 H, 
quin, J 8.0 Hz); δC (125 MHz, CDCl3) 171.3, 160.5 (d, 
1
JC-F 238.8 Hz), 146.2 (d, 
3
JC-
F 13.8 Hz), 140.5 (d, 
3
JC-F 5 Hz), 138.3, 129.63, 129.60, 123.4 (d, 
2
JC-F 28.8 Hz), 
122.0, 120.0, 67.1, 58.7, 53.9, 37.6, 26.2, 23.5; m/z (ESI) 358 ([M + H]
+
, 100); 
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Found: C, 67.27; H, 6.82; N, 11.58. Calc for C20H24FN3O2: C, 67.21, H, 6.77; N, 
11.76% 
3-Oxo-3-phenylpropanenitrile (240)
486
  
 
A cooled (0 °C) solution of methyl benzoate (7.0 g, 51.4 mmol) in toluene (60 mL) 
was treated portionwise with sodium hydride (60% dispersion in mineral oil, 4.08 g, 
102.8 mmol). The mixture was allowed to warm to room temperature and treated 
dropwise with a solution of acetonitrile (13.5 mL, 257.0 mmol) in toluene (15 mL). 
The mixture was heated at reflux for 18 h during which time a thick precipitate 
formed. The mixture was cooled (0 °C), quenched by addition of hydrochloric acid 
(3 M; 30 mL) and then partitioned between ethyl acetate (150 mL) and H2O (100 
mL). The aqueous layer was further extracted with ethyl acetate (2 × 70 mL) and the 
combined organic extracts washed with brine (150 mL), dried (MgSO4), filtered and 
the solvent removed under reduced pressure. The crude residue was then purified by 
flash chromatography on silica eluting with hexane-ethyl acetate (1:1) to give nitrile 
240 (4.7 g, 63%) as a colourless solid; mp 79–81 °C (lit mp 81–82 °C); νmax/cm
-1 
2950, 2837, 1690, 1427, 1365, 1210, 847; δH (500 MHz, CDCl3) 7.92 (2 H, d, J 8.0 
Hz), 7.66 (1 H, t, J 7.5 H), 7.52 (2 H, t, J 8.0 Hz), 4.10 (2 H, s); δC (125 MHz, 
CDCl3) 187.3, 134.9, 134.4, 129.3, 128.6, 114.0, 29.5. 
3-Phenyl-1H-pyrazol-5-amine (241)
487
  
 
A solution of compound 240 (3.5 g, 24.1 mmol) in absolute ethanol (50 mL) was 
treated with hydrazine monohydrate (2.5 mL, 48.3 mmol) and glacial acetic acid (2.4 
mL, 38.6 mmol) and heated at reflux for 18 h. The mixture was allowed to cool to 
ambient temperature and the solvent removed under reduced pressure. The residue 
was suspended between CH2Cl2 (100 mL) and hydrochloric acid (1M; 100 mL), the 
aqueous layer was further extracted with CH2Cl2 (50 mL) and then basified to pH 12 
with addition of aqueous sodium hydroxide (3 M; ca 40 mL). The aqueous layer was 
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then extracted with CH2Cl2 (3 × 100 mL) and the basified organic extracts combined, 
dried (MgSO4), filtered and the solvent removed in vacuo to give the crude residue 
which was purified by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (90:9.5:0.5) to give amine 241 (3.06 g, 80%) as an off-white solid; 
mp 144–145 °C (lit mp 145–146 °C); νmax/cm
-1 
3205, 1571, 1510, 758, 693; δH (500 
MHz, CDCl3) 7.55 (2 H, d, J 7.0 Hz), 7.36 (2 H, t, J 7.0 Hz), 7.30 (1 H, t, J 7.0 Hz), 
5.90 (1 H, s), 3NH protons not observed; δC (125 MHz, CDCl3) 154.5, 145.9, 130.5, 
129.0, 128.4, 125.6, 90.5; m/z (ESI) 160 ([M + H]
+
, 100).  
5-Bromo-N-(5-phenyl-1H-pyrazol-3-yl)pentanamide (242)  
 
5-bromovaleric acid (1.24 g, 6.8 mmol) was suspended in oxalyl chloride (ca. 5 mL), 
stirred at ambient temperature for 45 min, and the excess oxalyl chloride evaporated 
under reduced pressure. The residue was dissolved in CH2Cl2 (50 mL), cooled to –78 
°C, and treated dropwise with a solution of compound 241 (1.2 g, 7.5 mmol) and 
triethylamine (1.05 mL, 7.5 mmol) in CH2Cl2 (20 mL). The mixture was warmed to 
ambient temperature, stirred for 10 h, and CH2Cl2 (150 mL) was added. The solution 
was washed with H2O (100 mL), hydrochloric acid (1 M; 100 mL), saturated 
aqueous sodium hydrogencarbonate (100 mL), brine (100 mL), dried (MgSO4), 
filtered, and the solvent evaporated under reduced pressure to give the crude amide 
which was purified by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (95:4.5:0.5) to give amide 242 (1.6 g, 74%) as an off white solid. 
Due to the unstable nature of amide 242 it was used directly in the next step without 
further characterisation.  
5-Morpholino-N-(5-phenyl-1H-pyrazol-3-yl)pentanamide (209)  
 
Subjecting compound 242 to general procedure 2 using THF as the solvent, the crude 
amide was obtained and purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (92:8.5:1.5) to give compound 209 (0.12 g, 
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59%) as a colourless solid; mp 158–160 °C; νmax/cm
-1
 3218, 2949, 1664, 1578, 1547, 
1492, 1115, 1008; δH (500 MHz, CDCl3) 8.66 (1 H, s), 7.62 (2 H, d, J 7.5 Hz), 7.41 
(2 H, t, J 7.5 Hz), 7.35 (1 H, t, J 7.5 Hz), 6.83 (1 H, br s), 3.70 (4 H, t, J 4.5 Hz), 
2.41–2.38 (6 H, m), 2.35 (2 H, t, J 7.5 Hz), 1.75 (2 H, quin, J 7.5 Hz), 1.56 (2 H, 
quin, J 7.5 Hz), one NH peak not observed; δC (100 MHz, CDCl3) 171.0, 129.2, 
128.8, 125.6, 93.6, 67.0, 58.6, 53.9, 36.8, 26.0, 23.4, pyrazole peaks not observed; 
m/z (ESI) 329 ([M + H]
+
, 100); Found: C, 65.89; H, 7.32; N, 16.92. Calc for 
C18H24N4O2: C, 65.83; H, 7.37; N, 17.06% 
N-(5-Phenyl-1H-pyrazol-3-yl)-5-(piperidin-1-yl)pentanamide (210)  
 
Subjecting compound 242 to general procedure 2 using THF as the solvent and 
piperidine as the amine source, the crude amide was obtained and purified by flash 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(92:8.5:1.5) to give compound 209 (0.11 g, 56%) as a colourless solid; mp 163–164 
°C; νmax/cm
-1
 3239, 2932, 1658, 1577, 1550, 1492, 959; δH (500 MHz, CDCl3) 9.20 
(1 H, br s), 7.65 (2 H, d, J 7.5 Hz), 7.41 (2 H, t, J 7.5 Hz), 7.33 (1 H, t, J 7.5 Hz), 
6.83 (1 H, br s), 2.40–2.36 (8 H, m), 1.71 (2 H, quin, J 7.5 Hz), 1.60–1.54 (6 H, m), 
1.42 (2 H, m), one NH peak not observed; δC (125 MHz, CDCl3) 171.5, 146.4, 130.5, 
129.1, 128.5, 125.7, 93.5, 58.7, 54.7, 36.8, 26.3, 25.8, 24.4, 23.7, one pyrazole peak 
not observed; m/z (ESI) 327 ([M + H]
+
, 100); Found: C, 66.20; H, 8.47; N, 16.24. 
Calc for C19H26N4O + H2O: C, 66.25; H, 8.19; N, 16.27% 
5-(4-Methylpiperazin-1-yl)-N-(5-phenyl-1H-pyrazol-3-yl)pentanamide (211)  
 
Subjecting compound 242 to general procedure 2 using THF as the solvent and 1-
methylpiperazine as the amine source, the crude amide was obtained and purified by 
flash chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia 
(92:8.5:1.5) to give compound 209 (0.14 g, 62%) as a colourless solid; mp 162–164 
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°C; νmax/cm
-1
 3222, 3198, 2942, 2813, 1661, 1579, 1543, 1457, 1109; δH (500 MHz, 
CDCl3) 8.9 (1 H, br s), 7.63 (2 H, d, J 7.5 Hz), 7.40 (2 H, t, J 7.5 Hz), 7.33 (1 H, t, J 
7.5 Hz), 6.84 (1 H, br s), 2.45–2.34 (12 H, m), 2.56 (3 H, s), 1.72 (2 H, quin, J 7.5 
Hz), 1.56 (2 H, quin, J 7.5 Hz), one NH peak not observed; δC (125 MHz, CDCl3) 
171.2, 145.3, 130.4, 129.1, 128.7, 125.7, 93.7, 58.0, 55.0, 53.2, 46.1, 36.7, 26.2, 23.5, 
one pyrazole peak not observed; m/z (ESI) 705 ([2M + Na]
+
, 100), 342 ([M + H]
+
, 
100); Found: C, 63.72 ; H, 8.52; N, 19.54. Calc for C19H26N4O + H2O: C, 63.48; H, 
8.13; N, 19.48% 
6-chloropyridazin-3-amine (250)
488
 
 
To a thick-wall borosilicate glass vial was added 3,6-dichloropyridazine (1.5 g, 10.1 
mmol) and ammonium hydroxide solution (5 mL; NH3 content: 28 to 30%). The vial 
was sealed and placed in the microwave reactor for 30 min at 120 °C (power: 300 
W). After cooling, the precipitate that deposited was filtered off, washed with ethyl 
acetate-hexane (3:7) and dried to give amine 250 (0.86 g, 66%) as a yellow solid; mp 
decomposition >206 °C (lit mp 229–232 °C); νmax/cm
-1 
3147, 1643, 1596, 1455, 
1055, 838; δH (200 MHz, DMSO) 7.36 (1 H, d, J 10.0 Hz), 6.84 (1 H, d, J 10.0 Hz), 
6.61 (2 H, br s); δC (75 MHz, DMSO) 160.2, 145.0, 128.9, 117.5; m/z (ESI) 130 ([M 
+ H]
+
, 100). 
5-bromo-N-(6-chloropyridazin-3-yl)pentanamide (251)  
 
5-bromovaleric acid (0.46 g, 2.6 mmol) was suspended in oxalyl chloride (ca. 2 mL), 
stirred at ambient temperature for 45 min, and the excess oxalyl chloride evaporated 
under reduced pressure. The residue was dissolved in CH2Cl2 (20 mL), cooled to –78 
°C, and treated dropwise with a solution of amine 250 (0.3 g, 2.3 mmol) and 
triethylamine (355 µL, 2.6 mmol) in CH2Cl2 (20 mL). The mixture was warmed to 
ambient temperature, stirred for 10 h, and CH2Cl2 (100 mL) was added. The solution 
was washed with H2O (70 mL), saturated aqueous ammonium chloride (70 mL), 
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saturated aqueous sodium hydrogencarbonate (70 mL), brine (70 mL), dried 
(MgSO4), filtered, and the solvent evaporated under reduced pressure to give the 
crude amide. The orange residue was suspended in methanol and the resulting solid 
filtered off and dried to give amide 251 (0.13 g, 20%) as a colourless solid; mp 
decomposition >169 °C; νmax/cm
-1 
3191, 1690, 1582, 1515, 1409, 1141, 1088, 735; 
δH (300 MHz, CDCl3) 10.5 (1 H, br s), 8.66 (1 H, d, J 9.0 Hz), 7.58 (1 H, d, J 9.0 
Hz), 3.48 (2 H, t, J 6.0 Hz), 2.71 (2 H, t, J 6.0 Hz), 2.01–1.92 (4 H, m); δC (75 MHz, 
CDCl3) 173.1, 155.0, 152.0, 130.9, 122.2, 36.7, 33.1, 32.1, 23.9; m/z (ESI) 292 ([M + 
H]
+
, 100); Found: C, 36.97; H, 3.68; N, 14.06. Calc for C9H11BrClN3O: C, 36.95, H, 
3.79; N, 14.36%  
N-(6-chloropyridazin-3-yl)-5-morpholinopentanamide (254)  
 
A solution of amide 206 (0.1 g, 0.34 mmol) in DMF (8 mL) was treated with sodium 
iodide (0.051 g, 0.34 mmol), triethylamine (50 µL, 0.34 mmol) and morpholine (33 
µL, 0.38 mmol), and heated at reflux for 19 h. After cooling to ambient temperature, 
the solution was partitioned between H2O (50 mL) and ethyl acetate (50 mL), the 
layers separated, and the aqueous layer extracted with ethyl acetate (2 × 50 mL). The 
combined organic extracts were washed with H2O (100 mL), brine (50 mL), dried 
(MgSO4), filtered, and the solvent evaporated under pressure to give the crude 
residue which was purified by flash chromatography on silica eluting with CH2Cl2-
methanol-aqueous ammonia (90:9:1) to give amide 254 (0.061 g, 62%) as a 
colourless solid; mp decomposition >152 °C; νmax/cm
-1 
2937, 1686, 1588, 1518, 
1406, 1136, 1116, 866; δH (300 MHz, CDCl3) 10.47 (1 H, br s), 8.61 (1 H, d, J 9.0 
Hz), 7.52 (1 H, d, J 9.0 Hz), 3.71 (4 H, t, J 6.0 Hz), 2.70 (2 H, t, J 6.0 Hz), 2.47–2.41 
(6 H, m), 1.78 (2 H, m), 1.65 (2 H, m); δC (75 MHz, CDCl3) 173.5, 155.3, 151.7, 
130.3, 121.8, 66.9, 58.5, 53.8, 37.4, 25.8, 23.3; m/z (ESI) 299 ([M + H]
+
, 100); 
Found: C, 52.55; H, 6.46; N, 18.69. Calc for C13H19ClN4O2: C, 52.26, H, 6.41; N, 
18.75%  
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5-morpholino-N-(6-phenylpyridazin-3-yl)pentanamide (212)  
 
Subjecting amide 254 to general procedure 3 using phenylboronic acid gave, after 
purification by flash chromatography on silica eluting with CH2Cl2-methanol-
aqueous ammonia (90:9:1) compound 212 (0.027 g, 63%) as a colourless solid; mp 
decomposition >220 °C; νmax/cm
-1 
2942, 1679, 1590, 1519, 1406, 1218, 1147, 1120, 
866; δH (500 MHz, CDCl3) 10.46 (1 H, br s), 8.65 (1 H, d, J 9.0 Hz), 8.02 (2 H, d, J 
7.0 Hz), 7.91 (1 H, d, J 9.0 Hz), 7.54–7.48 (3 H, m), 3.67 (4 H, t, J 4.5 Hz), 2.79 (2 
H, t, J 7.5 Hz), 2.37–2.34 (6 H, m), 1.82 (2 H, quin, J 7.5 Hz), 1.61 (2 H, quin, J 7.5 
Hz); δC (125 MHz, CDCl3) 173.4, 156.4, 154.9, 136.2, 129.9, 129.2, 126.8, 126.3, 
119.7, 67.1, 58.7, 53.9, 37.6, 26.1, 23.5; m/z (ESI) 363 ([M + Na]
+
, 100); Found: C, 
67.10; H, 7.24; N, 16.53. Calc for C19H24N4O2: C, 67.04, H, 7.11; N, 16.46%  
N-(4-(1H-indol-5-yl)phenyl)-5-morpholinopentanamide (183) 
 
Subjecting amide 68 to general procedure 3 using 5-indolylboronic acid, the crude 
residue was obtained and purified by flash chromatography on silica eluting with 
CH2Cl2-methanol-aqueous ammonia (90:9:1) to give pentanamide 183 (0.14 g, 81%) 
as a colourless solid; mp 205–206 °C; νmax/cm
-1 
3290, 1663, 1597, 1470, 1318, 1114, 
807, 734; δH (500 MHz, DMSO-d6) 11.09 (1 H, br s), 9.88 (1 H, s), 7.76 (1 H, s), 
7.65 (2 H, d, J 9.0 Hz), 7.58 (2 H, d, J 9.0 Hz), 7.44 (1 H, d, J 8.5 Hz), 7.37–7.35 (2 
H, m), 6.46 (1 H, t, J 2.0 Hz), 3.56 (4 H, t, J 4.5 Hz), 2.32–2.27 (8 H, m), 1.62 (2 H, 
quin, J 7.5 Hz), 1.47 (2 H, quin, J 7.5 Hz); δC (125 MHz, DMSO-d6) 171.1, 137.7, 
136.5, 135.2, 131.0, 128.2, 126.7, 125.9, 120.1, 119.4, 117.6, 111.7, 101.4, 66.2, 
58.0, 53.4, 36.2, 25.5, 23.0; m/z (ESI) 378 ([M + H]
+
, 100); Found: C, 73.22; H, 
7.21; N, 11.13. Calc for C23H27N3O2: C, 73.18, H, 7.21; N, 11.13%  
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11.6 The synthesis of compounds from Chapter 6 
4-(6-chloropyridazin-3-yl)morpholine (283)
489
  
 
To a solution of 3,6-dichloropyridazine (1.0 g, 6.7 mmol) in DMF (67 mL) was 
added N,N-diisopropylethylamine (1.29 mL, 7.38 mmol) and morpholine (0.58 mL, 
6.7 mmol). The mixture was heated at reflux for 17 h and after cooling to room 
temperature, partitioned between ethyl acetate (200 mL) and H2O (100 mL). The 
aqueous layer was further extracted with ethyl acetate (2 × 80 mL) and the combined 
organic layers then further washed with H2O (200 mL), brine (200 mL) then dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the crude 
product. Purification by flash chromatograph on silica eluting with ethyl acetate 
yielded the desired pyridazine 283 (1.1 g, 83%) as a yellow solid; mp 132–135 °C 
(lit mp 132.5–134.5 °C); νmax/cm
-1
 2985, 2924, 1582, 1527, 1454, 1266, 1164, 1123, 
927, 821, 765; δH (300 MHz, CDCl3) 7.22 (1 H, d, J 9.0 Hz), 6.89 (1 H, d, J 9.0 Hz), 
3.82 (4 H, t, J 6.0 Hz), 3.58 (4 H, t, J 6.0 Hz); δC (75 MHz, CDCl3) 159.3, 147.4, 
128.9, 115.3, 66.4, 45.4; m/z (APCI) 200 ([M + H]
+
, 100).  
3-chloro-6-(piperidin-1-yl)pyridazine (284)
489
  
 
To a solution of 3,6-dichloropyridazine (0.3 g, 2.0 mmol) in DMF (20 mL) was 
added N,N-diisopropylethylamine (377 µL, 2.2 mmol) and piperidine (200 µL, 2.0 
mmol). The mixture was heated at reflux for 17 h and after cooling to room 
temperature, partitioned between ethyl acetate (100 mL) and H2O (100 mL). The 
aqueous layer was further extracted with ethyl acetate (2 × 80 mL) and the combined 
organic layers then further washed with H2O (200 mL), brine (200 mL) then dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the crude 
product. Purification by flash chromatograph on silica eluting with hexane-ethyl 
acetate (7:2) yielded the desired pyridazine 284 (0.29 g, 72%) as an off white solid; 
mp 75–77 °C (lit mp 74–76 °C); νmax/cm
-1 
3050, 2928, 2854, 1587, 1529, 1479, 
1438, 1263, 1249, 1213, 1171, 1004, 923, 830; δH (500 MHz, CDCl3) 7.14 (1 H, d, J 
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9.5 Hz), 6.88 (1 H, d, J 9.5 Hz), 3.60 (4 H, t, J 5.5 Hz), 1.69–1.65 (6 H, m); δC (125 
MHz, CDCl3) 159.1, 146.0, 128.5, 115.2, 46.3, 25.3, 24.4; m/z (APCI) 198 ([M + 
H]
+
, 100). 
3-chloro-6-(4-methylpiperazin-1-yl)pyridazine (285)
489
 
 
To a solution of 3,6-dichloropyridazine (1.0 g, 6.7 mmol) in DMF (67 mL) was 
added N,N-diisopropylethylamine (1.29 mL, 7.38 mmol) and 1-methylpiperazine 
(744 µL, 6.7 mmol). The mixture was heated at reflux for 17 h and after cooling to 
room temperature, partitioned between ethyl acetate (200 mL) and H2O (70 mL). The 
aqueous layer was further extracted with ethyl acetate (2 × 50 mL) and the combined 
organic layers then further washed with H2O (100 mL), brine (100 mL) then dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the crude 
product. Purification by flash chromatograph on silica eluting with CH2Cl2-
methanol-aqueous ammonia (95:4.5:0.5) yielded the desired pyridazine 285 (0.88 g, 
62%) as a pale yellow solid; mp 108–109 °C (lit mp 106–107 °C); νmax/cm
-1 
3780, 
2953, 2927, 1443, 1258, 1168, 1143, 613; δH (500 MHz, CDCl3) 7.12 (1 H, d, J 9.5 
Hz), 6.89 (1 H, d, J 9.5 Hz), 3.64 (4 H, t, J 5.0 Hz), 2.51 (4 H, t, J 5.0 Hz), 2.34 (3 H, 
s); δC (125 MHz, CDCl3) 159.2, 147.0, 128.8, 115.3, 54.7, 46.3, 45.2; m/z (APCI) 
213 ([M + H], 100).  
(1S, 4S)-tert-Butyl 5-(6-chloropyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate (286)
279
  
 
To a solution of 3,6-dichloropyridazine (0.11 g, 0.76 mmol) in DMF (7.5 mL) was 
added N,N-diisopropylethylamine (145 µL, 0.83 mmol) and compound 157 (0.15 g, 
0.76 mmol). The mixture was heated at reflux for 14 h and after cooling to room 
temperature, partitioned between ethyl acetate (200 mL) and H2O (70 mL). The 
aqueous layer was further extracted with ethyl acetate (2 × 50 mL) and the combined 
organic layers then further washed with H2O (100 mL), brine (100 mL) then dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the crude 
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product. Purification by flash chromatograph on silica eluting with hexane-ethyl 
acetate (1:1) yielded compound 286 (0.09 g, 37%) as a colourless solid;     
   −50.9 
(1.0, CHCl3); mp dec >195 °C; νmax/cm
-1 
3029, 2914, 1507, 1423, 1289, 1258, 
1172, 1103, 842; δH (400 MHz, CDCl3) 7.20 (1 H, d, J 9.2 Hz), 6.59 (1 H, d, J 9.2 
Hz), 5.08 (0.6 H, s), 4.93 (0.4 H, s), 4.70 (0.6 H, s), 4.57 (0.4 H, s), 3.54 (1 H, m), 
3.45–3.37 (3 H, m), 1.97 (2 H, m), 1.44 (9 H, m) (mixture of rotamers); δC (75 MHz, 
CDCl3) 157.1, 154.3, 146.4, 129.1, 115.1, 80.1, 57.2, 56.8, 56.4, 55.9, 55.6, 52.9, 
52.5, 37.7, 37.1, 28.5 (mixture of rotamers); m/z (APCI) 254 ([M – C4H9]
+
, 100), 311 
([M + H]
+
, 20.  
4-(6-Phenylpyridazin-3-yl)morpholine (264)
489
  
 
Subjecting 283 to general procedure 3 using phenyl boronic acid, the crude residue 
was obtained and purified by flash chromatography on silica eluting with ethyl 
acetate-hexane (2:1) to give pyridazine 264 (0.14 g, 61%) as a colourless solid; mp 
153–154 °C (lit mp 153–155 °C); νmax/cm-1 2854, 1594, 1451, 1432, 1378, 1263, 
1238, 1120, 930, 831, 784, 746, 697; δH (500 MHz, CDCl3) 8.0 (2 H, d, J 7.5 Hz), 
7.67 (1 H, d, J 9.5 Hz), 7.47 (2 H, t, J 7.5 Hz), 7.4 (1 H, m), 6.97 (1 H, d, J 9.5 Hz), 
3.87 (4 H, t, J 5.0 Hz), 3.67 (4 H, t, J 5.0 Hz); δC (125 MHz, CDCl3) 159.1, 151.7, 
136.6, 128.84, 128.75, 126.0, 125.5, 112.8, 66.6, 45.4; m/z (APCI) 242 ([M + H]
+
, 
100).  
3-Phenyl-6-(piperidin-1-yl)pyridazine (265)  
 
Subjecting compound 283 to general procedure 3 using phenyl boronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with ethyl acetate-hexane (1:1) to give pyridazine 265 (0.16 g, 68%) as a colourless 
solid; mp 120–121 °C; νmax/cm-1 2934, 2851, 1592, 1541, 1430, 1248, 1128, 923, 
745, 694; δH (500 MHz, CDCl3) 8.0 (2 H, d, J 7.5 Hz), 7.62 (1 H, d, J 9.5 Hz), 7.46 
(2 H, t, J 7.5 Hz), 7.39 (1 H, t, J 7.5 Hz), 6.98 (1 H, d, J 9.5 Hz), 3.71 (4 H, m), 1.71 
(6 H, br s, signals overlapping); δc (125 MHz, CDCl3) 159.1, 150.5, 137.1, 128.9, 
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128.6, 125.9, 125.2, 113.0, 46.4, 25.6, 24.8; m/z (APCI) 240 ([M + H]
+
, 100); Found: 
C, 75.07; H, 7.13; N, 17.90. Calc for C15H17N3: C, 75.28, H, 7.16; N, 17.56% 
3-(4-Methylpiperazin-1-yl)-6-phenylpyridazine (266)
490
  
 
Subjecting compound 283 to general procedure 3 using phenyl boronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with ethyl acetate-hexane (1:1) to give pyridazine 266 (0.14 g, 59%) as a colourless 
solid; mp 120–122 °C (lit mp 121–122 °C); νmax/cm-1 2927, 1592, 1443, 1236, 
1117, 985; δH (300 MHz, CDCl3) 8.0 (2 H, d, J 6.9 Hz), 7.65 (1 H, d, J 9.6 Hz), 
7.49–7.39 (3 H, m), 6.98 (1 H, d, J 9.6 Hz), 3.74 (4 H, t, J 5.1 Hz), 2.56 (4 H, t, J 5.1 
Hz), 2.36 (3 H, s); δc (75 MHz, CDCl3) 159.1, 151.3, 136.9, 128.9, 128.8, 126.0, 
125.3, 113.0, 54.8, 46.4, 45.2; m/z (APCI) 255 ([M + H]
+
, 100). 
(1S, 4S)-tert-butyl 5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate (287)
279
  
 
Subjecting compound 286 to general procedure 3 using phenyl boronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with ethyl acetate-hexane (1:1) to give pyridazine 287 (0.18 g, 78%) as a colourless 
solid; mp 208–210 °C;     
   −67.4 (1.0, CHCl3); νmax/cm
-1 
1650, 1489, 1476, 1452, 
1209, 1186, 809, 627; δH (500 MHz, CDCl3) 7.98 (2 H, d, J 7.0 Hz), 7.63 (1 H, t, J 
7.5 Hz), 7.45 (2 H, t, J 7.5 Hz), 7.38 (1 H, t, J 7.5 Hz), 6.67 (1 H, d, J 9.0 Hz), 5.16 
(0.6 H, s), 5.01 (0.4 H, s), 4.71 (0.6 H, s), 4.57 (0.4 H, s), 3.61 (1 H, m), 3.53–3.42 (3 
H, m), 1.99 (2 H, m), 1.43 (9 H, m) (mixture of rotamers); δc (125 MHz, CDCl3) 
156.9, 156.7, 154.3, 150.7, 136.9, 128.9, 128.6, 125.8, 125.4, 112.8, 112.7, 80.0, 
79.9, 57.3, 57.1, 56.6, 56.4, 55.7, 55.4, 53.0, 52.6, 37.6, 37.1, 28.6, 28.5 (mixture of 
rotamers); m/z (ESI) 353 ([M + H]
+
, 100). 
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(1S, 4S)-2-Methyl-5-(6-phenylpyridazin-3-yl)-2,5-diazabicyclo[2.2.1]heptane 
(139)
279
  
 
Subjecting compound 287 to general procedure 5 the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (92:7.5:0.5) to give methylated amine 139 (0.03 g, 66% over two steps) as 
a colourless solid; mp 137–138 °C;     
   −49.7 (1.0, CHCl3); νmax/cm
-1
 2853, 1709, 
1594, 1545, 1460, 1435, 1360, 1219, 1028, 834, 746, 695; δH (500 MHz, CDCl3) 
7.97 (2 H, d, J 7.0 Hz), 7.6 (1 H, d, J 9.0 Hz), 7.44 (2 H, t, J 7.0 Hz), 7.36 (1 H, t, J 
7.0 Hz), 6.66 (1 H, d, J 9.0 Hz), 3.62 (1 H, d, J 9.5 Hz), 3.61 (1 H, s), 3.44 (1 H, dd, 
J 2.0, 9.5 Hz), 2.97 (1 H, dd, J 2.0, 10.0 Hz), 2.73 (1 H, d, J 10.0 Hz), 2.41 (3 H, s), 
2.24 (1 H, s), 2.03 (1 H, d, J 9.5 Hz), 1.87 (1 H, d, J 10.0 Hz); δC (125 MHz, CDCl3) 
156.8, 150.3, 137.1, 128.9, 128.5, 125.8, 125.2, 112.7, 62.9, 60.4, 57.8, 51.1, 41.1, 
35.9; m/z (ESI) 267 ([M + H]
+
, 100). 
4-(6-(1H-indol-6-yl)pyridazin-3-yl)morpholine (267) 
 
Subjecting 283 to general procedure 3 using 5-indolylboronic acid, the crude residue 
was obtained and purified by flash chromatography on silica eluting with ethyl 
acetate-hexane (1:1) to give pyridazine 267 (0.11 g, 74%) as a colourless solid; mp 
decomposition > 160 °C; νmax/cm-1 3305, 1541, 1340, 1262, 1241, 1175, 1107, 
1071, 936, 810, 727, 540; δH (500 MHz, DMSO-d6) 11.2 (1 H, s), 8.18 (1 H, s), 7.97 
(1 H, d, J 9.5 Hz), 7.84 (1 H, dd, J 2.0, 8.5 Hz), 7.48 (1 H, d, J 8.5 Hz), 7,38 (1 H, t, 
J 3.0 Hz), 7.33 (1 H, d, J 9.5 Hz), 6.51 (1 H, t, J 4.0 Hz); 3.76 (4 H, t, J 4.5 Hz), 3.58 
(4 H, t, J 4.5 Hz); δC (125 MHz, DMSO-d6) 158.8, 152.3, 136.2, 131.5, 128.7, 126.2, 
125.1, 119.3, 117.7, 113.7, 111.7, 101.8; 65.9, 45.1; m/z (ESI) 281 ([M + H]
+
, 100); 
Found: C, 68.56; H, 5.71; N, 19.77. Calc for C16H16N4O: C, 68.55, H, 5.75; N, 
19.99% 
Chapter 11 Experimental 
 
269 
 
4-(4-Bromophenyl)morpholine (289)  
 
A solution of tris(dibenzylideneacetone)dipalladium(0) (0.093 g, 0.1 mmol) and (±)-
BINAP (0.13 g, 0.21 mmol) in toluene (7 mL) was degassed with argon for 10 min 
and then heated at 110 °C for 15 min. The reaction mixture was allowed to cool to 
room temperature before potassium tert-butoxide (0.53 g, 4.73 mmol), 1,4-
dibromobenzene (0.6 g, 2.54 mmol) and morpholine (332 µL, 3.82 mmol) were 
added. The resulting mixture was heated at reflux for 16 h, cooled to room 
temperature and filtered through a pad of Celite®, the pad was further washed with 
toluene (30 mL) and the combined filtrates evaporated under reduced pressure to 
give the crude product. Purification by flash chromatography on silica eluting with 
hexane-ethyl acetate (6:1) gave the desired amine 289 (0.19 g, 47%) as a colourless 
solid; mp 110–111 °C; νmax/cm-1 2965, 2857, 2831, 1589, 1495, 1259, 1236, 1120, 
923, 818; δH (300 MHz, CDCl3) 7.35 (2 H, d, J 9.0 Hz), 6.78 (2 H, d, J 9.0 Hz), 3.84 
(4 H, t, J 6.0 Hz), 3.11 (4 H, t, J 6.0 Hz); δC (75 MHz, CDCl3) 150.3, 132.0, 117.4, 
112.3, 66.8, 49.3; m/z (APCI) 242/244 ([M + H]
+
, 68/100). 
4-(4-(Pyridin-3-yl)phenyl)morpholine (268)  
 
Subjecting compound 289 to general procedure 3, the crude residue was obtained and 
purified by flash chromatography on silica eluting with ethyl acetate-hexane (2:1) to 
give amine 268 (0.085 g, 56%) as a colourless solid; mp 162–163 °C; νmax/cm-1 
2970, 2846, 1609, 1350, 1259, 921, 823; δH (300 MHz, CDCl3) 8.82 (1 H, s), 8.52 (1 
H, d, J 6.0 Hz), 7.84 (1 H, m), 7.52 (2 H, d, J 9.0 Hz), 7.34 (1 H, dd, J 6.0, 9.0 Hz), 
7.00 (2 H, d, J 9.0 Hz), 3.88 (4 H, t, J 6.0 Hz), 3.22 (4 H, t, J 6.0 Hz); δC (75 MHz, 
CDCl3) 151.2, 147.6, 147.4, 136.4, 133.9, 128.8, 127.9, 123.7, 115.9, 66.9, 48.9; m/z 
(APCI) 241 ([M + H]
+
, 100); Found: C, 74.36; H, 6.81; N, 11.29. Calc for 
C15H16N2O: C, 74.97, H, 6.71; N, 11.66% 
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4-([1,1'-biphenyl]-4-yl)morpholine (269)
491
  
 
Subjecting compound 289 to general procedure 3 using phenylboronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with ethyl acetate-hexane (6:1) to give amine 269 (0.093 g, 72%) as a colourless 
solid; mp 179–180 °C; νmax/cm-1 2837, 1607, 1490, 1259, 1234, 1121, 927, 820, 
761, 692; δH (500 MHz, CDCl3) 7.57–7.53 (4 H, m), 7.41 (2 H, t, J 8.0 Hz), 7.29 (1 
H, t, J 8.0 Hz), 6.99 (2 H, d, J 7.0 Hz), 3.89 (4 H, t, J 5.0 Hz), 3.21 (4 H, t, J 5.0 Hz); 
δC (125 MHz, CDCl3) 150.7, 141.0, 132.9, 128.9, 128.0, 126.69, 126.67, 115.9, 67.1, 
49.4; m/z (APCI) 240 ([M + H]
+
, 100). 
1-(4-Bromophenyl)piperidine (290)
391,492
  
 
A suspension of 4-bromophenylboronic acid (0.3 g, 1.5 mmol), copper(II) acetate 
monohydrate (0.03 g, 0.15 mmol) and powdered 4 Å molecular sieves (0.56 g) in 
CH2Cl2 (10 mL) was stirred at room temperature for 5 min. Piperidine (74 µL, 0.74 
mmol) was then added and the resulting mixture sealed and stirred under an 
atmosphere of air at room temperature for 20 h. The reaction mixture was filtered 
through a pad of Celite
®
 and the solvent removed under reduced pressure to give the 
crude residue. Purification by flash chromatography on silica eluting with hexane-
ethyl acetate (7:2) yielded amine 290 (0.1 g, 58%) as a colourless solid; mp 73–74 °C 
(lit mp 72–73 °C); νmax/cm-1 2937, 2816, 1588, 1496, 1246, 1221, 1127, 807, 537; 
δH (500 MHz, CDCl3) 7.31 (2 H, d, J 9.0 Hz), 6.79 (2 H, d, J 9.0 Hz), 3.12 (4 H, t, J 
5.5 Hz), 1.69 (4 H, quin, J 5.5 Hz), 1.58 (2 H, m); δC (125 MHz, CDCl3) 151.3, 
131.9, 118.1, 111.2, 50.6, 25.8, 24.3; m/z (APCI) 240, 242 ([M + H]
+
, 100). 
3-(4-(piperidin-1-yl)phenyl)pyridine (270)  
 
Subjecting compound 290 to general procedure 3, the crude residue was obtained and 
purified by flash chromatography on silica eluting with hexane-ethyl acetate (2:1) to 
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give amine 270 (0.05 g, 72%) as a colourless solid; mp 134–136 °C; νmax/cm-1 2934, 
1606, 1244, 1130, 802, 711; δH (500 MHz, CDCl3) 8.82 (1 H, d, J 2.0 Hz), 8.50 (1 H, 
dd, J 2.0, 5.0 Hz), 7.83 (1 H, dt, J 2.0, 8.5 Hz), 7.49 (2 H, d, J 8.5 Hz), 7.31 (1 H, m), 
7.02 (2 H, d, J 8.5 Hz), 3.24 (4 H, t, J 5.5 Hz), 1.73 (4 H, quin, J 5.5 Hz), 1.61 (2 H, 
m); δC (125 MHz, CDCl3) 152.0, 147.9, 147.5, 136.6, 133.7, 127.88, 127.82, 123.6, 
116.5, 50.3, 25.8, 24.5; m/z (ESI) 239 ([M + H]
+
, 100); Found: C, 80.53; H, 7.71; N, 
11.63. Calc for C16H18N2: C, 80.63, H, 7.61; N, 11.75% 
1-([1,1'-biphenyl]-4-yl)piperidine (271)
493
  
 
Subjecting compound 290 to general procedure 3 using phenylboronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with hexane-ethyl acetate (95:5) to give amine 271 (0.05 g, 71%) as a colourless 
solid; mp 122–123 °C; νmax/cm-1 2937, 2850, 1607, 1490, 1241, 820, 760, 692; δH 
(500 MHz, CDCl3) 7.56 (2 H, d, J 7.5 Hz), 7.5 (2 H, d, J 9.0 Hz), 7.39 (2 H, t, J 7.5 
Hz), 7.26 (1 H, t, J 7.5 Hz), 7.0 (2 H, d, J 9.0 Hz), 3.21 (4 H, t, J 5.5 Hz), 1.73 (4 H, 
quin, J 5.5 Hz), 1.60 (2 H, m); δC (125 MHz, CDCl3) 151.6, 141.2, 131.8, 128.8, 
127.8, 126.6, 126.4, 116.6, 50.6, 25.9, 24.5; m/z (ESI) 238 ([M + H]
+
, 100). 
1-(4-bromophenyl)-4-methylpiperazine (291)
494
  
  
A solution of tris(dibenzylideneacetone)dipalladium(0) (0.04 g, 0.084 mmol) and 
(±)-BINAP (0.10 g, 0.16 mmol) in toluene (10 mL) was degassed with argon for 10 
min and then heated at 110 °C for 15 min. The reaction mixture was allowed to cool 
to room temperature before potassium tert-butoxide (0.44 g, 3.94 mmol), 1.4-
dibromobenzene (0.5 g, 2.12 mmol) and 1-methylpiperazine (260 µL, 2.34 mmol) 
were added. The resulting mixture was heated at reflux for 16 h, cooled to room 
temperature and filtered through a pad of Celite
®
, the pad was further washed with 
toluene (30 mL) and the combined filtrates evaporated under reduced pressure to 
give the crude product. Purification by flash chromatography on silica eluting with 
hexane-ethyl acetate (3:1) gave the desired amine 291 (0.16 g, 50%) as a colourless 
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solid; mp 81–83 °C; νmax/cm-1 2940, 2814, 1568, 1456, 1245, 1220, 1107, 930; δH 
(500 MHz, CDCl3) 7.33 (2 H, d, J 9.0 Hz), 6.79 (2 H, d, J 9.0 Hz), 3.19 (4 H, t, J 5.0 
Hz), 2.57 (4 H, t, J 5.0 Hz), 2.35 (3 H, s); δC (125 MHz, CDCl3) 150.4, 132.0, 117.8, 
111.9, 55.1, 49.1, 46.3; m/z (ESI) 255/257 ([M + H]
+
, 70/100).  
1-methyl-4-(4-(pyridin-3-yl)phenyl)piperazine (272)  
 
Subjecting compound 291 to general procedure 3, the crude residue was obtained and 
purified by flash chromatography on silica eluting with hexane-ethyl acetate (2:1) to 
give piperazine 272 (0.048 g, 63%) as a colourless solid; mp 110–111 °C; νmax/cm-1 
2939, 2843, 2799, 1609, 1525, 1477, 1450, 1291, 1243, 1161, 1147, 1006, 919, 826; 
δH (400 MHz, CDCl3) 8.82 (1 H, dd, J 0.8, 2.4 Hz), 8.51 (1 H, dd, J 1.6, 4.8 Hz), 
7.82 (1 H, ddd, J 1.6, 2.4, 7.9 Hz), 7.50 (2 H, d, J 9.2 Hz), 7.31 (1 H, dd, J 4.8, 5.6 
Hz), 7.01 (2 H, d, J 9.2 Hz), 3.28 (4 H, t, J 5.2 Hz), 2.59 (4 H, t, J 5.2 Hz), 2.36 (3 H, 
s); δC (100 MHz, CDCl3) 151.2, 148.0, 147.7, 136.5, 133.7, 128.6, 127.9, 123.6, 
116.2, 55.2, 48.8, 46.3; m/z (ESI) 254 ([M + H]
+
, 100); Found MH
+
 254.16540 
C16H19N3 + H requires 254.16572. 
1-([1,1'-biphenyl]-4-yl)-4-methylpiperazine (273)  
 
Subjecting compound 291 to general procedure 3 using phenylboronic acid, the 
crude residue was obtained and purified by flash chromatography on silica eluting 
with hexane-ethyl acetate (2:1) to give piperazine 273 (0.055 g, 74%) as a colourless 
solid; mp 113–114 °C; νmax/cm-1 2940, 2846, 2837, 2791, 1735, 1607, 1527, 1491, 
1292, 1243, 1163, 1008, 921, 821; δH (400 MHz, CDCl3) 7.48 (2 H, d, J 8.8 Hz), 
7.44 (2 H, d, J 7.2 Hz), 7.32 (2 H, t, J 7.2 Hz), 7.20 (1 H, d, J 7.2 Hz), 6.92 (2 H, d, J 
8.8 Hz), 3.20 (4 H, t, J 5.2 Hz), 2.53 (4 H, t, J 5.2 Hz), 2.29 (3 H, s); δC (100 MHz, 
CDCl3) 150.7, 141.1, 132.4, 128.8, 127.9, 126.7, 126.6, 116.2, 55.3, 49.0, 46.3; m/z 
(ESI) 253 ([M + H]
+
, 100); Found MH
+
 253.17017 C17H20N2 + H requires 
253.17047. 
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(1S, 4S)-tert-Butyl 5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate (292)  
 
A solution of tris(dibenzylideneacetone)dipalladium(0) (0.034 g, 0.037 mmol) and 
(±)-BINAP (0.046 g, 0.074 mmol) in toluene (10 mL) was degassed with argon for 
10 min and then heated at 110 °C for 15 min. The reaction mixture was allowed to 
cool to room temperature before potassium tert-butoxide (0.19 g, 1.71 mmol), 1,4-
dibromobenzene (0.22 g, 0.92 mmol) and 157 (0.2 g, 1.01 mmol) were added. The 
resulting mixture was heated at reflux for 16 h, cooled to room temperature and 
filtered through a pad of Celite
®
, the pad was further washed with toluene (30 mL) 
and the combined filtrates evaporated under reduced pressure to give the crude 
product. Purification by flash chromatography on silica eluting with hexane-ethyl 
acetate (3:1) gave the desired amine 291 (0.27 g, 82%) as a colourless solid; mp 210–
211 °C;     
   −22.0 (0.5, CHCl3); νmax/cm
-1
 3543, 2965, 1693, 1592, 1496, 1406, 
1365, 1167, 1105; δH (400 MHz, CDCl3) 7.29 (2 H, d, J 8.4 Hz), 6.42 (2 H, d, J 8.4 
Hz), 4.62 (0.6 H, s), 4.48 (0.4 H, s), 4.33 (1 H, s), 3.54 (1 H, d, J 8.8 Hz), 3.45 (0.5 
H, d, J 9.6 Hz), 3.39–3.36 (1.5 H, m), 3.16 (0.6 H, d, J 8.8 Hz), 3.07 (0.4 H, d, J 8.4 
Hz), 1.99–1.87 (2 H, m), 1.43 (9 H, m) (mixture of rotamers); δC (100 MHz, CDCl3) 
154.2, 145.9, 132.1, 114.1, 108.6, 108.4, 57.4, 57.3, 57.0, 56.96, 56.47, 51.4, 51.1, 
37.9, 37.4, 28.7, 28.6 (mixture of rotamers); m/z (ESI) 353/355 ([M + H], 61/100); 
Found MH
+
 353.08620, 355.08412 C16H21BrN2O2 + H requires 353.08647, 
355.08647; Found: C, 54.49; H, 6.00; N, 7.55. Calc for C16H21BrN2O2: C, 54.40, H, 
5.99; N, 7.93% 
(1S, 4S)-tert-Butyl 5-(4-(pyridin-3-yl)phenyl)-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate (293) 
 
Subjecting compound 292 to general procedure 3 gave, after purification by flash 
chromatography on silica eluting with hexane-ethylacetate (1:1) compound 293 
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(0.053 g, 52%) as a colourless solid; mp 179–180 °C;     
   −25.0 (1.0, CHCl3); 
νmax/cm-1 2918, 1692, 1609, 1525, 1474, 1402, 1322, 1184, 1166, 1102, 813; δH 
(500 MHz, CDCl3) 8.81 (1 H, s), 8.49 (1 H, d, J 4.5 Hz), 7.81 (1 H, d, J 7.5 Hz), 7.47 
(2 H, t, J 9.0 Hz), 7.30 (1 H, dd, J 4.5, 8.0 Hz), 6.65 (2 H, d, J 8.0 Hz), 4.67 (0.6 H, 
s), 4.52 (0.4 H, s), 4.44 (1 H, s), 3.60 (1 H, m), 3.52 (0.5 H, d, J 10.0 Hz), 3.45–3.39 
(1.5 H, m), 3.27 (0.6 H, d, J 9.0 Hz), 3.18 (0.4 H, d, J 8.5 Hz), 2.01–1.92 (2 H, m), 
1.43 (9 H, m) (mixture of rotamers); δC (125 MHz, CDCl3) 154.2, 147.8, 147.4, 
146.8, 136.6, 133.3, 128.2, 16.0, 125.81, 123.6, 113.0, 79.9, 79.8, 57.4, 57.3, 57.2, 
57.0, 56.8, 56.5, 51.7, 51.3, 37.9, 37.5, 28.7, 28.6 (mixture of rotamers); m/z (ESI) 
352 ([M + H]
+
, 100); Found MH
+
 352.20195 C21H25N3O2 + H requires 352.20250. 
(1S, 4S)-tert-Butyl 5-([1,1'-biphenyl]-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate (294) 
 
Subjecting compound 292 to general procedure 3 using phenylboronic acid gave, 
after purification by flash chromatography on silica eluting with hexane-ethylacetate 
(3:1) compound 294 (0.059 g, 58%) as a colourless solid; mp 156–157 °C;     
   
−20.0 (1.0, CHCl3); νmax/cm
-1 
2950, 1695, 1491, 1405, 1365, 1186, 1167, 1103; δH 
(400 MHz, CDCl3) 7.57 (2 H, d, J 8.0 Hz), 7.51 (2 H, t, J 8.4 Hz), 7.42 (2 H, t, J 8.0 
Hz), 7.28 (1 H, m), 6.66 (2 H, d, J 8.0 Hz), 4.69 (0.6 H, s), 4.53 (0.4 H, s), 4.46 (1 H, 
s), 3.64 (1 H, d, J 8.4 Hz), 3.56 (0.4 H, d, J 9.6 Hz), 3.50–3.40 (1.6 H, m), 3.84 (0.6 
H, d, J 8.4 Hz), 3.20 (0.4 H, d, J 8.8 Hz), 2.04–1.93 (2 H, m), 1.46 (9 H, m) (mixture 
of rotamers); δC (100 MHz, CDCl3) 154.3, 146.3, 129.7, 129.5, 128.8, 128.2, 126.4, 
126.2, 112.9, 112.8, 79.8, 79.7, 57.5, 57.4, 57.2, 57.0, 56.9, 56.5, 51.6, 51.2, 37.9, 
37.5, 28.7, 28.6; m/z (ESI) 373 ([M + Na]
+
, 100); Found MNa
+
 373.18865 
C22H26N2O2 + Na requires 373.18920 
(1S, 4S)-2-Methyl-5-(4-(pyridin-3-yl)phenyl)-2,5-diazabicyclo[2.2.1]heptane 
(274)  
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Subjecting compound 293 to general procedure 5, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9.5:0.5) to give methylated amine 274 (0.03 g, 61% over two steps) as 
a colourless oil;     
   −14.6 (1.0, CHCl3); νmax/cm
-1
2877, 1608, 1525, 1476, 1370; δH 
(400 MHz, CDCl3) 8.81 (1 H, d, J 1.6 Hz), 8.47 (1 H, dd, J 1.2, 4.4 Hz), 7.81 (1 H, 
dt, J 8.0 Hz), 7.46 (2 H, d, J 8.8 Hz), 7.29 (1 H, dd, J 4.8, 7.6 Hz), 6.65 (2 H, d, J 8.8 
Hz), 4.26 (1 H, s), 3.51 (1 H, s), 3.41–3.37 (2 H, m), 2.98 (1 H, dd, J 2.0, 9.6 Hz), 
2.66 (1 H, d, J 9.2 Hz), 2.39 (3 H, s), 2.01 (1 H, d, J 9.2 Hz), 1.91 (1 H, d, J 9.6 Hz); 
δC (100 MHz, CDCl3) 147.7, 147.2, 147.1, 136.8, 133.3, 128.0, 125.4, 123.6, 113.0, 
63.1, 59.0, 58.2, 52.0, 40.7, 36.6; m/z (ESI) 266 ([M + H]
+
, 100); Found: MH
+ 
266.16517 C17H19N3 + H requires 266.16572. 
2-([1,1'-Biphenyl]-4-yl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane (275)  
 
Subjecting compound 293 to general procedure 5, the crude residue was obtained and 
purified by flash chromatography on silica eluting with CH2Cl2-methanol-aqueous 
ammonia (90:9.5:0.5) to give methylated amine 275 (0.02 g, 54% over two steps) as 
a colourless oil;     
   −16.5 (1.0, CHCl3); νmax/cm
-1
 2914, 1609, 1527, 1487, 1365, 
823; δH (500 MHz, CDCl3) 7.54 (2 H, d, J 7.5 Hz), 7.47 (2 H, d, J 8.5 Hz), 7.38 (2 H, 
t, J 8.5 Hz), 7.24 (1 H, t, J 9.0 Hz), 6.63 (2 H, d, J 8.5 Hz), 4.25 (1 H, s), 3.51 (1 H, 
s), 3.42–3.37 (2 H, m), 2.98 (1 H, dd, J 2.0, 9.8 Hz), 2.67 (1 H, d, J 9.5 Hz), 2.39 (3 
H, s), 2.0 (1 H, d, J 9.5 Hz), 1.91 (1 H, d, J 9.5 Hz); δC (125 MHz, CDCl3) 146.5, 
141.4, 129.1, 128.8, 128.0, 126.3, 126.0, 112.9, 63.1, 58.9, 58.2, 51.9, 40.5, 36.7; m/z 
(ESI) 265 ([M + H], 100); Found: MH
+ 
265.16993 C18H20N2 + H requires 265.17047. 
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11.7 The synthesis of compounds from Chapter 9 
11.7.1 The functionalisation of cubane-1,4-dicarboxylate  
4-Methoxycarbonylcubane carboxylic acid (332)
445
  
 
To a solution of dimethyl 1,4-cubanedicarboxylate (313) (5.0 g, 22.7 mmol) in THF 
(150 mL) at rt was added a solution of methanolic sodium hydroxide (9.1 mL, 22.7 
mmol). The mixture was stirred for 16 h and then concentrated in vacuo. The residue 
was dissolved in H2O (100 mL) and washed with CHCl3 (3 × 50 mL). The aqueous 
layer was acidified to pH 2 with slow addition of conc. hydrochloric acid (ca. 4 mL), 
followed by extraction with CHCl3 (3 × 50 mL). The combined organic extracts were 
dried (MgSO4), filtered and evaporated under reduced pressure to yield the ester-acid 
332 (3.85 g, 82%) as a colourless solid; mp 184–186 °C (lit. mp 182–183 °C); 
νmax/cm
-1
 3001, 1685, 1281, 1239, 830, 727; δH (200 MHz, CDCl3) 4.28 (6 H, m), 
3.72 (3 H, s) δC (75 MHz, CDCl3) 175.1, 173.4, 57.7, 57.2, 52.0, 48.1, 47.9;  
4-Iodocubane-1-carboxylic acid (334)
445
  
 
To a suspension of 4-methoxycarbonylcubane carboxylic acid (332) (3.85 g, 18.7 
mmol) in toluene (300 mL) at rt were added iodobenzene diacetate (18.04 g, 56.0 
mmol) and iodine (14.2 g, 56.0 mmol) and the reaction mixture was then heated at 
reflux for 16 h. Pentane (100 mL) was then added and solution was washed 
successively with saturated aqueous sodium sulfite (100 mL), H2O (100 mL) and 
brine (100 mL). The organic layer was dried (MgSO4), filtered and evaporated to 
near dryness to give an orange/brown liquid, which was dissolved in THF (100 mL). 
A solution of NaOH (0.77 g, 19.2 mmol) in MeOH (75 mL) and H2O (25 mL) was 
added and the mixture was stirred at rt for 16 h. The solvent was evaporated in vacuo 
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and the residue was dissolved in H2O (30 mL) and acidified to pH 1 with dropwise 
addition of conc. Hydrochloric acid (ca. 4 mL). The precipitate was collected and 
dried in a dessicator over sodium hydroxide for 2 days to give the acid 334 (4.40 g, 
86 % over 2 steps) as a grey solid; mp 172–175 °C (lit. mp 174–178 °C); νmax/cm
-1
 
2989, 1688, 1630, 1452, 1292, 1235, 1196, 1031, 828, 798; δH (200 MHz, CDCl3) 
4.37 (3 H, m), 4.28 (3 H, m); δC (75 MHz, CDCl3) 174.7, 57.6, 56.1, 51.1, 37.2;  
Cubane-1-carboxylic acid (331)
445
 
 
To a solution of 4-iodocubane carboxylic acid (334) (0.55 g, 2.0 mmol) in THF (200 
mL) at -78 °C was added a solution of n-BuLi in hexanes (4.5 mL, 1.3 M, 6.0 
mmol.). The mixture was allowed to stir for 30 min, maintaining the temperature at -
78 °C before cold MeOH (30 mL) was added dropwise. The mixture was allowed to 
warm to rt and hexane (50 mL) was added, followed by extraction with H2O (3 × 50 
mL). The combined aqueous layers were acidified to pH 1 with conc. hydrochloric 
acid, followed by extraction with CHCl3 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated to dryness to give cubane carboxylic 
acid 331 (0.27 g, 91%) as a light brown solid; mp 121–122 °C (lit. mp 124–125 °C); 
νmax/cm
-1
 3002, 1685, 1276, 1239, 842; δH (200 MHz, CDCl3) 4.27 (3 H, m), 4.01 (4 
H, m); δC (75 MHz, CDCl3) 117.5, 55.3, 49.5, 47.8, 45.1. 
Cubane-1-carboxylate (336)
447
 
 
Carboxylic acid 332 (1.0 g, 4.9 mmol) was suspended in chloroform (25 mL), and 
treated with oxalyl chloride (500 µL, 5.8 mmol) and one drop of DMF and the 
reaction was stirred at rt for 3 h. The crude reaction mixture was then added 
dropwise to a solution of 1-hydroxypyridine-2(1H) thione, Na salt (1.1 g, 7.3 mmol) 
and 4-N,N-dimethylaminopyridine (59 mg, 0.5 mmol) in chloroform (25 mL). The 
resulting mixture was then irradiated to reflux with a tungsten lamp; the reaction 
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mixture took on a bright yellow appearance and CO2 evolution became evident. After 
45 min the bright yellow colouration had faded and heating and irradiation was then 
discontinued. The solvent was removed in vacuo and the resulting residue partitioned 
between diethyl ether (100 mL) and aqueous hydrochloric acid (1M, 50 mL). The 
organic layer was then further washed with aqueous hydrochloric acid (2 × 20 mL) 
and brine (50 mL), dried (MgSO4), filtered and the solvent removed under reduced 
pressure. Purification by flash chromatography on silica eluting with hexane/ethyl 
acetate (9:1) to yield the desired mono-ester 336 (0.6 g, 80%) as a colourless solid; 
mp 137.8–139.2 °C; νmax/m
-1
 2623, 1847, 1729, 1693, 1508, 1282, 1134, 974, 583 
cm
-1; δH (300 MHz, CDCl3) 4.24 (3 H, m), 3.99 (4 H, m), 3.67 (3H, s);
 δC (75 MHz, 
CDCl3) 172.9, 55.8, 51.5, 49.6, 48.0, 45.3; m/z (APCI) 163 ([M + H]
+
, 100). 
Cubane-1-carboxylic acid (331)
445
  
 
To a solution of cubane-1-carboxylate (336) (0.5 g, 3.3 mmol) in methanol (33 mL) 
was added sodium hydroxide (0.2 g, 5.0 mmol) and the resulting mixture heated at 
reflux for 1.5 h. The solvent was then removed in vacuo, taking care not to evaporate 
the carboxylate to dryness, and the residue partitioned between CH2Cl2 (100 mL) and 
H2O (70 mL). The aqueous layer was further extracted with CH2Cl2 (50 mL) and 
then the aqueous layer acidied to pH 2 with the addition of concentrated hydrochloric 
acid (ca. 2 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 50 mL) and 
the organic extracts combined, dried (MgSO4), filtered and the solvent removed 
under reduced pressure to give carboxylic acid 331 (0.4 g, 76%) as a light brown 
solid; mp 121–122 °C (lit. mp 124–125 °C); νmax/cm
-1
 3002, 1685, 1276, 1239, 842; 
δH (200 MHz, CDCl3) 4.27 (3 H, m), 4.01 (4 H, m); δC (75 MHz, CDCl3) 117.5, 
55.3, 49.5, 47.8, 45.1. 
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11.7.2 The synthesis of amine 302 
Cubane-1-tert-butylcarbamate (344) 
 
Cubane-1-carboxylic acid (331) (0.12 g, 0.81 mmol) was dissolved in neat oxalyl 
chloride (2 mL) and stirred at ambient temperature for 1 h. The excess oxalyl 
chloride was removed and the oily residue dissolved in anhydrous THF (10 mL), 
cooled to 0 °C and treated with azidotrimethylsilane (0.21 mL, 1.62 mmol) and 
tetrabutylammonium fluoride in THF (1.0M, 1.62 mL, 1.62 mmol). The resulting 
reaction mixture was then stirred for 1 h, maintaining the temperature at 0 °C. The 
solvent was then removed in vacuo and the residue partitioned between H2O (50 mL) 
and CHCl3 (100 mL). The aqueous layer was further extracted with CHCl3 (50 mL) 
and the organic extracts combined, dried (MgSO4), filtered and solvent removed in 
vacuo. The crude azide was then further dried in vacuo and then suspended in 
anhydrous t-BuOH (10 mL) and heated at 60 °C for 16 h. The solvent was then 
removed in vacuo and the residue partitioned between H2O (50 mL) and CHCl3 (75 
mL). The aqueous layer was further extracted with CHCl3 (50 mL) and the organic 
extracts combined, dried (MgSO4) and solvent removed in vacuo. The crude product 
was then purified by flash chromatography on silica eluting with hexane-ethyl 
acetate (8:1) to give the desired amine 344 (0.065 g, 42% over 3 steps) as a light 
brown solid; mp 148–149 °C; νmax/cm
-1
 3244, 2978, 1716, 1390, 1364, 1335, 1214, 
1167, 1067, 775; δH (300 MHz, CDCl3) 5.08 (1H, br s, NH), 4.03 (3 H, m), 3.91 (4 
H, m), 1.43 (9 H, s); δC (75 MHz, CDCl3) 155.23, 79.51, 66.27, 52.63, 48.10, 42.40, 
28.36; m/z (ESI) 242 ([M + Na]
+
, 100); Found: M + Na 242.11515. C13H17NO2 + Na 
requires 242.11570. 
Cuban-1-amine hydrochloride (302) 
 
The carbamate 344 (0.063 g, 0.29 mmol) was dissolved in methanol (5 mL) and 
treated with hydrogen chloride in dioxane (2 mL). The resulting mixture was stirred 
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at ambient temperature for 30 min; the solvent was then removed to give the amine 
hydrochloride salt 302. Recrystallisation (diethyl ether:methanol) gave amine 302 
(0.042 g, 99%); νmax/cm
-1
 3018, 2910, 2864, 1601, 1235, 887; δH (300 MHz, 
CD3OD) 4.21 (3 H, m), 4.03 (4 H, m), NH protons not observed; δC (75 MHz, 
CD3OD) 66.0, 51.7, 49.7, 44.2; m/z (+ESI) 120 ([M - Cl]
+, 100); Found: M−Cl 
120.08129. C8H10N requires 120.08132. 
11.7.3 The Synthesis of amine 303 
1-Cubanemethylamine (303)
495
  
 
The acid 331 (0.26 g, 1.8 mmol) was dissolved in oxalyl chloride (ca. 2 mL) and 
stirred for 45 min at rt. Excess oxalyl chloride was removed under reduced pressure 
and the residue dissolved in CH2Cl2 (20 mL) in a three-neck round bottom flask fitted 
with a cold finger filled with dry ice and acetone. NH3 gas was condensed into the 
flask (ca. 3 mL) and the resulting suspension was stirred for 40 min. This mixture 
was then allowed to warm to RT and excess NH3 was evaporated under a stream of 
nitrogen. H2O (40 mL) was added, followed by extraction with CHCl3 (1 × 50 mL, 2 
× 30 mL). Combined organic extracts were dried (MgSO4), filtered and evaporated in 
vacuo to give 1-cubanecarboxamide (0.20 g) as a white solid. To a suspension of 
powdered LiAlH4 (0.4 g, 9 mmol, 2.8 equiv.) in THF (35 mL) was added a solution 
of crude cubanecarboxamide (0.20 g) in THF (3 mL) at 0 °C dropwise and the 
mixture was allowed to warm to RT before heating at reflux for 16 h. After cooling 
to 0 °C, excess LiAlH4 was quenched by the addition of sodium sulphate decahydrate 
(ca. 1 g), after which the mixture was stirred at RT for 1 h. The granular precipitate 
was then filtered off and resuspended in THF (ca. 20 mL) and heated with stirring 
for 30 min. The precipitate was then filtered off and the combined organic extracts 
were dried (MgSO4), filtered and evaporated under reduced pressure. The crude 
product was purified by flash chromatography on silica flash eluting with, CH2Cl2-
methanol-aqueous ammonia (90:9:1) to yield the amine 303 (0.1 g, 53% over three 
steps) as a light brown oil; νmax/cm
-1
 3021, 2923, 2845, 1601, 1203, 887; δH (200 
MHz, CDCl3) 4.03 (1 H, m), 3.85 (6 H, m), 2.83 (2 H, s); δC (75 MHz, CDCl3) 59.7, 
48.8, 46.8, 44.3, 44.1; m/z (+ESI) 134 ([M + H]
+
, 100)  
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11.7.4 The synthesis of amine 304 
Cubanylethanone (348) 
 
A solution of carboxylic acid 26 (0.1 g, 0.68 mmol) in anhydrous THF (13.5 mL) 
was cooled to -78 °C and treated with a solution of methyl lithium in diethyl ether 
(1.6 M, 1.27 mL, 2.03 mmol). The reaction mixture was allowed to warm to rt and 
stirred for an hour before cooling to 0 °C and quenching with H2O (3 mL). The 
solvent was then removed in vacuo and the residue partitioned between H2O (50 mL) 
and CHCl3 (100 mL). The aqueous layer was further extracted with CHCl3 (50 mL) 
and the organic extracts combined, dried (MgSO4), filtered and solvent removed in 
vacuo. The crude residue was purified by flash chromatography on silicia eluting 
with hexane-ethyl acetate (8:1) to afford the desired ketone 41 (0.063 g, 64 %) as a 
colourless solid; mp 138–140 °C; νmax/m
-1
 2987, 2864, 1750, 1623, 1348, 1290; δH 
(300 MHz, CDCl3) 4.29 (3 H, m), 4.00 (4 H, m), 2.12 (3 H, s); δC (75 MHz, CDCl3) 
206.78, 63.73, 49.68, 48.33, 44.82, 24.73. 
Cubanylethanone oxime (353) 
 
The ketone 348 (0.058 g, 0.40 mmol) was dissolved in anhydrous CH2Cl2 and 
triethylamine (0.083 mL, 0.60 mmol) and hydroxylamine hydrochloride (0.041 g, 
0.60 mmol) added and the mixture heated at reflux for 16 h. The reaction mixture 
was then allowed to cool to rt and concentrated in vacuo. The residue was partitioned 
between H2O (30 mL) and CHCl3 (30 mL) and the aqueous phase further extracted 
with CHCl3 (20 mL). The combined organic extracts were then washed with 
saturated aqueous ammonium chloride (30 mL) and brine (30 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude product was purified by 
flash chromatography on silica eluting with hexane-ethyl acetate (6:1) to yield oxime 
353 (0.037 g, 57%) as a colourless solid; mp 157–158 °C; νmax/m
-1
 3448, 3103, 1707, 
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1340, 1260; δH (300 MHz, CDCl3) 4.12 (3 H, m), 3.96 (4 H, m), 1.85 (3 H, s); δC (75 
MHz, CDCl3) 157,36, 59.23, 51.51, 48.91, 44.59, 9.55; m/z (ESI) 200 ([M + K], 
100). 
Cuban-1-yl ethanamine (303)  
 
via reductive amination 
A mixture of ketone 348 (0.059 g, 0.40 mmol), ammonium acetate (0.31 g, 4.0 
mmol) and sodium cyanoborohydride (0.03 g, 0.46 mmol) in MeOH (2.0 mL) was 
stirred at ambient temperature for 18 h. The pH was then adjusted to 2 with addition 
of conc. Hydrochloric acid (ca. 1 mL), the solvent was then removed under reduced 
pressure and the residue taken up in aqueous NaOH (3M, 15 mL) and extracted with 
CHCl3 (3 × 20 mL). The combined organic extracts were then extracted with 
aqueous hydrochloric acid (2M, 3 × 15 mL). The aqueous phase was then made 
basified to pH 14 by addition of aqueous sodium hydroxide (3M, 25 mL) and 
extracted with CHCl3 (3 × 50 mL), the combined organic extracts were dried 
(MgSO4) and the solvent removed in vacuo to give the desired amine 304 (0.018 g, 
31%) as a yellow oil; 
via oxime reduction 
Lithium aluminium hydride (0.052 g, 1.38 mmol) and nickel(II) chloride (0.18 g, 
1.38 mmol) was suspended in diethyl ether (10 mL) at 0 °C. A solution of oxime 353 
(0.037 g, 0.23 mmol) in diethyl ether (5 mL) was then added dropwise and the 
resulting mixture allowed to stir at ambient temperature for 16 h. The brown/green 
mixture was then cooled to 0 °C and quenched with the slow addition of sodium 
sulphite decahydrate (1.0 g). The mixture was then allowed to warm to rt and stirred 
vigorously for 1 h. The inorganic precipitate was filtered over a pad of celite
®
 and 
washed with methanol (50 mL). The solvent was then removed in vacuo and the 
residue taken up in H2O (40 mL) and extracted with CHCl3 (3 × 50 mL). The 
combined organic extracts were dried (MgSO4), filtered and the solvent removed 
under reduced pressure to give the crude product. Purification by flash column 
Chapter 11 Experimental 
 
283 
 
chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (90:9:1) 
gave the desired amine 303 (0.005 g, 15%) as a yellow oil 
νmax/cm
-1
 3008, 2922, 2794, 1686, 1299, 1117, 890, 504 cm
-1
; δH (300 MHz, CDCl3) 
4.03 (1 H, m), 3.84 (6 H, m), 3.01 (1 H, q, J  6.3 Hz), 0.97 (3 H, d, J 6.3 Hz);
 δC (75 
MHz, CDCl3) 63.19, 48.89, 47.75, 46.04, 43.87, 16.89; m/z (+ESI) 148 ([M + H]
+
, 
100). 
11.7.5 The synthesis of amine 304 via a protecting group strategy 
General procedure for synthesis of cuban-1-ylethanamines 
The ketone (348) (1 equiv) was dissolved in 1,2-dichloroethane (0.28 M) and treated 
with glacial acetic acid (1 equiv) and the appropriate benzyl amine (1.05 equiv). 
Sodium triacetoxy borohydride (1.4 equiv) was added and the reaction mixture 
stirred at ambient temperature for 16 h. The reaction was quenched with the addition 
of saturated aqueous sodium hydrogen carbonate. CH2Cl2 was added and the organic 
phased sequentially washed with saturated aqueous sodium hydrogen carbonate, H2O 
and brine. The organic layer was then dried (MgSO4), filtered and the solvent 
removed under reduced pressure to give the crude amine. 
N-benzyl-cuban-1-ylethananamine (350) 
 
Following the general procedure the crude product was obtained and purified by 
flash chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (95: 
4.5: 0.5) to yield the desired amine 350 (0.042 g, 86%) as a pale yellow oil; νmax/m
-1
 
2971, 1494, 1452, 1369, 1216, 1147; δH (300 MHz, CDCl3) 7.25 (5 H, m), 3.96 (1 H, 
m), 3.81 (6 H, m), 3.72 (2 H, s), 2.83 (1 H, q, J 9.6 Hz), 0.96 (3 H, d, J 9.5 Hz);
 δC 
(75 MHz, CDCl3) 141.13, 128.45, 128.14, 126.87, 62,51, 52.91, 51.60, 48.52, 46.90, 
44.27, 13.92; m/z (+ESI) 238 ([M + H]
+
, 100); Found: MH
+
 238.15989. C17H19N + H 
requires 238.15957. 
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Cuban-1-yl-N-(4-methoxybenzyl)ethanamine (351) 
 
Following the general procedure the crude product was obtained and purified by 
flash chromatography on silica eluting with CH2Cl2-methanol-aqueous ammonia (95: 
4.5: 0.5) to yield the desired amine 351 (0.039 g, 78%) as a yellow oil; νmax/m
-1
 2698, 
1611, 1509, 1462, 1242, 1172, 1034, 818 cm
-1
; δH (300 MHz, CDCl3) 7.25 (2 H, d, J 
8.4 Hz), 6.87 (2 H, d, J 8.4 Hz), 4.02 (1 H, m), 3.87 (6 H, m), 3.81 (3 H, s), 3.70 (2 
H, s), 2.87 (1 H, q, J 6.3 Hz), 1. (3 H, d, J 6.3 Hz);
 δC (75 MHz, CDCl3) 158.7, 133.3, 
129.3, 113.9, 62.5, 55.4, 52.8, 51.0, 48.5, 46.9, 44.3, 13.9; m/z (+ESI) 267 ([M + H]
+
, 
100); Found: MH
+
 268.16959. C18H21NO + H requires 268.17014 
Cuban-1-yl-N-(2,4-dimethoxybenzyl)ethanamine (352) 
 
Following the general procedure the crude product was obtained and purified by 
flash chromatography (90: 9: 1, CH2Cl2: MeOH: NH3) to yield the desired amine 352 
(0.038 g, 93%) as a yellow oil; νmax/m
-1
 2965, 1612, 1504, 1285, 1205, 1034, 832, 
473 cm
-1
; δH (300 MHz, CDCl3) 7.11 (1 H, d, J 8.1 Hz), 6.43 (3 H, m), 4.00 (1 H, m, 
cubane proton), 3.84 (6 H, m), 3.80 (3 H, s), 3.78 (3 H, s), 3.67 (2 H, s), 2.75 (1 H, q, 
J 6.3 Hz), 0.97 (3 H, d, J 6.30 Hz);
 δC (75 MHz, CDCl3) 160.1, 158.9, 130.6, 121.2, 
103.8, 98.7, 62.5, 55.5, 55.3, 52.4, 48.5, 46.8, 44.3, 13.6; m/z (+ESI) 320 ([M + Na]
+
, 
90); Found: MH
+
 298.18109. C19H23NO2 + H requires 298.18070. 
11.7.6 The Synthesis of amine 305 via the tosylate precursor 
Cubylcarbinol (356)
445
  
 
Carboxylic acid 331 (0.25 g, 1.69 mmol) was suspended in anhydrous THF (26 mL) 
and cooled to 0 °C. Borane dimethylsulfide (1.4 mL, 2.8 mmol) was added and the 
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mixture was stirred for 20 min, maintaining the temperature at 0 °C. The solution 
was allowed to warm to ambient temperature and then stirred for an additional 2 h. 
The reaction was then quenched with H2O (5 mL) and stirred at ambient temperature 
for 16 h. Ethyl acetate (50 mL) was added and then organic layer washed with H2O 
(2 × 20 mL), brine (20 mL), dried (MgSO4), filtered and the solvent removed under 
reduced pressure to give the crude product. Purification by flash chromatography on 
silica eluting with hexane-ethyl acetate (3:1) afforded the alcohol (356) (0.20 g, 
90%) as a colourless solid; mp 62.8–64.0 °C (lit mp 62–62.5 °C); νmax/m
-1
 3340, 
2970; δH (300 MHz, CDCl3) 4.20 (1 H, m), 3.90 (6 H, m), 3.69 (2 H, s); δC (75 MHz, 
CDCl3) 63.9, 58.7, 48.9, 47.8, 44.5; m/z (+ESI) 157 ([M + Na]
+
, 100).  
Cuban-1-ylmethyl 4-methylbenzenesulfonate (355)  
 
Alcohol 356 (0.18 g, 1.43 mmol) was dissolved in CH2Cl2 (10 mL) and treated with 
p-toluenesulfonyl chloride (0.41 g, 2.14 mmol) and pyridine (0.23 mL, 2.85 mmol). 
The mixture was then stirred at ambient temperature for 2 d followed by the addition 
of CHCl3 (30 mL) and H2O (30 mL). The organic layer was then washed 
successively with aqueous hydrochloric acid (2M, 20 mL), saturated aqueous sodium 
hydrogen carbonate (20 mL) and H2O (20 mL). The organic phase was then dried 
(MgSO4), filtered and the solvent removed in vacuo to give the crude residue which 
was purified by flash chromatography on silica eluting with hexane-ethyl acetate 
(8:1) to yield the cubane tosylate 355 (0.31 g, 75%) as a colourless solid; mp 152–
153 °C; νmax/m
-1
 2988, 1357. 1237, 1168, 1122, 1037, 996, 665, 573, 496 cm
-1
; δH 
(300 MHz, CDCl3) 7.81 (2 H, d, J 8.10 Hz), 7.32 (2 H, d, J 8.10 Hz), 3.50 (2 H, m), 
3.37 (2 H, m), 3.29 (1 H, m), 3.11 (2 H, m), 2.44 (3 H, s, CH3), 2.06 (2 H, s, CH2);
 δC 
(75 MHz, CDCl3) 144.4, 135.7, 129.8, 127.7, 98.1, 46.9, 46.1, 44.0, 42.2, 40.5, 39.6, 
21.7; m/z (+ESI) 289 ([M + H]
+
, 100); Found: MH
+
 289.09011. C16H16O3S + H 
requires 289.08984. 
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11.7.7 The Synthesis of amine 305 via the Kowalski Homologation 
α,α-dibromo-1-cuban-1-ylethanone (358)  
 
The methyl ester 336 (0.39 g, 2.38 mmol) was dissolved in THF (9.5 mL) and treated 
with dibromomethane (0.42 mL, 5.96 mmol) and cooled to -78 °C. In a separate 
flask, a solution of 2,2,6,6-tetramethylpiperidine (1.1 mL, 6.44 mmol) was cooled to 
-78 °C and treatment n-BuLi (4.29 mL, 1.33 M in hexane, 5.72 mmol). The solution 
of lithium 2,2,6,6-tetramethylpiperidine was immediately added dropwise to the ester 
solution, the reaction mixture was then stirred for a further 30 min, maintaining the 
temperature at -78 °C. The reaction mixture was then added with caution to aqueous 
hydrochloric acid (2 M, 25 mL) and extracted with hexane (3 × 30 mL). The 
combined organic layers were washed with H2O (50 mL), dried (MgSO4), filtered 
and the solvent removed in vacuo. The crude residue was then purified by flash 
chromatography on silica eluting with hexane-ethyl acetate (98:2) to yield the desired 
dibromoketone 358 (0.43 g, 60%) as a yellow oil: νmax/m
-1
 2984, 1680, 1299, 1217, 
1145, 1026, 842, 730, 648, 456 cm
-1
 δH (300 MHz, CDCl3) 5.87 (1H, s, CH), 4.44 
(3H, m), 4.05 (4H, m);
 δC (75 MHz, CDCl3) 193.8, 60.4, 51.9, 47.2, 45.3, 40.7. 
Cuban-1-yl)acetic acid (357)  
 
The dibromoketone 358 (0.43 g, 1.42 mmol) was dissolved in anhydrous THF (6.2 
mL) and cooled to -78 °C. A solution of freshly made lithium hexamethyldisilazide 
(1.5 mL, 1.0 M in THF, 1.5 mmol) was added dropwise to the dibromoketone 
solution and resulting mixture allowed to stir for a further 20 min, maintaining the 
temperature at -78 °C. n-BuLi (2.14 mL, 1.45 M in hexane, 3.11 mmol) was then 
added and stirring continued for a further 30 min. The reaction mixture was then 
slowly quenched in a stirred solution of acidic ethanol (24 mL, 1:5 v/v acetyl 
chloride/ethanol, pre-stirred at ambient temperature for 20 min) at 0 °C over 5 min. 
Diethyl ether (50 mL) was then added and the mixture washed with aqueous 
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hydrochloric acid (2 M, 40 mL). The aqueous layer was further extracted with 
diethyl ether (30 mL) and the combined organic layers were dried (MgSO4), filtered 
and the solvent removed under reduced pressure. Unfortunately, the two products 
could not be separated by flash chromatography on silica eluting with hexane-ethyl 
acetate (98:2).  
The mixture (0.17 g) was suspended in THF/H2O (30 mL, 3:1), treated with lithium 
hydroxide (0.15 g, 6.3 mmol) and then heated at reflux for 12 h. After cooling to 
ambient temperature, the mixture was concentrated in vacuo with care being taken 
not to evaporate the crude carboxylate to dryness. H2O (30 mL) was added and the 
unreacted ester extracted with CHCl3 (3 × 30 mL). The aqueous layer was then 
acidified to pH 1 with the addition of conc. hydrochloric acid (ca. 4 mL) and the 
aqueous layer extracted with CHCl3 (3 × 40 mL). The combined organic extracts 
were then dried (MgSO4), filtered and the solvent removed under reduced pressure to 
give the desired homologated acid 357 (0.12g, 53 %) as a tan coloured solid: mp 
135–137 °C; νmax/m
-1
 2981, 1692, 1424, 1306, 1245, 1214, 926, 844, 695; δH (300 
MHz, CDCl3) 4.01 (1 H, m), 3.87 (6 H, m), 2.66 (2 H, s); δC (75 MHz, CDCl3) 178.2, 
54.2, 49.1, 48.6, 44.5, 38.4; m/z (+ ESI) 161 ([M + H]
+
, 100).  
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11.8 General biological details  
11.8.1 Binding affinity studies of α7 ligands 
Tissue culture medium and antibiotics were obtained from Invitrogen Corp 
(Carlsbad, California). Foetal bovine serum was purchased from Gemini Bio-
products (West Sacramento, California). [
3
H]±EB was obtained from PerkinElmer 
Life and Analytical Sciences (Boston, Massachusetts). Three cell lines, KXα3β4R2, 
KXα4β2R2 and KXα7R1, which express defined rat nAChR subtypes, were 
established previously by stably transfecting HEK293 cells with rat nAChR subunit 
genes.
496-499
  
These cell lines were maintained in minimum essential medium (MEM) 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin G, 100 mg/mL 
streptomycin and selective antibiotics at 37 °C with 5% CO2 in a humidified 
incubator. Membrane preparation procedures and binding assays were described 
previously.
496-499
 Briefly, cultured cells at >80% confluence were removed from their 
flasks (80 cm
2
) with a disposable cell scraper and placed in 10 mL of 50 mM 
Tris
.
HCl buffer (pH 7.4, 4 °C). The cell suspension was centrifuged at 10,000 x g for 
5 min and the pellet was collected. The cell pellet was then homogenised in 10 mL 
buffer with a polytron homogenizer and centrifuged at 36,000 g for 10 min at 4 °C. 
The membrane pellet was resuspended in fresh buffer, and aliquots of the membrane 
preparation were used for binding assays. The concentrations of [
3
H]EB used in 
competition binding assays were ~500 pM for α3β4 and α4β2 nAChRs and ~2 nM for 
α7 nAChRs. Nonspecific binding was assessed in parallel incubations in the presence 
of 300 µM nicotine. Bound and free ligands were separated by vacuum filtration 
through Whatman GF/C filters treated with 0.5% polyethylenimine. The filter-
retained radioactivity was measured by liquid scintillation counting. Specific binding 
was defined as the difference between total binding and nonspecific binding. Data 
from competition binding assays were analyzed using Prism 5.  
11.8.2 Functional activity studies of α7 ligands from Chapter 2  
Whole-cell two-electrode voltage clamp (TEVC) recordings were performed on 
Xenopus laevis oocytes expressing cloned rat wildtype (WT) α7 receptors as 
previously described.
500
 Oocytes were bathed in a small volume (150 µL) oocyte 
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bath and viewed with a dissection microscope. Bath solution for whole-cell oocyte 
recordings was 96 mM NaCl, 4 mM KCl, 0.7 mM MgCl2, 1 mM CaCl2, and 10 mM 
HEPES, pH 7.4. The resistance of the TEVC pipettes ranged from 0.2 to 2 MΩ and 
were filled with 3 M KCl. Experiments were performed 24 to 48 h after mRNA 
injection. Cells were held at –60 mV and drugs were administered extracellularly at 
the required concentrations. All responses were standardised to the maximal ACh 
concentration (3 mM). Compounds were tested at concentrations of 0.3, 1, 3 and 10 
µM (n=3). Fluo4 Direct Dye from Molecular Probes was used and the assay was 
performed on a Perkin Elmer CellLux high throughput fluorescent reader. A baseline 
read was recorded prior to addition of compound. Peak/Base ratios were calculated to 
show activity. Peak/Base values >1.00 were indicative of agonist activity. 
11.8.3 Functional activity studies of α7 ligands from Chapter 3 and 
Chapter 7 
All compounds were tested for agonist activity on the α7 nAChR in a fluorescent 
calcium assay using a GH4C1 cells stably expressing rat 7 nAChR. To determine 
EC50 values, all compounds were tested at 0.03, 0.1, 0.3, 1, 3 and 10µM (n=3) except 
for compound 139 which was tested (n=3) at 0.001–0.3µM. Fluo4 Direct Dye from 
Molecular Probes was used and the assay was performed on a Perkin Elmer CellLux 
high throughput fluorescent plate reader. A baseline read was recorded prior to 
addition of compound. Peak/Base (P/B) ratios were calculated. Values >1.00 indicate 
agonist activity. GraphPad Prism, Version 4.03 was used to produce dose response 
curves for each compound and calculate the EC50 for agonist activity at rat α7 
nAChR. 
11.8.4 BBB permeability studies of cubylamines 302–305 
All animal experiments were approved by Monash University Animal Ethics 
Committee and were performed in accordance with the Australian National Health 
and Medical Research Council guidelines for the care and use of animals for 
scientific purposes. Male Swiss Outbred mice (6−8 weeks of age) were obtained 
from the Monash University animal breeding facility and were maintained on a 12 
h:12 h light:dark cycle with free access to food and water. Mice were administered a 
100 μL aqueous solution of amine 302, 303 or 304 in sterile saline by oral gavage at 
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nominal doses of 3 or 10 mg/kg body weight (free base equivalence) as summarised 
in Table 42.  
Table 42.  Concentrations of amines 302 ,  303  and 304  in IV dosing solutions.  
Compound Sample number Concentration (mg/mL) 
302 
1 1.6 
2 1.6 
3 1.6 
303 
1 1.3 
2 1.4 
3 1.3 
304 
1 1.6 
2 1.8 
3 1.8 
 
Blood and brain samples were then obtained at 0.25, 0.5, 1, 2, 4, 6, and 8 h (n= 5 
mice at each time point) from individual animals under anaesthesia (intraperitoneal 
injection of ketamine and xylazine (133 mg/kg and 10 mg/kg, respectively). 
Approximately 500 μL of blood was withdrawn by cardiac puncture and transferred 
to Eppendorf tubes containing 10 μL of heparin. Blood samples were immediately 
centrifuged to obtain 50 μL plasma samples, which were stored at −20 °C until 
analysis. Immediately following blood collection, the whole brain (excluding the 
brainstem and cerebellum) was removed, placed into preweighed polypropylene vials 
and stored at −20 °C until analysis. In separate mice, the microvascular plasma 
volume was determined such that the amount of amines 302, 303 or 304 remaining in 
the microvasculature could be subtracted from the brain homogenate concentration. 
To determine this microvascular volume, 50 μL of the nonabsorbable marker 14C-
inulin (0.04 μCi/μL in saline) was administered to mice (n= 8) by tail vein injection, 
and brain and blood samples were collected 5 min postdose. A 50 μL aliquot of 
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plasma supernatant was removed and placed into 6 mL polyethylene scintillation 
vials. Two milliliters of Ultima Gold scintillation cocktail was added to each of the 
vials, which were then briefly vortexed and analysed for radioactivity by liquid 
scintillation counting using a Tri-Carb 2800TR liquid scintillation analyzer (Perkin-
Elmer, Boston, MA). The whole brain was placed into preweighed 20 mL 
polyethylene scintillation vials, and 2 mL of Solvable was added to each of the vials, 
which were maintained at 50 °C overnight to ensure total tissue solubilization. To 
remove color that formed during the overnight tissue solubilization, 200 μL of 30% 
v/v hydrogen peroxide was added to each vial, after which vials were maintained at 
50 °C for a further 30 min. 10 mL of Ultima Gold scintillation cocktail was added to 
each of the vials, which were then briefly vortexed and analysed for radioactivity by 
liquid scintillation counting. Using this approach, the plasma volume of the brain 
microvasculature was determined to be 26 ±6 μL/g of brain tissue, which is 
concordant with that previously reported in rodents
501
. This value was subsequently 
used to adjust the brain homogenate concentrations of amines 302, 303 or 304 
determined by LCMS. The subsequent area under the brain concentration versus time 
profile from time zero to 8 h (AUCbrain), area under the plasma concentration versus 
time profile (AUCplasma) and their associated variances were calculated using Bailer’s 
method
502
 and a brain-to-plasma exposure ratio was determined. The recordings are 
shown in Table 43. 
Chapter 11 Experimental 
 
292 
 
Table 43.  Concentrations of amines 302 ,  303  and 312  in mouse plasma and brain 
samples following 3mg/kg IV dose.  
Compound 
Sample 
number 
Plama 
concentration 
(ng/mL) 
Brain 
concentration 
(ng/g) 
Brain/Plasma 
ratio 
302 1 581.1 2634.9 4.5 
2 209.9 820.2 3.9 
3 623.8 3187.1 5.1 
4 663.8 2462.1 3.7 
5 528.9 3353.0 6.3 
Mean 521.5 2491.4 4.7 
%RSD 34.8 40.3 22.4 
303 1 369.2 1767.4 4.8 
2 389.4 1666.0 4.3 
3 32.6 117.1 3.6 
4 308.2 1950.5 6.3 
5 220.1 1190.9 5.4 
Mean 263.9 1338.4 4.9 
%RSD 55.0 55.2 21.5 
304 1 665.9 6595.0 9.9 
2 579.7 5954.2 10.3 
3 481.3 4938.4 10.3 
4 487.1 4737.5 9.7 
5 521.7 5029.6 9.6 
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Mean 547.1 5450.9 10.0 
%RSD 14.1 14.5 3.0 
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APPENDIX 
5-Morpholino-N-(4-(pyridin-3-yl)phenyl)pentanamide (45, SEN12333) 
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4-(4-(5-([1,1'-Biphenyl]-4-yl)-1H-tetrazol-1-yl)butyl)morpholine 78 
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N-(4-(Piperidin-1-yl)butyl)-4-(pyridin-3-yl)benzamide 102 
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(1S,4S)-tert-Butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 157 
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N-(4-(2-fluoropyridin-3-yl)phenyl)-5-morpholinopentanamide 208 
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(1S,4S)-2-Methyl-5-(4-(pyridin-3-yl)phenyl)-2,5-diazabicyclo[2.2.1]heptane 274 
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5-Morpholino-N-(4-(pyridin-3-yl)phenyl)pentanamide (45, SEN12333) 
Table 1 Crystal data and structure refinement for SEN12333. 
Identification code SEN12333 
Empirical formula C20H27N3O3 
Formula weight 357.44 
Temperature/K 150 
Crystal system triclinic 
Space group P-1 
a/Å 7.8461(4) 
b/Å 9.7170(5) 
c/Å 13.2220(7) 
α/° 87.616(5) 
β/° 74.446(5) 
γ/° 73.175(5) 
Volume/Å
3
 928.85(9) 
Z 2 
ρcalcmg/mm
3
 1.278 
m/mm
-1
 0.087 
F(000) 384.0 
Crystal size/mm
3
 0.2 × 0.1 × 0.1 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection 5.63 to 58.758° 
Index ranges -10 ≤ h ≤ 10, -12 ≤ k ≤ 13, -18 ≤ l ≤ 13 
Reflections collected 8444 
Independent reflections 4337 [Rint = 0.0243, Rsigma = 0.0473] 
Data/restraints/parameters 4337/0/243 
Goodness-of-fit on F
2
 1.053 
Final R indexes [I>=2σ (I)] R1 = 0.0468, wR2 = 0.1025 
Final R indexes [all data] R1 = 0.0673, wR2 = 0.1189 
Largest diff. peak/hole / e Å
-3
 0.24/-0.24 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for SEN12333. Ueq is defined as 1/3 of of the 
trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 -77(2) -417.9(16) 1453.1(12) 27.4(3) 
C2 -63(2) -194.4(15) 2575.0(12) 24.4(3) 
C3 412(2) 1799.1(16) 1011.5(12) 26.0(3) 
C4 443(2) 2096.6(16) 2119.6(12) 24.2(3) 
C5 -535(2) 1521.1(16) 3951.3(11) 24.7(3) 
C6 -1399(2) 3039.4(16) 4429.7(12) 24.8(3) 
C7 -1269(2) 3080.0(16) 5560.6(12) 26.4(3) 
C8 -2137(2) 4557.9(16) 6103.4(11) 24.6(3) 
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C9 -1992(2) 4549.8(16) 7230.4(12) 24.5(3) 
C10 -3460(2) 5967.5(15) 8922.2(11) 20.8(3) 
C11 -4792(2) 7232.8(15) 9371.6(12) 23.3(3) 
C12 -5023(2) 7664.8(16) 10394.8(12) 23.7(3) 
C13 -3925.2(19) 6849.9(15) 11008.3(11) 20.5(3) 
C14 -2625(2) 5574.1(15) 10555.2(12) 23.5(3) 
C15 -2379(2) 5122.8(15) 9531.4(12) 23.8(3) 
C16 -4107.9(19) 7336.5(15) 12089.7(11) 21.4(3) 
C17 -3716(2) 6391.7(16) 12869.5(12) 26.3(3) 
C18 -3902(2) 6921.2(17) 13863.0(13) 30.0(4) 
C19 -4482(2) 8385.2(18) 14055.2(13) 31.4(4) 
C20 -4659(2) 8801.6(16) 12370.8(12) 25.6(3) 
N1 -689.1(17) 1352.8(12) 2880.8(9) 21.4(3) 
N3 -3286.8(17) 5631.5(12) 7866.4(10) 22.6(3) 
N4 -4855.7(19) 9334.8(14) 13325.0(11) 30.5(3) 
O1 1077.4(14) 298.5(11) 750.2(8) 27.6(3) 
O2 -779.9(17) 3647.2(13) 7508.4(9) 41.8(3) 
O1W -4557.8(18) 2228.5(12) 3192.6(9) 30.7(3) 
 
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for SEN12333. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 35.7(9) 24.1(8) 22.7(8) -2.0(6) -8.1(7) -8.4(7) 
C2 31.8(8) 19.1(7) 21.6(8) 0.6(6) -8.2(7) -5.1(6) 
C3 29.8(8) 26.4(8) 20.6(8) 2.6(6) -5.2(7) -7.7(6) 
C4 28.8(8) 24.0(8) 19.5(8) 0.4(6) -5.6(7) -8.0(6) 
C5 31.5(8) 25.8(8) 16.7(8) 0.8(6) -8.8(7) -6.0(6) 
C6 31.5(8) 24.3(8) 19.8(8) 0.5(6) -8.7(7) -8.1(6) 
C7 32.1(8) 26.7(8) 20.0(8) -2.0(6) -9.1(7) -5.7(6) 
C8 30.1(8) 26.3(8) 18.5(8) 1.2(6) -7.2(7) -9.1(6) 
C9 28.6(8) 24.5(8) 20.5(8) -0.8(6) -7.3(7) -7.0(6) 
C10 23.7(7) 22.1(7) 17.8(7) 0.4(6) -4.5(6) -9.4(6) 
C11 22.9(7) 25.4(8) 21.5(8) 1.9(6) -8.1(6) -4.7(6) 
C12 21.9(7) 23.0(8) 21.9(8) -4.0(6) -3.5(6) -1.5(6) 
C13 22.5(7) 21.8(7) 16.9(7) 0.4(6) -3.2(6) -8.0(6) 
C14 28.4(8) 21.6(7) 19.8(8) 3.3(6) -8.0(7) -4.9(6) 
C15 28.9(8) 18.8(7) 21.0(8) -0.8(6) -6.6(7) -2.8(6) 
C16 19.4(7) 24.0(7) 19.5(8) -1.2(6) -2.6(6) -6.0(6) 
C17 29.8(8) 25.1(8) 22.3(8) -0.2(6) -5.3(7) -6.6(6) 
C18 35.0(9) 34.3(9) 21.3(8) 3.9(7) -10.0(7) -9.1(7) 
C19 37.6(9) 38.0(9) 20.1(8) -3.8(7) -6.8(7) -13.7(7) 
C20 30.1(8) 26.0(8) 20.6(8) 1.0(6) -5.6(7) -8.9(6) 
N1 27.1(6) 20.5(6) 15.5(6) -0.1(5) -5.1(5) -5.4(5) 
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N3 27.1(7) 23.2(6) 17.9(6) 0.4(5) -8.8(5) -5.2(5) 
N4 37.0(8) 29.0(7) 25.5(8) -4.7(6) -6.3(6) -10.7(6) 
O1 31.0(6) 27.7(6) 20.1(6) -3.4(4) -2.8(5) -5.5(5) 
O2 48.1(8) 40.3(7) 26.0(7) -8.8(5) -16.4(6) 11.3(6) 
O1W 31.5(7) 25.9(6) 34.1(7) -0.4(5) -14.3(6) -1.7(5) 
 
Table 4 Bond Lengths for SEN12333. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.511(2)   C10 C15 1.396(2) 
C1 O1 1.4243(19)   C10 N3 1.4086(18) 
C2 N1 1.4771(18)   C11 C12 1.382(2) 
C3 C4 1.513(2)   C12 C13 1.398(2) 
C3 O1 1.4222(18)   C13 C14 1.392(2) 
C4 N1 1.4683(19)   C13 C16 1.4817(19) 
C5 C6 1.518(2)   C14 C15 1.387(2) 
C5 N1 1.4722(17)   C16 C17 1.389(2) 
C6 C7 1.529(2)   C16 C20 1.398(2) 
C7 C8 1.516(2)   C17 C18 1.386(2) 
C8 C9 1.524(2)   C18 C19 1.374(2) 
C9 N3 1.3569(19)   C19 N4 1.338(2) 
C9 O2 1.2191(18)   C20 N4 1.3371(19) 
C10 C11 1.393(2)     
  
 
Table 5 Bond Angles for SEN12333. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
O1 C1 C2 110.86(11)   C14 C13 C12 117.32(13) 
N1 C2 C1 110.92(12)   C14 C13 C16 121.21(12) 
O1 C3 C4 111.01(12)   C15 C14 C13 122.31(13) 
N1 C4 C3 110.84(11)   C14 C15 C10 119.57(13) 
N1 C5 C6 114.54(12)   C17 C16 C13 122.98(13) 
C5 C6 C7 110.40(12)   C17 C16 C20 116.21(13) 
C8 C7 C6 113.71(12)   C20 C16 C13 120.80(13) 
C7 C8 C9 112.06(12)   C18 C17 C16 119.98(14) 
N3 C9 C8 114.28(12)   C19 C18 C17 118.77(15) 
O2 C9 C8 121.42(13)   N4 C19 C18 123.27(14) 
O2 C9 N3 124.29(14)   N4 C20 C16 124.78(14) 
C11 C10 C15 118.78(13)   C4 N1 C2 108.99(12) 
C11 C10 N3 117.03(12)   C4 N1 C5 111.47(11) 
C15 C10 N3 124.19(13)   C5 N1 C2 108.95(11) 
C12 C11 C10 120.90(13)   C9 N3 C10 128.08(12) 
C11 C12 C13 121.11(13)   C20 N4 C19 116.98(13) 
C12 C13 C16 121.46(13)   C3 O1 C1 109.19(11) 
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Table 6 Torsion Angles for SEN12333. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 N1 C4 -54.43(15)   C13 C14 C15 C10 0.2(2) 
C1 C2 N1 C5 -176.26(12)   C13 C16 C17 C18 179.45(14) 
C2 C1 O1 C3 -60.53(15)   C13 C16 C20 N4 -179.84(14) 
C3 C4 N1 C2 54.41(15)   C14 C13 C16 C17 -30.0(2) 
C3 C4 N1 C5 174.70(11)   C14 C13 C16 C20 148.62(14) 
C4 C3 O1 C1 60.67(15)   C15 C10 C11 C12 1.3(2) 
C5 C6 C7 C8 -178.86(13)   C15 C10 N3 C9 -6.4(2) 
C6 C5 N1 C2 -171.29(13)   C16 C13 C14 C15 -177.52(14) 
C6 C5 N1 C4 68.40(16)   C16 C17 C18 C19 0.2(2) 
C6 C7 C8 C9 179.56(13)   C16 C20 N4 C19 0.4(2) 
C7 C8 C9 N3 -156.21(13)   C17 C16 C20 N4 -1.1(2) 
C7 C8 C9 O2 24.9(2)   C17 C18 C19 N4 -0.9(3) 
C8 C9 N3 C10 -176.06(13)   C18 C19 N4 C20 0.6(2) 
C10 C11 C12 C13 0.2(2)   C20 C16 C17 C18 0.7(2) 
C11 C10 C15 C14 -1.5(2)   N1 C5 C6 C7 176.56(12) 
C11 C10 N3 C9 173.08(14)   N3 C10 C11 C12 -178.29(13) 
C11 C12 C13 C14 -1.4(2)   N3 C10 C15 C14 178.07(13) 
C11 C12 C13 C16 177.33(13)   O1 C1 C2 N1 58.37(16) 
C12 C13 C14 C15 1.2(2)   O1 C3 C4 N1 -58.68(16) 
C12 C13 C16 C17 151.26(15)   O2 C9 N3 C10 2.8(3) 
C12 C13 C16 C20 -30.1(2)           
 
 
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for SEN12333. 
Atom x y z U(eq) 
H1A 354 -1439 1267 33 
H1B -1331 -50 1390 33 
H2A -870 -680 3040 29 
H2B 1178 -613 2648 29 
H3A -842 2168 948 31 
H3B 1175 2294 522 31 
H4A 1706 1775 2173 29 
H4B -25 3124 2281 29 
H5A 763 1223 3937 30 
H5B -1118 880 4402 30 
H6A -2685 3369 4420 30 
H6B -765 3681 4016 30 
H7A -1872 2412 5961 32 
H7B 23 2756 5560 32 
H8A -3429 4888 6106 30 
H8B -1528 5229 5712 30 
H11 -5537 7794 8978 28 
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H12 -5923 8512 10680 28 
H14 -1895 5005 10953 28 
H15 -1501 4263 9252 29 
H17 -3329 5404 12725 32 
H18 -3639 6297 14390 36 
H19 -4621 8733 14726 38 
H20 -4908 9453 11857 31 
H3 -4104 6180 7591 27 
H1WA -4810(30) 1340(30) 3273(19) 72(7) 
H1WB -3350(30) 2010(20) 3032(18) 59(7) 
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4-(4-(1-(4-(Pyridin-3-yl)phenyl)-1H-tetrazol-5-yl)butyl)morpholine (75) 
Table 1 Crystal data and structure refinement for Compound 
75 
Identification code Compound 75 
Empirical formula C20H24N6O 
Formula weight 364.45 
Temperature/K 150 
Crystal system monoclinic 
Space group P21/c 
a/Å 17.7691(5) 
b/Å 8.8187(2) 
c/Å 12.2769(3) 
α/° 90 
β/° 95.050(3) 
γ/° 90 
Volume/Å
3
 1916.33(9) 
Z 4 
ρcalcmg/mm
3
 1.263 
m/mm
-1
 0.082 
F(000) 776.0 
Crystal size/mm
3
 0.15 × 0.15 × 0.1 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection 5.696 to 58.862° 
Index ranges -23 ≤ h ≤ 20, -10 ≤ k ≤ 12, -14 ≤ l ≤ 16 
Reflections collected 12044 
Independent reflections 4602[R(int) = 0.0304] 
Data/restraints/parameters 4602/0/244 
Goodness-of-fit on F
2
 1.002 
Final R indexes [I>=2σ (I)] R1 = 0.0462, wR2 = 0.1094 
Final R indexes [all data] R1 = 0.0725, wR2 = 0.1312 
Largest diff. peak/hole / e Å
-3
 0.22/-0.27 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic 
Displacement Parameters (Å
2
×10
3
) for Compound 75. Ueq is defined as 1/3 of of 
the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C16 13178.8(8) 1493.0(16) 7177.7(12) 22.6(3) 
C17 13871.7(9) 1578.8(18) 7800.4(12) 29.3(4) 
C18 14470.0(9) 2290(2) 7368.1(13) 34.8(4) 
C19 14361.7(9) 2915.5(18) 6334.3(14) 33.7(4) 
C20 13137.0(9) 2133.5(16) 6143.4(12) 26.0(3) 
N6 13706.3(8) 2841.2(15) 5711.1(11) 31.5(3) 
C1 5732.1(9) 1297.8(18) 4692.6(14) 31.0(4) 
C2 6188.5(8) 713.6(17) 5698.1(13) 27.7(3) 
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C3 6677.0(9) 3004.7(18) 4361.9(14) 33.5(4) 
C4 7160.1(9) 2446.3(17) 5350.6(13) 27.7(3) 
C5 7433.1(8) 327.8(17) 6567.7(12) 26.1(3) 
C6 8268.6(8) 100.3(17) 6459.2(12) 25.6(3) 
C7 8665.6(8) -453.3(17) 7537.3(12) 25.8(3) 
C8 9511.0(8) -678.6(18) 7487.8(12) 27.5(3) 
C9 9876.2(8) -1277.7(16) 8538.0(12) 23.1(3) 
C10 11234.4(8) -428.9(16) 8425.8(11) 22.0(3) 
C11 11719.4(8) 470.7(16) 9092.5(12) 23.9(3) 
C12 12352.2(8) 1060.6(16) 8678.8(11) 23.9(3) 
C13 12500.3(8) 803.3(16) 7596.0(11) 21.4(3) 
C14 11993.7(8) -72.1(16) 6933.5(11) 24.4(3) 
C15 11364.5(8) -709.0(17) 7346.1(12) 25.0(3) 
N1 6997.5(6) 857.3(13) 5573.6(10) 21.9(3) 
N2 9530.7(7) -2002.5(15) 9293.9(10) 29.2(3) 
N3 10074.0(8) -2287.0(15) 10129.0(11) 31.0(3) 
N4 10723.5(7) -1778.4(14) 9906.7(10) 28.0(3) 
N5 10612.1(7) -1132.2(13) 8896.6(9) 22.3(3) 
O1 5893.2(6) 2850.0(12) 4493.2(9) 33.6(3) 
 
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for Compound 75. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
C16 22.4(8) 23.7(7) 21.8(7) -3.0(6) 3.2(6) 3.7(6) 
C17 29.4(9) 38.4(9) 19.5(8) -3.5(6) -0.8(6) 3.2(7) 
C18 24.3(8) 49.2(10) 30.2(9) -10.1(7) -1.5(7) -1.7(7) 
C19 28.3(9) 37.6(9) 36.1(9) -6.2(7) 7.6(7) -6.4(7) 
C20 24.6(8) 29.7(8) 23.4(8) 1.7(6) 0.1(6) 1.2(6) 
N6 30.7(8) 36.1(7) 28.2(7) 2.7(6) 4.9(6) -3.8(6) 
C1 22.0(8) 31.6(8) 38.3(9) 0.2(7) -3.3(6) -2.7(6) 
C2 20.6(8) 30.3(8) 32.0(9) 2.0(6) 0.9(6) -2.8(6) 
C3 27.6(9) 30.9(8) 41.5(10) 9.4(7) 0.7(7) -1.6(7) 
C4 23.3(8) 25.0(7) 34.6(9) 0.2(6) 1.0(6) -3.8(6) 
C5 24.1(8) 30.6(8) 23.2(8) 1.9(6) 0.6(6) -1.0(6) 
C6 23.4(8) 29.8(8) 23.1(8) 0.0(6) -0.2(6) -1.8(6) 
C7 20.7(8) 33.1(8) 23.4(8) 0.0(6) 0.8(6) -1.5(6) 
C8 23.0(8) 37.2(8) 22.2(8) 3.2(6) 1.0(6) 0.9(6) 
C9 22.3(8) 25.8(7) 21.6(7) -2.7(6) 4.5(6) 3.5(6) 
C10 19.6(7) 25.3(7) 21.2(7) 2.7(6) 2.7(5) 5.8(6) 
C11 26.6(8) 28.1(7) 17.1(7) -1.1(6) 2.7(6) 4.9(6) 
C12 25.0(8) 26.6(7) 19.6(7) -3.4(6) -0.8(6) 2.1(6) 
C13 22.2(7) 23.3(7) 18.4(7) 1.0(5) 0.5(5) 6.0(5) 
C14 26.5(8) 31.0(8) 15.6(7) -0.2(6) 2.2(6) 5.5(6) 
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C15 23.4(8) 30.5(8) 20.4(7) -3.1(6) -1.8(6) 2.1(6) 
N1 17.1(6) 24.5(6) 23.7(6) 0.5(5) -0.3(5) -2.6(5) 
N2 27.3(7) 34.6(7) 26.1(7) 3.7(5) 4.7(5) 3.7(5) 
N3 31.2(8) 36.9(7) 25.2(7) 6.1(6) 4.9(5) 4.4(6) 
N4 29.5(7) 34.0(7) 20.6(7) 6.2(5) 2.9(5) 5.0(6) 
N5 22.3(6) 26.4(6) 18.3(6) 2.5(5) 2.0(5) 4.8(5) 
O1 25.8(6) 30.4(6) 43.4(7) 5.0(5) -3.1(5) 2.7(4) 
 
Table 4 Bond Lengths for Compound 75. 
Atom Atom Length/Å   Atom Atom Length/Å 
C16 C17 1.393(2)   C6 C7 1.524(2) 
C16 C20 1.386(2)   C7 C8 1.522(2) 
C16 C13 1.482(2)   C8 C9 1.488(2) 
C17 C18 1.380(2)   C9 N2 1.3218(19) 
C18 C19 1.382(2)   C9 N5 1.3487(18) 
C19 N6 1.338(2)   C10 C11 1.385(2) 
C20 N6 1.3376(19)   C10 C15 1.388(2) 
C1 C2 1.507(2)   C10 N5 1.4331(18) 
C1 O1 1.4241(18)   C11 C12 1.376(2) 
C2 N1 1.4646(18)   C12 C13 1.3963(19) 
C3 C4 1.506(2)   C13 C14 1.392(2) 
C3 O1 1.4226(19)   C14 C15 1.386(2) 
C4 N1 1.4615(18)   N2 N3 1.3681(18) 
C5 C6 1.516(2)   N3 N4 1.2897(18) 
C5 N1 1.4629(18)   N4 N5 1.3633(16) 
 
Table 5 Bond Angles for Compound 75. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C17 C16 C13 122.60(13)   C11 C10 N5 118.14(12) 
C20 C16 C17 117.02(14)   C15 C10 N5 120.51(13) 
C20 C16 C13 120.35(13)   C12 C11 C10 118.99(13) 
C18 C17 C16 119.16(15)   C11 C12 C13 121.24(13) 
C17 C18 C19 119.01(15)   C12 C13 C16 119.37(13) 
N6 C19 C18 123.35(15)   C14 C13 C16 121.94(13) 
N6 C20 C16 124.92(14)   C14 C13 C12 118.67(13) 
C20 N6 C19 116.53(14)   C15 C14 C13 120.79(13) 
O1 C1 C2 111.57(12)   C14 C15 C10 118.98(13) 
N1 C2 C1 110.33(12)   C4 N1 C2 108.33(11) 
O1 C3 C4 111.81(13)   C4 N1 C5 111.32(11) 
N1 C4 C3 110.88(12)   C5 N1 C2 109.72(11) 
N1 C5 C6 114.79(12)   C9 N2 N3 105.90(12) 
C5 C6 C7 110.38(12)   N4 N3 N2 111.30(12) 
C8 C7 C6 112.97(12)   N3 N4 N5 106.07(11) 
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C9 C8 C7 111.62(12)   C9 N5 C10 132.05(12) 
N2 C9 C8 125.86(13)   C9 N5 N4 108.43(12) 
N2 C9 N5 108.29(13)   N4 N5 C10 119.50(11) 
N5 C9 C8 125.83(13)   C3 O1 C1 108.98(11) 
C11 C10 C15 121.28(14)         
 
 
Table 6 Torsion Angles for Compound 75. 
A B C D Angle/˚   A B C D Angle/˚ 
C16 C17 C18 C19 0.9(2)   C9 N2 N3 N4 -0.38(16) 
C16 C20 N6 C19 0.5(2)   C10 C11 C12 C13 1.8(2) 
C16 C13 C14 C15 179.79(13)   C11 C10 C15 C14 0.0(2) 
C17 C16 C20 N6 -1.0(2)   C11 C10 N5 C9 135.45(16) 
C17 C16 C13 C12 39.8(2)   C11 C10 N5 N4 -42.78(18) 
C17 C16 C13 C14 -141.61(15)   C11 C12 C13 C16 178.48(13) 
C17 C18 C19 N6 -1.5(3)   C11 C12 C13 C14 -0.2(2) 
C18 C19 N6 C20 0.9(2)   C12 C13 C14 C15 -1.6(2) 
C20 C16 C17 C18 0.3(2)   C13 C16 C17 C18 -177.55(14) 
C20 C16 C13 C12 -138.01(15)   C13 C16 C20 N6 176.89(13) 
C20 C16 C13 C14 40.6(2)   C13 C14 C15 C10 1.7(2) 
C1 C2 N1 C4 56.64(16)   C15 C10 C11 C12 -1.8(2) 
C1 C2 N1 C5 178.35(12)   C15 C10 N5 C9 -47.7(2) 
C2 C1 O1 C3 58.80(17)   C15 C10 N5 N4 134.06(14) 
C3 C4 N1 C2 -56.10(16)   N1 C5 C6 C7 -179.88(12) 
C3 C4 N1 C5 -176.82(13)   N2 C9 N5 C10 -178.74(13) 
C4 C3 O1 C1 -58.05(17)   N2 C9 N5 N4 -0.36(16) 
C5 C6 C7 C8 -179.02(12)   N2 N3 N4 N5 0.16(16) 
C6 C5 N1 C2 167.53(12)   N3 N4 N5 C9 0.12(15) 
C6 C5 N1 C4 -72.57(16)   N3 N4 N5 C10 178.74(12) 
C6 C7 C8 C9 -177.71(12)   N5 C9 N2 N3 0.44(16) 
C7 C8 C9 N2 21.3(2)   N5 C10 C11 C12 175.05(12) 
C7 C8 C9 N5 -156.46(14)   N5 C10 C15 C14 -176.71(12) 
C8 C9 N2 N3 -177.67(14)   O1 C1 C2 N1 -59.48(17) 
C8 C9 N5 C10 -0.6(2)   O1 C3 C4 N1 58.20(17) 
C8 C9 N5 N4 177.75(13)           
 
 
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for Compound 75. 
Atom x y z U(eq) 
H17 13930 1162 8499 35 
H18 14939 2347 7767 42 
H19 14765 3413 6058 40 
H20 12679 2066 5718 31 
H1A 5844 696 4065 37 
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H1B 5198 1187 4785 37 
H2A 6063 1285 6333 33 
H2B 6065 -342 5813 33 
H3A 6791 4063 4237 40 
H3B 6798 2434 3725 40 
H4A 7689 2554 5227 33 
H4B 7065 3059 5980 33 
H5A 7220 -626 6788 31 
H5B 7376 1056 7147 31 
H6A 8492 1050 6252 31 
H6B 8335 -637 5889 31 
H7A 8584 277 8106 31 
H7B 8441 -1406 7735 31 
H8A 9595 -1381 6903 33 
H8B 9741 282 7323 33 
H11 11619 673 9809 29 
H12 12688 1642 9129 29 
H14 12079 -232 6206 29 
H15 11035 -1315 6906 30 
 
 
